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Abstract  
Epidemiological evidence suggests that due to its high isoflavone (genistein and 
daidzein) content a diet rich in soy could protect against breast cancer, particularly 
tumours expressing oestrogen receptor alpha (ERα+).  Isoflavones are weakly 
oestrogenic, and have other wide ranging cellular activities.   Contradictory in vitro 
evidence means that isoflavones’ mechanism(s) of action remain to be elucidated.   
ERα+ MCF7 and ERα-/ERβ+ MDA-MB-231 cell proliferation and apoptosis were 
quantified at a range of achievable serum concentrations of genistein or daidzein 
(0.01nM to 31.6µM) with or without pre-/post-menopausal 17β-oestradiol (E2) levels 
(1nM and 1pM).  Additionally, cell volume regulation and macroscopic K+ current 
modulation by isoflavones and E2 in MCF7 cells were investigated.  
In MCF7 cells isoflavones (≥1µM) induce apoptosis, even in the presence of E2, but 
this did not reverse the synergistic effect of postmenopausal E2 and isoflavones on 
proliferation.  Isoflavones slightly reduced MDA-MB-231 proliferation at all 
concentrations, dropping dramatically at 31.6µM.  This response was partially 
maintained in the presence of postmenopausal E2.  Isoflavones also induced 
markers of apoptosis.  Treating MCF7 with 1nM E2 or 1µM genistein resulted in cell 
swelling, and a significant increase in whole cell current (E2 only), indicating a 
proliferative response.  Conversely, treatment with 31.6µM genistein resulted in 
shrinkage, and inhibition of outward K+ current (not statistically significant).  
Daidzein treatment inhibited current to a lesser extent.  Co-treatment with K+ 
channel blockers indicated the hEAG channel as a potential molecular target of 
genistein in MCF7.  
These results suggest that in ERα+ breast cancers, isoflavones may act by inducing 
apoptosis, shrinkage, and inhibition of hEAG current.   There was no evidence 
suggesting that isoflavones reduce E2-promoted ERα+ cancer cell proliferation.  
Importantly, the inhibition of K+ channel activity by isoflavones represents a novel 
target for anti-cancer therapies.  However, even low levels of isoflavones may be 
beneficial chemotherapeutic agents against ERα-/ERβ+ breast cancer, indicating an 
urgent requirement for further characterization of the effects of isoflavones in these 
breast cancers. 
 
 
 
 
 
 
Key words: breast cancer, soy, isoflavones, proliferation, apoptosis, potassium 
channel 
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CHAPTER 1. Introduction 
1.1 Overview of breast cancer 
Breast cancer is defined as a malignant tumour of the breast, and is classified by the 
International Classification of Diseases (ICD10) code C50 (WHO 2012).  It is 
typically a painless lump in the breast or under the armpit.  Bleeding or discharge 
from the nipple can occur, but are not diagnostic.  Fibrosis around the tumour can 
lead to pitting or discoloration of the skin.  The tumour can metastasize further to the 
other breast, bones, lungs or liver.  Diagnosis is typically by mammography and 
physical examination, and confirmed by biopsy (Baum and Schipper 2000).  Breast 
cancers can be classified according to their invasiveness, and site, but also by the 
presence or absence of various hormone receptors, including oestrogen receptors 
(positive or negative; ER+/-) progesterone receptors (PR+/-) and human epidermal 
growth factor receptor 1 or 2 (HER1/HER2+/-).  A tumour is classed as receptor 
positive if over 5% of the cells express that receptor.  The receptor status of the 
disease affects rate of invasion and has implications for treatment choices (Smith 
and Chua 2006a; Smith and Chua 2006b; Suzuki et al. 2008). 
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1.1.1 Incidence and mortality 
In the United Kingdom, breast cancer is the most common female cancer, 
accounting for 37% of all female cancer incidence between 2007 and 2009, at a rate 
of 124.2 incident cases per 100 000 adults in the age adjusted female population 
(Office for National Statistics 2012).  Rates in males are very low and will not be 
discussed.  Female breast cancer mortality rates are relatively low, at 21% of the 
incidence rate, or 26.1 deaths per 100 000 adults, with female mortality from lung 
cancer occurring at a higher rate.  Since 1993 the incidence rate of breast cancer in 
the UK has been steadily increasing.  During the same period mortality rates have 
fallen by 22% (Westlake and Cooper 2008).  Data from developed countries 
worldwide is similar (Jemal et al. 2011).  The introduction of breast screening, which 
reached full UK coverage in the mid-1990s has made a significant contribution to 
both trends, allowing earlier diagnosis and treatment, resulting in an improved 
prognosis for affected women (Reddy and Given-Wilson 2006).  Developments in 
treatment have also contributed the downward trend in mortality (Westlake and 
Cooper 2008).  
Most breast cancers are ER+, with one cohort reporting over 70% (Balfe et al. 2004; 
Suzuki et al. 2008; Ziv et al. 2004).  However, in human tissue two ERs are 
expressed.  The classical ER is known as ERα.  In the mid-1990s a second ER, 
referred to as ERβ was identified.  Their expression levels vary throughout the body, 
but they are both expressed in breast and most female reproductive tissues (Taylor 
and Al-Azzawi 2000).  Traditionally, the ER status of a patient is determined based 
on their ERα expression level.   This ER is the dominant form in human breast 
cancer (Balfe et al. 2004).  However, both ER+ and ER- tumours have been found 
to express ERβ, complicating classification (Skliris et al. 2008).   
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1.1.2 Breast cancer treatment 
Effective treatment for breast cancer depends on the size, stage and characteristics 
of the tumour.  Frequently, treatment is surgery to remove the tumour (lumpectomy) 
or the entire affected breast (mastectomy), with or without radiotherapy, followed by 
a course of adjuvant chemotherapy.  For large inoperable tumours, adjuvant therapy 
is used first, to attempt to slow growth or even promote regression (NICE 2009a; 
NICE 2009b; Pollak 2001; Smith and Chua 2006a).  However each causes 
additional physiological and psychological challenges for the patient, including the 
physical risks associated with any surgery, and the side effects of chemotherapy 
which may include alopecia, nausea, fatigue, weight gain and early menopause 
(Miller et al. 2007; Smith and Chua 2006a).   
Endocrine chemotherapy regimes, designed to block either the production or actions 
of oestrogens, are well established treatments for postmenopausal women with 
ERα+ breast cancer (NICE 2009b)1.  Modern endocrine breast cancer treatments 
are diverse (Miller et al. 2007; NICE 2009b).  Selective oestrogen receptor 
modulators (SERMs), such as tamoxifen, reduce breast cancer proliferation by 
competitively binding to the ER and partially inhibiting its signaling, although they act 
as agonists in some other tissues.  Selective oestrogen receptor down-regulators 
(SERDs) act similarly but more completely inhibit the ER-signal.  Aromatase 
inhibitors selectively bind to and inhibit aromatase, a key enzyme in the synthesis of 
oestrogens, thereby reducing oestrogen levels.   
However, around a third of breast cancers are ERα-, which are frequently more 
aggressive but fail to respond to endocrine therapies (Balfe et al. 2004; Suzuki et al. 
2008; Ziv et al. 2004).  Alternative chemotherapies exist, such as the HER2-receptor 
antibody trastuzumab (Herceptin).  This treatment is advised for women with early 
stage ER-/HER2+ breast cancer, but it is associated with cardiotoxicity, and is 
unsafe for women with cardiac disease (NICE 2006).  Furthermore, a major obstacle 
to the treatment of breast cancer is the development of resistance to therapies over 
long term treatment regimes, resulting in relapse, and requiring a switch to another 
                                                 
1
 The pioneer of these treatments was the physician George Beatson, who discusses in his 
1896 letter to The Lancet how the removal of the ovaries reversed the progression of three 
cases of breast cancer (Beatson 1896).    
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therapy (Miller et al. 2007).  There is a great need to develop more effective 
preventative strategies and therapeutic treatments for breast cancer.  
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1.1.3 Unmodifiable risk factors 
Being female is the major risk factor for breast cancer, closely followed by 
increasing age, with relative risk doubling every 10 years (Information Services 
Division Scotland 2012; Kurian et al. 2010; McPherson et al. 2000).  In addition, 
genetic predisposition for the condition is implicated in around 10% of cases in 
Western countries, with mutations in the genes BRCA1 and BRCA2 accounting for 
much of this (McPherson et al. 2000).  Many of the remaining risk factors relate to a 
woman’s reproductive history.  Risk is reduced by late onset of menstruation, early 
menopause (natural or induced), pregnancy (reducing further with each subsequent 
pregnancy after the first), being younger at first pregnancy, and breast feeding 
(Chlebowski et al. 2009; Clavel-Chapelon and the E3N-EPIC group 2002).  
Extended use of Hormone Replacement Therapy (HRT) or oral contraceptives can 
lead to an increase in risk, although this decreases upon cessation of use (Beral 
2003; Collaborative Group on Hormonal Factors in Breast Cancer 1997).  Many of 
these risk factors are inter-related, and have a complex relationship with risk, 
depending on receptor status of the cancer, and whether pre- or post-menopausal 
breast cancer risk is being assessed.  Importantly, they are all unmodifiable, or 
difficult/unethical to modify.  Each of these factors affects a woman’s levels of serum 
sex hormones.   
In postmenopausal women not taking HRT, serum total concentrations of 17β-
oestradiol (E2), the main circulating human oestrogen,  are typically between 40 and 
100 pM (Braunstein et al. 2008; Kaaks et al. 2005a; Rock et al. 2008).  
Premenopausal women (not taking oral contraceptives) have higher levels, ranging 
between 0.1 to 1 nM depending on the point in their menstrual cycle (Eliassen et al. 
2006; Gruber et al. 2002; Kaaks et al. 2005b; Rubin et al. 2005).  However, a 
proportion of this E2 is bound in the serum by sex hormone binding globulin (SHBG) 
preventing its biological activity, or albumin (Fortunati et al. 2010; Gruber et al. 
2002).  Accordingly, the levels of unbound, or free, bioavailable E2 are lower.  In 
premenopausal women, the level of serum SHBG was found to be between 50 and 
60nM, and does not vary with the menstrual cycle (Eliassen et al. 2006; Kaaks et al. 
2005b).  Levels were slightly lower in postmenopausal women: closer to 35nM 
(Kaaks et al. 2005a).  Consequently, in postmenopausal women free E2 has been 
determined to be between 1 and 30 pM (Braunstein et al. 2008; Kaaks et al. 2005a; 
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Rock et al. 2008).  In premenopausal women free E2 varied between around 200pM 
during the follicular phase, and 500pM during the luteal phase (Eliassen et al. 2006).   
In a nested case-control group comprising nearly 2000 postmenopausal women 
taking part in the European Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort study, elevated levels of both E2 and free E2 were positively 
associated with breast cancer risk (p < 0.0001) while SHBG levels were inversely 
related to risk (p = 0.04) (Kaaks et al. 2005a).   Likewise, elevated levels of 
oestrogens and testosterone (a precursor of oestrogen) have been linked to risk of 
breast cancer independent of other risk factors (Cummings et al. 2005; Dorgan et al. 
2010; Eliassen et al. 2006; Mady 2000; Platet et al. 2004).   
There are two mechanisms through which E2 exposure may cause breast cancer.  
Firstly, oestrogens promote mitotic cell growth in the breast epithelium, directly 
promoting  the growth of the cancerous tissue (Matsumura et al. 2005; Schmidt et 
al. 2005), and by increasing the number of cell divisions also result in a 
proportionately larger number of possibilities for DNA mutation (Yager 2000).  
Secondly, oestrogens may be metabolized into genotoxic products, resulting again 
in DNA damage (Jefcoate et al. 2000).  These two mechanisms are likely to be 
synergistic, with mutations caused by carcinogenic oestrogens propagated rapidly 
by oestrogen enhanced growth, with insufficient time for repair.   
Genetic predisposition accounts for approximately 10% of breast cancer cases in 
western countries.  Additionally, a history of previous benign breast disease, such as 
cysts, can increase breast cancer risk.  Previous breast cancer greatly increases a 
woman’s chances of developing a tumour in the other breast (contralateral) 
(McPherson et al. 2000).  There is growing evidence to suggest that exposure to 
xenoestrogens (chemicals which mimic oestrogens), found in some plastics, 
packaging and pesticides, can increase risk of breast cancer also (Mitra et al. 2004).   
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1.1.4 Modifiable risk factors 
The modifiable risk factors for breast cancer are few, and often have little influence 
on final risk compared to the factors discussed above.  Smoking divides opinion 
regarding breast cancer.  Iwasaki and Tsugane (2011) argue that it is a risk factor, 
although others suggest that it is not (McPherson et al. 2000).  Among 
postmenopausal women who are not using HRT, adult weight gain or high Body 
Mass Index (BMI) contributes to increased risk (Feigelson et al. 2004).  For most 
dietary factors, such as dietary fat, fruit, vegetables, antioxidant vitamins or whole 
grains, there is no, or very limited evidence for an affect on breast cancer risk (World 
Cancer Research Fund / American Institute for Cancer 2007).  However, high levels 
of alcohol consumption may increase risk by as much as 10% per 10 g/day ethanol 
(Iwasaki and Tsugane 2011; World Cancer Research Fund / American Institute for 
Cancer 2007).   
However, there is a considerable field of research demonstrating an inverse 
relationship between breast cancer risk and the consumption of high levels of plant-
derived oestrogens known as phytoestrogens, and in particular the isoflavones 
found in soy.  There are countless proposed mechanisms through which isoflavones 
might mediate these effects.  These include but are not limited to modulating 
oestrogen responsive gene expression, oestrogen synthesis, cell cycle control, 
induction of apoptosis, breast tissue development, antioxidant actions, angiogenesis 
and protein tyrosine kinase inhibition (Steiner et al. 2008).  However the precise 
mechanisms of isoflavone action in breast cancer remain to be elucidated. 
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1.2 Soy isoflavone phytoestrogens 
Isoflavones are natural, plant metabolites with weak oestrogenic activity (Hwang et 
al. 2006; Kuiper et al. 1998).  For this reason they are often referred to as 
phytoestrogens.  Many plants produce oestrogenic compounds (Table 1.1), but, of 
the types consumed by humans, the isoflavones and lignans are most relevant for 
health.   Phytoestrogens have a structure similar to mammalian oestrogens like E2 
(Figure 1.1).  The main groups of plant derived phytoestrogens are the isoflavones, 
flavonoids, lignans and coumestans (Dixon 2004).  They each arise naturally in a 
range of grains, legumes and fruits.   
Of these phytoestrogens, the isoflavones have received the most scientific attention.  
They are a distinctive class of flavonoids, almost entirely limited to the subfamily 
Papilionoideae of the Leguminosae family, and all sharing the same diphenolic 
skeleton.  There are many hundreds of isoflavone chemical structures discovered to 
date, differentiated by their substituent groups, oxidation levels and the presence of 
extra heterocyclic rings (Dewick 1994).  Most significant to human health are the soy 
isoflavones genistein and daidzein, the chickpea isoflavone biochanin A, and equol, 
a metabolite of daidzein which around half of the population can synthesize.  
Genistein differs from daidzein only by the presence of an additional hydroxyl group 
on the 5 position.   
Table 1.1: Classification of the main types of plant-derived phytoestrogens 
Class of 
phytoestrogen 
Main types Main sources 
Isoflavone Genistein, daidzein, 
glycitein  
Soybean, clover 
Biochanin A Chickpea 
Flavonoid Resveratrol Grapes (and wine), peanuts 
Quercetin Tea, onions, fruits 
Lignan Enterodiol, 
enterolactone 
Whole cereals and grains 
(especially rye and flaxseed), 
berries, garlic 
Coumestans Coumestrol Alfalfa sprouts, clover, soybean 
(Adlercreutz 1995; Dixon 2004) 
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Figure 1.1: Structure of the main isoflavones and 17β-oestradiol 
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1.2.1 Food sources of isoflavones 
The main dietary sources of isoflavones are soy foods.  Miso, tofu, natto and soy 
beans are particularly rich sources, as is texturized vegetable protein (Bhagwat et al. 
2008).  These soy foods contain between 100 and 200 mg/100g total genistein and 
daidzein.  In addition, products such as doughnuts made with soy flour contain 
isoflavones, although to a lesser extent, as does red clover extract.  Finally, other 
legumes such as mung beans, and kidney beans contain low levels, as do some 
nuts, and fruits (Bhagwat et al. 2008; Kuhnle et al. 2008; Liggins et al. 2000).  There 
is likely to be variation in preparation techniques and brands used, which will affect 
the ultimate isoflavone content (Fletcher 2003).  Furthermore, within a product, the 
isoflavone content varies over time, possibly due to changes in the cultivar and 
growing conditions of the soy plants (Setchell and Cole 2003).  Despite this, it is 
clear that soy products contain more isoflavones than other sources, by several 
orders of magnitude, and that the method of processing can influence the isoflavone 
content.   Soy based infant formulas are also rich sources of isoflavones, although 
the precise content can vary greatly by brand (Setchell et al. 1997).  Some infant 
formulae can contain up to 30 mg/100g dry (powder) weight (Bhagwat et al. 2008).  
Isoflavones can also pass from a soy-consuming mother to her infant, through 
breast milk (Franke et al. 2006). 
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1.2.2 Intakes of isoflavones 
Soy foods, including tofu and miso, are associated with a “traditional” Eastern-Asian 
diet, such as Japanese, North Korean and some parts of China, and so isoflavone 
intakes are much higher in these populations than in Western countries.  Average 
Eastern Asian intakes have been shown to range between 25 and 50 mg/day 
isoflavones (Arai et al. 2000; Iwasaki et al. 2008; Lee et al. 2009; Shu et al. 2009).  
In these populations intake increases with age and rural location (Messina et al. 
2006).  Consumption of two cups of soy milk, 20g roasted soy beans or 120g tofu 
will provide around 40mg of isoflavones (Zhan and Ho 2005).  
Western countries have lower isoflavone intakes, typically between 0 and 3 mg/day, 
and often highly skewed towards the lower end of this scale (dos Santos Silva et al. 
2004; Grace et al. 2004; Hedelin et al. 2008; Horn-Ross et al. 2002; Linseisen et al. 
2004; Travis et al. 2008; Ward et al. 2010).  This is due, for the most part, to lack of 
familiarity with soy foods and the feeling that they are bland compared to the animal 
products they substitute (Schyver and Smith 2005).  Asian migrants to Western 
countries maintain relatively high isoflavone intakes, although these are higher in 
direct migrants than their descendants, and decrease with increasing length of time 
since migration (Wu et al. 2002).  Vegetarian women (Travis et al. 2008), and 
postmenopausal breast cancer patients (Lammersfeld et al. 2009) are also more 
likely to consume isoflavones than the general population.  In the latter group, use of 
isoflavone supplements can lead to intakes of over 100 mg/d isoflavones.  Only a 
very few in Asian countries achieve this level through diet alone. 
In Western countries soy foods such as tofu and miso are available, but they are not 
consumed widely beyond small sub-groups of the population.  For most European 
and American consumers the soy in their diet comes from other sources.  Small 
quantities of isoflavones are consumed in other (non-soy) legumes and vegetables.  
However, the bulk of isoflavone consumption for these populations can be split into 
two categories: ‘second-generation soy foods’, and ‘hidden’ soy ingredients 
(Fletcher 2003).  The first category largely comprises soy analogues of familiar 
Western foods, particularly dairy and meat products, such as milk, yogurt, cheese, 
sausages and bacon.  These are sold as lactose-free, healthier, or vegetarian 
alternatives, again to small, defined groups within the population.  The second 
category is where soy derivatives are used in manufactured foods often for 
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economic or technological reasons, such as soy flour in bread to improve the quality 
of the loaf, and texturised soy protein (texturised vegetable protein) as a meat 
extender.  In particular this latter group of foods makes dietary analysis of isoflavone 
intake in the West difficult due to the unavailability of sufficient data (Fletcher 2003; 
Horn-Ross et al. 2000). 
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1.2.3 Bioavailability and metabolism 
Dietary assessment may not provide an accurate picture of physiological isoflavone 
levels due to differences in bioavailability between individuals.  In the plant, the 
isoflavones exist mostly in a glycoside form (genistin, daidzin).  These have 
relatively low oestrogenic activity, but are hydrolyzed by food processing, or gut wall 
enzymes and gut bacteria into their aglycone forms (genistein, daidzein), with 
greater activity (Kano et al. 2006; Peterson et al. 1998).  The bioavailability (based 
on plasma levels of genistein and daidzein up to 48 hours after ingestion) is 
comparable regardless of whether the aglycone or glycoside forms are consumed 
(Zubik and Meydani 2003).  In general, studies have shown that daidzein is more 
bioavailable that genistein, but that between individuals absorption can vary greatly 
depending on the gut bacteria present (Xu et al. 1995; Xu et al. 1994).   
In the human liver and intestine a large proportion (as high as 99%) of these 
aglycones are further conjugated to glucuronic or sulphate (Bloedon et al. 2002; Gu 
et al. 2006; Peterson et al. 1998; Setchell 1998; Setchell et al. 2011).  In addition to 
modification by gut enzymes and microflora, the ratio of glycosides, aglycones and 
conjugates can be altered by cooking and processing method (Coward et al. 1998).  
This is of particular significance for equol, a metabolite of daidzein.  Its formation is 
entirely dependent on gut microflora (germ-free animals and human infants do not 
produce it), and 30-50% of human adults do not excrete it (Setchell et al. 2002).  
The precise bacteria and reasons behind this are unclear.  There is evidence of 
further metabolism of these metabolites into other forms, and deconjugation back 
into the aglycones (Yuan et al. 2012).   
Many of these have been found to have biological effects of their own.  Equol acts in 
a similar, although more oestrogenic, manner to genistein and daidzein (Setchell et 
al. 2002).  The glucuronides of genistein and daidzein are less oestrogenic than 
their aglycone counterparts, but can activate human natural killer cells (Zhang et al. 
1999).  Sulfate 4’- and 7-conjugation of genistein and daidzein also reduced the 
oestrogenic capacity of the parent compounds (Pugazhendhi et al. 2008). 
A supplementation trial in healthy postmenopausal women (n=24) found that the 
plasma half-life of free (unconjugated) genistein and daidzein to be relatively short, 
averaging at 3.8 and 7.7 hours respectively (Bloedon et al. 2002).  The half-life for 
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total genistein and daidzein (including metabolites) was found to be slightly longer 
(10.1 and 10.8 hours respectively for genistein and daidzein).  However, in each 
case the range of values measured was large, varying from 1.7 to 21 hours between 
individuals.  A parallel intervention in a group of 30 men of comparable age 
produced similar results (Busby et al. 2002).  This argues against progressive 
accumulation of these isoflavones upon repeated consumption.   
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1.2.4 Biomarkers of intake 
Due to the difficulties associated with measuring intake, urine or plasma isoflavone 
levels are frequently used as biomarkers of intake.  They are relatively non-invasive, 
and a variety of assessment methods have been used, including gas 
chromatography-mass spectrometry (GC-MS) and High Pressure Liquid 
Chromatography (HPLC).  Unlike the dietary assessment methods, serum and urine 
measurements are found to be consistent and reproducible (Zeleniuch-Jacquotte et 
al. 1998).  In addition, they correlate well with the results of dietary assessment 
(Grace et al. 2004; Lampe 2003; Verkasalo et al. 2001; Wu et al. 2004).  
Furthermore, 24 hour urinary isoflavone levels correlate strongly with plasma values 
(Arai et al. 2000; Grace et al. 2004), and with dose in supplementation interventions 
(Perez-Jimenez et al. 2010).  Age and gender had no significant effect (Kunisue et 
al. 2010).   
Mean plasma levels of genistein and daidzein from Western populations consuming 
low levels of isoflavones are typically beneath 10nM (Adlercreutz et al. 1993; Grace 
et al. 2004; Piller et al. 2006; Verheus et al. 2007; Verkasalo et al. 2001; Wu et al. 
2004).  As with the dietary intakes, this remains highly skewed towards the lower 
end of the scale.  Plasma levels measured in Eastern-Asian, high soy consuming 
populations were several orders of magnitude higher, with the mean level typically 
between 0.1 and 1µM for both genistein and daidzein (Adlercreutz et al. 1993; Arai 
et al. 2000a; Iwasaki et al. 2008).  UK women consuming a high soy diet achieved 
comparable mean levels to these Eastern Asian individuals (Verkasalo et al. 2001).  
Concerningly, American (caucasian) infants four months old fed exclusively on soy-
based infant formulae had particularly high mean plasma isoflavone levels of over 
1µM (Setchell et al. 1997).  As the safe high doses have been determined 
historically, based on traditional eastern-Asian diets in adults, this could have 
implications for the reproductive development of these infants (see section 1.2.6). 
While blood or urine samples are relatively non-invasive to collect, it may be the 
case that the effects of isoflavones in breast cancer are related specifically to their 
levels in the breast.  Nipple Aspirate Fluid is secreted into the breast ducts 
continuously in non-pregnant and non-lactating women.  It can be collected, and 
may better reflect hormone and isoflavone levels within the breast than serum 
concentrations.  However, to date there has been very little research in this field, 
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participant numbers were small, drop-out rates were high, and the results are 
contradictory (Hargreaves et al. 1999; Maskarinec et al. 2008).  Additionally these 
results still do not inform directly about the distribution of isoflavones within breast 
epithelial tissue. 
Among two groups of women taking soy or isoflavone supplements (between 50 and 
70mg isoflavones per day) or a placebo for five days prior to undergoing elective 
breast reduction surgery, no significant relationships were seen between the 
serum/urine levels of isoflavones, and the levels detected in the breast tissue 
(homogenised), breast adipocytes, or mammary gland epithelial cells (Bolca et al. 
2010; Maubach et al. 2004).  However as before, numbers were small, and there 
were problems with compliance.   
Overall, the only conclusion that can be drawn from these studies is that further 
investigation is required to establish whether serum and urine concentrations of 
isoflavones correlate with tissue levels, and if tissue levels reflect dietary exposure 
at all.  Studies suffer from low numbers, large inter-individual variation in 
bioavailability, differences in the length of time from supplementation to sampling, 
varied dosing regimens, and differing formulation of the supplement given (i.e. ratio 
of glycoside:aglycone, or genistein:daidzein).  In addition, due to the invasive nature 
of the investigations, these studies suffer from a high level of recruitment bias.  
Considerably more research is required to determine whether isoflavones 
accumulate in the breast tissue, and if so, whether this is limited to discrete regions. 
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1.2.5 Health benefits of isoflavones 
Evidence exists suggesting that isoflavones could provide benefits for numerous 
health conditions.  Most of the protective effects of isoflavones against 
cardiovascular disease (CVD) are related to their ability to improve lipid profiles.  
There is considerable evidence, including a number of recent meta-analyses, 
suggesting that intake of soy or isoflavones lowers serum total and low density 
lipoprotein (LDL) cholesterol, may reduce serum triglycerides, and can increase high 
density lipoprotein (HDL) cholesterol (Taku et al. 2007; Zhan and Ho 2005).  
Together these changes lower both the total:HDL and LDL:HDL cholesterol ratios, 
reducing CVD risk.  Additionally, these effects are much greater in 
hypercholesterolemic individuals than in healthy adults.  Animal studies, including 
those using primates, have yielded similar results (Anthony et al. 1998). Based on 
data such as these, the US Food and Drugs Administration made the health claim 
that foods containing at least 6.25g of soy protein per serving could be of benefit to 
heart health (Food and Drug Administration 1999).  The cardio-protective role of 
isoflavones may be supported by their antioxidant effects, reducing oxidative DNA 
damage and lipid oxidation (Djuric et al. 2001; Wiseman et al. 2000) although results 
of other groups are contradictory (Heneman et al. 2007; Vega-Lopez et al. 2005). 
The evidence that isoflavones could protect against osteoporosis is inconclusive.  A 
number of studies have demonstrated that isoflavones, either habitual dietary or 
supplemental, can attenuate femoral and spinal bone loss in peri- and post-
menopausal women (Alekel et al. 2000; Mei et al. 2001; Ye et al. 2006).  However, a 
recent meta-analysis shows little overall effect after several months of 
supplementation with an average of 56mg isoflavones on markers of bone turnover 
in this population (Taku et al. 2010).  Likewise, evidence for similar effects in 
premenopausal women is contradictory (Ho et al. 2001; Mei et al. 2001).   
There is a suggestion that isoflavones may be protective against other endocrine 
cancers such as prostate cancer in men.  Urinary excretion of isoflavones, in 
particular daidzein, was significantly lower in prostate cancer cases than controls 
(Park et al. 2009).  In prostate cancer cell lines genistein down-regulates growth and 
survival genes such as survivin, DNA topoisomerase II and cell cycle progression 
genes (Suzuki et al. 2002).  In addition, isoflavone supplementation reduced 
Prostate Specific Antigen (PSA) levels in prostate cancer patients (Hussain et al. 
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2003).  However, many human dietary studies have failed to show a link between 
dietary isoflavones and prostate cancer (Park et al. 2008; Ward et al. 2010). 
In the last decade there have been a number of large and well designed studies 
looking into the effects of HRT on breast cancer risk (Beral 2003; Chlebowski et al. 
2003).  These showed conclusively that current and recent use of HRT, regardless 
of the specific oestrogens and progestins prescribed, increased risk of breast cancer 
and delayed diagnosis.  The latter trial was very publicly halted before completion 
due to safety concerns.  This had a dramatic and immediate effect on HRT use, with 
current users discontinuing, and less new users (Kim et al. 2005).  Upon breast 
cancer diagnosis, HRT use is now contraindicated (NICE 2009b).  This is of 
particular significance, since breast cancer chemotherapy can often induce 
menopause (Smith and Chua 2006a).   
In light of this, many studies have been conducted looking into the effectiveness of 
plant extracts as ‘safe’ and ‘natural’ ways to treat menopausal symptoms, including 
soya isoflavone extracts.  One small study found that soy isoflavone 
supplementation (60 mg/day for 3 months, n = 51) reduced hot flushes and night 
sweats (Cheng et al. 2007).  However, on the whole there is little evidence with 
regard to isoflavone remedies, with comparison between studies difficult due to trials 
providing limited data, and suffering from methodological shortcomings such as 
being underpowered or lacking control groups.  It is generally agreed that there are 
few side effects to isoflavone supplementation, unless a very large dose is taken 
long-term (150 mg a day for five years).  However, the effects of isoflavones on 
menopausal symptoms appear minimal or non-existent (Low Dog 2005; Tice et al. 
2003; Van Patten et al. 2002).  Due to their possible oestrogenic effects, and little or 
no evidence supporting their efficacy, soy or isoflavones are currently not 
recommended for treatment of menopausal symptoms in women with, or survivors 
of, breast cancer (NICE 2009b). 
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1.2.6 Isoflavone toxicity 
Epidemiological evidence suggests that dietary levels of isoflavones are safe for 
humans.  In addition, a supplementation intervention where women consumed a 
single genistein dose of 2, 4, 8 or 16 mg/kg body weight (approximate total genistein 
intakes of from 100 to 1000mg), resulting in plasma levels peaking at approximately 
10µM and 0.1µM total and free (unconjugated) genistein respectively, found that 
there was no change in lymphocyte apoptosis 24 hours after supplementation, and a 
slight (non-significant) drop in blood pressure observed in one group (Bloedon et al. 
2002).  Despite observing several isolated cases of pedal oedema and breast 
tenderness, they concluded that there was very minimal clinical toxicity as a result of 
this treatment.  The long term toxicity of these doses in women is not known. 
The feeding of soy formulas to infants is a relatively new practice, and little is known 
about its long term safety.  However, preliminary data from an American longitudinal 
prospective study of around 300 children suggests that all formula fed infants, 
regardless of whether it is soy or milk-based, grow and develop normally (Badger et 
al. 2009).  Similarly, Gilchrist et al. (2010) found no evidence that soy formula 
feeding produces any oestrogenic effects on the reproductive organs of four month 
old infants. 
Toxicity studies in rats suggest that pharmacological doses of 1000x higher than a 
typical Japanese isoflavone intake (calculated as mg per kg body weight) reduced 
adult body weight and slightly altered reproductive development, although did not 
affect fertility (Guan et al. 2008; Lamartiniere et al. 2002). This raises some 
concerns about the safety of high dose isoflavone supplementation, especially in 
women of child bearing age, as a safe upper dose is yet to be established.   
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1.3 Isoflavones and breast cancer risk in vivo 
1.3.1 Human epidemiological evidence 
The possible protective effect of soy and isoflavones originated from epidemiological 
studies which consistently showed lower rates of breast cancer among women in 
Eastern Asian countries than in the West (Parkin et al. 2002; Parkin et al. 2005).  
The most recent data available estimates that in Western Europe in 2008 the rate of 
breast cancer incidence (age standardized per 100 000 population) was 89.9 while 
in Eastern Asia the rate was 25.3 (Jemal et al. 2011).  Evidence that this might be 
related to lifestyle rather than genes comes from numerous sources.  Migration 
studies demonstrated that when Asian women moved to the West, their breast 
cancer rates increased quickly with each successive generation born in the new 
home country (Ziegler et al. 1993).  This suggests that exposure to a Western 
lifestyle and environment, including reduced consumption of soy, is responsible.  
Additionally, since the 1970s many Eastern Asian countries such as South Korea, 
and more recently China, have rapidly become ‘Westernised’ in terms of their 
economies, lifestyle and diets.  This has brought with it an increase in saturated fat 
intake, and a fall in use of cereals, with animal products replacing soy as the main 
dietary protein.  In parallel, their breast cancer rates have quickly risen to near-
Western levels (Kim et al. 2000; Popkin and Du 2003).  It is important to note that in 
a Western lifestyle, soy is a marker for a healthier lifestyle, with lower energy intake, 
less saturated fat, and more fruit and vegetables, not smoking (Nechuta et al. 2012).   
There have been many studies looking for an association between isoflavone intake 
and breast cancer.  However, comparison is difficult, and should be interpreted with 
caution, since they are often highly variable in the population studied, exposure 
measures and the level of controlling for confounders.  Study design varied, with 
some being prospective cohorts, some nested case-controls, and some population- 
or hospital-based case-controls.  A number of the studies have stratified their results 
according to menopausal status or the oestrogen receptor status of the tumour, but 
this has been carried out inconsistently.  In addition, in many of the studies the 
subgroups had relatively small numbers of breast cancer cases, meaning that the 
results may have occurred by chance.   
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These studies have been collated in a meta-analysis carried out by Trock et al. 
(2006). This review of 23 studies reported an overall significant, although slight, 
inverse association between soy intake and breast cancer risk (odds ratio, OR = 
0.86, 95% confidence interval (CI) = 0.75 to 0.99).  They found that this inverse 
association was stronger for breast cancers diagnosed premenopausally (OR = 
0.70, 95% CI = 0.58 to 0.85) than post menopausal women (OR = 0.77, 95% CI = 
0.60 to 0.98), and similarly was stronger among women from Western countries 
(including two studies of Asian Americans; OR = 0.84, 95% CI = 0.70 to 1.00) than 
in Asian women (OR = 0.89, 95% CI = 0.71 to 1.12).  However, the latter two odds 
ratios did not differ significantly.  It is possible that the slightly greater inverse 
association between soy intake and breast cancer risk in Western women may be 
because soy intake in Asian countries is fairly universal, and that even low intake 
(which is similar to high Western intakes) may be enough to reduce risk.  
Alternately, in Western countries soy intake may act as a marker for other risk 
reducing behaviour. 
A more recent publication described a separate meta-analysis for the Asian (n = 8) 
and Western (n = 11) studies (Wu et al. 2008), as each set of populations possess 
distinct lifestyle characteristics relating to breast cancer, and consume very different 
amounts and sources of soy, which may reduce the value of any direct comparison.  
Their findings contradicted those of Trock et al. by proposing a significant protective 
effect of consuming high levels of soy in Asian but not Western populations.  Among 
Asian consumers, compared to the lowest level of soy food intake (≤ 5 mg/day 
isoflavones), breast cancer risk was intermediate (OR = 0.88, 95% CI = 0.78 – 0.98) 
for those with modest isoflavone intake (around 10 mg/day) and lowest (OR = 0.71, 
95% CI = 0.60–0.85) among those with high isoflavone intake (≥20 mg/day).  In 
contrast, the 11 Western populations (with average highest and lowest soy 
isoflavone intakes of 0.8 and 0.15 mg/day) included in the analysis demonstrated no 
relationship between isoflavone intake and breast cancer.  However, it must be 
noted that this meta-analysis excluded much of the prospective cohort data 
available, on the grounds that they contained an insufficient level of detail about the 
soy foods consumed.  Much of the remaining evidence came from case-control 
studies.  Additionally, and perhaps significantly, Wu et al. included Asian American 
women in the Asian group, and not the Western group.  The result is that while a 
relationship between soy intake and breast cancer risk can be proposed, inferences 
regarding the mechanism must be interpreted with caution. 
22 | P a g e  
 
Although data is limited, where the results have been stratified according to the 
oestrogen receptor status of the tumour, protective effects of isoflavones have been 
limited to the ERα+ subgroup, having no effect on ERα- tumours, although 
individuals in this group may have tumours expressing ERβ (Linseisen et al. 2004; 
Suzuki et al. 2008).   
Interestingly, these groups and a third meta-analysis reporting similar findings (Dong 
and Qin 2011) did not observe any dose-response relationship associated with soy 
intake and breast cancer risk, other than that reported as the difference between 
high and low intakes.  This may relate to the study designs used, and a limited 
number of eligible studies for each meta-analysis, or it could imply a threshold 
isoflavone level is required for protective effects to be seen. 
High intake of soy isoflavones has been associated not only with reduced risk of 
breast cancer, but also reduced breast cancer mortality (Zhang et al. 2012).  
Although they did not find a linear relationship between soy intake and mortality, 
they suggested that intakes above 17.3mg isoflavones per day might reduce 
mortality by 36% (n = 616 breast cancer cases), after adjusting for other factors 
which may have an influence such as age, smoking, alcohol consumption, physical 
activity and treatment regime. 
In humans, there has only been one occasion where a significant relationship 
between high urinary and serum isoflavones (equol and daidzein) and increased 
breast cancer risk has been observed in a prospective (UK) cohort (Grace et al. 
2004).  They determined the log2 odds ratios (where the risk estimates represent a 
doubling in phytoestrogen exposure) to be 1.220 (1.005–1.481; p = 0.044) and 
1.455 (1.051–2.017; p = 0.024) for serum daidzein and equol respectively.  The 
effect of genistein did not achieve statistical significance.  However, this study 
included a small number of breast cancer cases (n = 114 out of 333 women) 
increasing the chance that the results were coincidental.   
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1.3.2 Adolescent isoflavone intake 
Several studies have looked retrospectively at adolescent soy intake in women of 
different backgrounds (Shu et al. 2001; Thanos et al. 2006; Wu et al. 2002).  In a 
case-control study of Chinese (Shanghai) women with 1459 cases of breast cancer 
and 1556 controls, adolescent soy intake was found to be inversely associated with 
breast cancer risk, with ORs for the second to the highest quintiles of soy intake 
compared to the lowest reported as 0.75 (95% CI, 0.57– 0.93), 0.69 (95% CI, 0.55– 
0.87), 0.69 (95% CI, 0.55– 0.86), and 0.51 (95% CI, 0.40–0.65) respectively (p for 
trend < 0.001; Shu et al. 2001). Similar ORs were reported for breast cancer 
diagnosed both pre- and postmenopausally.  Adolescent soy intake was assessed 
by FFQ, with measures for portion size as well as frequency, of intake of 17 soy 
food ingredients or food groups.  This group attempted to control for confounding 
issues arising from recall of historical diet by assessing not only self reported 
adolescent intake, but also using the same FFQ with mothers of study participants 
(where possible) regarding their daughter’s adolescent intake.  Significant 
correlations were reported between maternal and self reported adolescent soy 
intakes among both cases and controls. 
Similar ORs were reported for Asian American women (Los Angeles; Wu et al. 
2002) and white Canadian women (Thanos et al. 2006).  This reduction in risk is 
independent of adult isoflavone intake, and the effects combine additively, leading to 
the greatest reduction in risk among women with high adult and adolescent intakes 
(Wu et al. 2002). 
It is thought, through work in rats and mice, that in prepubertal mammary tissue, 
genistein upregulates the epidermal growth factor (EGF) signaling pathway, 
promoting differentiation and proliferation.  The resulting adult mammary cells 
experience reduced proliferation and less EGF signaling, and the adult tissue has 
more lobules and branching, and fewer terminal end buds, rendering it less sensitive 
to carcinogens (Brown et al. 2010; Lamartiniere et al. 1998; Rowell et al. 2005). In 
humans, self reported high soya or isoflavone intake, over the long term, is 
associated with reduced mammographic parenchymal patterning (a function of the 
breast density and structure) and consequently, reduced breast cancer risk (Jakes 
et al. 2002; Maskarinec et al. 2004; Ziv et al. 2004).   
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There have been no studies to date considering the impact of maternal soy 
consumption during pregnancy, and subsequent breast cancer risk in the female 
offspring.  However, due to the ability of isoflavones to modify the hormone 
environment (see Section 1.3.4) it is possible that they can alter the oestrogen 
environment in utero.  Furthermore, a study of maternal and neonatal isoflavone 
levels during birth found comparable total and individual isoflavone levels in the 
plasma of the mother (Japanese women aged 20 to 30 years, n = 7), umbilical cord, 
and amniotic fluid, suggesting that isoflavones can freely pass the placental barrier 
and may influence development of the foetus (Adlercreutz et al. 1999).   
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1.3.3 Contradictory results from animal studies  
There are numerous studies showing the protective effects of isoflavone feeding 
(between 50 and 250 mg/kg diet) or treatment (intraperitoneal injection) on both 
chemically induced and spontaneous mammary tumours in rats, and xenografts in 
mice.  In each of these studies isoflavones have reduced tumour size, latency, or 
aggressiveness, although they have had little or no effect on tumour incidence rate 
(Gallo et al. 2001; Garvin et al. 2006; Hewitt and Singletary 2003; Jin and 
MacDonald 2002; Kang et al. 2009; Moon et al. 2008).   
Interestingly, dietary genistein or daidzein (200 mg/kg diet) alone or combined (100 
mg/kg each) had very little in the way of chemoprotective effects on 
dimethylbenzanthracene (DMBA)-induced mammary tumours in female Sprague-
Dawley rats (Constantinou et al. 2001).  However, in the same study, a soy protein-
containing diet reduced tumour number, weight, incidence and latency.  This diet 
had similar isoflavone content to the above diets, each resulting in serum genistein 
and daidzein levels of around 1µM.  This suggests that it was some other 
unforeseen component of soy that was responsible for the protective effect in this 
case.  It is important to note, that in this, and many of the previously mentioned 
studies, soy/isoflavone feeding and tumour induction began when the mammary 
tissue of the rats was fully developed, so any protective effects seen were on mature 
breast tissue, and not in the tissue differentiation and development stage.  
Furthermore, the mouse models used implanted tumours, such as MCF7, so do not 
provide any information regarding the transformation of normal breast tissue into 
tumours.    
A recent study suggested that feeding a regimen to neonatal and prepubertal female 
Sprague-Dawley rats (via lactating dam) of equol or genistein (250 mg/kg diet) 
resulted in significantly altered regulation of 23 proteins involved in a range of 
pathways including metabolism, structure, motility, cell cycle control and transport at 
either (or both) 21 (prepubertal) and 50 days (young adult) post partum, again for 
female Sprague-Dawley rats (Wang et al. 2011).  This group found that prepubertal 
genistein significantly reduced proliferation (determined by K i67 antigen staining) in 
the 50 day old rat mammary gland, although not at 21 days.   
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In addition, a study by Brown et al. (2010) suggests that neonatal or prepubertal 
exposure of rats to equol (250mg/kg diet) resulted in a significant increase in the 
differentiation of mammary tissue (i.e. a greater number of mature lobules and 
significantly reduced numbers of immature terminal end buds) which should confer 
protection against carcinogens.   
However, numerous groups failed to demonstrate any long term protective effect of 
isoflavones in female rats against chemically induced breast tumour development 
(Brown et al. 2010; Cohen et al. 2000; Ueda et al. 2003).  In addition, under certain 
experimental conditions soy isoflavones stimulated the growth of oestrogen-
sensitive breast tumours in rodents due to their oestrogen-like effects.   Ju et al. 
(2001) found that the growth of implanted ERα+ MCF7 breast cancer cells in mice 
was promoted in an oestrogenic manner by dietary genistein between 125 and 1000 
mg/kg diet (resulting in serum levels between 0.39 and 3.36 µM).  Similar results 
were also seen in mice with dietary isoflavones (Allred et al. 2001) and E2 or 
chemically induced (MNU: 1-methyl-1-nitrosourea) mammary tumours in rats (Allred 
et al. 2004; Ju et al. 2001; Singh et al. 2010).   
Concerningly, the inhibitory effect of tamoxifen on E2-induced implanted MCF7 
tumours in ovariectomised athymic mice was abrogated by genistein feeding (250 or 
500 p.p.m. in their standard diet) (Du et al. 2012).  The serum levels of genistein and 
its metabolites that this regimen led to was not determined, but the higher dose used 
(1000 p.p.m.) did not interfere with the inhibitory tamoxifen effect.  This echoes the 
biphasic effect of isoflavones on breast cancer cell proliferation often seen in vitro 
(see Section 1.4).  Similar results were seen in earlier studies, also using this model 
(Ju et al. 2002; Liu et al. 2005).  In this case they determined the total (conjugated 
and aglycone) plasma genistein after four weeks of feeding to be between 4 and 5 
µM (Ju et al. 2002), and again, the treatments began when the mice were adult.  
On the contrary, a study looking DMBA induced mammary tumours in rats (female 
Sprague-Dawley) found daidzein to improve the tumour-preventing capacity of 
tamoxifen (Constantinou et al. 2005).   Again, the study began once the rats were 50 
days old, so only looked at the effects of isoflavones on adult breast tissue.  
Daidzein or genistein were provided in the diet (140 and 105 mg/kg diet) as was 
tamoxifen (0.125 mg/kg diet), and serum levels of total genistein, and total daidzein 
and equol, were determined to be approximately 0.5µM after prolonged feeding.  
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Tamoxifen was found to reduce tumor multiplicity, latency and weight, and as 
before, genistein slightly reduced the efficacy of tamoxifen.  However, daidzein 
alone was slightly beneficial, and the combination of daidzein and tamoxifen 
resulted in the greatest protection against mammary DMBA-induced carcinogenesis 
in each case.  The relevance of DMBA-induced mammary tumours in rats to women 
is not apparent.  However this result suggests that in terms of their interaction with 
tamoxifen, genistein and daidzein may not act in the same manner. 
Overall, the impact of genistein and daidzein on the development of mammary 
tumours in rat or mouse models of the disease is inconclusive.  In some cases a 
protective effect is seen, but this could depend upon the dose, age upon 
commencement of treatment, and route of tumor induction.  Furthermore, genistein 
and daidzein appear to interact in opposite manners with tamoxifen, and there could 
be other as yet undiscovered elements of a high soy diet that provide protection 
against mammary carcinogenesis to rodents. 
It must be noted that in many cases the doses described which induce the 
proliferation of mammary tumours in rodents are comparable to the protective doses 
used in other rodent studies.  In particular, one study found that while 10 mg/kg 
body weight dietary daidzein increased mammary tumour growth and the level of 
metastasis to other organs of green fluorescent protein tagged MDA-MB-435 
tumours implanted into mice, the same dose of genistein reduced both tumour 
growth and metastasis compared to a vehicle only control (Martinez-Montemayor et 
al. 2010).   
There are a number of major criticisms of rodent models of breast cancer, which 
must be borne in mind when considering these results.  Firstly, murine models of 
breast cancer are rarely hormone responsive, unlike the majority of human cases, 
due to low expression of ERα and PR (Cardiff 2001).  In addition, spontaneous 
murine breast tumours tend to develop while the mouse is fertile, which again differs 
from human breast cancer.  Finally, the mouse tumours are known to develop and 
metastasise differently than the human variants.  With regard to NMU induced 
tumours, their validity compared to human breast tumours has been assessed by 
comparative gene expression profiling (Chan et al. 2005).  Of the 25 NMU-induced 
tumours assessed, they were found to be largely ERα+, and not invasive or 
metastatic.  They were most similar to non-invasive human ERα+ breast tumours of 
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a low or intermediate grade.  This suggests that this model may be of some value 
when considering the impacts of isoflavones upon this type of breast cancer, but the 
results should not be generalized. 
A number of other criticisms can be leveled at these rodent isoflavone studies which 
may be the cause of this inconsistency.  These are described in detail by Messina 
and Wood (2008) but will be summarized here.  Firstly, numerous rodent studies 
used doses of isoflavones of over 50 times higher than is found in traditional Asian 
diets, and many injected purified isoflavones directly into the animals.  Both result in 
comparatively higher serum levels that are found in humans.   
In addition, while the levels used in animals are based on doses known to induce 
oestrogenic effects in these animals, the corresponding level in humans is unknown 
despite years of investigation.  In order to investigate oestrogenic effects of 
isoflavones ovariectomised animals are frequently utilized, to minimize the impact 
endogenous oestrogens.  Consequently, these animals have considerably lower 
circulating levels of oestrogens than postmenopausal women, meaning that the 
effect seen is of isoflavones in an oestrogen-depleted environment, of questionable 
physiological relevance.  Primate or human models would generate more 
representative results, but both bring ethical concerns and complications. 
Finally, the rate of isoflavone absorption and metabolic profile of soy isoflavones is 
strikingly different between species (Gu et al. 2006; Setchell et al. 2011).  Both the 
extent of isoflavone metabolism, and the range of metabolites detected after a 
comparable soy meal fed to human women, and female Sprague-Dawley rats, 
Hampshire/Duroc Cross pigs and cynomolgus monkeys differed (Gu et al. 2006).  
Presumably mice would metabolise isoflavones differently to humans also.  Of the 
species tested, pigs provided the closest metabolite profile to humans, although 
even then there were considerable differences noted.  This implies that soy feeding 
of rodents would not generate a human-like profile of isoflavone metabolites, and 
consequently the implications for breast cancer incidence, proliferation and 
protective mechanisms may not be the same, and the relevance of inter-species 
comparison of specific dose-effects is limited.   
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1.3.4 Human isoflavone supplementation trials and breast cancer risk 
factors 
Increased mammographic density is a risk factor for breast cancer (Ziv et al. 2004).  
It has been shown that self reported high levels of soy intake, determined by FFQ, is 
associated with higher breast density in a study of over 500 pre- and post-
menopausal women (Maskarinec and Meng 2001).  The same effect was found with 
recalled lifetime soy intake (Maskarinec et al. 2004).  However, in three separate 
interventions this group found no significant effect of a range of daily isoflavone 
supplement doses from 50 to 100 mg/day over one or two years in pre- or post-
menopausal women (Maskarinec et al. 2003; Maskarinec et al. 2004; Maskarinec et 
al. 2009).  These results offer some reassurance that isoflavone supplements may 
not increase breast density.  On the other hand, it is possible that the adult and 
lifetime intakes of soy described by Maskarinec et al. (2001; 2004) are markers for 
adolescent intakes, which could modify breast development and consequently 
increase risk.   
Another three interventions are described where women of varying age, 
menopausal status, and breast cancer status, underwent an exploratory breast 
biopsy before and after a period of isoflavone supplementation with doses ranging 
from 36 to 200 mg/day, and durations between two weeks and three months (Cheng 
et al. 2007; Hargreaves et al. 1999; Sartippour et al. 2004).  None of these groups 
reported any change in breast epithelial cell proliferation as a result of the 
supplementation intervention.  A study of premenopausal women suggested that 
isoflavone supplementation (n = 14, 45mg isoflavones daily for 14 days) enhanced 
proliferation of non-malignant breast cells, and increased expression of 
progesterone receptors and the number of cells in S-phase (McMichael-Phillips et 
al. 1998).  However, once again numbers were small, and the invasive nature of 
each of these procedures is likely to introduce considerable selection bias.   
Supplementation studies in women have highlighted several other physiological 
mechanisms through which isoflavones may reduce breast cancer risk.  A recent 
meta-analysis has shown that isoflavone supplementation reduces circulating levels 
of luteinizing hormone and SHBG in premenopausal women, although it has no 
significant effects in postmenopausal women (Hooper et al. 2009).  Moreover, 
isoflavone supplementation increased menstrual cycle length by one day due to 
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lengthening of the follicular phase, which reduces overall exposure to the luteal 
phase, where breast tissue proliferation is more rapid due to higher progesterone 
levels (Kumar et al. 2002).  Finally, while no significant effects on overall circulating 
oestrogen levels were seen, isoflavones have been demonstrated to alter the ratios 
of various oestrogen metabolites, increasing the benign 2(OH) forms, while reducing 
the levels of the more carcinogenic 16α (OH)-oestrone and 4(OH)-oestrogens (Xu et 
al. 2000).  
The insulin-like growth factors IGF1 and IGF2 are important regulators of mammary 
gland proliferation at key developmental stages including pregnancy, lactation and 
involution (Hadsell 2003).  Furthermore they are potent mitogens, and both IGF1 
and its associated receptor tyrosine kinase (IGF1-R) play key roles in breast cancer 
cell proliferation, survival, and metastasis (Jin and Esteva 2008).  High levels of 
IGF1 and its main binding protein IGFBP-3 are associated with an increased risk of 
premenopausal breast cancer incidence and mortality (Burgers et al. 2011; 
Renehan et al. 2004).  A two year soy isoflavone supplementation reported no 
significant impact of isoflavone supplementation on IGF1, IGFBP-3, or their molar 
ratio at any point during the intervention (Maskarinec et al. 2005).  In this study 196 
premenopausal Hawaiian women consumed two servings of soy foods daily 
(equivalent to approximately 100mg isoflavones daily) for two years, as a 
replacement for a meat, dairy, or snack food.  Likewise, there was no correlation 
between habitual soy intake and serum IGF1 and IGFBP-3 in a group of 261 
premenopausal Japanese women (Nagata et al. 2003).   
However, one smaller intervention (55 American postmenopausal women) found 
that 10 week supplementation with a powdered soy product (approximately 75g soy 
protein per day; isoflavone content unknown) resulted in a slight, although significant 
increase in serum IGF1 and IGFBP-3 (increased by 21.6 and 154.7 µM respectively, 
p = 0.001 for both), and a reduction in SHBG by 5.4µM (p < 0.001; McLaughlin et al. 
2011).  The implications of this result are unclear, as elevated IGF1 levels do not 
appear to be a risk factor for postmenopausal breast cancer (Renehan et al. 2004). 
Overall, isoflavone supplementation appears safe, and interventions show no 
increased risk of breast cancer.   None-the-less, concerns remain regarding the 
safety of supplements, as isoflavones are known to act oestrogenically, and could 
increase risk of recurrence.   
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1.3.5 Isoflavones and recurrence in breast cancer survivors 
Little is known about the effects of isoflavones on cancer recurrence in breast 
cancer survivors, or regarding how they interact or interfere with the oestrogen 
antagonists used to treat breast cancer, such as tamoxifen.  Animal research gives 
contradictory results (Constantinou et al. 2005; Ju et al. 2002) and human evidence 
is scant.   
However, there exist a number of prospective cohorts where isoflavone intake and 
breast cancer recurrence have been examined.  A pooled analysis of these cohorts, 
where n = 4856 (China) and 4658 (United States) breast cancer cases found a net 
reduction in risk of breast cancer specific mortality (HR: 0.83; 95% CI: 0.64, 1.07) 
and a statistically significant reduction in risk of recurrence (HR: 0.75; 95% CI: 0.61, 
0.92) associated with isoflavone intakes of ≥ 10mg/day (Nechuta et al. 2012).  By 
country, a slight reduction in risk associated with consumption of ≥10mg/day 
isoflavones remained for the Chinese women, although non-significant, but in the 
United States the effect of consumption of this level of isoflavones maintained its 
statistical significance.  
The results of individual cohorts tend to agree (Kang et al. 2012), and furthermore, 
suggest that the reduction in mortality and recurrence seen occurs irrespective of 
anastrozole, an inhibitor of aromatase, a key enzyme in E2 biosynthesis (Kang et al. 
2010) or tamoxifen use (Shu et al. 2009).  Where a protective effect was seen, it 
was stronger among women with ERα+ or PR+ breast cancers, and 
postmenopausal women (Guha et al. 2009; Kang et al. 2010). 
One prospective study (n = 339 breast cancer cases in South Korean women) found 
that high soy of isoflavone intakes increased risk of cancer recurrence in women 
with HER2+ cancer (Woo et al. 2012).   However these increases in risk failed to 
achieve statistical significance, and the numbers with recurring HER2+ cancer were 
very low (n = 8 out of 25 recurrent cases). 
Overall, this data implies that dietary soy may reduce risk of breast cancer 
recurrence, particularly among postmenopausal women diagnosed with ERα+ 
cancers, although its effects in cancers of differing receptor statuses may vary.  
More importantly, these studies suggest no increased risk associated with dietary 
soy intake in breast cancer survivors regardless of endocrine therapy use, and that 
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soy does not appear to abrogate the effects of these therapies.  The use of 
isoflavone supplements in post menopausal breast cancer survivors is currently 
contraindicated in the UK (NICE 2009b) and accordingly, reported supplement 
usage amongst this group is low.  Likewise, the level reported in an American cohort 
(n = 1954) was 2.7% (Guha et al. 2009), and 4% reported isoflavone supplement 
use (soy and/or red clover) in a Canadian (n = 417) group of breast cancer patients 
(Boucher et al 2012).  However, this remains an area where further study is 
required, as very little is known about the effects or safety of isoflavone supplements 
(pharmacological doses) in breast cancer survivors.   
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1.4 Proliferative effects of oestrogen and isoflavones in vitro  
1.4.1 Expression levels of the oestrogen receptors in breast cancer 
cell lines 
In an attempt to understand the mechanisms behind the effects of isoflavones on 
breast cancer risk, there have been many investigations in vitro, typically using the 
human breast cancer cell lines MCF7, T47-D, MDA-MB-231, and several others with 
varying genetic make-up (Table 1.2).  The use of cultured breast cancer cell lines as 
a model for breast cancer will be discussed in section 6.5.2.  It is apparent that 
many of the effects of isoflavones on the growth of cultured cell lines are mediated 
through the ERs.   Where present, oestrogens and isoflavones bind to ERs and 
initiate transcription of oestrogen responsive genes.  Typically, genistein and 
daidzein bind to the ERs dose responsively, with around 100- to 1000-fold lower 
affinity than E2 (Hwang et al. 2006; Sotoca et al. 2008).    
Table 1.2: Expression levels of ERα and ERβ in the breast cancer cell lines 
discussed in this review (Tong et al. 2002) 
Cell line Source1 ERα2 ERβ2, 3 
BT20 Breast carcinoma - + 
BT474 Ductal carcinoma + + 
MCF7 Breast adenocarcinoma, pleural effusion + + 
MDA-MB-231 Breast adenocarcinoma, pleural effusion - + 
MDA-MB-361 Breast adenocarcinoma derived from brain 
metastatic site 
+ + 
MDA-MB-
435(s) 
Melanocyte – previously described as pleural 
effusion, ductal carcinoma 
- + 
MDA-MB-468 Breast adenocarcinoma, pleural effusion - ? 
SK-BR-3 Breast adenocarcinoma, pleural effusion - - 
T47D Ductal carcinoma, pleural effusion + + 
ZR75-1 Ductal carcinoma,  malignant ascitic effusion  + + 
1 References (Health Protection Agency 2012; LGC-ATCC 2012) 
2 (Tong et al. 2002) 
3 Refers to ERβ1 expression, the full length isoform (Moore et al. 1998) 
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In human breast tissue, normal, non-malignant breast epithelial cells are significantly 
more likely to be ER-, or solely express ERβ, than cells from malignant breast tissue 
which frequently express ERα (Speirs et al. 1999).  The levels of the two ERs differ 
between cultured breast cancer cell lines (Table 1.2).  Along with the majority of 
breast cancers, MCF7 cells express both ERs, although with much lower levels of 
ERβ mRNA (Kurebayashi et al. 2000; Le Corre et al. 2004; Tong et al. 2002; Yuan 
et al. 2012).  Similarly, ER+ T47D and BT474 cells express both receptors (Lattrich 
et al. 2011; Strom et al. 2004; Yuan et al. 2012).  In MDA-MB-231 breast cancer 
cells, traditionally thought to be ER-, expression of ERα is absent but low level ERβ 
expression occurs (Kurebayashi et al. 2000; Lattrich et al. 2011; Rajah et al. 2009; 
Tong et al. 2002).  In breast tumour biopsy samples ERβ protein was also present, 
although at a lower level in most cases than ERα protein (Saunders et al. 2002). 
It is important to note that although the full length ERβ isoform (ERβ1) is the 
dominant form, there exist 4 truncated isoforms, ERβ2, -3, -4 and -5 (Skliris et al. 
2008).  They have varying transcriptional activating ability, and are expressed at a 
range of levels in cancerous tissue and cell lines (Lattrich et al. 2011; Tong et al. 
2002; Wong et al. 2005; Zhao et al. 2007).  Representations of the five isoforms are 
provided in Figure 1.2.  Their expression levels, on the whole, display no clear 
relationship to tumor invasiveness or ERα expression level.  The cell lines MCF7 
and MDA-MB-231 each express the ERβ1, 2, 4 and 5 isoforms (Tong et al. 2002).  
Little is known about the function of the truncated ERβ isoforms.  The full length 
isoform, ERβ1, will be referred to as ERβ throughout this document. 
As with E2, isoflavone treatment can moderate the expression level of numerous 
proteins, including the ERs.  Treatment of MCF7 cells for 48 hours with 25 µM 
genistein reduced the expression level of ERα mRNA (Lavigne et al. 2008).  
Similarly, 24 hour treatment with 1µM genistein or apigenin reduced the mRNA and 
protein levels of ERα in MCF7 (Seo et al. 2006).  However, 48 hour treatment with 
the phytoestrogen resveratrol (30 µM) increased mRNA levels of ERβ in MCF7, 
MDA-MB-231 and a fibrocystic mammary cell line MCF10A (50 µM), although the 
reported increase in MCF7 was non-significant (Le Corre et al. 2006; Le Corre et al. 
2004).  This group found that resveratrol treatment had no impact upon ERα mRNA 
levels in MCF7.   
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Figure 1.2: Known isoforms of human ERβ  
Based on the description by Moore et al. (1998).  The main, wild type, human ERβ 
(ERβ1, 530 amino acids long), and its four isoforms (ERβ2-5), generated by 
alternate exon splicing.  N-D (black bar) represents the N-terminal domain, DBD 
(grey bar) is the DNA binding domain, and LBD represents the ligand binding 
domain.  Of the latter, the white bar represents the conserved LBD sequence, and 
the striped bars show where sequences diverge between the isoforms. 
However, an in vivo study investigating the effect of a soy phytochemical-rich diet on 
MCF7 tumour xenografts in mice showed that the isoflavone diet reduced levels of 
ERα protein (by Western blot), but had no effect on transfected wild-type ERβ 
protein levels (Zhou et al. 2004).  Genistein (up to 30 µM), or E2 (0.01 to 1 µM) 
treatment both increased the levels of the full length and β2 isoforms of ERβ in 
T47D cells, whilst reducing the levels of β5 (Cappelletti et al. 2006).  At the same 
time, quercetin had slight but not significant effects, and only E2 treatment increased 
the levels of ERα present.  Three or six months tamoxifen treatment reduced the 
level of ERα antibody staining observed in tumour biopsy samples from women with 
ERα+ breast cancer (n = 33). However, at the same time, this treatment had no 
impact upon the level of ERβ, or ERβ2 antibody staining (Miller et al. 2006).  
Furthermore, this group found no correlation between ERα, ERβ, and ERβ2 levels. 
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This suggests isoflavones, and other SERMS such as tamoxifen regulate the levels 
of ERα and ERβ differently in these breast cancer models.  There may be an 
additional effect of the type of isoflavones used, or differences post-transcription in 
the transfected mouse model compared to the human colorectal and bovine models 
described previously.  This would require further study to confirm. 
In humans, the presence of ERα remains an important biomarker in breast cancer 
as it indicates a possible beneficial effect to the patient of endocrine treatment, 
although much remains to be determined regarding its precise role in mammary 
development and carcinogenesis (for review see Palmieri et al. 2002).  Studies 
using individual or combined knock-outs of ERα and ERβ in mice have 
demonstrated that the two receptors have different roles in mouse fertility.  These 
two knockout mouse lines, known as αERKO and βERKO respectively, are widely 
used, and their reproductive phenotype is well established.  They both display 
differing sexual behaviour, and both αERKO males and females are infertile, but 
βERKO males have normal fertility, and βERKO females are subfertile to varying 
degrees (Dupont et al. 2000; Hewitt and Korach 2003; Kudwa and Rissman 2012).   
Although the role of ERα and ERβ in mammary development is difficult to measure 
due to the presence of ERβ splice variants, and also the likelihood of ovarian 
disruption which is common in ERKO mice, prepubertally, βERKO female mice 
develop mammary glands which appear normal (Hewitt and Korach 2003).  
However, sexually mature βERKO female mammary glands are less developed with 
less branching than wild type, although often able to function and lactate near-
normally, and have a normal proliferation response upon E2 treatment (Hewitt and 
Korach 2003; Palmieri et al. 2002).  By contrast, αERKO females do not develop 
mammary glands (Hewitt and Korach 2003).  This implies that ERβ has a role in the 
differentiation of the mammary gland during puberty, but is not required for E2-
induced mammary proliferation or pre-pubertal mammary gland formation, while 
ERα has an indispensable role early on in mammary gland development.   
The two receptor subtypes have overlapping and yet unique sets of downstream 
oestrogen responsive target genes, as shown by gene expression profiling 
microarrays (Zhao et al. 2008).  Similarly, gene expression profiling of aortas 
isolated from mice with either ERα or ERβ knockout have shown that while ERα is 
essential for the majority of E2-mediated increases in gene expression, ERβ 
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mediates nearly 90% of E2-induced decreases in gene expression (O'Lone et al. 
2007). 
In human breast cancer cells it is generally agreed that ERα mediates the 
proliferative effects of E2 and isoflavones (Maggiolini et al. 2001), and transfection 
with an antisense ERα gene to silence ERα expression inhibited E2 induced 
proliferation in human BG-1 and 2008 ovarian cancer cells (Albanito et al. 2007). 
Regrettably there have been few quality studies examining the role of ERβ in breast 
cancer, and its role is not fully understood.  Expression of full length ERβ (wild type; 
ERβ1) appears to relate to more aggressive tumor types, such as HER2+ or triple 
negative (ERα-, PR-, HER2-) cancers, and acts as an independent predictor of 
recurrence, but also indicates promising response to endocrine therapy and overall 
survival (Skliris et al. 2008; Speirs 2008).  This positive association with good 
response to endocrine therapy and promising prognosis may relate to the fact that in 
approximately 58% of breast tumours ERβ1 is co-expressed with ERα, or 60% in 
the case of total ERβ (Skliris et al. 2008).  However, a further 18% of all breast 
tumours can be classified as ERα-/ERβ+ (Skliris et al. 2008).  Evidence also exists 
to suggest that ERβ is a tumor suppressor gene: compared to normal or benign 
breast tissue, expression of ERβ is lost or reduced in the majority of malignant 
breast tumours (Rody et al. 2005; Zhao et al. 2003).    
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1.4.2 Techniques for assessing the impact of isoflavones on breast 
cancer cell proliferation in vitro 
Numerous techniques have been used to assess the effect of isoflavones on the 
proliferation of breast cancer cell lines (Table 1.3).  Traditionally, cell counting using 
a haemocytometer with or without Trypan Blue dye has been widely used in this 
field (Maggiolini et al. 2001; Ying et al. 2002).  This method is discussed in detail in 
(Sections 2.2 and 2.3).  However, it is relatively insensitive and open to error (Burton 
2005).  This can be overcome by use of an automated cell counter (Matsumura et 
al. 2005).   
Frequently, labeled thymidine (3H-thymidine) is incorporated into cell growth 
medium, allowing proliferation to be quantified by the degree of incorporation of the 
radioactive label into newly synthesized DNA during cell division (Hwang et al. 2006; 
Kang et al. 2009).  While this method considered valid for this use by some (Burton 
2005), considerable evidence exists suggesting that the presence of the low energy 
β-irradiation emitting tracer can inhibit proliferation, induce apoptosis, and reduce 
DNA synthesis (Hu et al. 2002).   
However, the most widely used method in this subject area is the MTT assay 
(Cherdshewasart and Sriwatcharakul 2008; Liu et al. 2010; Rajah et al. 2009; Theil 
et al. 2011; Umehara et al. 2009; Yang et al. 2010; Ying et al. 2002; Yuan et al. 
2012).  This technique is discussed further in sections 2.4 and 6.11).  Briefly, it 
utilizes a yellow, water soluble dye, 3-(4, 5-dimethylthiazol-2-yl)2, 5-diphenyl 
tetrazolium bromide (MTT), which is metabolized by viable, actively metabolizing 
cells into a purple product.  The intensity of the purple colour can be quantified using 
a spectrophotometer, and directly reflects the number of actively metabolizing cells 
present.  Other groups have used the WST-1 assay (Ying et al. 2002), or the MTS 
assay (Seo et al. 2006), which are related techniques, with slight variations to the 
tetrazolium-type dye used.  The AlmarBlue dye used by Umehara et al. (2009) 
works by a similar mechanism, whereby the stain is metabolized by viable cells into 
a fluorescent product.  
 Table 1.3: Summary of methods used to investigate the effects of isoflavones on breast cancer cell proliferation 
Study Cell line Vehicle (dose used 
for control) 
Proliferation assay Isoflavone 
treatment (days) 
Cherdshewasart 
and Sriwatcharakul 
(2008) 
MCF7 DMSO (2%) MTT 3 
Choi et al. (2009) MCF7 DMSO (x) MTT 1 
Constantinou et al. 
(1998) 
MCF7,        
MDA-MB-468 
DMSO (x) Haemocytometer / Trypan Blue dye 
exclusion 
3 
Davis et al. (2008) MCF7,         
MDA-MB-231 
DMSO (x) CellTiter 96® aqueous non-radioactive 
cell proliferation assay (MTS) 
6  
Ferenc et al. (2010) MCF7,         
MDA-MB-231 
Vehicle unknown -   
Untreated control 
MTT / automated cell counter 1, 2 
Hwang et al. (2006) MCF7 Vehicle unknown (x) Labelled thymidine incorporation 2 
Jacobs et al. (2000) MCF7, T-47D, 
MDA-MB-231 
DMSO (0.2%) MTT 5-14 * 
Jin et al. (2010) MCF7 DMSO (0.1%) MTT 1, 2, 3 
Kang et al. (2009) MCF7,         
MDA-MB-231 
Vehicle unknown (x) Labelled thymidine 3 
  
3
9
 | P
a
g
e
 
 Study   
  
Cell line  Vehicle (dose used 
for control) 
Proliferation assay  Isoflavone 
treatment (days) 
Li et al. (2008) MDA-MB-231 Ethanol (0.1%) MTT 2 
Liu et al. (2010) MCF7,        
MDA-MB-231 
Ethanol (0.1%) MTT 3 
Maggiolini et al. 
(2001) 
MCF7 Vehicle unknown (x) Haemocytometer, MTT 6 
Matsumura et al. 
(2005) 
MCF7 Ethanol (0.1%) Automated cell counter 7, 14 
Peterson and 
Barnes (1996) 
MCF7, T47D, 
BT20, ZR75-1 
DMSO (1%) MTT, labelled thymidine incorporation 4 
Rajah et al. (2009) MDA-MB-231, 
T-47D 
DMSO (0.1%) MTT 3 
Sakamoto et al. 
(2010) 
MCF7 DMSO (x) Colony formation assay 14 
Schmidt, Michna 
and Diel (2005) 
MCF7 DMSO - untreated 
control 
Flow cytometry - % cells in S phase of 
cell cycle 
5 
Seo et al. (2006) MCF7 Ethanol (0.1%) CellTiter 96® aqueous non-radioactive 
cell proliferation assay (MTS) 
2, 3, 6, 8  
Seo et al. (2011) MDA-MB-231 DMSO (0.2%) Haemocytometer 3 
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 Study Cell line Vehicle (dose used 
for control) 
Proliferation assay Isoflavone 
treatment (days) 
Shim et al. (2007) MCF7 DMSO/Ethanol, 1:1 
(0.05%) 
MTT 1 
Shon et al. (2006) MCF7,        
MDA-MB-231 
Vehicle unknown (x) MTT 2, 4, 6 
So et al. (1997) MCF7 DMSO (0.6%) MTT, labelled thymidine incorporation 3 
Song et al. (2007) MCF7 Ethanol (x) Automated cell counter 4  
Theil et al. (2011) MCF7, BT20 Ethanol (1%) MTT, BrdU 1 
Umehara et al. 
(2009) 
MCF7, T47D DMSO (1%) AlmarBlue fluorescence 4 
Yang et al. (2010) MCF7, ZR75-1, 
MDA-MB-435,  
Vehicle unknown (x) MTT 6  
Ying et al. (2002) T47D DMSO (0.1%) WST1, Trypan Blue dye exclusion 1, 2 
Yuan et al. (2012) MCF7, T47D DMSO/Ethanol,    
1:4 (0.1%) 
MTT 3 
Zava and Duwe 
(1997) 
MCF7, T47D, 
MDA-MB-468 
Ethanol (0.1%) Total DNA content (by propidium iodide 
fluorescence assay) 
10 
* Not isoflavones, E2 only; (x) dose for control not given 
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1.4.3 Oestrogen and isoflavones at physiological concentrations 
enhance the proliferation of ERα+ breast cancer cells similarly 
Numerous animal and in vitro studies suggest that E2 induces proliferation in a 
range of mammalian cell types (Dos Santos et al. 2010; Kumar et al. 2010; Miki et 
al. 2009; Ren et al. 2010).  Likewise, in ERα+ breast cancer models such as MCF7, 
ZR75-1 or T47D cells, at its range of physiological concentrations (between 1 pM 
and 10 nM) E2 stimulates proliferation (Davis et al. 2008; Jacobs et al. 2000; Lau et 
al. 2009; Matsumura et al. 2005; Rajah et al. 2009; Schmidt et al. 2005; Song et al. 
2007; Sotoca et al. 2008; Zava and Duwe 1997).  However, E2 (1nM) had no 
significant effect on the proliferation of ERα-/ERβ+ MDA-MB-231 cells (Jacobs et al. 
2000; Rajah et al. 2009). 
Similarly, low doses of isoflavones (ranging from 1 nM to 10 µM, reflecting serum 
levels seen with low to high consumers of soy) induce the proliferation of ERα+ 
breast cancer cells including MCF7 and T-47D dose dependently.  This effect 
occurs with genistein, daidzein, equol, and other isoflavones, although daidzein 
frequently results in a lower magnitude effect than genistein.  This effect of the 
isoflavones is similar to that of E2, although at least 1000-fold higher concentrations 
of isoflavones are required to achieve comparable proliferation (Cherdshewasart 
and Sriwatcharakul 2008; Hendrix et al. 2006; Hwang et al. 2006; Kang et al.  2009; 
Liu et al. 2010; Maggiolini et al. 2001; Matsumura et al. 2005; Rajah et al. 2009; Seo 
et al. 2006; Umehara et al. 2009; Yang et al. 2010; Ying et al. 2002; Yuan et al. 
2012; Zava and Duwe 1997).  Microarray gene expression analysis confirms that 48 
hour treatment of MCF7 cells with 1 or 5 µM genistein elicits gene expression 
patterns indicative of increased mitotic growth (Lavigne et al. 2008). 
A wide range of techniques have been used to generate this information, 
summarized in Table 1.3.  On the whole, broadly similar growth conditions have 
been used in each instance.  These comprise a period of 1 to 3 days oestrogen 
washout prior to treatment, in phenol red free2 growth medium supplemented with 
dextran/charcoal stripped fetal bovine serum (DC-FBS), to eliminate the possibility 
of the oestrogenic content of these components confounding the oestrogenic effects 
                                                 
2
 Phenol red, a pH indicator commonly added to tissue culture medium has a weak 
oestrogenic effect (Katzenellenbogen et al. 1987). 
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seen.  This is followed by isoflavone treatment for between one and 14 days, then 
measurement.  On the one hand the range of methods and time scales used argues 
that the effects of isoflavones on the proliferation of breast cancer cells is 
reproducible regardless of method used, and stands up to scrutiny.  However, as 
different methods have been used, care must be taken when comparing their 
results.   
Notable exceptions are Ying et al. (2002), who conducted their experiments with 
standard media containing phenol red, and Kang et al. (2009) used FBS that was 
not stripped of hormones.  While their results do not appear to differ from those of 
the other groups, the presence of phenol red and standard serum in the media can 
increase the growth rate of MCF7 cells in a weakly oestrogenic manner, and this 
could influence their results (Katzenellenbogen et al. 1987).  
Most groups have compared their treatments to a control treated with the ligand 
vehicle alone: dimethyl sulfoxide (DMSO), ethanol, or a mixture of both.  The 
majority of these groups used these solvents at a dose of 0.1% in the final solution, 
which is unlikely to cause any significant effects.  However, in some cases, 
discussed in further detail in section 6.1.2, the choice and dose of solvent may have 
an impact on cell proliferation.  Furthermore, in several cases it is not apparent 
which solvents and doses were used.    
It is interesting to note that the phase II metabolites of genistein (genistein-7-
glucuronide, genistein-7-sulfate and genistein-4’-sulfate) had very little impact upon 
the proliferation of MCF7 or T47D cells after 72 hour treatment with 5.1nM to 80µM 
doses (Yuan et al. 2012).  However, the overall impact of these metabolites can only 
be guessed at, as the preparations used in this study were not pure.  In addition, this 
group demonstrated that even in the cell lines, genistein was quickly and extensively 
metabolized to these products, and others, which also demonstrated metabolism 
back into the aglycone form.  Based on this, and the low oestrogenic activity of 
numerous of the metabolites compared to the parent aglycones (Pugazhendhi et al. 
2008; Zhang et al. 1999), Yuan et al. concluded that the metabolism of genistein 
had no discernible impact upon its effects on the proliferation of the cell lines tested. 
Concerningly, these proliferation-enhancing concentrations of isoflavones echo the 
circulating levels seen in most European and American women.  However, this 
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growth-enhancing effect is limited to ERα+ cells.  Addition of oestrogen receptor 
blockers such as tamoxifen or ICI 182780, also known as fulvestrant or Faslodex, 
prevents isoflavones from inducing proliferation (Hwang et al. 2006; Liu et al. 2010; 
Maggiolini et al. 2001).  This suggests that isoflavones may act on proliferation 
through the ERs, and are acting as oestrogen agonists.   
Interestingly, tamoxifen (10 nM) also promotes the proliferation of MCF7 breast 
cancer cells (Coiret et al. 2007).  This effect has been shown in a number of ERα+ 
breast cancer cell models, and is associated with the development of tamoxifen 
resistance (Clarke et al. 2001; Keeton and Brown 2005).  Higher concentrations of 
tamoxifen, from 1μM upwards, inhibit the growth of both MCF7 and MDA-MB-231 
breast cancer cells, in addition to a number of human prostate and colon cancer cell 
lines (Abdul et al. 2003; Tanos et al. 2002).  On the contrary, the full oestrogen 
antagonist ICI 182 780 inhibits proliferation and induces apoptosis in MCF7 cells at 
all doses tested between 10 nM and 10 µM (Schmidt et al. 2005). 
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1.4.4 Physiological doses of isoflavones and ERα-/β+ cell proliferation 
As ERα-/β+ cell lines such as MDA-MB-231 have traditionally been regarded as ER-
negative, there has been very little research into the effects of the doses of 
isoflavones known to promote proliferation in an oestrogenic manner (≤ 1 μM).  
However, the few studies identified yield some very interesting results.  Rajah et al. 
(2009) showed that while 1 nM to 1 μM genistein treatment for 72 hours resulted in 
a dose-dependent increase in the proliferation of T47D cells, compared to the 
vehicle (0.1% DMSO) alone, the same regime with MDA-MB-231 cells resulted in 
approximately 20% inhibition of proliferation.  Similar results have been generated 
by Kang et al. (2009) using MCF7 and MDA-MB-231 cells, although with the higher 
dose of 18 μM genistein.  
A different approach was taken by Sotoca et al. (2008).  This group used T47D 
cells, with or without a tetracycline-inducible ERβ gene.   This cell line normally 
expresses ERβ at a relatively low level compared to ERα (Tong et al. 2002).  With 
this low level of ERβ expression, 48 hours of genistein or quercetin treatment (0.001 
to 5 μM) increased proliferation compared to a DMSO only control.  However, 
increasing the expression of ERβ reduced the isoflavone induced enhancement of 
proliferation previously seen.  Similarly, it was found that by artificially increasing 
ERβ levels in a number of ERα-dominant breast cancer models (including MCF7 
and T47D cell culture, and MCF7 tumours implanted into mice) E2 treatment began 
to exert a negative effect on cell proliferation as ERβ expression levels increased to 
match ERα (Chang et al. 2006; Paruthiyil et al. 2004; Sotoca et al. 2008; Strom et 
al. 2004).   A variety of different methods were used in these studies to quantify ERβ 
expression and protein levels, including use of FLAG antibodies, polymerase chain 
reaction (PCR), and quantification of the levels of fluorescence from a luciferase 
reporter gene product stably transfected along with the ERβ gene.  It has been 
hypothesised that ERα mediates the growth promoting effects of physiological levels 
of isoflavones, while through ERβ they act in a growth inhibitory manner, with the 
outcome depending upon the ratio of ERα:ERβ  This will be further discussed in 
section 6.1.5. 
In the apparently ERα-/ERβ- cell line MDA-MB-435, genistein treatment at levels 
between 0.1 and 10 μM had no significant effect on cellular proliferation (Seo et al. 
2006; Yang et al. 2010).  Similar results were also demonstrated with the 
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phytoestrogen apigenin (Seo et al. 2006).  Interestingly, genistein up to 10µM had 
no effect on the proliferation of MDA-MB-435 cells transfected with ERβ (Yang et al. 
2010).   However, the relevance of these results are debatable.  Firstly, a variant of 
this cell line known as MDA-MB-435s is known to express ERβ, calling into question 
its ERβ- status.  Secondly, evidence exists suggesting that this cell line is in fact of 
melanoma origin, not breast (Rae et al. 2007).   
Likewise, genistein treatment at levels up to 10µM had no impact upon the 
proliferation of the breast cancer cell line BT20 (Theil et al. 2011).  They proposed 
this cell line to be ERα-/β-, as it showed no reaction with an ERβ antibody.  
However, ERβ mRNA for a number of the known ERβ isoforms (β1, β2 and β4) is 
present in BT20 cells (Tong et al. 2002).  This discrepancy may relate to post-
transcriptional events, or may be an artefact introduced by the choice of antibody 
used by Thiel et al., and as a result the ERβ status of BT20 remains unclear.   
Similarly, genistein treatment up to and including 1µM had no significant impact 
upon the proliferation of MDA-MB-468 cells (Zava and Duwe 1997).  This cell line is 
known to be ERα-, but its levels of ERβ are not known (Table 1.2). 
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1.4.5 Inhibition of proliferation by isoflavones in breast cancer cells 
The effect of isoflavones on the growth of ERα+ breast cancer cells is biphasic.  At 
higher concentrations (10 µM upwards), similar to the circulating levels in the very 
highest soy consuming Eastern-Asians (Arai et al. 2000), isoflavones are cytotoxic, 
reducing proliferation in MCF7 (Table 1.4), ZR75-1 and T47D breast cancer cell 
lines in a dose responsive manner (Choi et al. 2009; Constantinou et al. 1998; Davis 
et al. 2008; Ferenc et al. 2010; Jin et al. 2010; Kang et al. 2009; Liu et al. 2010; 
Maggiolini et al. 2001; Peterson and Barnes 1996; Sakamoto et al. 2010; Shim et al. 
2007; Shon et al. 2006; Theil et al. 2011; Yang et al. 2010; Ying et al. 2002).   
As with the lower isoflavone concentrations, a wide range of techniques and time 
scales have been used to investigate the impact of this higher concentration range 
of isoflavones on breast cancer cell proliferation (Table 1.4).  Most studies have 
used phenol red free medium supplemented with 10% DC-FBS for the duration of 
their experiments.  Exceptions to this are Liu et al. (2010), who used 5% FBS, and a 
number of groups used standard phenol-red containing medium and 10% FBS for 
experimental treatments (Choi et al. 2009; Ferenc et al. 2010; Seo et al. 2011; Shon 
et al. 2006).   
These differences in protocol make direct comparisons between these studies 
difficult.  Accordingly, the groups propose a wide range of concentrations at which 
genistein ceases to promote MCF7 proliferation, and begins to inhibit it.   In MCF7 
the IC50 (dose required for inhibition of the maximal response by 50%) for the 
inhibition of proliferation by 24 hour genistein treatment has been proposed to be 
27.5µM (Shim et al. 2007).   This figure seems broadly representative of the studies 
described, with the exceptions of Liu et al. (2010) and Yuan et al. (2012) which 
suggest that genistein concentrations vastly in excess of this would be needed to 
see an inhibitory effect on proliferation.  The treatment duration does not appear to 
have an impact upon the concentration of genistein required to inhibit proliferation in 
MCF7.   
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Table 1.4: Inhibition of MCF7 proliferation by genistein, summary of previous 
results 
Study  Lowest genistein conc. at which 
growth inhibition occurs 
Time (days) 
Choi et al. (2009) 3.5µM 1 
Constantinou et al. (1998) 10µM 3 
Davis et al. (2008) 10µM 6 
Shim et al. (2007) 15µM 1 
Yang et al. (2010)  17µM 6 
Kang et al. (2009) 37µM 3 
Ferenc et al. (2010) 50µM 1, 2 
Shon et al. (2006) 50µM 2, 4, 6 
Maggiolini et al. (2001) >10µM* 6 
Sakamoto et al. (2010) >10µM* 14 
Liu et al. (2010) >50µM* 3 
Yuan et al. (2012) >80µM* 3 
* Proliferation at these concentrations was still greater than with the control 
treatment, although it had peaked at a lower concentration and was dropping. 
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Microarray gene expression analysis has shown that 48 hour treatment of MCF7 
cells with 25 µM genistein results in a reduced proliferative gene expression profile 
(Lavigne et al. 2008).  However, often the isoflavone doses used are very high, up to 
150 μM.  These doses are not achievable in the blood through diet alone, making 
their physiological relevance questionable.   
Where daidzein has been used the effect is comparable (Jin et al. 2010; Ying et al. 
2002), although possibly slightly higher concentrations may be required to have the 
same effect (Constantinou et al. 1998).  This again is dose dependent.   
A similar effect is seen in the ERα-/ERβ+ breast cancer cell lines MDA-MB-231 
(Table 1.5), and BT20 and MDA-MB-468 (ERβ-status not known), with treatment 
with isoflavones above 10 μM reducing proliferation in a dose responsive manner 
(Constantinou et al. 1998; Ferenc et al. 2010; Kang et al. 2009; Li et al. 2008; 
Peterson and Barnes 1996; Rajah et al. 2009; Seo et al. 2011; Shon et al. 2006; 
Theil et al. 2011; Zava and Duwe 1997).  Most studies have used genistein for this, 
although resveratrol, daidzein, equol and biochanin A act similarly.  As discussed, 
lower concentrations of genistein (down to 1nM) have only been used with MDA-
MB-231 cells on one occasion, and were also found to inhibit proliferation (Rajah et 
al. 2009).   
Interestingly, 2’ hydroxylation of genistein by the enzyme isoflavone 2’-hydroxylase 
made it approximately twice as effective at decreasing MCF7 viability at the same 
dose of unhydroxylated genistein (Choi et al. 2009).    This genistein metabolite also 
has greater antioxidant capacity than its parent molecule, and may more closely 
reflect the impact of partial metabolism of genistein by gut microflora.   
Concentrations of genistein above 10µM have not been widely used to assess their 
impact on proliferation of breast cancer cell lines with other hormone receptor 
status.  However, 17 and 50µM genistein reduced the proliferation (MTT assay) of 
MDA-MB-435, ZR75-1 and SK-BR-3 breast cancer cells (Tong et al. 2002; Yang et 
al. 2010).  This suggests that the inhibition of proliferation by high (upwards of 10 or 
50µM) concentrations of isoflavones may be a universal phenomenon in breast 
cancer cell lines, regardless of ER status.  Furthermore, inhibition of MCF7 
proliferation by the pharmacological dose of 100µM genistein was not abrogated by 
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the ER-antagonist ICI 182780 (Maggiolini et al. 2001).  However, the significance of 
the use of this very high dose is limited, as it was likely to be acting in a non-specific 
cytotoxic manner. 
Table 1.5: Inhibition of MDA-MB-231 proliferation by genistein, summary of 
previous studies 
Study  Lowest genistein conc. at which 
growth inhibition occurs 
Time (days) 
Rajah et al. 2(009) 1nM 3 
Li et al. (2008) 5µM 2 
Kang et al. (2009) 18.5µM 3 
Ferenc et al. (2010) 50µM 1, 2 
Seo et al. (2011) 100µM 3 
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1.4.6 Combinatory effects of isoflavones and oestrogen on breast 
cancer cell proliferation  
These studies do not explain why in epidemiological studies isoflavones appear to 
be more protective against premenopausal, and ERα+ breast cancers, or why 
dietary isoflavones do not significantly increase breast cancer risk when in low 
doses.  The interactions between isoflavones and endogenous oestrogens have 
been investigated to attempt to answer some of these questions. 
At high isoflavone concentrations previously shown to reduce proliferation (5µM and 
above) several laboratories have shown that in ERα+ MCF7 and T47D cells, 
genistein partially or fully reversed the growth stimulatory effect of premenopausal 
and postmenopausal E2 levels (Maggiolini et al. 2001; Matsumura et al. 2005; 
Miodini et al. 1999; Peterson and Barnes 1996; So et al. 1997; Wang and Kurzer 
1998; Zava and Duwe 1997).  This ability of the isoflavones is unrelated to their 
oestrogenic activity, as an identical response was seen in a hormone insensitive 
strain of MCF7 (Maggiolini et al. 2001), and in ERα- MDA-MB-231 cells (Rajah et al. 
2009).   In a more recent study, 10 nM E2 and 10 µM glycitein (and genistein and 
daidzein to a lesser extent) resulted in significantly less MCF7 proliferation than the 
control (vehicle only) or E2 alone (Sakamoto et al. 2010).   These results correspond 
with data from epidemiological studies showing a reduction in breast cancer risk 
(premenopausally) associated with high isoflavone intake (Section 1.3.1), although 
the isoflavone concentrations used in vitro are frequently higher than those 
observed in vivo.   
However, the results of studies looking at the effects of lower (more relevant to 
Western populations) concentrations of isoflavones at physiological E2 levels are 
less conclusive.  At postmenopausal E2 concentrations (10pM), one study 
suggested that expression of a reporter gene tagged to an oestrogen responsive 
(ERα or ERβ) promoter in human embryonic kidney 239 cells was increased by 
treatment of 1 nM to 1 µM daidzein or several of its metabolites (tetrahydrodaidzein, 
equol and O-desmethylangolensin), making them oestrogen agonists in these 
conditions, and acting in an additive manner with E2 (Hwang et al. 2006).  With 
premenopausal E2 (1 nM) equol and tetrahydrodaidzein tended to inhibit oestrogen 
induced reporter transcription via ERα, and to a greater extent via ERβ (Hwang et 
al. 2006).   The same group reported a similar pattern of results for proliferation in 
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MCF7 cells, although did not show the results.  Likewise, activity of rat ERα and 
ERβ-mediated luciferase reporter gene (where the ERs and reporter were 
transfected into human hepatoma HepG2 cells) was enhanced in an additive 
manner by genistein (0.1µM to 1nM) at low concentrations of E2 (10pM and 
100pM), but at E2 concentrations above this (1nM to 100nM) there was maximal 
reporter activity which was not affected by the presence of genistein (Casanova et 
al. 2012).   
In MCF7 cells, 24 hour treatment with genistein up to 1µM and low levels (10pM or 
100pM) of E2 had a synergistic effect on DNA synthesis (labeled thymidine 
incorporation), which was not apparent at higher E2 concentrations (Wang and 
Kurzer 1998).  Similarly, others present data demonstrating that the ability of these 
lower concentrations of genistein to induce MCF7 proliferation or expression of 
ERE-reporter gene constructs in MCF7 was lost when they were treated with 
genistein or daidzein in combination with physiological levels of E2 between 0.1 and 
1nM (Matsumura et al. 2005; Schmidt et al. Diel 2005).   
Overall, these studies imply that in vitro, post-menopausally, low (1nM to 1µM) 
levels of isoflavones may function as oestrogen agonists, promoting ERα-induced 
transcription and the growth of ERα+ breast cancer cells, while pre-menopausally 
they are masked by the stronger oestrogenic effect, or may have some slight 
inhibitory effect.   
On the other hand, Rajah et al. (2009) present evidence for a synergistic inhibitory 
effect of genistein (1nM to 100µM) and 1nM E2 on MDA-MB-231 proliferation.  In 
this case they report approximately 40% reduction in proliferation with the combined 
treatments, compared to around 17% with genistein alone.   
These studies provide some evidence for the mechanism through which high levels 
of isoflavones, similar to those achieved in the diet of Eastern-Asians consuming 
‘traditional’ high-soy diets, could protect against breast cancer.  Additionally, lower 
levels of genistein may be of benefit against ERα- tumours, and ERα+ breast cancer 
in a premenopausal E2-environment, but could increase risk postmenopausally.  
However, many of the conclusions regarding the effects of lower levels of 
isoflavones at physiological E2 levels are based on ER-induced transcription 
(including that mediated by the rat homologues of ERα and ERβ) rather than cell 
proliferation, and what remains regarding MCF7 proliferation, particularly at 
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postmenopausal E2 levels, is less convinving.  Many of the studies have replicated 
either pre- or postmenopausal E2 concentrations (not the full set) and there is no 
data available regarding the effect of daidzein at postmenopausal E2 levels on 
proliferative outcomes.  Additionally, in epidemiological studies, the protective effect 
of isoflavones appears stronger for ERα+ breast cancers, but in vitro the anti-
proliferative and cytotoxic properties of isoflavones are independent of the ER status 
of the cells.  Furthermore, the majority of studies described are limited by only using 
ERα+ cell lines.   
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1.4.7 Summary of the effects of isoflavones on breast cancer cell 
proliferation 
Overall, the impact of isoflavones on breast cancer cell proliferation relates to the 
oestrogen environment and relative levels of the receptors ERα and ERβ.  E2 alone 
at its physiological range of concentrations promotes the proliferation of ERα+ cell 
lines such as MCF7, but not ERα-/ERβ+ MDA-MB-231 cells. 
Likewise, in the absence of E2, isoflavones promote the proliferation of ERα+ breast 
cancer cell lines in a dose responsive manner up to concentrations of around 10µM.  
This occurs oestrogenically, via ERα, and is inhibited by the addition of ER 
antagonists.  Proliferation is biphasic in these cell lines, and peaks at around 10µM 
then begins to drop.  The inhibition of proliferation in MCF7 is not mediated by the 
ERs. 
In MDA-MB-231 and other ERα-/ERβ+ cell lines however, even relatively low 
concentrations of genistein (1nM to 1µM) result in a slight inhibition of proliferation, 
although more dramatic inhibitory effects are seen at higher concentrations 
(>10µM).  The inhibitory effect appears to be related to the ratio of ERα:ERβ, with 
increasing expression of ERβ resulting in a more pronounced inhibitory effect on 
proliferation.   
As many of the effects of isoflavones are oestrogen-agonistic, and are mediated by 
the ERs, it follows that the presence of endogenous oestrogens will impact upon 
their effectiveness.   However, there is little data regarding their impact upon 
proliferation in the presence of E2, and what exists to date is of questionable value.  
In MCF7 high (>10µM) concentrations of genistein antagonize the proliferative effect 
of physiological E2 levels, in an ER-independent manner.  However, depending on 
the concentration of E2 present, lower (more physiologically relevant) genistein 
concentrations have been shown variously to act synergistically with E2 
(postmenopausally), have no net effect, or act as E2 antagonists (premenopausally).   
As discussed, much of this is based on data regarding ER-mediated transcription of 
reporter genes rather than proliferation.  This requires clarification. 
Many questions remain regarding the effects of isoflavones at endogenous E2 
levels, particularly postmenopausally, and in ERα-/ERβ+ cell lines.  In addition to 
this, caution must be exercised when directly translating in vitro results to in vivo 
55 | P a g e  
 
effects, as many factors may affect the physiological response in the different 
systems.  It is vital that evidence regarding the mechanisms through which 
isoflavones act in vitro is confirmed in vivo before recommendations are made.  
However, it remains possible that much of the proposed anti-proliferative activity of 
isoflavones lies in their ability to compete with endogenous oestrogens for oestrogen 
receptor binding sites.   
However, it is apparent that they may also moderate breast cancer risk through their 
pro-apoptotic, anti-angiogenic, antioxidant and numerous other non-genomic 
mechanisms. 
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1.5 Induction of apoptosis in breast cancer cells 
The mechanisms through which isoflavones have been proposed to mediate their 
anti-proliferative effects are many, and cannot all be discussed in this review.  Some 
of these effects include acting as antioxidants (Choi et al. 2009), modifying the 
activity of growth factor signaling including the Mitogen Activated Protein Kinase 
(MAPK) and IGF1 pathways (Chen et al. 2007; Liu et al. 2010; Lucki and Sewer 
2011), antagonizing oestrogen and androgen mediated signaling (Banerjee et al. 
2008), inhibition of angiogenesis (Garvin et al. 2006; Yu et al. 2012) and inhibition of 
oestrogen biosynthesis (Brooks and Thompson 2005).  Furthermore, E2 and 
isoflavones have been shown to regulate a number of the intracellular processes 
required for apoptosis in breast cancer cells.  These include modifying intracellular 
calcium levels and caspase activation, both of which may be central to their effects 
on the induction of apoptosis.  
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1.5.1 Morphological definition of apoptosis 
The term ‘apoptosis’3 was first coined in 1972 to describe a distinct series of well 
defined morphological events known as programmed cell death (Kerr et al. 1972).  
Apoptosis is a highly regulated process, which is essential to growth and 
development.  It is triggered extrinsically by membrane bound ‘death’ receptors or 
ligand deprivation-induced dependence receptor, or intrinsically by intracellular 
stress conditions, leading to the permeablization of the mitochondrial outer 
membrane which triggers mitochondria mediated signaling pathways (Galluzzi et al. 
2011; Roy and Hajnoczky 2008).   
Following this are the morphological events which give apoptosis its name.  This 
begins with the severing of attachments to other cells and extracellular matrix and 
the cell becoming more round.  In parallel, the cell shrinks.  This is followed by the 
plasma membrane forming protrusions known as “blebs” whilst retaining its integrity.  
Meanwhile chromatin condenses (pyknosis) then DNA and the nucleus fragments 
(karyorrhexis).  Vacuoles have been observed in the cytoplasm of dying cells.  
Finally the cell disintegrates into membrane bound apoptotic bodies which are taken 
up by phagocytes (Hacker 2000; Kroemer et al. 2009; Krysko et al. 2008; Maeno et 
al. 2000; Orrenius et al. 2003). 
These morphological changes, along with changes to mitochondrial  outer 
membrane permeability (MOMP), externalization of phosphatidyl serine on the outer 
leaflet of the plasma membrane, and activation of caspases make apoptosis readily 
distinguishable from other forms of cell death (Galluzzi et al. 2011; Krysko et al. 
2008).  Most notably this differs from necrosis, which is characterized by the 
unregulated swelling and bursting of cells, release of their contents, and resulting 
inflammation in neighbouring tissue.   
  
                                                 
3
 word “apoptosis” is derived from the Greek word “απόπτώσις” describing the “dropping off” 
of petals from flowers or leaves from trees. 
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1.5.2 Biochemical events leading to intrinsic apoptosis 
Intracellular stress such as DNA damage, oxidative stress and cytosolic Ca2+ 
overloading can result in the triggering of intrinsic apoptosis.  Intracellular Ca2+ 
concentrations are a particularly versatile signaling mechanism in cells.  Ca2+ levels 
can be controlled locally and at a cellular or tissue level by plasma membrane Ca2+ 
channels and the release of intracellular stores in the endoplasmic reticulum.  
Extracellular [Ca2+] is usually over 1 mM, and under normal growth conditions 
cytoplasmic [Ca2+] is around 100 nM (Roy and Hajnoczky 2008).  Nuclear and 
mitochondrial matrix concentrations are typically similar, and concentrations inside 
the endoplasmic reticulum between 100 and 500 μM.  Low amplitude transient 
fluctuations in concentrations activate processes such as secretion into vesicles and 
muscle contraction, and longer term oscillations in Ca2+ levels control many 
processes including proliferation and smooth muscle contraction.  However, 
prolonged high levels of cytoplasmic Ca2+ result in apoptosis (Berridge et al. 1998; 
Roy and Hajnoczky 2008).   
Sustained high concentrations of free intracellular Ca2+ induce Ca2+ uptake into the 
mitochondria, triggering the intrinsic apoptotic pathway (Figure 1.3).  This is 
characterised by an increase in MOMP, as the Bcl2 family proteins, Bax and Bak, 
activated by Bid, form mitochondrial pores.  This allows the release of the pro-
apoptotic molecules cytochrome C, apoptosis inducing factor (AIF), apoptotic 
protease activating factor (APAF-1) and second mitochondrial activator of caspases 
(SMAC).  Cytochrome C triggers the formation of the apoptosome, which recruits 
and mediates auto-activation of caspase 9 (Galluzzi et al. 2011; Orrenius et al. 
2003; Roy and Hajnoczky 2008; Yigong 2009).  Caspase 9 belongs to the cysteine-
aspartic protease (caspase) family.  Caspase 9, along with the extrinsically activated 
caspases 8 and 10 are known as initiator caspases.   They exist as monomers in 
their inactive forms, and in response to various signals oligomerise into proteolytic 
caspases.  They in turn cleave and activate a cascade of inactive effector caspase 
zymogens (Figure 1.4) into active proteins (Boatright and Salvesen 2003; 
Kauffmann et al. 2008; Riedle and Scott 2009).  The effector caspases have over 
400 substrates within the cell, and result in the morphological changes discussed, 
including DNA fragmentation and chromatin condensation.  Inhibitors of apoptosis 
such as survivin and X chromosome-linked inhibitor of apoptosis (XIAP) bind to 
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caspases and deactivate them (Boatright and Salvesen 2003; Kauffmann et al. 
2008; Yigong 2009).  
 
Figure 1.3: Genistein activates the intrinsic apoptotic pathway in MCF7 cells 
AIF: Apoptosis inducing factor, G: genistein, SMAC: second mitochondrial activator 
of caspases 
The triggering of the proteolytic caspase cascade results in activation of the pro-
apoptotic proteins.  Also among their many target proteins are the usually anti-
apoptotic Bcl2 and Bcl-xl, which are converted to pro-apoptotic forms by proteolysis, 
and are then known to deactivate cyclin D1, DNA polymerase and several other 
growth and survival proteins (Orrenius et al. 2003).   
In their anti-apoptotic forms, Bcl2 and Bcl-xl bind to Bax and Bak, preventing 
formation of the mitochondrial pore to release cytochrome C.  Bcl2 can also block 
the release of Ca2+ from the endoplasmic reticulum.  Both are oncogenes which are 
frequently overexpressed in tumours (Wen-Xing and Xiao-Ming 2009).  E2 treatment 
of MCF7 cells has been shown to down-regulate expression of Bcl2 antagonists and 
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caspase 9, preventing induction of apoptosis by the intrinsic pathway in these cells 
(Frasor et al. 2003). 
 
Figure 1.4: Role of the caspase activation cascade in apoptosis 
During extrinsically induced apoptosis, the ligand activated death receptor (such as 
Fas receptor bound to Fas ligand) triggers the dimerization of caspase 8 (or 
caspase 10) from inactive zymogen monomers, forming a Death Inducing Signaling 
Complex (DISC).  Intrinsic apoptosis is triggered by extracellular cues such as 
radiation and chemotherapeutic drugs, developmental cues, or mitochondrial stress.  
The mitochondrion triggers the formation of the apoptosome, including cytochrome 
C (Cyt C), apoptotic protease activating factor (Apaf-1), and dimerized, active 
caspase 9.  Both caspase 8 and caspase 9 trigger proteolytic cleavage and hence 
exposure of the active sites of caspases 3 and 7.  Activation of caspases 3, 7 and 9 
can be inhibited by X-chromosome-linked inhibitor of apoptosis (XIAP).  Active 
caspases 3 and 7 have many downstream targets, leading to the regulated death of 
the cell. 
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1.5.3 Techniques to assess apoptosis in breast cancer cells 
The previously discussed morphological changes undergone by most apoptotic cells 
are very similar, and well defined.  The key events of shrinkage of the cell, plasma 
membrane “blebbing”, chromatin and nuclear condensation, nuclear fragmentation, 
and then disintegration of the cell into membrane bound ‘apoptotic bodies’  can be 
identified by microscopy (light or fluorescent), and are cheap and widely used 
methods for measurement of apoptosis (Hacker 2000; Krysko et al. 2008).  However 
they are subjective and laborious to assess and fail to detect the early stages of 
lethal cascades which often do not result in gross morphological changes (Doonan 
and Cotter 2008; Galluzzi et al. 2009; Martin 2008).  At the magnification levels used 
for light microscopy healthy cells containing large granules, and some cells which 
have recently undergone mitosis can appear apoptotic (Doonan and Cotter 2008).  
This can be avoided by using electron microscopy (Krysko et al. 2008), but many 
laboratories lack the facilities for this.  So while light microscopy remains the 
simplest and most cost effective method to detect apoptosis, it must be used in 
combination with biochemical methods to generate reliable data. 
Furthermore, many microscopy techniques (light, fluorescent and electron) require a 
fixation step prior to visualization.  However, all fixatives modify cell structure to a 
greater or lesser extent (Bacallo et al. 2006).  In particular, ethanol, methanol and 
acetone fixation result in cell shrinkage in the “z” dimension, and glutaraldehyde 
renders tissue auto-fluorescent so is of no use for fluorescence techniques.  
Formaldehyde/formalin fixation avoids these issues and it crosslinks nucleic acids, 
recommending it for the study of nuclear changes.  However it can lead to extensive 
vesiculation of the plasma membrane.    
Gross morphological changes in apoptotic cells can also be detected by flow 
cytometry.  This is a laser based technique routinely used for cell sorting and 
biomarker detection.  Cells are suspended in a stream of liquid and passed through 
a detection apparatus.  This technique allows simultaneous detection of multiple 
parameters in 1000’s of cells per minute.  It can be used to assess the size of cells, 
presence of blebs, and granularity (Krysko et al. 2008).  However, it requires the 
cells to be in suspension.  Treatment of adherent cell lines such as MCF7 with 
trypsin can result in damage or permeablisation of the plasma membrane, 
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influencing the result, and their ability to grow in suspension may be limited so 
should be tested in advance. 
Changes in nuclear morphology unique to apoptosis are widely used in its 
assessment, due to the ease with which they are detected with light, or fluorescence 
microscopy using DNA intercalating dyes such as Hoescht (Akter et al. 2012) or 
4',6-diamidino-2-phenylindole (DAPI; Lai et al. 2003; Miglietta et al. 2006).  Initially 
this comprises chromatin condensation around the nuclear membrane, which then 
spreads to encompass the whole nucleus (Hacker 2000).  The condensation 
appears firstly as a brighter ring of fluorescence around the outside of the nucleus, 
then the whole nucleus becomes smaller, more circular and more brightly stained.  
The condensed nucleus then fragments within the cell.  In MCF7 cells DAPI is 
known to bind to DNA with greater affinity than Hoechst, and is less toxic (Bielawski 
et al. 2001).   The use of DAPI to assess apoptosis is described further in section 
2.6.  Apoptotic nuclei can appear smaller than normal nuclei, and this can be 
assessed by calculating the Nuclear Area Factor (NAF), which is a ratio of the size 
of the nucleus and its circularity (Daniel and DeCoster 2004; DeCoster 2007).  
However, this method is only effective in the very early stages of apoptosis (a matter 
of hours after the inducing treatment), before the nucleus fragments (Daniel and 
DeCoster 2004). 
Nuclear morphological changes occur in parallel to caspase dependent 
fragmentation of chromosomal DNA.  One widely used and sensitive method to 
assess this is the identification of the extensive fragmentation of nuclear DNA by 
Terminal deoxynucleotidyl transferase-mediated d-UTP Nick End Labeling (TUNEL) 
staining (Darzynkiewicz et al. 2008).  An alternate way to identify this was to look for 
“DNA laddering” when DNA is extracted and separated by agarose gel 
electrophoresis.  However, both methods are labour intensive, with the risk of 
disrupting or losing much of the signal.  Furthermore, while DNA breaks are 
common in apoptosis, they are not a universal event, and the degree to which they 
occur can vary (Hacker 2000; Martin 2008).  Searching for DNA ladders is now 
considered obsolete in this field (Kroemer et al. 2005). 
Fragmentation and loss of nuclear DNA can also be assessed by flow cytometry 
using fluorescent DNA binding agents such as DAPI.  Propidium iodide (PI), while 
frequently used as a counterstain to  determine cell viability as it is excluded from 
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viable cells, is also widely used to assess cellular DNA content (Krysko et al. 2008).  
In this instance it allows classification of cells according to the quantity, and degree 
of fragmentation of DNA that they possess.  Cells in the G1 stage of the cell cycle 
are diploid, and contain a uniform quantity of DNA.  Cells in G2/M phase contain 
twice as much DNA as G1 cells (tetraploid).  Apoptotic cells are hypodiploid, 
containing less DNA, which is fragmented.  These cells are described as sub-G1 or 
sub-G0, and can be readily identified by this method.  It is rapid and reproducible, 
and allows simultaneous use of other flurochromes such as Annexin V.  However, 
as with the above techniques, there are a number of criticisms to consider.  The 
non-universal nature of DNA fragmentation is a concern, and with this method the 
group of sub-G1 cells can also represent nuclear fragments and cells with abnormal 
chromatin structure (Riccardi and Nicoletti 2006).  Additionally, the process 
recognizes apoptosis based on a reduced amount of DNA, but if the cell enters 
apoptosis from the tetraploid G2 or M stage then it is likely to have a greater DNA 
content than the diploid G1 population (aneuploiud) and so will not appear in the 
sub-G1 peak. 
For these reasons a growing number of biochemical methods have been developed 
to measure features of apoptotic cells.  The activation of caspases is commonly 
considered to be an unambiguous sign of apoptosis, detected either 
immunologically or fluorochrometrically, by cleavage of specific substrates or of the 
caspases themselves (Krysko et al. 2008).  The initiator pro-caspases 8 or 9 are 
widely activated during apoptosis, but this feature is not universal (Galluzzi et al. 
2011; Shim et al. 2007).  Likewise, different downstream effector caspases can be 
activated in different caspase cascades depending upon the cell line and method of 
induction of apoptosis (Galluzzi et al. 2011).  Effector caspase 3 is very widely 
involved in apoptosis in many cell lines (Jakob et al. 2008) but is absent in MCF7 
(Janicke et al. 1998).  Similarly, caspases 2, -6 and -7 are not universal (Galluzzi et 
al. 2011; Kauffmann et al. 2008).  Care must be taken to make an appropriate 
choice of marker caspase.   
Additionally, caspases are known to participate in non-death related scenarios 
meaning that specific substrates must be examined which are only cleaved by 
caspases in death scenarios (Galluzzi et al. 2009; Martin 2008).  However, even the 
use of specific caspase substrates is limited, due to variable background caspase 
activity, and considerable overlap in the substrates available to each caspase 
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(Kauffmann et al. 2008).  Immunoblotting to detect cleaved (active) forms of the 
effector caspases is an important approach to assess their activity.  But this does 
not take into account the variable stability of the active form, or the presence of 
inhibitors such as XIAP inside the cell, meaning that the amount of cleaved caspase 
present may not reflect the amount that has been activated, or indeed whether they 
retain their activity (Kauffmann et al. 2008).  Additionally, as discussed, some 
caspases acquire at least some of their activity without proteolytic cleavage.  Taken 
together, complementary caspase assays should be used to demonstrate caspase 
activation.   
Where caspase inhibitors have been used to disrupt apoptosis, caution is also 
required.  The “universal” caspase inhibitor Z-VAD-fmk does not in fact inhibit all 
caspases to the same extent.  In addition, while caspase inhibition does prevent 
some caspase-dependent signs of apoptosis such as chromatin condensation of 
DNA fragmentation, it has been shown to only retard, and not prevent death 
(Kroemer et al. 2005). 
Fluorescent or immunofluorescent microscopy is more sensitive than light 
microscopy and can allow simultaneous or independent analysis of multiple 
apoptotic parameters as long as care is taken to ensure that emission spectra of 
dyes do not overlap (Galluzzi et al. 2009).  Likewise, numerous fluorescent 
techniques have been modified for use with flow cytometry.  Annexin V coupled 
fluorochromes are frequently used to detect phosphatidyl serine (PS) externalisation 
on the plasma membrane, and use of counterstains such as DAPI, PI or hoescht are 
common to detect nuclear changes.   However, while fluorescence techniques are 
popular, they have several limitations which must be considered (Cannel and 
Thomas 1994).  Firstly, the photons supplied to the cells will interact with any 
molecule which absorbs in the range of that photon, which can lead to false 
positives or autofluorescence.  This energy supplied to the cell generates heat which 
can lead to cell damage, and bleaching of the fluorescent probe.  Finally, frequently, 
the fluorescent molecule is required to be inside the cell.  This can disturb the 
system, influencing the cells viability or other parameters.  There may also be the 
issue of getting the probe to the correct compartment within the cell.  These 
limitations must be addressed in any technique utilizing fluorescent probes. 
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Quenching of fluorescent probes can lead to the reduction or loss of signal.  
Quenching refers to any process which reduces the intensity of fluorescence, such 
as energy transfer or complex formation.  Oxygen, iodide or acrylamide ions are 
common quenchers.  However, quenching does not appear to be a concern for the 
commonly used fluorescent dyes such as PI, DAPI, Annexin V-conjugates, or 
Hoescht under the experimental conditions commonly used (Galluzzi et al. 2009).  
However, leakage and bleaching of the fluorescent molecule may occur.  To reduce 
the impact of these, rapid capture of images and minimal exposure to ultraviolet light 
sources are necessary. 
PS is normally almost completely confined to the inner leaflet of the plasma 
membrane (Martin et al. 1995).  During apoptosis it is actively and rapidly 
transported to the outer leaflet.  This is a widespread apoptotic event, occurring 
regardless of the route of induction of apoptosis, and it occurs early in the process, 
preceding nuclear changes and loss of membrane integrity by several hours.  
Externalised PS acts as a “flag” to attract macrophages, facilitating the engulfment 
of the cell preventing membrane rupture and release of cytoplasmic contents.   
Annexins, of which there are 12 known, are human proteins which are membrane 
impermeable, and have a high affinity for aminophospholipids in the presence of 
calcium.  Annexin V (Annexin A5) is a 36 kDa member of this family which 
preferentially binds to PS.  It can be conjugated with fluorescent or radio-labelled 
moieties and used to specifically label externalised PS.  The results of this can be 
quantified using microscopy or flow cytometric techniques (Krysko et al. 2008; 
Martin et al. 1995; Martin 2008).  Use of Annexin V to quantify apoptosis is a rapid, 
reliable, and widely used tool, and will be discussed in greater detail in sections 2.5 
and 6.2.1.   
This list is by no means exhaustive, and new techniques and fluorescent dyes or 
antibodies allowing the detection of numerous apoptotic events are continuously 
being developed.  However, there are a number of major limitations which can be 
leveled at any apoptosis assay.  Firstly, each method discussed is hampered by the 
fact that in the absence of phagocytes (i.e. pure cultured cell lines) apoptotic cells 
eventually proceed to secondary necrosis, which shares many features with primary 
necrosis, including cell swelling and membrane rupture (Krysko et al. 2008).  
Secondly, the term “apoptosis” covers a range of morphologically similar apoptotic 
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subtypes which are distinct in their triggering and biochemistry, and differences in 
phenotype occur between in vitro and in vivo apoptosis, and with different cell lines 
and stimuli (Hacker 2000; Kroemer et al. 2009).  Finally, discussed are some of the 
drawbacks associated with each specific technique.  Taken together, along with the 
lack of any absolute “gold standard” assay for apoptosis, the Nomenclature 
Committee on Cell Death (NCCD) emphasises the importance of combining at least 
two distinct methods to quantify apoptosis in vitro, which are complementary but 
unrelated (Galluzzi et al. 2009; Galluzzi et al. 2011).  Likewise they advise against 
use of terms like “percentage apoptosis” instead opting for specific definitions such 
as “percentage Annexin V-binding” or “percentage cells with condensed chromatin” 
(Kroemer et al. 2005).   
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1.5.4 Isoflavones regulate apoptosis, intracellular calcium, and the 
activity of caspases and calpain in breast cancer cell lines 
Isoflavones, in particular genistein, are thought to trigger a novel alternative to the 
intrinsic apoptotic pathway (Figure 1.3).  Treatment of MCF7 cells with 50 or 25µM 
genistein or daidzein up to 100μM caused an increase in the prevalence of 
numerous apoptotic markers including fragmented DNA, accumulation of subG0/G1 
cells in the cell cycle, apoptotic nuclear morphology and PS externalization (Davis et 
al. 2008; Ferenc et al. 2010; Jin et al. 2010; Sergeev 2004; Shim et al. 2007).  This 
occurred at a range of treatment durations from 24 to 72 hours.  There is little 
information available regarding the effect of lower, more physiologically relevant 
isoflavone concentrations on the induction of MCF7 apoptosis.  However, under 
these conditions, 5 day treatment with genistein or daidzein between 0.1 and 10µM 
resulted in a slight inhibition of apoptosis compared to an untreated control (Schmidt 
et al. 2005).  These studies are summarized in Table 1.6.   
Under low serum conditions (0.5% FBS, 24 hours) 10µM genistein was also found 
to induce apoptosis (Sakamoto et al. 2010).  Silencing of the ERα gene in MCF7 
cells had no effect on this (Sakamoto et al. 2010).  Similar apoptotic events were 
seen in response to genistein in ERα- MDA-MB-231 cells (Davis et al. 2008; Li et al. 
2008; Seo et al. 2011), although in this case concentrations of as low as 5µM were 
effective.  Furthermore, addition of the ER-blocker ICI 182780 caused an additional 
increase in the number of apoptotic cells (Sakamoto et al. 2010).  These factors 
suggest that ER-independent mechanisms may be involved in the induction of 
apoptosis by isoflavones.   
Genistein also induced apoptosis in fibrocystic mammary MCF10A cells (Seo et al. 
2011) and neuroblastoma cells (Mohan et al. 2009).  Additionally, the 
phytoestrogens resveratrol and glycitein induced apoptosis in MCF7 and MDA-MB-
231 cells (Garvin et al. 2006; Sakamoto et al. 2010), and daidzein in MDA-MB-453 
cells (Choi and Kim 2008).   
  
 
 
 
Table 1.6: Summary of the methods used to investigate the induction of apoptosis by isoflavones in breast cancer cell lines 
Reference  Cell line Vehicle (control 
dose used) 
Apoptosis assay Isoflavone 
treatment  
Davis et al. 
(2008) 
MDA-MB-231, 
MCF7 
Vehicle? (Control 
untreated) 
- ELISA: ssDNA 48h 
Ferenc et al. 
(2010) 
MCF7, MDA-
MB-231 
Vehicle? (Control 
untreated) 
- Flow cytometry: cell cycle analysis 
- Caspase 7 activity (cleaved fluorescent substrate MCA-
VDQVDGWK(dnp)-NH2) 
- DAPI nuclear morphology 
- Relative expression and protein levels of Bcl2/Bax 
6h to 48h 
Garvin et al. 
(2006) 
MDA-MB-231 Ethanol (0.46%) - Caspase 3 activity (substrate Ac-DEVD-AMC) 
- Nuclear morphology (Giesma staining and electron microscopy) 
- Flow cytometry of PI stained cells 
- TUNEL staining of implanted tumour sections from mice 
48h 
Jin et al. (2010) MCF7 DMSO (0.1%) - Nuclear morphology (Hoechst and PI) 
- Flow cytometry: Annexin V-FITC, PI 
- Measurement of MOMP with DiOC6 
- Western blot: cleaved caspases 7 and 9, Bcl2, Bax, subcellular location 
of cytochrome C 
24h 
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Study Cell line Vehicle (control 
dose used) 
Apoptosis assay Isoflavone 
treatment  
Li et al. (2008) MDA-MB-231 Ethanol (x) - Flow cytometry: Annexin V-FITC, PI 
- Caspase 3 activity (substrate DEVD-pNA) 
- Western blot: Bcl2, Bax, cleaved caspases 3 and 8 
48h 
Sakamoto et 
al. (2010) 
MCF7 DMSO (x) - Flow cytometry (PI) cell cycle analysis 
- PCR: Bcl2/Bax transcription level  
- p53 dependent transcription: luciferase reporter plasmid 
24h 
Schmidt et al.  
(2005) 
MCF7 DMSO (untreated 
control) 
- Flow cytometry: cell cycle analysis 120h 
Seo et al. 
(2011) 
MDA-MB-231 
MCF10A 
DMSO (0.2%) - Flow cytometry (PI) cell cycle analysis 
- PCR: p53 and Bcl-xL transcription 
24h, 72h 
Sergeev (2004) MCF7 DMSO (0.1%) - Brd-U TUNEL assay kit 
- Plasma membrane changes: Annexin V staining for PS externalisation, 
YOPRO-1 and PI for membrane disruption 
- Nuclear fragmentation: Hoechst 33258 
- Calpain/caspase12 activity: substrates BOC-LM-CMAC and ATAA-AFC 
respectively 
72h 
Shim et al. 
(2007) 
MCF7 Ethanol and DMSO 
1:1 v/v (0.05%) 
- DNA laddering 
- Calpain activity (substrate DABCYL-TPLKSPPPSPR-EDANS) 
- Western blot: pro- and cleaved caspase 7 and poly(ADP ribose) polymerase 
(PARP) 
24h (up to 
48h for DNA 
laddering) 
(x) vehicle dose for control unknown 
6
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The apoptosis assays have been carried out at a range of different time-points, 
between six hours and three days depending on the method used, and the results 
are similar.  This allows both early and late apoptotic events to be characterized.  
However, a wide range of methods has been used to quantify apoptosis.  This can 
make cross-study comparison difficult, but it shows that numerous apoptotic 
markers are induced by isoflavone treatment, and avoids the individual drawbacks 
associated with each specific technique.  Notably, numerous groups used multiple 
assays to quantify apoptosis, in accordance with the advice of the NCCD.   
Treatment of MCF7 cells with 50 µM genistein for up to 6 days showed that 
genistein-induced apoptosis was associated with a sustained increase in 
intracellular [Ca2+], and co-treatment with thapsigargin (prevents Ca2+ re-entry into 
the endoplasmic reticulum) or ionomycin (a Ca2+ ionophore) suggested that this may 
be the result of the release of intracellular Ca2+ from the endoplasmic reticulum 
(Sergeev 2004).  Treating MCF7 cells with dantrolene, an inhibitor of Ca2+ release 
from the endoplasmic reticulum, or the cytosolic Ca2+ buffer BAPTA prevented 
genistein induced apoptosis (Sergeev 2004; Shim et al. 2007).  A number of other 
studies have also implicated Ca2+ deregulation and a rise in intracellular Ca2+ levels 
in apoptosis in MCF7 cells and lung carcinoma cell lines (Gil-Parrado et al. 2002; 
Mathiasen et al. 2002).  One study determined that the antioestrogen tamoxifen (2 
to 10µM) induced an increase in intracellular Ca2+ in the breast cancer cell line 
ZR75-1, which was suggested to be due not only to Ca2+ release from the 
endoplasmic reticulum, but also to increased influx from the extracellular medium 
(Chang et al. 2002).  It is not known whether isoflavones act similarly.   
In MCF7 cells 50 µM genistein treatment activated the protease µ-calpain (Sergeev 
2004; Shim et al. 2007).  The calpains, like the caspases, are cysteine proteases, 
although they differ in their target sequence specificity.  There are two isoforms, µ-
calpain and m-calpain, which are both Ca2+ activated, but require relatively high (µM 
and mM respectively) Ca2+ concentrations for their activity, hence their names 
(Orrenius et al.  2003). Treatment of MCF7 cells with dantrolene reduced genistein-
enhanced calpain and caspase 7 activity (Shim et al. 2007).  Additionally, treatment 
of MCF7 cells with a calpain inhibitor (PD 151746) reduced apoptosis in genistein 
treated cells (Sergeev 2004).  In vitro, both µ- and m-calpain cleaved Bid, Bcl2 and 
Bcl-xl into their pro-apoptotic forms, resulting in the release of cytochrome C from 
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the mitochondria (Gil-Parrado et al. 2002; Nakagawa and Yuan 2000; Orrenius et al.  
2003).   
Interestingly, initial studies into the role of calpains in apoptosis indicated a possible 
role for them as negative regulators, as they also cleaved pro-caspases 3, 7, 8 and 
9 into inactive fragments (Chua et al. 2000).  Further investigation suggested a 
complex pattern of cross-talk between the caspase and calpain apoptotic pathways.  
An endogenous calpain inhibitor exists, calpastain, which is cleaved by caspase 3, 
activating the calpains (Orrenius et al.  2003). Overexpression of calpastain reduced 
calpain activity, increased caspase 3 activity, and accelerated apoptosis (Neumar et 
al. 2003).  In wild type human neuroblastoma cells (SH-SY5Y), calpain initially 
slowed the execution phase of apoptosis, but was necessary in the later stages, 
adding to the effects of the caspases (Neumar et al. 2003).   
In MCF7 cells this is possibly the case, as inhibition of either the calpains or 
caspases reduced apoptosis (Sergeev 2004), and treatment with 100 µM genistein 
resulted in the activation and cleavage of both µ-calpain and caspase 7 (Shim et al. 
2007), and cleavage of a caspase 7 substrate (Ferenc et al. 2010).  However Shim 
et al. (2007) found no activation of caspases 8 or 9 by genistein treatment up to 200 
µM (results were not shown)4.  On the contrary, both caspase 7 and 9 were cleaved 
into active forms in MCF7 and MDA-MB-453 (ERα-) cell lines upon 24 hour 
treatment with daidzein between 10 and 100µM compared to untreated controls 
(Choi and Kim 2008; Jin et al. 2010).  As caspase 9 is known to activate caspase 7 
in the intrinsic apoptotic pathway (see Figure 1.4) it is probable that it plays a role in 
isoflavone-induced apoptosis in MCF7.  Genistein treatment (50 µM) of  MCF7 cells 
also resulted in an increase in the cleavage of a specific caspase 12 substrate 
(Sergeev 2004).  Finally, treatment of MCF7 with the pan-caspase inhibitor Z-VAD-
FMK prevented or reduced genistein induction of apoptosis (Jin et al. 2010; Sergeev 
2004).   
Downstream of these events, 24 hour treatment with pro-apoptotic concentrations of 
daidzein in MCF7 has been observed to result in an increase in the ratio of Bax:Bcl2 
proteins (Jin et al. 2010), and genistein (10μM for 24 hours) resulted in a 
corresponding increase in Bax:Bcl2 mRNA levels, which occurred irrespective of the 
                                                 
4
 MCF7 does not express caspase 3 (Janicke et al. 1998; Janicke 2009).  This may partly 
explain its carcinogenicity (i.e. the cells are resistant to some apoptosis inducing factors), 
although to a certain extent other caspases compensate. 
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presence or absence of 10 nM E2, and was unaffected by ERα silencing (Sakamoto 
et al. 2010).  This was associated with a dose-responsive increase in cytochrome C 
relocation to the cytoplasm, and a reduction in mitochondrial transmembrane 
potential (Jin et al. 2010).  However, no change was reported in Bcl2 mRNA levels 
after 24 hour 50μM genistein treatment (Ferenc et al. 2010). 
In MDA-MB-231 breast cancer cells a very similar series of apoptotic events occurs.  
Treatment with 50μM genistein for 24 hours resulted in an increase in cleavage of a 
caspase-7-specific substrate and an increase in the ratio of Bax:Bcl2 protein and 
mRNA (Ferenc et al. 2010).  The higher dose of 100μM also reduced protein levels 
of anti-apoptotic Bcl-xL (Seo et al. 2011).  Longer treatment with a lower dose (48 
hours of 5 to 20μM genistein) also increased the Bax:Bcl2 protein ratio, and 
increased the levels of active caspase 3 and cleavage of a specific caspase 3 
substrate (Li et al. 2008).  As in MCF7, no effect on caspase 8 activity was observed 
by this group.   
In MDA-MB-231 cells 100 µM genistein treatment induced phosphorylation of p53 
tumour suppressor protein (Seo et al. 2011).  This increases the stability and 
transcriptional activating ability of the protein, and accordingly, pro-apoptotic 
concentrations of genistein (and other isoflavones) result in an increase in the 
amount of p53 protein and p53-induced transcriptional activity in MDA-MB-231 and 
MCF7 cells respectively (Ferenc et al. 2010; Sakamoto et al. 2010).  Studies have 
shown that in MCF7 cells, Bcl2 promoter activity is downregualted by the p53 
transcription factor, while it enhances Bax promoter activity (Kim et al. 2008).  This 
suggests that the impact of genistein on Bax:Bcl2 may be mediated by p53 activity.  
Additionally, Bcl2 promoter activity is negatively regulated by the nuclear 
transcription factor κB (NF-κB), and 5 to 20 µM genistein treatment dose 
dependently reduces NF-κB levels in MDA-MB-231 cells suggesting another 
mechanism of action (Kim et al. 2008; Li et al. 2008).   
Finally, genistein resulted in the activation of apoptosis signaling kinase 1 (ASK1) 
and p38 MAPK (Shim et al. 2007), the latter leading to phosphorylation of various 
downstream apoptotic activators.  Simultaneous treatment with dantrolene 
diminished these latter responses.  Additionally, expression levels of the MAPK 
family growth genes were reduced by treatment of MDA-MB-231 cells with 5 to 20 
µM genistein (Li et al. 2008). The involvement of numerous genes such as these 
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has been confirmed by microarray gene expression analysis, showing that overall 
48 hour treatment of MCF7 cells with 25 µM genistein results in a pro-apoptotic, 
reduced proliferation gene expression profile (Lavigne et al. 2008). 
Overall, in MCF7 cells genistein in µM concentrations appear to increase 
intracellular Ca2+ levels, associated with depletion of the endoplasmic reticulum 
stores.  The result is calcium-dependent µ-calpain activation, which then cleaves 
and activates caspases 7 and 12.  These feed into the intrinsic pathway, increasing 
Bax:Bcl2, inducing MOMP and the subsequent release of cytochrome C from the 
mitochondria.  Daidzein treatment had similar results, and activated initiator caspase 
9.  The inclusion of this step in genistein-induced MCF7 apoptosis should not be 
ruled out.   Caspase 8 is not involved.  The latter mitochondrial events may be 
mediated by the activity of the transcription factors p53 and NF-κB, which also are 
modulated by genistein treatment.  There is no apparent involvement of the ERs 
during any stage of this, and events unfold in the ERα-/ERβ+ MDA-MB-231 cell line 
similarly. 
  
74 | P a g e  
 
1.5.5 17β-oestradiol, and isoflavone/17β-oestradiol combinations 
regulate the induction of apoptosis in MCF7 breast cancer cells 
In MCF7 cells, physiological concentrations of E2 (10 and 100pM) have been 
demonstrated to inhibit the induction of apoptosis (Schmidt et al.  2005; Song et al. 
2007).  This is in line with the protective / growth promoting effect that E2 is known 
to have on this cell line (section 1.4.4).  These studies are summarized in Table 1.6.   
Information regarding the impact of isoflavone/E2 combinations of the induction of 
MCF7 apoptosis is scant.    Schmidt et al. (2005) present evidence suggesting that 
1µM genistein or daidzein in a physiological E2 environment (1 to 100pM E2) inhibit 
apoptosis to a greater extent than the untreated control.  However they present no 
comparison of these results to those of any treatment individually, so although it 
appears that the isoflavone/E2 combinations act in a similar manner to the 
isoflavones alone, this should only be concluded with caution.    
Sakamoto et al. (2010) demonstrated that alone, a premenopausal E2 concentration 
(10 nM) prevented apoptosis during serum starvation (0.5% FBS, 24 hours), and 
treatment with genistein (10 µM) caused more apoptosis than the control cells 
(serum starvation, no treatment).  Combinations of E2 and genistein, or E2 and 
daidzein, at these concentrations induced apoptosis to a similar extent to the 
isoflavone treatment alone. 
Although these results suggest that isoflavone/E2 combinations induce apoptosis in 
MCF7 to a similar extent to the isoflavones alone, it is important to note that one 
investigates basal (no stress) induction of apoptosis, while the latter has used serum 
starvation induced apoptosis, and each has focused on a single isoflavone 
concentration. In particular, there is very little information available regarding the 
impact of daidzein on MCF7 apoptosis in the presence of physiological E2 levels, or 
lower (Western) levels of isoflavones.  A comprehensive study in this field is urgently 
required, as the induction of apoptosis by dietary levels of isoflavones represents a 
potential route through which their protective effects in vivo may be mediated. 
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1.5.6 Summary of the apoptotic effects of isoflavones 
Overall, what is known regarding the induction of apoptosis in breast cancer cell 
lines by isoflavones appears to feed into their net effect on proliferation.  In MCF7, 
concentrations of genistein and daidzein previously shown to reduce proliferation 
(>25µM) induce many markers of apoptosis.  They trigger the intrinsic apoptosis 
pathway, including activation of µ-calpain and caspase 7, an increase in the ratio of 
Bax:Bcl2 and cytochrome C release.  Similar events occur in MDA-MB-231, 
although lower concentrations of isoflavones (>5µM) are equally effective.  There 
does not appear to be any involvement of the ERs in these processes, although E2 
does inhibit apoptosis in MCF7 cells. 
However, common experimental practice is to use pharmacological concentrations 
of isoflavones (>50µM), and the physiological relevance of this is not known.  
Nothing is known regarding the impact of isoflavones on the induction of apoptosis 
at physiological concentrations more relevant to Western women (<1µM), or how the 
presence of E2 may interact with these responses. 
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1.6 Potassium channels and breast cancer 
1.6.1 The role of potassium channels in cell physiology 
The membrane potential (Em) of a cell is the difference in voltage between the 
interior and exterior of the plasma membrane.  As the membrane itself is 
impermeable to ions, the membrane potential arises from the actions of various ion 
channels and pumps embedded in the lipid bilayer.  The majority of these channels 
regulate the flow of K+, Na+, Cl- and Ca2+ ions.  Ion channels are classified according 
to how they are regulated.  The main groups consist of: ligand gated channels, 
voltage gated channels, channels which respond to sensory stimuli such as 
stretching or temperature, and finally leakage, or rectifier channels.  The latter group 
are the simplest, with very little in the way of regulation, although they frequently 
operate better in one direction (rectification) than the other, and may be closed by 
some ligands.  In addition to being gated in these manners, the majority of voltage 
and ligand gated channels are susceptible to regulation by tyrosine phosphorylation.  
This allows intracellular signaling pathways and growth factors to acutely regulate 
the electrophysiological properties of both excitable and non-excitable cells (Davis et 
al. 2001 and references therein).  Further information regarding the activities of ion 
channels can be found in the comprehensive handbook by Hille (2001).    
In excitable cells such as neurons or muscle cells (resting Em = -70mV; Schwarz and 
Bauer 2004), ion channels (voltage gated Na+ and Ca2+ channels) are used to 
generate action potentials, where an electric current transmits signals through the 
cell.  Non-excitable cells on the other hand, are characterized by their inability to 
generate action potentials due to a lack of voltage gated Na+ or Ca2+ channels 
(Mahaut-Smith et al. 1999). Resting Em in these cells varies widely with cell type, 
from -20 to -40mV (human and murine neuroblastoma cells; Arcangeli et al. 1995), 
and -33mV in cells from mouse mammary epithelial tissue (Enomoto et al. 1986), to  
-85mV (MCF7; Klimatcheva and Wonderlin 1999; Wonderlin and Strobl 1996), and 
generally corresonds to the ability of the cell to proliferate (Sundelacruz et al. 2009).  
In numerous non-excitable cell types, including breast cancer cells, regulation of Em 
is key to many processes including osmolarity, proliferation and apoptosis (Davis et 
al. 2001; Felipe et al. 2006; Ouadid-Ahidouch and Ahidouch 2008).  The interactions 
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between membrane potential regulation and various physiological cellular processes 
are summarized in the review by Sundelacruz et al. (2009). 
In addition, through their ability to regulate the osmolarity of cells, and consequently 
the inward and outward flow of water and osmolytes, ion channels play an important 
role in cell volume regulation.  It is widely accepted that swelling is necessary for S 
phase progression during proliferation (Dubois and Rouzaire-Dubois 2004; 
Hoffmann 2011), and that shrinkage inhibits proliferation and is an essential early 
step in apoptosis (Vu et al. 2001).  There is a role in cell volume regulation for the 
aquaporins, a family of membrane proteins which facilitate transport of water across 
the plasma membrane, and these proteins have been linked to proliferation and 
migration (Chen et al. 2011; Ishibashi et al. 2011).  However, more relevant to this 
work is the fact that a number of ion channel types are implicated in volume 
regulation, including the potassium channels (Bortner and Cidlowski 1999; Gow et 
al. 2005; Hughes, Jr. et al. 1997; Storey et al. 2003; Wang 2004). 
Potassium is maintained in the cytosol at a considerably greater concentration than 
in the extracellular fluid.  Typical mammalian cells have an intracellular K+ level of 
139mM, compared to extracellular (blood) concentrations of 4mM (Lodish et al. 
2008).  Inward movement of K+ into the cell to maintain this high intracellular 
concentration is mediated by the Na+ K+-ATPase pump.  This ubiquitous protein 
uses the energy from the hydrolysis of ATP to move K+ ions into the cell against 
their concentration gradient, in exchange for Na+ ions.  This channel has been 
identified as a potential target for breast cancer drugs, due to its roles in signal 
transduction and cancer progression (for a review see Chen et al. 2006).  However, 
far more versatile regulation of K+ currents and intracellular K+ concentrations lies 
with the role of the K+ channels themselves. 
Potassium channels are the largest and most diverse family of ion channels.  They 
play well established roles in many diseases such as congenital deafness, 
arrhythmias, and multiple sclerosis, and show cell and tissue-specific regulation of 
expression levels (Felipe et al. 2006).  In addition, the deregulation of potassium 
channels is implicated in breast cancer development and progression (Ouadid-
Ahidouch and Ahidouch 2008; Wang 2004; Wonderlin and Strobl 1996).  Table 1.7 
lists all the K+ channels referred to within this text.    
  
78 | P a g e  
 
Table 1.7: Potassium channel nomenclature and gene names 
IUPHAR
1 
HUGO
2 
Other names 
Kv1.1 KCNA1 Shaker-related 
Kv1.2 KCNA2 
Kv1.3 KCNA3 
Kv1.5 KCNA5 
Kv1.6 KCNA6 
Kv7.1 KCNQ1 KVLQT 
Kv10.1 KCNH1 Human ether-a-go-go K
+
 channel, hEAG, eag1 
Kv11.1 KCNH2 Human ether-a-go-go related gene, hERG, erg1 
KCa1.1 KCNMA1 Large conductance calcium-activated K
+
 channel, BK, 
BKCa 
KCa2.1 KCNN1 Small conductance calcium-activated K
+
 channel, SK, 
SKCa KCa2.2 KCNN2 
KCa2.3 KCNN3 
KCa3.1 KCNN4 Intermediate conductance calcium-activated K
+
 
channel, IK, IKCa 
K2P5.1 KCNK5 Two-pore domain K+ channel subunit, TWIK-related 
acid sensitive channel 2, TASK2 
K2P9.1 KCNK9 Two-pore domain K
+
 channel subunit, TWIK-related 
acid sensitive channel 3, TASK3 
Kir3.1 
  
KCNJ3 G-protein coupled inwardly rectifying K+ channel, 
GIRK1 
Kir3.2 KCNJ6 G-protein coupled inwardly rectifying K
+
 channel, 
GIRK2 
Kir3.3 KCNJ9 G-protein coupled inwardly rectifying K
+
 channel, 
GIRK3 
Kir6.1 KCNJ8 ATP-sensitive K
+
 channel 
Kir6.2 KCNJ11 ATP-sensitive K
+
 channel 
  ---- KCNE1 mink/ IsK, voltage gated potassium channel auxiliary 
subunit associated with Kv7.1 and Kv11.1 
1 Protein names assigned by the International Union of Pharmacology (IUPHAR) 
(International Union of Pharmacology 2010) 
2HUGO Gene Nomenclature Committee (HGNC) approved gene name (HUGO 
Gene Nomenclature Committee 2011) 
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Potassium channels can be broadly grouped into four families (Felipe et al. 2006).  
These are the voltage gated, calcium-activated, inward rectifier (Kir), and two pore 
domain K+ channels (K2P).  The voltage gated potassium channels (VGKCs) form 
the largest group, comprising the peptides Kv1 to Kv12 (Gutman et al. 2005).  Each 
Kv peptide forms a channel subunit, of which four are required to act as a functional 
K+ channel.  These can be as homo- or hetero-tetramers.   Their structure is 
summarized in Figure 1.5.  The activity of these channels is voltage dependent.  
They tend to be closed at resting potential and open upon membrane depolarization 
to mediate an outward K+ current, resulting in hyperpolarization.   The current that 
this family of channels mediates is a well defined delayed rectifier K+ current (Ik) 
(Wang 2004). 
There are two groups of calcium-activated K+ (KCa) channels.  The small 
conductance (SK) and intermediate conductance (IK) calcium activated channels 
are voltage insensitive and are activated by low concentrations of internal calcium 
(<1 μM).  These channels do not directly bind Ca2+, but instead detect it using a 
calmodulin-dependent mechanism.   On the contrary, the large conductance (BK) 
calcium activated K+ channel is activated by voltage and internal Ca2+.  The latter it 
detects not via calmodulin, but probably utilizing several cation binding sites on the 
C terminal domain of each channel subunit (Wei et al. 2005).  
The K2P group can be regulated by a range of chemical and physical stimuli 
including pH, mechanical stretch, lipids, and various ligands.  They are active at 
resting potentials, and mediate background, or “leak” outwardly rectifying K+ 
currents that stabilize membrane potential and allow repolarisation (Enyedi and 
Czirjak 2010; Goldstein et al. 2005).   Finally, the Kir channels mediate an inward K
+ 
current activated upon hyperpolarization (Kubo et al. 2005).  Significant amongst 
this group of channels are the ATP-sensitive inwardly rectifying channels (Kir6.1 and 
Kir6.2) which perform the important role of linking ion channel physiology to the 
metabolic state of the cell, as they are closed by the presence of ATP and opened 
by ADP (Seino and Miki 2003). 
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Figure 1.5: Voltage gated potassium channel structure 
This diagram is based on work by Jiang et al. (2003), Sanguinetti et al. (2006) and 
Yellen (2002), characterising the relatively conserved structure of the VGKCs.  The 
same colour scheme for subunits is used throughout the image.  Each channel is a 
homotetramer or heterotetramer of 4 subunits (A), each with 6 transmembrane α-
helices, and C and N terminal domains for protein-protein interactions or other 
regulatory functions.  Helices 1 to 4 form the voltage sensing mechanism, and 
helices 5 and 6 make up the channel pore.  The “Shaker” channels (Kv1. to Kv4.) 
share a similar structure (C), with the N-terminal domains combining to form a 
“tetramerisation domain” which determines the specific subunits which bind, and 
acts as an anchor for additional β-subunits.  The hEAG and hERG channels have a 
related structure (D), although their N and C terminal domains have differing 
regulatory functions.  These frequently are the sites for binding other regulatory 
subunits, and in hERG, the C-terminal domain binds cAMP.  The voltage gating 
mechanism of these channels is thought to be similar (B), whereby upon membrane 
depolarization the gating charges (+ signs) are carried across the membrane from 
bottom to top by voltage sensing “paddles”, which as they turn, open the pore.  
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1.6.2 Techniques to investigate potassium channel physiology in 
breast cancer cells 
1.6.2..1 Whole cell patch clamping 
Patch clamping is considered to be the gold standard method with which to measure 
ion currents as it allows the channels to be gated by physiologically relevant 
membrane potentials (Birch et al. 2004).  This technique and its limitations are 
discussed further in sections 4.3 and 6.4.2.  It is based on the principle that 
variations in channel activity (i.e. opening or closing of channel proteins) results in 
changes in membrane resistance, which can be studied by measuring the resulting 
current at a constant (clamped) membrane voltage (Sontheimer and Olsen 2007).  
Modifications have been made to the patch clamping procedure to allow analysis of 
the activity of channels in excised patches, or single channels.  The latter facilitates 
the investigation of particular parameters of individual channel proteins, such as the 
durations of opening and shutting, or the rate of flow of ions.   
However, whole cell patch clamping assesses the net activity of thousands of 
channels present in the whole cell membrane, generally of multiple types (the 
macroscopic current).  A critical step in the analysis of macroscopic currents is their 
separation into component parts.  Numerous methods exist to facilitate this, 
however five are commonly used (Sontheimer and Olsen 2007; Standen et al. 
1994).  
1.6.2..1.1 Kinetic 
The speed of activation or inactivation of a channel can vary substantially, so 
assessing macroscopic currents at different time points following stimulation can 
facilitate isolation of different current types.  For instance, Na+ currents activate and 
inactivate more rapidly than other channel types, typically becoming activated within 
300µs, and inactivating completely by 5ms.  On the other hand, K+ currents are 
slower, taking several milliseconds to activate, and inactivating very slowly or not at 
all.  Measuring current 500µs after activation will determine Na+ current activity, and 
tens or hundreds of milliseconds later K+ current amplitude can be assessed.  
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1.6.2..1.2 Stimulus protocols 
The voltage dependence of activation or inactivation of certain ion channels can 
allow separation of the activities of some subpopulations using voltage stepping 
protocols.  Large or small amplitude Ca2+ currents can be separated depending 
upon the holding potential used for the voltage stepping.  Similarly, voltage steps 
applied from particularly negative potentials (-110mV) activates the transient and 
delayed rectifying K+ currents.  However stepping from a more positive holding 
potential (-50mV) inactivates the transient K+ currents whilst not affecting activation 
of the delayed rectifying K+ channels.  The latter group includes numerous VGKCs.   
1.6.2..1.3 Ion dependence 
The compositions of bath and pipette solutions are commonly manipulated to favour 
movement of the ions of interest, and inhibit others.  Replacement of K+ ions in the 
pipette solution with impermeable N-methyl-D-glucamine prevents the majority of K+ 
channel activity allowing isolation of the Na+ currents.  Similarly, tetramethyl-
ammonium chloride can replace Na+, allowing isolation of the K+ currents.   
1.6.2..1.4 Pharmacology 
Numerous toxins and synthetic agents are utilized to inhibit specific or broad groups 
of ion channels.  The best practice is to record the current trace in the presence and 
absence of the pharmacological agent, and the difference in current represents the 
effect of the drug.  An advantage of this technique is the elimination of capacitance 
and leak currents.  However, in numerous instances, doses of pharmacological 
agents used have been in vast excess of their IC50 to guarantee an effect.   They 
may be cytotoxic or generate non-specific effects at these high doses.  Validation of 
the relevance of the doses used is required, possibly by comparison of the patch 
clamp results with results of other methods of assessing K+ movement, such as use 
of radiolabelled rubidium or fluorescent probes, such as potassium-binding 
benzofuran isophthalate (PBFI), although these methods too are not without their 
limitations. 
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1.6.2..1.5 I-V curves 
Current-voltage relationships are an effective way to summarize the activity of ion 
channels.  These allow dissemination of a number of key parameters which are not 
apparent from the raw data, such as reversal potential (the potential at which the 
current reverses direction: goes from negative to positive), voltage dependence 
(rectification), activation threshold, and quality of the clamp. 
1.6.2..2 Fluorescent methods to assess potassium movement 
The most widely used potassium sensing fluorescent probe is PBFI, used in several 
of the studies previously described (Bortner and Cidlowski 1999; Hughes, Jr. et al. 
1997; Vu et al. 2001) either by conventional fluorescent microscopy or flow 
cytometric analysis.  Dyes such as this are theoretically useful tools due to the 
complex and time consuming nature of patch clamping.  They are considerably 
easier to use than patch clamping, and allow simultaneous measurement of 
numerous cells (Sundelacruz et al. 2009).  However PBFI is limited in its biological 
applications due to a relatively low fluorescence level and low selectivity for K+ over 
other actions such as Na+ (Hirata et al. 2011).  Novel fluorescent potassium probes 
such as B3TAC which overcome some of these problems are available, but are not 
widely used.  This may relate to the fact that even a very sensitive fluorescent probe 
will only detect net changes in intracellular K+, compared to the wealth of kinetic, 
voltage-sensitive, and single channel data that is it possible to extract from a patch 
clamped cell.  In addition, a major disadvantage to using fluorescent dyes to assess 
membrane potential is that they are difficult to calibrate, and so most data is 
reported as percentage changes in fluorescence, rather than absolute potential 
values (Sundelacruz et al. 2009). 
A different approach is to use fluorescent probes to detect changes in plasma 
membrane potential directly such as the bis-barbituric acid oxonol, DiBAC4, with or 
without flow cytometric analysis.  This is relatively widely used, and robust to 
changes in cell volume influencing intracellular dye concentration.  However, as with 
the potassium sensing dyes it is limited in the sense that it can only detect overall 
changes in potential.  Furthermore, dyes such as DiBAC4 are relatively slow to 
respond to changes in potential, so they are only of value to study steady state 
membrane potential, or slow- and non-inactivating ion channels (Wolff et al. 2003).  
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A number of novel dye systems based on fluorescence resonance energy transfer 
(FRET) have been developed which are sensitive to rapid changes in membrane 
potential.  However, none are ideal, and the choice of which should depend on the 
target channel and equipment available (Wolff et al. 2003).  
The intensity of fluorescence can be influenced by changes in protein content, which 
will modify the levels of bound to free dye.  Fixation of the cells will increase the 
number of dye binding sites and consequently fluorescence. The results of this 
method can also be influenced by depolarization of organelle membranes such as 
the mitochondria.   However, as Klapperstruck et al. (2009) suggest, with careful 
calibration, this method is capable of generating results that are comparable with 
patch clamping.  Each of these fluorescent methods is further constrained by the 
general limitations of use of fluorescent molecules, discussed previously (section 
1.5.3). 
1.6.2..3 Modification of expression levels of ion channels 
Effective isolation of an ionic current through a given channel is frequently possible 
by expressing artificially that channel in a cell type which contains few or no intrinsic 
ion channels, so that measured currents represent the pure current through the 
channel of interest.  The most commonly used system is Xenopus oocytes, which 
have very little in the way of endogenous ion channel activity.   However, a limitation 
of this is that the cloned channel activity may not always reflect the behaviour of the 
native channel due to alterations in subunit structure or lack of certain regulatory 
proteins (Standen et al. 1994).  This is particularly relevant for the VGKCs which 
exist as functional hetero-tetramers (Gutman et al. 2005).  
1.6.2..4 Radiolabelled rubidium as a potassium tracer 
Use of radiolabelled rubidium (86Rb+) as a tracer is a relatively common method to 
assess K+ flux, and has been used several times in the studies described, both with 
MCF7 and MDA-MB-231 breast cancer cell lines, and other cell types (Caplanusi et 
al. 2006; Gow et al. 2005; Huang et al. 2011; Kirkegaard et al. 2010).  This method 
allows real time measurements of net K+ movements to be made, by loading the 
cells with  86Rb+, washing them, then scintillation counting of the extracellular 
supernatant can be carried out at various time-points to determine its 86Rb+ content.  
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It is based on the assumption that 86Rb+ will behave in the same manner as K+, and 
is not toxic at the doses used.  Again, as with the use of fluorescent dyes, this 
method cannot extract data on the kinetic, voltage activated and single channel 
scale.  However, in addition to the inherent safety concerns when working with 
radioisotopes, numerous laboratories do not have the facilities to safely store and 
dispose of these materials. 
1.6.2..5 Changes in cell volume 
Due to the regulatory role of K+ channels in cell volume regulation, measurement of 
volume changes is frequently carried out alongside K+ channel activity assessment.   
However, this must not be used as a direct measure of K+ channel activity, as other 
ions including Na+ and Cl- are also involved in volume regulation.    
The most widely used method of assessing changes in cell volume is electronic 
sizing using a Coulter-type multisizer (Feranchak et al. 2003; Hoffmann 2011; 
Huang et al. 2011; Kirkegaard et al. 2010; Kossler et al. 2012).   This technique is 
based on the principle that when particles flow through a small aperture over which 
an electric current is passed, they will displace their own volume of liquid, increasing 
the resistance to the current flow by a tiny, but proportional and measurable amount.    
This is a reproducible and automatable method which is sensitive enough to detect 
very small changes in cell size.   However, due to the nature of the technique it is 
only possible to measure populations of cells in suspension before or after a 
treatment, and changes to individual cells cannot be followed over time.  Care must 
be taken regarding the choice of time-points measured to ensure that compensatory 
mechanisms such as regulatory volume decrease (RVD) do not obscure results. 
Another frequently used and reproducible method is the assessment of light 
scattering by flow cytometry (Bortner and Cidlowski 1999; Storey et al. 2003; Vu et 
al. 2001).  However a criticism of this technique is that it is limited by variations in 
cell surface geometry and intracellular refractive indices (Farinas and Verkman 
1996).  As with the coulter method, changes in cells cannot be followed over time, 
and only inferred to by measurements taken in populations treated for different 
timescales. 
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There exist techniques to assess changes in size over time, using microscopy, with 
or without fluorescent dyes.  A number of groups have used light microscopy 
together with image analysis software to measure the cross sectional area of cells 
(Okumura et al. 2009; Roy et al. 2008; vanTol et al. 2007).  However, with numerous 
software types this is limited to the analysis of spherical objects, which may not 
represent the entire population, and the method is relatively labour-intensive.  
Another group used height (z axis dimension of a composite image) as an index for 
volume (Caplanusi et al. 2006), however this too assumes a uniformity of shape 
across the population. 
To avoid these limitations several groups have utilized fluorescent intracellular dyes, 
frequently calcein-AM (-acetomethoxy derivative).  Dyes such as this will be taken 
up into the cell in ester form.  The ester group is then cleaved making them plasma 
membrane impermeable, so the content inside the cell is relatively constant.  In this 
manner, changes in cell volume will be expressed by changes in fluorescence 
intensity, i.e. shrinkage will make the intracellular dye more concentrated and so 
fluoresce brighter, with the opposite occurring upon swelling.  This technique was 
first described in 1995 (Crowe et al. 1995), and is considered to be a sensitive 
technique for the measurement of volume changes in single cells.  This is discussed 
further in sections 4.1 and 6.3.1.  Changes in the intensity of fluorescence can be 
assessed by image analysis software (Chen et al. 2011), or using the higher 
throughput microplate method (Pan et al. 2007).  Either method is reproducible and 
accurate.  However, as previously, there are a number of general limitations of 
fluorescent techniques which apply to these methods also (section 1.5.3). 
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1.6.3 Expression levels of potassium channels in MCF7 breast cancer 
cells and cancerous mammary tissue 
In MCF7 breast cancer cells many plasma membrane K+ channels have been 
identified (Table 1.8).  A number of these channels have been found to have roles in 
the proliferation of breast cancer cells, and their overexpression is associated with 
the promotion of tumour formation and resistance to apoptotic stimuli (Abdul et al.  
2003; Brevet et al. 2008; Mu et al. 2003).  
Of particular note is the human ether-a-go-go5 (hEAG) K+ channel, also known as 
KCNH1 or Kv10.1.  This was found, by use of both reverse transcription real time 
PCR (RT-PCR) and immunostaining, to be overexpressed in over 80% of breast 
carcinoma biopsies.  In normal tissue its distribution was restricted to areas of the 
brain and several other tissues (Hemmerlein et al. 2006).   
A related channel is human ether-a-go-go related gene (hERG), also known as 
KCNH2 or Kv11.1.  This channel carries a rapidly activated delayed rectifier K
+ 
current.  Like hEAG, hERG is expressed in numerous human cancer cell lines and 
tissues but not in corresponding healthy cells (Bianchi et al. 1998; Cherubini et al. 
2000; Lastraioli et al. 2004; Pillozzi et al. 2002), suggesting that it may also confer 
some selective advantage to the tumour cells.  In cancer cell lines hERG expression 
varies greatly, but appears to relate to chemosensitivity, with the highest expression 
levels corresponding with the greatest sensitivity to anticancer drugs (Chen et al. 
2005).  In colonic cancerous tissue hERG expression level and activity appears to 
correlate with the invasiveness of the cancer (Lastraioli et al. 2004). 
 
 
 
 
                                                 
5
 The gene was named in the 1960s by William Kaplan and William Trout of the City of Hope 
Medical Centre, Duarte, California.  From their work in the Drosophila fly they discovered a 
mutation which resulted in convulsions in the legs when the flies were anaesthetized with 
ether, which reminded them of the style of dancing at the Whisky A-Go-Go nightclub in West 
Hollywood (Kaplan and Trout, III 1969) 
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Table 1.8: Potassium channels found in MCF7 breast cancer cells 
Channel 
Family 
K+ Channel References 
Voltage gated hEAG (Human ether-a-go-go; 
Kv10.1) 
Borowiec et al. 2007; 
Hemmerlein et al. 2006; Roy et 
al. 2008 
hERG (Human ether-a-go-go 
related gene; Kv11.1) 
Bianchi et al. 1998; Chen et al. 
2005; Roy et al. 2008; Wang et 
al. 2002 
Kv1.1 Ouadid-Ahidouch et al. 2000 
Kv7.1 vanTol et al. 2007 
Ca2+ activated IK (Intermediate Ca2+ 
activated channel) 
Ouadid-Ahidouch et al. 2004b 
BK (Large Ca2+ activated 
channel) 
Khaitan et al. 2009; Lee et al. 
2012; Ouadid-Ahidouch et al. 
2004a; Roger et al. 2004 
SK (Small conductance Ca2+ 
activated K+ channel)  
Abdul et al. 2003  
Inwardly 
rectifying 
Kir3.1 (GIRK1; G-protein 
inwardly rectifying) 
Dhar and Plummer, III 2006 
Kir3.2 (GIRK2) Dhar and Plummer, III 2006 
Kir3.3 (GIRK3) Dhar and Plummer, III 2006 
Two pore 
domain 
K2P9.1 (TASK3) Lee et al. 2012 
 
Similarly, the Shaker family potassium channel subunit Kv1.3 was detected by 
immunostaining in high or moderate levels in nearly 90% (53 out of 60) of breast 
cancer biopsy epithelial samples, while none was detected in four corresponding 
non-cancerous samples (Abdul et al. 2003).  However, Brevet et al. (2008) found the 
opposite, suggesting that both Kv1.3 and related Kv1.1 proteins were present at 
lower levels in cancerous tissue than normal tissue.  For this study immunostaining 
methods were used on 33 primary invasive breast carcinomas of varying stages and 
invasiveness, and 31 normal breast specimens.  They related the reduction in Kv1.1 
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and Kv1.3 to their role in apoptosis in breast epithelial cells.  Kv1.3 channel protein 
was not detected in MCF7 cells by immunohistochemical analysis (Ouadid-Ahidouch 
et al. 2000), indicating its absence from this cell line.   
Jang et al. (2009) proposed that this discrepancy in results may be because 
expression of the Kv1.3 gene depends upon the invasiveness and stage of the 
cancer.  This group found that weakly invasive M13SV1R2 cells showed 
considerable and significantly greater Kv1.3 mRNA expression levels than in normal, 
untransformed M13SV1 cells, but that in the highly invasive line M13SV1R2-N1, 
Kv1.3 gene expression was half of that seen in the normal line.  They also 
discovered that compared to normal breast tissue, the expression of Kv1.3 was only 
higher during early (I, IIA, and IIB), late (IIIC), and metastatic (IV) stage breast 
cancer tissue.  Expression during the mid-stages IIIA and IIIB, was not significantly 
different from normal tissue.  However, Jang et al. (2009) also analyzed protein 
levels of Kv1.3 using Western blot analysis, and found that this was significantly 
higher in both the weakly and highly invasive cell lines compared to the 
untransformed cells, and that protein levels were related to the tumourigenicity of 
the cell line.  Kv1.3 protein levels did not correlate with mRNA levels.  This is not an 
uncommon occurrence, and suggests differences in translation regulation, post-
translational events, or protein half-life.   
This data suggests a possible explanation for the discrepancies in results between 
Abdul et al. (2003) and Brevet et al. (2008).  However, it must be noted that the 
latter group did not find any significant relationships between the levels of Kv1.1 or 
Kv1.3 and markers of tumour grade or invasiveness, such as ER status or Ki67 
levels.  Clearly further research into the regulation of Kv1.3 is required.  Whether the 
regulation of Kv1.3 levels according to tumour stage and invasiveness can account 
for the apparent absence of Kv1.3 in MCF7 cells reported by Ouadid-Ahidouch et al. 
(2000) is not known. 
Similarly, the K+ channel K2P9.1 (TASK3), encoded by the gene KCNK9,  was found 
to be overexpressed at least 5-fold and up to over 100-fold in 44% (28 out of 64) 
human breast cancer biopsy samples (Mu et al. 2003).  It was also overexpressed in 
35% of lung cancer samples analyzed (Mu et al. 2003).  In the breast cancer 
samples, the KCNK9 locus was amplified between 3- and 10-fold in 10% of the 
samples.  Immunohistochemical analysis of the same samples confirmed the 
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presence of high levels of K2P9.1 protein in the samples where the gene was 
overexpressed, and Mu et al. (2003) also found overexpression of KCNK9 to be 
associated with tumour formation, increased viability in low-serum conditions, and 
resistance to hypoxia.  Conversely, reduced cellular levels of both gene expression 
and protein for this channel have been linked with increased cell migration (Lee et 
al. 2012).  In this study, relatively high levels of K2P9.1 were found in MCF7 (non-
invasive), while considerable lower levels of both its mRNA and protein were 
present in MDA-MB-231 (invasive).  Modifying K2P9.1 levels by either 
overexpression or knock-out (siRNA) generated corresponding results.  This 
suggests that K2P9.1 can act either oncogenically or to reduce tumour invasiveness 
depending on the cancer model used, and could potentially be more oncogenic in 
vivo than in cell culture.  Alternately, its levels may change depending on tumor 
stage, with high protein levels present during the tumor formation and initial non-
invasive stages, but dropping as the tumor becomes metastatic. 
Kir3.1 has been found to be overexpressed in cancerous breast tissue compared to 
normal tissue, using immunostaining methods (Brevet et al. 2008).  Unlike the other 
K+ channels differentially expressed in cancerous compared to normal breast tissue, 
which mediate outward K+ currents, Kir3.1 facilitates an inwardly rectifying K
+ 
current.  Kir3.1 levels related to tumour grade, with significantly higher expression 
seen in grade II than grade III tumours (Brevet et al. 2008).  These results agree 
with those of Stringer et al. (2001), who used a gene expression profiling technique 
with a paired sample of breast carcinoma and adjacent normal breast tissue from 
the same patient, followed by RT-PCR with 56 separate benign and invasive breast 
carcinomas and 6 normal, non-malignant breast tissue samples.  In the latter 
investigation, Kir3.1 overexpression was found to correlate significantly with the 
presence of lymph node metastasis.  Kir3.1 has also been identified by both 
immunostaining and RT-PCR in a number of breast cancer cell lines including 
MCF7, MDA-MB-453, and ZR75-1 (Dhar and Plummer, III 2006).   
Of the SK channels, the expression of SK1 (KCNN1) is restricted to neuronal tissues 
(Chen et al. 2004).  While SK2 (KCNN2) is more widespread, there remains very 
little or no expression in the mammary epithelium.  On the contrary, SK3 (KCNN3) 
was detected in almost every tissue tested, including the mammary gland.  However 
this study was limited to healthy, not cancerous tissue samples.  At the time of 
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writing, the protein or expression levels of the SK channels have not been compared 
between healthy and cancerous breast epithelial cells. 
Similarly, the IK channel (KCNN4) mRNA is expressed in the normal mammary 
gland (Chen et al. 2004), but no comparison to cancerous breast tissue has been 
made by this group.  IK channel mRNA, protein, and functional channel activity have 
been detected in human breast cancer epithelial primary cell cultures and breast 
cancer tissue samples (Haren et al. 2010).  However, again no non-cancerous 
controls were used for comparison so how the levels of IK compare between 
cancerous and non-cancerous breast tissue is not known.  However, Haren et al. 
(2010) also demonstrated that IK expression level correlates significantly with 
tumour grade, indicating that this channel may contribute to tumour formation or 
progression. 
Khaitan et al. (2009) documented very low levels of both expression and protein 
levels for the BK channel in normal mammary tissue and untransformed mammary 
cell line MCF10A.  They found slightly higher expression levels in primary breast 
cancer tissue samples (n = 6).  On the contrary, Brevet et al. (2008) found lower 
levels of BK protein among 33 primary invasive ductal breast carcinomas compared 
to normal breast tissue from the same individuals.  Regrettably, the low numbers of 
specimens used by both groups makes it impossible to reach a definitive conclusion 
regarding the relative levels of BK in cancerous and normal breast tissue at this 
stage.   However, BK expression appears to be considerably higher among tissue 
samples of breast cancer metastasised to other organs, particularly the brain (n=4), 
suggesting a role for the BK channel in brain metastasis (Khaitan et al. 2009).  BK 
channel mRNA is present in MDA-MB-231 cells at a similar level as was seen in 
MCF7 (Lee et al. 2012). 
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1.6.4 The involvement of potassium channels in the proliferation of 
MCF7 breast cancer cells 
K+ currents are frequently studied in the MCF7 breast cancer cell model.  Treatment 
of MCF7 cells with the ATP-sensitive K+ channel opener minoxidil resulted in an 
increase in cell proliferation (Abdul et al.  2003).  Similarly, treatment of other cell 
lines with agents known to increase proliferation, such as 5nM prolactin added to the 
LNCaP prostate cancer cell line, increased the macroscopic K+ current and open 
probability of individual K+ channels in a tyrosine kinase dependent manner (Van 
Coppenolle et al. 2004).  This has not been repeated with MCF7 cells. 
In addition, treatment of MCF7 cells with a number of specific and non-specific K+ 
channel blockers results in inhibition of proliferation, as summarized in Table 1.9.  
This data implicates the SK channels, ATP sensitive channels (K ir6.1 and Kir6.2) and 
the voltage-gated channels (Pardo 2004; Wonderlin and Strobl 1996) in the 
proliferation of MCF7 cells.  Interestingly, the role of K+ channels in proliferation 
appears to be cell line-specific, as in colorectal adenocarcinoma cells, blocking 
VGKC activity, but not calcium activated- or ATP sensitive K+ channel activity, 
significantly inhibited proliferation (Yao and Kwan 1999).  This means that results 
from one cell line should not be generalized to other cell types. 
Incubation with iberiotoxin or charybdotoxin (both Ca2+ activated K+ channel 
blockers) had no effect on MCF7 proliferation, even at doses far in excess of their 
IC50 for the reduction of K
+ channel activity (Abdul et al.  2003; Ouadid-Ahidouch et 
al. 2000; Ouadid-Ahidouch et al. 2004a).  Neither did E-4031, a specific hERG 
blocker, have any effect, even though the drug was shown to be stable in the cells 
over the duration of proliferation assessment, and this channel is known to be 
present in MCF7 and is functional in the regulation of cell volume in this cell line 
(Roy et al. 2008).  Given that astemizole (AST) treatment reduces MCF7 
proliferation, and is known to block both hERG and hEAG, this connects hEAG, but 
not hERG, with the proliferation of these cells.   
Another VGKC with a potential role in the proliferation and cell cycle progression of 
MCF7 cells is Kv1.1.  This channel is expressed in these cells, while a number of 
other VGKCs, including Kv1.2 and Kv1.3, have not yet been identified, or are absent 
(Ouadid-Ahidouch et al. 2000; Ouadid-Ahidouch and Ahidouch 2008).  
 
 
Table 1.9: The effects of K+ channel blockers on MCF7 proliferation and channel activity 
Channel Blocker Channel  Inhibition of MCF7 
proliferation 
K+ channel activity IC50  
(cell line1) 
References 
4-amino-pyridine 
(4-AP) 
VGKCs 
 
IC50  1.6 mM
2 Between 0.1 and 4 mM 
(range of cell types including 
3T3, human T lymphocytes 
and human melanoma cells) 
Grissmer et al. 1994; Wonderlin and Strobl 
1996; Yao and Kwan 1999 
α-Dendrotoxin  
(α-DTx) 
Kv1.1 30% inhibition: 10 
nM 
0.6 nM Ouadid-Ahidouch et al. 2000 
Amiodarone Non-specific ion 
channel blocker 
IC50 1 μM (approx)  Abdul et al. 2003  
Astemizole 
(AST) 
hEAG and hERG IC50 between 5 and 
30 μM 
hEAG: 196nM (HEK-293), 
5µM effective in MCF7 
hERG: 0.9nM (HEK-293) 
Borowiec et al. 2007; Garcia-Ferreiro et al. 
2004; Ouadid-Ahidouch et al. 2004b; Roy et 
al. 2008; Salata et al. 1995; Zhou et al. 
1999 
Charybdotoxin 
(CTx) 
BK and IK No effect up to 100 
nM 
50 nM Coiret et al. 2005; Ouadid-Ahidouch et al. 
2000; Ouadid-Ahidouch et al. 2004a; 
Ouadid-Ahidouch et al. 2004b 
Clotrimazole IK 25% inhibition: 5μM 2 μM (approx.) Ouadid-Ahidouch et al. 2004b 
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Channel Blocker Channels 
affected 
Inhibition of MCF7 
proliferation 
K+ channel activity IC50  
(cell line1) 
References 
Dequalinium SK  IC50 1 μM (approx.)  Abdul et al. 2003 
E-4031 hERG No effect < 300 nM 7.7 nM (HEK-293) Roy et al. 2008; Zhou et al. 1998 
Glibenclamide ATP-sensitive K+ 
channels 
IC50 50 μM <0.05nM (pancreatic type in 
HEK-293) 51 nM (cardiac 
type in HEK-293) 
Abdul et al. 2003; Stephan et al. 2006; 
Wonderlin and Strobl 1996 
Iberiotoxin (IbTx) BK No effect up to 500 
nM 
100 nM approx. Ouadid-Ahidouch et al. 2000; Coiret et al. 
2005; Ouadid-Ahidouch et al. 2004a 
Tetraethyl-
ammonium 
(TEA) 
VGKCs,          
ATP-sensitive K+ 
channels,                
BK 
 
IC50 5.8 mM 2 mM 
500 μM blocks BK channel 
Coiret et al. 2007; Coiret et al. 2005; 
Grissmer et al. 1994; Ouadid-Ahidouch et 
al. 2000; Ouadid-Ahidouch et al. 2004a; 
Wonderlin and Strobl 1996; Yao and Kwan 
1999 
1 if no data available for MCF7 
2 Doses ≤1mM were not found to inhibit MCF7 proliferation (Abdul et al. 2003) 
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Care must be taken when extrapolating the IC50 data summarized in Table 1.9, as in 
several cases (indicated) no data exists for MCF7 cells.  However, in general, the 
data for MCF7 cells corresponds with other cell lines (Wonderlin and Strobl 1996).   
This highlights areas where the effects of these compounds in MCF7 require further 
characterization. 
Where dose-response relationships have been studied, the IC50 for inhibition of 
proliferation is frequently higher than the IC50 for inhibition of K
+ current activity.  
This suggests that inhibition of proliferation may be through non-specific, or 
cytotoxic actions of the channel blocker, rather than through inhibition of K+ channel 
activity, or that the effects on channel activity contribute a proportion of the response 
only.  However, serum is added to the proliferation media but not the solutions used 
to record K+ movement, and it is thought that components of  the serum (e.g. 
albumin, the major FBS protein; Zheng et al. 2006) may either bind the channel 
blocker, reducing its effectiveness, or further promote proliferation (Wonderlin and 
Strobl 1996).  In addition, where these channels have been ablated by silencing the 
gene (Koeberle et al. 2010; Weber et al. 2006), or transfected into cells known to not 
normally express them, similar results have been achieved (Cayabyab and 
Schlichter 2002; Dong et al. 2010; Gierten et al. 2008; Grissmer et al. 1994; Szabo 
et al. 2008; Zhang and Wang 2000) .  These studies add strength to the argument 
that the channel blockers inhibit proliferation through blockade of K+ channels, rather 
than through non-specific mechanisms. 
Work is ongoing to understand the mechanisms through which these channels and 
channel blockers affect proliferation in breast cancer cells.  As discussed, IGF1 is an 
important regulator of mammary gland development, and plays a key role in the 
initiation and progression of breast cancer (Hadsell 2003; Jin and Esteva 2008; 
Weinstein et al. 2009).  Treatment of MCF7 with the growth factor IGF1 (0.1 to 
20ng/ml for 48 hours) results in an increase in proliferation (Allan et al. 2006; 
Borowiec et al. 2007).  This increase in proliferation was associated with a rapid 
(within 1 to 2 minutes) increase in K+ current, membrane hyperpolarisation, and an 
increase in levels of the K+ channel hEAG mRNA  (Borowiec et al. 2007).  IGF1 
stimulated increase in proliferation was prevented by AST treatment, showing that 
hEAG is not only regulated by IGF1, but also plays a vital role in IGF1 mitogenic 
signaling in breast cancer cells.  However, as discussed, AST is a relatively non-
specific channel blocker, and has been shown to block hERG also (Pardo et al. 
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2005; Roy et al. 2008).  It is possible that the results of these studies may reflect the 
combined activities of the two channels, although the lack of any effect of the hERG 
antagonist E4031 may suggest that hEAG is physiologically more important in this 
instance.   
Activation of hEAG in MCF7 cells, by membrane depolarization to potentials higher 
than -20 mV, results in membrane hyperpolarisation.  This is associated with cell 
cycle progression from G1 to S phase (Borowiec et al. 2007; Ouadid-Ahidouch and 
Ahidouch 2008; Ouadid-Ahidouch et al. 2004b; Strobl et al. 1995).  Membrane 
hyperpolarisation is generally accepted to be involved in cell cycle progression, in 
what is known as the “membrane potential model” of proliferation (Ouadid-Ahidouch 
and Ahidouch 2008; Pardo 2004).   Blocking hEAG or IK by silencing with small 
interfering RNA (siRNA) or use of inhibitors AST (blocks hEAG and hERG) and 
clotrimazole (IK blocker), leads to membrane depolarization, reduced intracellular 
Ca2+ [Ca2+]i  and accumulation of the cell cycle progression inhibitor p21 (Ouadid-
Ahidouch and Ahidouch 2008; Ouadid-Ahidouch et al. 2004b).  Their inhibitory effect 
was additive, but blocking hEAG resulted in greater proliferation inhibition and G1 
phase arrest, than did blocking IK, leading to the suggestion that progression 
through G1 towards S phase is dependent on hEAG activity, while IK regulates 
membrane potential at the G1/S transition.   
The relationship between calcium and potassium channels in breast cancer cells is 
complex, at times paradoxical, and poorly understood.  Both hEAG and IK are 
regulated by an increase in [Ca2+]i  and calmodulin (CaM), a Ca
2+ binding protein.  
However, while hEAG activity is inhibited by Ca2+/CaM binding to its N-terminal 
domain (Ziechner et al. 2006), IK is activated by Ca2+/CaM (Fanger et al. 1999).  
These effects can occur simultaneously in MCF7 cells (Ouadid-Ahidouch and 
Ahidouch 2008). 
Calmodulin is required for the proliferation of numerous breast cancer cell lines 
including MCF7, T47D and MDA-MB-231, regardless of E2 treatment or ER status.  
This is demonstrated by incubation with CaM antagonists (Jacobs et al. 2000).  In 
addition, inhibition of the calcium-calmodulin-dependent kinases (CaM-Ks) by siRNA 
or antagonists  also reduced proliferation and caused G1 phase arrest in MCF7 cells 
(Rodriguez-Mora et al. 2005), possibly by inhibiting cyclin D1 synthesis and 
retinoblastoma protein phosphorylation.  Interestingly, CaM also binds to the ERs, 
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increasing their stability and cellular levels, in a Ca2+-dependent, E2-independent 
manner (Li et al. 2001), and calcium-calmodulin-dependent kinase IV was 
determined to be activated by ERα/E2 in MCF7 cells, although not by ERα in 
combination with resveratrol or a number of xenoestrogens (Li et al.2006).  
Ouadid-Ahidouch et al. (2008) propose the following basic model for the regulation 
of hEAG and IK by Ca2+/CaM, and their role in proliferation, which is summarized in 
Figure 1.6.  In early G1 phase membrane potential is depolarized (around -20mV) 
and [Ca2+]i is low, resulting in the activity of hEAG but not IK.  The Ca
2+ channels are 
inactive at this point.  Mitogenic stimuli result in an increase in hEAG expression, 
and activity (hEAG is depolarization activated, so operational at this potential).  The 
result is that the membrane becomes hyperpolarized (more negative) as G1 phase 
progresses.  This deactivates hEAG, but causes an influx of Ca2+ into the cell 
cytoplasm from internal stores, and from the external environment by way of the 
increased electrochemical driving force for Ca2+ promoting its movement through 
inwardly rectifying (voltage-insensitive) plasma membrane channels (depolarisation 
induced an increase in [Ca2+]i in rat megakaryocytes even in Ca
2+ free medium; 
Mahaut-Smith et al. 1999).  Increasing levels of [Ca2+]i and Ca
2+/CaM activate IK, 
resulting in stronger membrane hyperpolarization.  As G1 progresses to S phase, 
CaM and the CaM-Ks are also involved in the regulation of levels of cell cycle 
proteins such as cyclin D1 and p21.  The end result is progression to s phase, and 
enhanced proliferation of the breast cancer cells. 
In MCF7 cells, a non-inactivating outward K+ current was found which was inhibited 
dose- and voltage-dependently by α-dendrotoxin (α-DTx), with maximal inhibition 
being obtained at 10nM  α-DTx after 7 minutes of treatment, and an IC50 of 0.6 ± 0.3 
nM (Ouadid-Ahidouch et al. 2000).  Alpha-DTx is a toxin from the Black Mamba 
(Dendroaspis augusticeps), and blocks the channels Kv1.1, Kv1.2 and Kv1.6 (Harvey 
and Robertson 2004).  RT-PCR and immunocytochemical methods have shown that 
Kv1.1 is present in MCF7 cells, but anti-Kv1.2 antibodies did not label these cells 
(Ouadid-Ahidouch et al. 2000), indicating that Kv1.1 may be the pharmacological 
target of α-DTx in this case.  Kv1.6 was not included in this examination, and it is not 
known whether this channel is present in MCF7.  [3H]-Thymidine labeling of DNA 
was used to determine that α-DTx inhibited MCF7 proliferation in a dose-dependent 
manner, at the same doses which inhibited K+ current.  Ouadid-Ahidouch et al. 
(2000) suggest that this implicates Kv1.1 in the proliferation of MCF7 breast cancer 
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cells, however, the involvement of Kv1.6 cannot be ruled out.  Down-regulation of 
Kv1.1 expression by siRNA significantly reduced the proliferation of rat gastric 
mucosal epithelial cells, also measured by [3H]-Thymidine incorporation (Wu et al. 
2006).   
 
Figure 1.6: Membrane potential model of breast cancer cell proliferation 
Ast, Astemizole; CaM, Calmodulin; Clt, Clotrimazole; CTx, Charybdotoxin; hEAG, 
Human ether-a-go-go K+ channel; IGF1, Insulin-like growth factor 1; IK, Intermediate 
conductance K+ channel; TEA, Tetraethyl Ammonium 
Membrane depolarization and mitogenic stimuli in early G1 resuslts in the activation 
of hEAG.  The resulting K+ efflux causes membrane hyperpolarization, and an 
increase in [Ca2]i due to an influx along  its the electrochemical gradient (through 
voltage-insensitive inwardly rectifying Ca2+ channels, and the release of internal 
stores. This activates the IK channel, resulting in further hyperpolarization and the 
cell progresses to S phase. 
  
99 | P a g e  
 
The BK channels appear to have only a minor role in the normal proliferation of 
MCF7 cells, and their blockade induces only weak depolarization.  However, their 
expression level and activity is cell cycle dependent, both peaking at the end of G1 
phase (Ouadid-Ahidouch et al. 2004a).  The relevance of this linkage to the cell 
cycle is unknown, but may signify that they have small a regulatory role.  However, 
BK expression may relate to the invasiveness of breast cancer cell lines.  MDA-MB-
361 cells, with high levels of both KCNMA1 mRNA and BK protein, were 
considerably more invasive on a matrigel coated membrane than either MDA-MB-
231 or MCF7 cells, which both display much lower levels of the protein and mRNA.  
Un-transformed mammary epithelial cell line MCF10A was not invasive and had 
very low levels of BK protein present (Khaitan et al. 2009). 
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1.6.5 Potassium channels mediate an essential early stage of 
apoptosis 
Interestingly, the K+ channels have also been implicated as key regulators of 
apoptosis in many cell types (Wang 2004).  Cell shrinkage under isotonic conditions 
is known to be an essential early stage in apoptosis in a wide range of mammalian 
cell types including MDA-MB-231 breast cancer cells, Jurkat T lymphocytes and 
human renal HEK239 cells, epithelial HeLa cells, lymphoid U937 cells and the 
neuronal cell lines NG-108-15 and PC12 (Gow et al. 2005; Kossler et al. 2012; 
Maeno et al. 2000; Vu et al. 2001).   It is also referred to as apoptotic volume 
decrease (AVD).   AVD occurs prior to other hallmarks of apoptosis such as 
cytochrome C release, caspase activation and DNA degradation (Maeno et al. 
2000).   A number of studies have shown that AVD is attributable largely to K+ efflux, 
on the basis that net changes in cell osmolarity regulates the flow of water (Bortner 
and Cidlowski 1999; Bortner and Cidlowski 2004; Gow et al. 2005; Hughes, Jr. et al. 
1997; Storey et al. 2003). However, Cl- efflux, and the activity of the sodium-
potassium exchanger (Na+/K+-ATPase) also play a role in this process (Bortner and 
Cidlowski 2004; Maeno et al. 2000).   
In vitro studies have shown that K+, at normal, non-apoptotic intracellular levels, 
directly inhibits apoptotic DNA fragmentation and caspase 3 activation in rat 
thymocytes (Hughes, Jr. et al. 1997).  In the same study, disrupting K+ efflux in these 
cells by incubating them in high K+ medium inhibited apoptosis and caspase 3 
activation in response to apoptotic agents, suggesting that K+ efflux is a necessary 
event in apoptosis.   
The interaction between caspase activation, shrinkage and K+ efflux is complex.  
Caspase activation correlates with K+ efflux in lymphocytes treated with Fas 
apoptosis inducer or UV exposure (Vu et al.  2001).  This laboratory found that 
caspase 3 and 8 inhibitors blocked DNA degradation in lymphocytes treated with 
Fas, but failed to prevent AVD and K+ efflux, suggesting that K
+ efflux is an early 
cellular response which occurs prior to caspase activation (Bortner and Cidlowski 
1999).  Refer to Figure 1.4 for a summary of Fas (extrinsic) and UV (intrinsic) 
apoptotic pathways.  In apparent contradiction to this, the same group later 
demonstrated that the polycaspase inhibitor z-VAD-fmk abrogated AVD and K+ 
efflux, in addition to preventing DNA damage and caspase activation in Fas-treated 
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lymphocytes (Vu et al.  2001). However, it was less effective at preventing UV-
induced apoptosis.  They went on to show, using specific caspase inhibitors and 
mutants lacking individual caspase genes, that caspase 8 is required for Fas-
induced AVD, K+ efflux, and programmed cell death.  This confirms the role of 
caspase 8 described in the literature (Medema et al. 1997).  Correspondingly, 
caspase 9 has similar indispensable roles in UV induced apoptosis (Vu et al. 2001).  
In EATC cells, AVD mediated by the loss of K+, Na+, Cl- and amino acids is essential 
for caspase 3 activation in response to 5µM cisplatin (Hoffmann 2011).   Together, 
these findings suggest that apoptotic K+ efflux and caspase activation are tightly 
coupled but differentially regulated depending on the route of apoptosis induction, 
and are possibly also cell line specific. 
In a number of human tumour cell lines functional hERG K+ channels are required 
for effective induction of apoptosis in response to H2O2, and H2O2 treatment 
increased the outward flow of K+ (Wang et al. 2002).  In this study, cells lacking 
functional hERG required much higher concentrations of H2O2 to induce apoptosis, 
and in cells with functional hERG, co-treatment with the hERG blocker dofetilide 
(1µM) caused a dramatic reduction in the number of apoptotic cells after H2O2 
treatment.  It is possible that this function of hERG relates to the relationship 
between the expression levels of this channel and the increasing sensitivity to 
anticancer drugs described by Chen et al. (2005).  However, while the hERG 
channel protein is present in MCF7, this effect has not been investigated in these 
cells.   
Expression of hERG is similarly required for tumour necrosis factor α (TNFα; 1 and 
10 ng/ml) induced apoptosis (Wang et al. 2002).  Interestingly, lower doses of TNFα 
(1 and 0.1 ng/ml), which were less effective at inducing apoptosis, also enhanced 
proliferation.  Again, this effect was more pronounced in cells expressing hERG, but 
was not affected by dofetilide treatment.  Fluorescent antibodies were then used to 
suggest that hERG recruits the TNF-receptor (TNFR1) to the plasma membrane.  
The TNFRs (TNFR1 and TNFR2) have complex roles in the regulation of both 
apoptosis and proliferation, which are incompletely understood (Baxter et al. 1999; 
Haider and Knofler 2009).  In apoptosis TNFR1 activates caspase 3, triggering the 
caspase cascade in this manner.  The TNFRs induce proliferation through the 
transcription factor NF-κB (Haider and Knofler 2009).  In accordance with this, cells 
expressing hERG showed higher levels of NF-κB activity than cells lacking hERG 
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expression, and that TNFα treatment induced a further increase in NF-κB activity 
(Wang et al. 2002).  Interestingly, hERG has also been implicated in tumour 
proliferation (Pardo et al. 2005). 
In T lymphocytes activity of the IK channel appears to be an essential early stage in 
calcimycin induced apoptosis and AVD (Elliott and Higgins 2003).  This apoptosis 
inducer acts by increasing the inward flow of Ca2+ into the cell, initiating the Ca2+ 
dependent intrinsic apoptotic pathway.  In this cell line at least, an increase in [Ca2+]i 
triggered AVD via IK-mediated K+ current, which was essential for the induction of 
apoptotic PS externalization, and later, increased membrane permeability. 
In addition to their roles in the proliferation of breast cancer, there is also evidence 
to suggest that the channels Kv1.1 and Kv1.3 are involved in apoptosis in some cell 
lines.  One group used the lymphocyte cell line CTTL-2, which is known to be 
deficient in Kv channels, and transfected them with a Kv1.3 expression vector or 
control expression vector.  It was found that the presence of Kv1.3 specifically on the 
mitochondrial membrane both amplified and accelerated the ability of the 
lymphocytes to induce apoptosis in response to a number of stimuli, including TNFα, 
actinomycin-D and staurosporine (Bock et al. 2002; Szabo et al. 2008).  They also 
demonstrated that overexpression of Bax triggered massive apoptosis in the Kv1.3-
positive cells, but had no effect in cells lacking Kv1.3. Similarly, in rat retinal 
ganglions which constitutively express Kv1.3, blocking this channel with the relatively 
specific channel blockers agitoxin-2 or margatoxin greatly inhibited the ability of 
these cells to undergo apoptosis, and reduced the expression of the pro-apoptotic 
genes encoding caspase 3, caspase 9 and Bad, as determined by RT-PCR.  
Silencing the gene with siRNA had the same effect (Koeberle et al. 2010).  
Likewise, in Jurkat T lymphocytes K+ efflux through KV1.3 was stimulated by Fas 
ligand (inducer of extrinsic, death receptor-stimulated apoptosis), accompanied by 
cell shrinkage and DNA degradation (Storey et al. 2003).  This increase in current 
was prevented by Kv1.3-specific margatoxin or Shk-Dap
22 (a mono-substituted 
analogue of a sea anemone toxin).  Activity of caspase 8, but not caspase 3, was 
required for Fas-activated Kv1.3 channel activity, as demonstrated by use of broad 
and caspase 8 specific pharmacological inhibitors, and a line of lymphocytes which 
did not express caspase 8. 
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Kv1.1 has also been identified on the mitochondrial membrane in addition to the 
cytoplasmic membrane and, like Kv1.3, appears to have a role in the induction of 
apoptosis in lymphocytes (Szabo et al. 2008) and retinal ganglions (Koeberle et al. 
2010).  However, the mechanisms through which the two channels induce apoptosis 
may be different, as siRNA silencing of the Kv1.1 gene in rat retinal ganglions had 
no significant effect on the expression levels of caspase 3, caspase 9 and Bad (pro-
apoptotic member of the Bcl2 family), but increased the levels of the anti-apoptotic 
gene Bcl-xl (Koeberle et al. 2010).  Neither Kv1.1 nor Kv1.3 knockdown was found to 
affect the levels of Bcl2 mRNA. 
Silencing of the gene encoding Kv1.2 in rat retinal ganglions caused some reduction 
in their ability to undergo apoptosis, although this was to a much lesser extent than 
Kv1.1 or Kv1.3 silencing, and ablation of Kv1.5 was found to have no effect (Koeberle 
et al. 2010).  The VGKCs  are also involved in induction of apoptosis in pulmonary 
artery smooth muscle cells, where incubation with 4-AP prior to an apoptotic stimuli 
reduces apoptosis significantly, increases intracellular K+ concentration, inhibits 
caspase activity and prevents mitochondrial cytochrome c release (Park et al. 2010).  
Breast cancer cells have been demonstrated to express a number of VGKCs at 
different levels to untransformed cells or normal tissue.  While the involvement of 
Kv1.3 in breast cancer cells is controversial, it has been reported in lower levels in 
cancerous breast tissue compared to normal breast tissue by one group (Brevet et 
al. 2008).  In addition, Ouadid-Ahidouch et al. (2000) confirmed that the protein is 
not present in MCF7 cells.  Absence or low levels of this K+ channel may be related 
to the low levels of apoptosis seen in cancerous cells.  However, surprisingly, the 
involvement of the VGKCs in the induction of apoptosis in breast cancer cells has 
not been investigated. 
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1.6.6 Effect of oestrogen and anti-oestrogens on MCF7 potassium 
channel activity 
In MCF7 cells 10 nM E2 rapidly and irreversibly induced the BK channels (Coiret et 
al. 2005).  This induction was not prevented by co-treatment with the ER antagonist 
ICI 182780 (1 µM).  The rapid induction of BK channel activity by E2 treatment was 
considered likely to occur extra-cellularly since membrane impermeable BSA-
conjugated E2 (10 nM) also caused the same effect.  This study argues that E2 and 
BSA-E2 non-genomically and dose dependently stimulate proliferation of MCF7 
cells.  They also found that BSA-E2 stimulated proliferation was reduced by non-
toxic doses of the BK channel blockers iberiotoxin (100 nM), charybdotoxin (50 nM) 
and TEA (500 µM), implicating this channel in E2-induced proliferation.   
Interestingly, the same channels in MCF7 breast cancer cells were also induced by 
10 nM treatment with the partial oestrogen antagonist tamoxifen (Coiret et al. 2007).  
This effect was not additive to the effects of E2 or BSA-E2, and it was unaffected by 
the presence of ICI 182780.  Together, these results suggest that tamoxifen also 
acts independently of the ERs, possibly through the same extra-cellular mechanism 
as E2 in this case.  Both 10nM E2 and 10nM tamoxifen induced proliferation of 
MCF7 cells, but similarly this effect was not additive.  In addition, the BK  channel 
blockers significantly reduced the 10nM tamoxifen effect on proliferation, 
suggesting, as with E2-induced proliferation, this channel may play a role in (low 
dose) tamoxifen-induced growth of MCF7 cells.  It is important to note that this study 
was carried out using a low dose of tamoxifen, which was known to induce 
proliferation in MCF7 cells.  In patients receiving tamoxifen as chemotherapy, there 
is considerable inter-individual variance in serum levels, but generally it is in the 
range of 0.1 to 5µM (Fahey et al. 1994). 
The effects of higher, growth-inhibitory concentrations of tamoxifen, from 1μM 
upwards, on K+ channel activity in breast cancer cells have not been investigated.  
However, the growth inhibitory effects of tamoxifen, and amiodarone (1μM) or 
dequalinium (1μM) strengthened each other, suggesting that tamoxifen may inhibit 
growth of MCF7 cells in a manner unrelated to ion channel activity (Abdul et al. 
2003).   
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The effects of tamoxifen and ICI 182780 on the BK channels in other cell lines vary.  
They have both been shown to activate this channel in canine colonic smooth 
muscle cells (1 μM tamoxifen and 10 μM ICI 182780) (Dick et al. 2001; Dick 2002), 
but 10µM tamoxifen treatment had no effect on BK activity in vascular endothelial 
(HUVEK) cells (Li et al. 2000).  ICI 182780 had an inhibitory effect on BK channel 
activity in human coronary artery epithelial cells, with all doses between 1 and 30 
µM rapidly reducing channel activity in a dose dependent manner, with an IC50 of 3 
µM (Liu et al. 2003).  However, in human coronary artery smooth muscle cells, ICI 
182780 caused a bell shaped dose-response for BK channel activity, with doses 
below 3 µM increasing the number of open channels, while higher doses reduced 
channel activity (Dick 2002; Liu et al. 2003). 
Evidently, the effects of oestrogen and antioestrogens on BK channel activity are 
complex and differ depending on cell type, but are unlikely to relate to their ability (or 
otherwise) to activate transcription through the ERs.  In MCF7 cells, the ability of E2 
and low dose-tamoxifen to induce proliferation is associated with their ability to 
activate BK channel activity, but the effect of ICI 182780, which does not induce 
proliferation, or growth-inhibitory doses of tamoxifen, on BK in MCF7 cells is 
unknown. 
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1.6.7 Effects of isoflavones on the activity of potassium channels: a 
possible breast cancer protective mechanism 
Due to its non-specific protein tyrosine kinase (PTK) inhibitory actions, genistein is 
frequently utilized in studies investigating the regulation of K+ channel activity.  In 
this manner it has been determined that genistein and other isoflavones, at 
concentrations ranging from 10 to 100 µM inhibit K+ current through many channels 
in a number of expression models or excitable cardiac cells and lymphocytes, with 
resting membrane potentials of around -70 mV.   In the majority of these cases the 
response to genistein, or other protein tyrosine kinase inhibitors has been very rapid 
(within seconds or minutes of treatment) arguing for a direct influence on signaling 
pathways or the channel proteins themselves, rather than changes in gene 
expression.   
Since many of these channels have roles in proliferation and apoptosis, the impact 
of K+ channel inhibition by isoflavones may be relevant to the pro-proliferative or 
pro-apoptotic actions of these compounds.  However, as far as can be ascertained, 
no studies to date investigating the effects of isoflavones on K+ channels in breast 
cancer cells (resting membrane potential of around -50 mV) have been conducted, 
so their impact on breast cancer proliferation or apoptosis is unknown.  The next 
section addresses current knowledge regarding the impact of soy isoflavones on the 
potassium channels known to be associated with breast cancer proliferation, 
apoptosis, or the MCF7 cell line.   
1.6.7..1  hERG and the rat homologue rERG 
Using human embryonic kidney (HEK293) cells stably transfected with hERG, it was 
found that the K+ current through this channel was inhibited by 30 μM genistein 
(Zhang et al. 2008).  Co-treatment with 1 mM orthovanadate, a protein tyrosine 
phosphatase (PTP) inhibitor, countered the suppression of current, signifying that 
hERG K+ current inhibition by genistein is dependent upon its ability to inhibit protein 
tyrosine kinase activity.  Orthovanadate alone failed to have the opposite, current 
promoting effect suggesting that basal levels of TK-substrate phosphorylation may 
be saturated.  Daidzein (a PTK inactive analogue of genistein) treatment resulted in 
some current inhibition at higher doses, although this was much less pronounced, 
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making it impossible to rule out the possibility that higher doses of genistein may 
have some direct channel blocking properties also.   
Additionally, Zhang et al. (2008) demonstrated that the hERG current was inhibited 
by the selective PTK inhibitors AG556 and PP2 (both at 10 μM).  These compounds 
inhibit epidermal growth factor receptor (EGFR) and Src-family tyrosine kinase 
activity respectively, and consequently implicate both kinases in the regulation of 
hERG.  Whether genistein, AG556 and PP2 inhibit current through hERG in the 
same manner was not investigated.  However, Western blots demonstrate that 
genistein, AG556 and PP2, at the doses described, each reduce phosphorylation of 
the channel protein in a manner antagonized by orthovanadate (Zhang et al. 2008).  
Again the PTP inhibitor alone had no effect on channel phosphorylation suggesting 
that under control conditions hERG phosphorylation is saturated. 
Whole cell patch clamp recordings taken from MSL-9 cells derived from rat microglia 
identified a depolarization activated inwardly rectifying current that was fully and 
specifically blocked by 1 μM E-4031 treatment, suggesting that it was mediated by 
the rat homologue of hERG (rERG; 99% homology) (Cayabyab and Schlichter 
2002).  Following 15 to 20 minutes of treatment with the broad spectrum PTK 
inhibitors lavendustin A or genistein (each at 50 μM) current amplitude was reduced 
to a significantly greater extent than the spontaneous rundown effect (35% and 60% 
respectively).  Daidzein (50 μM) had no significant effect. The same group 
demonstrated that treatment with the Src-selective PTK inhibitor herbimycin A for 
over 12 hours, reduced current amplitude by around 70%.  This data indicates that 
rERG K+ current is inhibited by broad and Src-specific PTK inhibitors.  Using 
Western blots with anti-rERG and anti-phosphotyrosine antibodies, Cayabyab and 
Schlichter (2002) proceeded to show that rERG was constitutively tyrosine 
phosphorylated in these circumstances, and that 12 hours of pre-treatment with 
genistein (50 μM) or herbimycin A (3 μM) significantly reduced tyrosine 
phosphorylation of rERG, by 40% or 25% respectively.   
These studies together suggest that hERG, and the rat homologue rERG, are 
regulated by PTK activity, including by the EGFR and Src-related kinases, and that 
genistein treatment inhibits h/rERG K+ current through its ability to inhibit a broad 
spectrum of PTK activity.  No attempt has been made to distinguish between direct 
inhibition of PTK phosphorylation of the channel or upstream interactions with other 
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signaling molecules.  The precise mechanism of inhibition is not known in either 
case.  The close homology between rERG and hERG makes it likely that the two 
channels are regulated in a similar manner, although caution must be used when 
making direct comparisons.   
The hERG channel does not appear to have a role in the proliferation of breast 
cancer cells (Roy et al. 2008), so its inhibition by genistein is unlikely to directly 
relate to the growth inhibitory effects of this isoflavone.  Instead, the inhibition of 
hERG by genistein may dampen the pro-apoptotic effects of this channel, and so in 
this manner relate to the growth-promoting properties of isoflavones.  Although the 
doses of genistein used to inhibit hERG K+ current are comparable to the range of 
doses used to inhibit proliferation and induce apoptosis in both ERα+ and ER- 
breast cancer cell lines, as discussed it may be of little value to directly compare 
effective concentrations between patch clamping and proliferation experiments.  
Regrettably, neither of the above groups has provided data for a dose-response or 
IC50 for genistein and hERG activity.  It would be of considerable interest to 
investigate the effect of genistein on the activity of hERG in breast cancer tissue or 
cell lines. 
1.6.7..2  Kv1.3  
 Whole cell voltage-sensitive K+ current amplitude was reduced to below 50% by 
40µM genistein in circulating human T lymphocytes by the whole cell patch clamp 
method (Teisseyre and Michalak 2005).  Current blockade by genistein was dose-
dependent, with half-maximal blockage occurring in the concentration range 
between 10 and 40 μM.  Current activation was also slower after genistein 
treatment.  In these cells the VGKC current is carried predominantly by the Kv1.3 
channel (Cahalan et al. 2001), and the current was completely blocked by addition 
of 5 mM 4-AP, suggesting that these channels may be the target of genistein 
inhibition in lymphocytes.   
Teisseyere and Michalak (2005) also found that the current measured, after co-
treatment with 10 μM genistein and 1 mM orthovanadate, was not significantly 
different to that after genistein treatment alone.  This suggests that in the case of 
Kv1.3 channels in human T lymphocytes, current inhibition by genistein occurs in a 
predominantly PTK-independent manner.  Kv1.3 current was unaffected by 
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treatment with 40 μM daidzein.  In both T lymphocytes and breast cancer cells 
expressing Kv1.3, treatment with the VGKC blocker tetraethyl ammonium (TEA) 
inhibited proliferation, as measured by the MTT assay and [3H]-thymidine 
incorporation into DNA respectively (Cahalan et al.2001; Jang et al. 2009).  In both 
cases the doses of TEA used were non toxic.   
The doses of genistein used in to inhibit current through Kv1.3 (10 to 40 μM) 
correspond with the range of doses known to inhibit proliferation and induce 
apoptosis in breast cancer cell lines.  These doses are slightly higher than the 
physiologically relevant high serum levels (1 to 10μM), however, as discussed, 
differences in experimental conditions and media may account for incongruities 
between the IC50s for genistein on K
+ channel activity and proliferation.  Bearing this 
in mind it is possible that genistein may inhibit breast cancer proliferation via 
inhibition of the Kv1.3 channel.  Kv1.3 is also involved in the induction of apoptosis in 
a number of cell lines, but there is no evidence to suggest that genistein treatment 
inhibits the induction of apoptosis.  However, while this channel is expressed in 
many breast cancer tissues, it has not been detected in MCF7 cells (Ouadid-
Ahidouch et al. 2000).  It is interesting to note that Kv1.3 in human T lymphocytes 
was also inhibited in a similar manner by resveratrol, a phytoestrogen found in 
grapes and wine, with an IC50 value calculated to be 40.9 ± 5.0 μM (Teisseyre and 
Michalak 2006). 
1.6.7..3  BK channel 
Resveratrol has been demonstrated to dose dependently stimulate outward BK  and  
IK channel activity in vascular endothelial HUVEC cells, with an EC50 (concentration 
required for a half-maximal effect) of 20 µM, using the whole cell patch clamp 
technique. This same group found that quercetin (30 µM) had no effect (Li et al. 
2000).  Resveratrol appeared to enhance channel activity by increasing the length of 
time that each channel was open for, rather than raising the conductance of 
individual channels.  
Puerarin, the main isoflavone found in the root of the leguminous creeper Kudzu 
(Pueraria lobata), also potently and rapidly activated the BK channel in Xenopus 
oocytes, when applied to the cytoplasmic side of an excised cell membrane patch at 
negative potentials in a Ca2+ dependent manner, with EC50s of 12.6nM and 0.8nM 
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with and without 10 μM Ca2+ respectively (Sun et al. 2007).  This indicates either 
that calcium may facilitate BK activation by puerarin, or that puerarin increases the 
Ca2+ sensitivity of the channel.  Daidzein, a hydrolysate of puerarin, lacking a 
glycosyl residue at the 8-position, also increased the BK current, but to a lesser 
extent than puerarin, suggesting that the 8-glucosyl residue has a role in the 
activation of the channel. 
To the author’s knowledge, the effect of genistein on the activity of the BK channel is 
not known.  While BK channel activity appears to be unrelated to the regulation of 
proliferation in breast cancer, there is evidence suggesting that it plays a role in 
invasiveness or metastasis (Khaitan et al. 2009).  This may be a mechanism 
through which isoflavones exert some of their protective effects against breast 
cancer. 
1.6.7..4 The delayed rectifier K+ current (IKS)  
The slowly activated delayed rectifier current IKS in Guinea pig ventricular myocytes 
is an outward K+ current carried by a channel formed from KCNQ1 (Kv7.1) and 
KCNE1 subunits (Chen et al. 2009; Vanoye et al. 2010).  Mutations in these proteins 
are implicated in severe hereditary cardiac arrhythmias such as long QT syndrome.  
Kv7.1 was dose-dependently inhibited by treatment with genistein at concentrations 
between 3 and 100μM (Dong et al. 2010).  This team used the perforated patch 
clamp technique6 with HEK293 cells stably expressing recombinant Kv7.1.  Daidzein 
(100μM; PTK inactive analogue of genistein) treatment resulted in some current 
inhibition, although it was much less pronounced than lower doses of genistein, 
making it impossible to rule out the possibility that higher doses of genistein may 
have some direct channel blocking properties also.  Co-treatment with 1mM 
orthovanadate (PTP inhibitor) countered the suppression of current by 30 μM 
genistein, suggesting that Kv7.1 current inhibition by genistein is dependent upon its 
ability to inhibit PTK activity.  Orthovanadate alone failed to have the opposite, 
current promoting effect suggesting that basal levels of TK-substrate 
phosphorylation may be saturated.   
                                                 
6
 Perforated patch: whereby the pipette pulls back once the gigaseal is formed, rupturing the 
membrane and leaving a membrane-vesicle over the end of the pipette tip.  As the 
membrane is now inside out, this allows changes to the bath solution composition to reflect 
changes in the cytosol. 
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By using the selective PTK inhibitors PP2 (Src-related kinase inhibitor; 1 μM) and 
tyrphostin AG556 (EGFR kinase inhibitor; 20 μM) at doses vastly in excess of their 
IC50 for PTK inhibition, it was determined that Kv7.1 was regulated by EGFR kinase 
but not the Src kinases.  Similarly, immunoprecipitation and Western blotting 
revealed that both genistein (30 μM) and AG556 (30 μM) significantly reduced 
phosphorylation of Kv7.1 in a manner reversible by addition of 1 mM orthovanadate, 
while PP2 had no effect.  Interestingly, Dong et al. (2010) demonstrated that the 
higher dose of 20 μM PP2 substantially inhibited the current, but this effect was not 
countered by addition of orthovanadate, implying that it acts through PTK-
independent mechanisms at these doses, or again masks the weaker opposing 
effect of orthovanadate. 
Overall, it appears that genistein reduces IKS by inhibiting the tyrosine 
phosphorylation of Kv7.1, either directly or by inhibiting EGFR kinase, while 
daidzein, with far lower PTK-inhibitory action, had a significantly reduced effect.  
However, no significant alterations in EGFR phosphorylation were seen after 
treatment with genistein concentrations up to twice the IC50 for growth inhibition 
(Peterson and Barnes 1996).  This points to direct inhibition of PTK phosphorylation 
of the channel by genistein, possibly in a similar manner to AG556.  However in this 
case the hypothesis was not investigated further.   
Similarly IKS in guinea pig ventricular myoctyes was dose-dependently and reversibly 
inhibited by genistein, with an IC50 of 64 ± 4 μM (Missan et al. 2006).  The Hill 
coefficient of this response was significantly different from one, indicating that other 
molecules may be involved in regulation of IKS.  On this occasion the current was 
measured by voltage clamping using the whole cell method.  They found that 
treatment of myocytes with the non-specific PTK inhibitors tyrphostin A25 and A23 
also suppressed IKS (IC50 12.1 ± 2.1 and 4.1 ± 0.6 μM respectively).  Current 
inhibition was likely to be caused by the PTK–inhibitory actions of each of these 
compounds, as the PTK-inactive analogues genistin, tyrphostin A1 and tyrphostin 
A63 had no effect on current amplitude up to doses of 200 μM.  Daidzein inhibited 
current dose-dependently but to a substantially lesser extent, again suggesting that 
genistein may also have some direct channel-blocking activity.   
In agreement with Dong et al. (2010), Missan et al. (2006) demonstrated that current 
inhibition by 50 μM genistein was significantly reduced by co-treatment with 
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orthovanadate (1 mM), while the PTP inhibitor alone had no effect.  This confirms 
that genistein regulates IKS through its PTK inhibitory properties.  They present data 
which appears to rule out the possibility of orthovanadate acting through parallel 
mechanisms, by regulating the activity of serine/threonine kinases such as PKA.  
This tends to suggest simply that a stronger inhibition of PTK activity by higher 
doses weakens the ability of orthovanadate to restore IKS.  Inhibition of the 
serine/threonine kinases PKA, PKB, PKC, ERK1/2 and the stress-activated protein 
kinase p38 had no effect on the inhibition of IKS by PTK inhibitors, although these 
experiments used tyrphostin A25 in the place of genistein, suggesting that IKS is not 
regulated by any of these signaling kinases.   
Missan et al. (2006) demonstrate that treatment with the Src-related kinase inhibitor 
PP2 (10 μM) reduced the amplitude of IKS while AG1478, another EGFR PTK 
inhibitor (10 μM) had little effect, suggesting that Src-PTK activity is involved in 
regulating IKS activity, but EGFR-PTK is not.  This directly contradicts the results of 
Dong et al. (2010) who proposed that EGFR but not Src played a role in the 
regulation of this current.  The discrepancies between these results may relate to 
the different cell line used by each group.  However, it is possible that it reflects 
different regulatory mechanisms of the two channel subunits, KCNQ1/Kv7.1 and 
KCNE1.  While Missan et al. (2006) studied “wild type” currents in cardiac cells, 
Dong et al. (2010) transfected the Kv7.1 subunit into another cell line to study it in 
isolation. 
Overall, these two groups have generated clear evidence for the tyrosine kinase 
regulation of IKS, and each concludes that genistein inhibits K
+ flux through this 
channel via its ability to inhibit PTK activity.  In each case daidzein, with weaker PTK 
activity than genistein, resulted in weaker inhibition of current, and inactive genistin 
(precursor molecule) had no effect at the doses used.  Their conclusions regarding 
the mechanisms of inhibition are inconclusive.   However, while Kv7.1 is known to be 
present in MCF7 cells, any involvement it may have in the regulation of proliferation 
or apoptosis is yet to be documented. 
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1.6.8 Osmotic volume regulation 
It is apparent that an element of the involvement of K+ channels in proliferation, and 
more so in apoptosis, is related to their effects on osmolarity and volume regulation.  
Alterations in the osmolarity of the extracellular medium result in rapid movements 
of water in or out of the cell, driven by the osmotic gradient, and resulting in volume 
change.  Swelling is induced by a change into a hypotonic solution, and shrinkage 
by a hypertonic solution.  Following this, in numerous cell types plasma membrane 
ion pumps or channels are activated, resulting in a loss or gain (as appropriate) of 
intracellular ions, and corresponding osmotic movement of water returning cell 
volume to its former level (Dubois and Rouzaire-Dubois 2004).  Regulatory Volume 
Increase (RVI) refers to the process of the cell swelling after shrinkage in a 
hypertonic solution, and is largely related to the activity of Na+-K+-Cl- cotransporters 
and/or the Cl--H+ and Cl- HCO3
- exchangers.  The corresponding pathway 
Regulatory Volume Decrease (RVD) occurs after hypotonic-induced swelling, and is 
mediated by the Cl- and K+ channels (Caplanusi et al. 2006; Dubois and Rouzaire-
Dubois 2004).  
RVD occurs in numerous cell types, including MCF7 and MDA-MB-231 breast 
cancer cells (Gow et al. 2005; Roy et al. 2008; vanTol et al. 2007), and can reduce 
cell volume back to near isotonic levels within 30 minutes (Huang et al. 2011; Pan et 
al. 2007).  It is regulated by the MAPKs, although in a tissue specific manner, and 
can be prevented by agents which block these pathways.  Little is known about the 
regulation of RVI.  Although RVD is a response to a non-physiological stimulus, very 
similar regulatory mechanisms are proposed to play a role in volume regulation 
during proliferation and apoptosis (Wonderlin and Strobl 1996).  Likewise, RVD is 
coupled to AVD, and both are regulated by similar mechanisms in numerous 
cancerous cell lines (Hoffmann 2011; Maeno et al. 2000). 
1.6.8..1 Regulatory volume decrease in MCF7 
Upon treatment of MCF7 with relatively non-specific K+ channel blockers such as 
BaCl (5mM), quinine (0.5mM), TEA (10mM), and imipramine (100µM) in a hypotonic 
solution, the cells underwent swelling as expected, but RVD was reduced or 
prevented (Roy et al. 2008; vanTol et al. 2007).  This helps to confirm the role of K+ 
channels in RVD in MCF7.  Charybdotoxin (100nM) and clotrimazole (30µM) had no 
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effect, ruling out the BK and IK channels in this response.  However treatment with a 
hypotonic solution and 300nM E4031 or 30µM AST both prevented RVD, 
suggesting that the hERG, and perhaps hEAG channels are involved in this 
response (Roy et al. 2008).  This supports the role of hERG in AVD and apoptosis. 
Similarly, the Kv7.1 channel blockers 293B and XE991 were also found to prevent 
MCF7 RVD (vanTol et al. 2007).  To confirm the role of this channel in volume 
regulation, this group transfected MCF7 with a dominant-negative KCNQ1 (Kv7.1 
gene), which also prevented RVD.  In MCF7 (wild type) they were able to record a 
small 293B-sensitive current using whole cell patch clamping under hypotonic but 
not isotonic conditions, and overexpression of KCNQ1 increased this current 
component.  The apparent parallels between RVD and AVD indicate that Kv7.1 may 
have a role in the induction of apoptosis in MCF7, although this is circumstantial, 
and yet to be proven. 
1.6.8..2 Isoflavones and regulatory volume decrease 
Treatment with upwards of 100µM genistein has been shown to attenuate RVD and 
swelling induced K+ efflux in a wide range of cell types, including human bronchial 
epithelial 16HBE14o- cells (Caplanusi et al. 2006), Ehrlich ascites tumour cells 
(EATC; Kirkegaard et al. 2010) and the human erythroleukemic cell line K562 
(Huang et al. 2011).  Other K+ channel inhibitors such as gadolinium and quinine 
(both 0.5mM), the PTK inhibitor tyrphostin (100µM) and other Src and EGFR-kinase 
specific inhibitors acted similarly (Caplanusi et al. 2006; Huang et al. 2011).   In 
addition, the PTK inhibitor monoperoxo(picolinato)-oxo-vanadate (mpVpic; 10µM) 
prevented genistein-inhibition of K+ efflux and RVD in EATC cells (Kirkegaard et al. 
2010).  The latter group also present evidence to suggest that RVD in this cell line is 
mediated by the TASK2 channel, and does not involve the K+-Cl- cotransporter as 
K+ efflux continued to occur when all extracellular Cl- was replaced with NO3
-.  It is 
possible based on this that PTK regulation of RVD is cell line specific.  Regardless, 
in each of these studies discussed a large, non-physiological genistein dose has 
been used, which may have non-specific or cytotoxic effects.  In the case of 
Kirkegaard et al. (2010) this went as high as 371µM (at least 10-fold greater than a 
physiological dose).   
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There was only one instance of use of a lower, genistein dose to study cell volume 
regulation.  Treatment with 30µM genistein inhibited the swelling activated chloride 
current in isolated rabbit articular chondrocytes (Okumura et al. 2009).  The same 
concentration of daidzein had a related, although lower magnitude effect.  Treatment 
of rat hepatoma HTC cells with 10µM genistein prevented RVI (Feranchak et al. 
2003).  However this was related to an effect on Na+ channels rather than K+.   The 
impact of these concentrations of isoflavones on K+- related volume regulation is not 
known.   
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1.6.9 Summary of the impact of isoflavones on K+ current and volume 
regulation 
This section has discussed the growing body of evidence supporting the theory that 
K+ channels, through their ability to regulate Em and cell volume regulation, have 
roles in the proliferation of breast cancer cell lines, and progression of the disease in 
patients.  Of the numerous K+ channels discovered, some of those to show altered 
expression in cancerous breast tissue biopsies include hEAG, hERG and Kv1.3.  
While the latter channel is not present in MCF7 cells, hEAG and hERG are, along 
with Kv1.1, and a number of Ca
2+ activated and inwardly rectifying K+ channels. 
Through altering their expression levels, and pharmacological blockade or 
activation, hEAG, Kv1.1, and several of the Ca
2+ activated K+ channels have been 
demonstrated to play important roles in MCF7 proliferation.  This is conjectured to 
be through the mitogen-stimulated “membrane potential model of breast cancer 
proliferation”, whereby altered patterns of K+ channel activity result in changes in 
membrane potential on a large scale, stimulating cell cycle progression. 
However, paradoxically, a number of the K+ channels (often the same ones that are 
involved in proliferation) have indispensable roles in the induction of apoptosis in a 
range of cell types including some tumour cell lines.  The major players in this 
process appear to be hERG, the IK channel, and some VGKCs.  Their involvement 
in apoptosis seems to relate not to their impact on membrane potential, but their 
ability to regulate osmolarity, and consequently cell volume (shrinkage is widely 
accepted to be an essential early stage in apoptosis). 
In its capacity as a tyrosine kinase inhibitor, genistein is frequently called upon to 
block the activity of numerous K+ channels in a wide range of cell types, although 
never in cultured breast cancer cell lines.  A number of these channels have 
significance to breast cancer, in the context discussed.  Genistein blocks the activity 
of the hERG channel, and in this manner may lessen the role of hERG in the 
induction of apoptosis. Likewise, genistein inhibits the activity of several of the other 
VGKCs (Kv1.3 and Kv7.1), which may relate to inhibition of breast cancer cell 
proliferation seen with higher concentrations of isoflavones.  On the whole, 
pharmacological concentrations of genistein have been used (typically in excess of 
50µM).  The effect of physiological concentrations is not known.  The impact of 
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daidzein on K+ channel activity is not widely known, but where it has been 
investigated it tends to be less active than genistein.  Interestingly, E2 and the 
selective antioestrogen tamoxifen have been found to activate the BK channel in 
MCF7.  In each case, genistein, daidzein and E2 have acted upon the K+ channels 
quickly (within minutes of treatment) arguing a direct interaction with the channel 
protein or activation of a rapid signaling cascade rather than a genomic response. 
An element of the role of K+ channels is linked to their impact on cell volume.  This is 
of particular significance for shrinkage and the induction of apoptosis.  AVD is 
coupled in its regulatory mechanisms to the non-physiological process of RVD, 
which is widely studied in MCF7 and other cell lines.  There is evidence supporting 
the role of hERG in apoptosis, and also Kv7.1, through their implication in RVD.   
Genistein attenuates RVD in many cell types, although once again often very high 
concentrations are used.  The prevention of RVD by genistein, and accordingly 
prevention of AVD, may contribute to a pro-proliferative mechanism of isoflavones.  
However considerable further testing of these hypotheses is required, importantly, at 
physiologically relevant isoflavone concentrations. 
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1.7 Proposed investigations 
1.7.1 Study design and aims 
The aim of this project was to further investigate the effects of common dietary soy 
isoflavones on breast cancer cell proliferation, apoptosis, and potassium channel 
activity. 
To achieve this there were two main objectives: 
 
1.  To determine the effect of achievable levels of specific isoflavones, at pre- and 
post- menopausal oestrogen concentrations, on breast cancer cell apoptosis and 
proliferation 
 
2.  To characterize the effect of isoflavones on volume regulation and K+ channel 
activity in breast cancer cells, and to investigate whether this contributed to their 
pro-apoptotic or pro-proliferative properties 
 
This was a two phase project.  Both stages were conducted in vitro.  Firstly 
apoptosis and proliferation were measured in ERα+ and ERα-/ERβ+ breast cancer 
cell lines after treatment with a range of concentrations of genistein and daidzein, 
the main isoflavone phytoestrogens in soy, and either pre- or post-menopausal E2.  
These were as single treatments or in combination with each other.  Secondly, the 
impact of several concentrations of genistein, daidzein and 17β-oestradiol identified 
in the first stage was investigated on cell volume (mediated by ion movement, 
including K+) and the activity of the VGKCs, specifically hEAG and hERG.  How 
these factors related to the proliferative effects of these isoflavones was explored.   
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1.7.2 Rationale and study design for the investigation of the 
proliferative and apoptotic effects of isoflavones and oestrogen, 
alone and in combination 
The proliferative effects of the soy isoflavones genistein and daidzein at a wide 
range of physiologically relevant concentrations (<10µM) are well defined in ERα+ 
and ERα-/ERβ+ breast cancer cell lines.  Furthermore, there is a considerable body 
of evidence suggesting that the induction of apoptosis may be a mechanism through 
which the soy isoflavones mediate their putative breast cancer protective effects. 
However, the induction of apoptosis by isoflavones in these cell lines has not been 
reported on at physiologically relevant concentrations of the isoflavones below 5µM.  
Likewise, their effects on proliferation and apoptosis in combination with pre-and 
post-menopausal oestrogen levels are relatively unclear.  It has been suggested that 
at premenopausal E2 levels high concentrations of isoflavones, comparable to those 
seen in the blood of individuals consuming a very high soy diet, reduce proliferation 
and induce apoptosis in breast cancer cells.  However the effects of soy isoflavones 
on ERα-/ERβ+ breast cancer cells and at post-menopausal E2 levels is less clear.  
Research in these areas is a priority as this population of women are at greater risk 
of the disease, and frequently consume isoflavone supplements for relief of 
menopausal symptoms.   
The neoplastic human breast epithelial cell lines MCF7 and MDA-MB-231 were 
used as models of ERα+ and ERα-/ERβ+ breast cancer, respectively.  While this 
environment may not be identical to that of an in vivo model of the disease, they are 
regarded as valid for this use, are well characterized, and behave reproducibly.  The 
cell lines were treated with physiologically relevant levels (serum levels achievable 
through the diet) of two soy isoflavones at pre- and post-menopausal 17β-oestradiol 
levels, to determine the effects of these combinations of treatments on the ability of 
the cells to proliferate and/or induce apoptosis. 
Proliferation was assessed in both cell lines using the MTT assay. This is a very 
widely used method, which is sensitive, reproducible, and relatively high throughput.  
This method, and the rationale behind its choice is discussed fully in sections 2.4 
and 6.1.1.  The method was also validated against the Trypan blue dye exclusion 
assay in both cell lines for a range of the treatments used.  The impact of the vehicle 
solvent, genistein and daidzein at a range of physiological concentrations, and pre- 
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and post-menopausal E2 concentrations on proliferation were investigated.  
Following this, the effect of combined treatments of genistein or daidzein at pre- and 
post-menopausal E2 levels was assessed. 
In accordance with the advice of the NCCD, two methods to assess the impact of 
the isoflavones on the induction of apoptosis in MCF7 and MDA-MB-231 cells were 
used.  The first was the Annexin V-Cy3™ Apoptosis Detection Kit (Sigma), which 
identified apoptotic cells externalizing phosphatidyl serine on their plasma 
membrane (sections 2.5 and 6.2.1).  Following this the DAPI fluorescent nuclear 
stain was used to characterize nuclear morphology and identify apoptotic changes 
(sections 2.6 and 6.2.1).  Hydrogen peroxide was used as a positive control for the 
induction of apoptosis.  Following this, the effect of the solvent, and a range of 
physiological concentrations of genistein, daidzein, and E2 (alone and in 
combination with each other) was assessed on the induction of apoptosis in both 
cell lines using the two techniques. 
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1.7.3 Rationale and study design for the investigation into the effects 
of isoflavones on K+ channel activity and volume regulation in 
breast cancer cells 
Potassium channels appear to have a central role in the regulation of proliferation 
and apoptosis in breast cancer, in both breast tissue and breast cancer cell lines 
such as MCF7.  Their role in apoptosis appears to relate particularly to their 
involvement in cell volume regulation. To date, much remains to be determined 
regarding their mechanisms of action.   
An enhancing effect of 17β-oestradiol has been demonstrated on K+ channel activity 
in MCF7 cells, and this appears to relate directly to its proliferation promoting 
properties.  Genistein, through its ability to inhibit protein tyrosine kinase activity and 
other mechanisms, has been shown inhibit K+ channel activity in a number of cell 
lines, but surprisingly never in neoplastic breast epithelial cells.  Likewise, 
isoflavones may induce apoptotic volume changes, which, as discussed, are largely 
mediated by the osmoregulatory effects of the K+ channels (including hERG).  
Evidence suggests that an early event in the mechanism through which soy 
isoflavones reduce proliferation may involve their ability to inhibit key membrane 
potassium channels.  Similarly, their impact on other K+ channels and cell volume 
regulation may relate to their pro- or anti-apoptotic properties.  However, this is a 
new field and currently only based on conjecture.   
Pilot data regarding the impact of isoflavones on potassium channels in breast 
cancer cells, and how this relates to their regulation of proliferation or apoptosis 
could open up a new avenue of investigation in the field of isoflavone therapy in the 
prevention and treatment of breast cancer.  K+ channels show some promise as a 
pharmacological target against breast cancer, and may represent a mechanism 
through which isoflavones act on these cells.  Since a major characteristic of many 
tumours is the development of resistance to therapies, the discovery of treatments 
targeting alternative key processes such as this in breast cancer cells is much 
needed. 
Only the MCF7 cell line was used for this part of the investigation, as the K+ 
channels it expresses are relatively well characterized.  The intention was to focus 
on the activity of the VGKCs, in particular hEAG and hERG, as these channels are 
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known to be expressed in MCF7 cells, and they have demonstrated an involvement 
in the processes of proliferation and apoptosis.  Additionally, several VGKCs, 
including hERG have previously been shown to be inhibited by genistein in other cell 
lines, suggesting that this channel may be a target of genistein in MCF7 breast 
cancer cells also.   
Firstly, the impact of key concentrations of soy isoflavones and E2, identified in the 
previous stage of the project, on MCF7 volume regulation was ascertained.  Due to 
the known roles of swelling and AVD in cell proliferation and apoptosis, and the 
potential involvement of K+ ion flux in these processes, it was hypothesized that 
genistein and E2 treatment could regulate MCF7 volume accordingly.  Changes in 
MCF7 volume were assessed using the Calcein fluorescence volume change assay 
(sections 4.1 and 6.3.1).  This technique was chosen based on its reproducibility 
and its ability to assess volume changes in cells regardless of their shape.  
In parallel, the effect of a number of specific and broad range K+ channel blockers 
was tested with regard to their influence on the proliferation in MCF7 cells (section 
6.4.1).  The MTT assay was again used for this purpose.  This was to confirm their 
presence and proliferative role in MCF7. 
Finally, the impact of the soy isoflavones and E2 on K+ channel activity was 
investigated.  If the isoflavones were found to influence K+ channel activity then the 
intention was to explore whether the VGKCs, specifically hEAG and hERG, are their 
targets.  This was conducted using the whole cell patch clamping technique 
(sections 4.3 and 6.4.2), which is the gold standard technique for measuring the 
characteristics of ion channels, as it allows the channels to be gated by 
physiologically relevant membrane potentials. 
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CHAPTER 2. Methods: proliferation and apoptosis  
Apoptosis and proliferation were assessed in MCF7 and MDA-MB-231 breast 
cancer cell lines at a range of physiological isoflavone concentrations in the 
presence and absence of E2.  The MTT assay was used to measure proliferation 
(section 2.4).  This is a standard and widely used procedure.  Two methods of 
apoptosis quantification were utilised: the Annexin V-Cy3™ apoptosis kit (Sigma: 
APOAC) and staining with DAPI to assess nuclear morphological changes (sections 
2.5 and 2.6).  There exist numerous techniques to measure apoptosis in cultured 
cells, and regrettably no “gold standard” method.  However, the use of two 
complementary but unrelated techniques to quantify apoptosis is in accordance with 
the advice of the NCCD (Galluzzi et al. 2009; Galluzzi et al. 2011).  The protocol for 
each assay was optimised prior to use with positive and negative controls. 
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2.1 Culture techniques for MCF7 and MDA-MB-231 cell lines 
To investigate the effects of isoflavones on breast cancer, MCF7 and MDA-MB-231 
cell culture models of the disease were used.  Both cell lines were held in storage at 
-70oC, and were a gift from Strathclyde University (Prof. D. Flint, Hannah Research 
Institute, Ayr).    
All work with cell lines, or medium and solutions required for the growth of the cell 
lines, was conducted in a class two biological safety hood (Microflow MS1310/1).  
All surfaces and containers upon entering and leaving the hood were sterilised with 
70% ethanol and allowed to dry.  When changing from one cell line to the other, all 
equipment and surfaces were sterilised, and left for a minimum of ten minutes to 
prevent cross-contamination.  All waste was decontaminated by autoclave (121oC 
for 15 minutes) or soaking overnight in a hypochlorite solution (1 x 2.5g Presept 
tablet in a maximum of 500ml water, 2500ppm). 
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2.1.1 Preparation of growth and experimental medium 
Growth medium 
Growth medium for the MDA-MB-231 cell line was prepared in sterile conditions.  To 
a 500ml bottle of Dublecco’s Modified Eagle’s Medium (DMEM, Sigma) with phenol 
red, 1000 mg/L glucose, and sodium bicarbonate, without L-glutamine: Foetal 
Bovine serum (FBS; Biosera), L-Glutamine (Sigma) and penicillin/streptomycin 
(BioWhittaker) were added to final concentrations of 10%, 2mM, 100 units/ml 
(penicillin) and 100µg/ml (streptomysin) respectively.   
Growth medium for the MCF7 cell line was identical to this other than the addition of 
1 mM non-essential amino acids (NEAA; Sigma). 
Experimental medium 
All experimental treatments were conducted in medium made with phenol red free 
DMEM and dextran/charcoal-stripped FBS (DC-FBS; Biosera) to minimise the 
possibility of weak oestrogenic effects of endogenous serum oestrogens and phenol 
red in the medium confounding results.  Both cell lines used the same experimental 
medium, which was prepared as follows.  In sterile conditions, to a 500ml bottle of 
phenol red free DMEM with 1000 mg/L glucose, and sodium bicarbonate, without   
L-glutamine (Sigma), 10% DC-FBS, 2 mM L-Glutamine  and 0.1% 
penicillin/streptomycin were added.  Extended periods of growth in phenol red free 
medium with DC-FBS can result in MCF7 cells adapting to the low oestrogen 
environment and losing their ability to exhibit stimulated growth in response to 
added oestrogen (Katzenellenbogen et al. 1987), so this medium was used for 
experimental treatments only.   
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2.1.2 Resuscitation of frozen cell samples 
Polypropylene cryogenic vials (0.5ml; Wheaton Science Products) of MCF7 and 
MDA-MB-231 cells were stored at -70oC in a freezing medium comprising 10% 
DMSO (Fisher Scientific) in FBS until needed.  To reanimate, vials were thawed in a 
waterbath set at 37oC for around 1 minute, whereupon the contents of the vial were 
pipetted into a 75cm2 culture flask with a filtered cap (Greiner) containing 20ml of 
the appropriate pre-warmed growth medium.  These were placed in a humidified 
incubator (Sanyo MCO-17AIC) at 37oC with a 5% CO2/95% air atmosphere.  After 
24 hours, any dead cells and debris were removed by careful extraction of the 
growth medium, and replaced with 20ml pre-warmed, fresh medium. 
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2.1.3 Maintenance of cell lines – normal growth and experimental 
Cells were maintained at 37oC in an incubator (as above) in 75cm2 culture flasks 
(Greiner) with 20ml of growth medium.  All cells, whether in growth medium or 
experimental medium were maintained under these conditions, and only removed 
from the incubator environment for the minimum required time.  To ensure sufficient 
nutrients, medium was changed every three to four days.  Cells were maintained in 
exponential growth phase and passaged as they approached 90% confluence, 
assessed visually using a Nikon Phase Contrast microscope at a total magnification 
of x100.  This also verified the absence of contamination.   
All medium, solutions and reagents used were warmed to 37oC in a waterbath prior 
to use.  As both cell lines were adherent, to subculture they were rinsed gently with 
10ml PBS (Sigma) and then treated with 3ml of 0.25% trypsin-EDTA (Sigma) at 
37oC for 5 minutes to detach.  Once all cells were dislodged, the trypsin was 
deactivated by addition of 10 ml of culture medium (as above).  The cell suspension 
was decanted into a centrifuge tube and centrifuged (Biofuge Primo, Heraeus) at 
161xG for 5 minutes at room temperature.  The spent medium was then removed.   
The cells were then subcultured or prepared for freezing as appropriate.  To 
subculture, the cells were resuspended in 3 ml of fresh medium and divided equally 
into three flasks containing pre-warmed medium, and placed in an incubator.  To 
freeze, the cells were resuspended in 3ml chilled freezing medium (4oC; 10% DMSO 
in FBS).  Aliquots of this suspension were pipetted quickly into each of three cooled 
cryo-vials.  These were immediately placed on ice then removed to a -70oC freezer. 
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2.2 Enumeration of cells using the haemocytometer  
To ensure accurate and reproducible seeding, cells were counted using a 
haemocytometer (Neubauer Improved, Hawksley, Sussex).  The flask of cells was 
trypsinized as above, and resuspended in 5ml of medium.  The haemocytometer 
and cover slip were wiped clean using a lens wipe, and the cover slip was then 
placed tightly over the counting squares.  Appearance of Newton’s rainbow rings 
indicates that this was achieved satisfactorily.  A small pipette was used to place a 
drop of cell suspension next to the cover slip, which then filled the counting chamber 
by capillary action.  The haemocytometer was viewed with a standard microscope 
(Nikon Phase Contrast) at a total magnification of x100 so that a single square filled 
the viewing field (see Figure 2.1: where the single squares are numbered 1 to 5).  
The number of cells was counted in 5 of the 9 large squares, including cells on the 
top and right boundary lines (represented by the labels A and B in Figure 2.1), and 
excluding those on the bottom or left boundary lines (labels C and D in Figure 2.1).  
Care was taken to ensure the same five squares were always counted.   This was 
repeated for the other counting chamber.  If the results for each chamber differed by 
over 20%, a third counting chamber was prepared to validate.  
The number of cells per ml of sample was calculated with the following formula: 
Cell number = mean number of cells per square x 104 x dilution factor (if 
appropriate) 
(104 corrects for the size of the counting square) 
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Figure 2.1: Diagrammatic representation of the Neubauer Improved 
haemocytometer counting chamber 
Large squares to be counted are numbered 1 to 5.  Cells of the top and right-hand 
boundary lines of any square (labelled A and B) are included in the count. 
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2.3 Viability assay: Trypan Blue dye exclusion method 
2.3.1 Background to method 
This is a routinely used technique to count the number of viable and non-viable 
cells, based on their membrane integrity.  It is considered to be valid in the cell lines 
to be investigated here (Cherdshewasart and Sriwatcharakul 2008; Maggiolini et al. 
2001; Shim et al. 2007).  In order to determine the number of viable cells present, 
the cells were treated with Trypan Blue dye.  This is membrane-impermeable for 
healthy viable cells, so these do not take up the dye, and remain opalescent.  
However, non-viable, or dead cells, can take up the dye and appear dark blue.  
Visualisation of the cells using a standard microscope and haemocytometer allows 
the number of viable cells in a given volume of medium to be counted.   
As this method it based on the loss of membrane integrity as the cell becomes non-
viable, it has a number of limitations.  Firstly, damage to the membrane may allow 
the dye to enter the cell, making it appear non-viable in the short term, however the 
cell may be able to repair itself and restore viability.  More likely, the cell may be 
non-viable without yet losing membrane integrity, making it impermeable to they dye 
and appear viable for a short time.  Finally, as the determination of viability is 
subjective, by visualisation, small amounts of damage, leading to small amounts of 
dye entering the cell, may go unnoticed. For these reasons, this method is 
considered too insensitive to accurately determine proliferation.  However, for the 
purposes of cell counting, when they have been used together, the results of the 
Trypan Blue dye exclusion assay and the MTT assay to assess proliferation in 
MCF7 and MDA-MB-231 cells correlate well (Simoes-Wust et al. 2002). 
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2.3.2 Procedure for Trypan Blue viability assay 
The procedure was as for standard haemocytometer counting, however, once the 
cell suspension was prepared, 50μl was placed in a microfuge tube, with 75μl PBS 
and 125μl (0.4%) Trypan blue solution (Sigma) and vortexed briefly to mix.  The 
total dilution factor was 5.  This was left at room temperature for 5 minutes, vortexed 
again to resuspend the cells, then counted using the haemocytometer method as 
described. 
Viable cells (those which have excluded the blue stain) and total cells were counted, 
and percentage viability calculated as: 
% viability  =  (number viable cells  /  total number of cells counted)  x  100 
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2.4 MTT proliferation assay 
2.4.1 Background to MTT assay method 
The MTT assay is a widely used, robust, reproducible, and high throughput method 
to determine the degree of cellular proliferation (Twentyman and Luscombe 1987).  
It utilizes a tetrazolium-type dye (MTT) which is yellow, water soluble, and can cross 
both the plasma and mitochondrial membranes of cells.  In the mitochondria of 
viable, actively metabolising cells, MTT is reduced into an insoluble purple formazan 
product by mitochondrial dehydrogenase enzymes.  The amount of purple formazan 
produced depends on the number of cells present and their viability.  As the reaction 
progresses, the cells die, and the formazan can be dissolved by addition of a 
solvent.  The intensity of the purple colour in solution is measured as optical density 
(OD), using a multiwell plate reader, and reflects the number of viable cells present 
after the given period of proliferation (Burton 2005).  The absorption maximum for 
formazan solubilised in DMSO is in the range of 560 to 570 nm (Plumb et al. 1989).  
The same 96 well plate is used for both cell growth and measurement, reducing the 
number of steps needed.   
This assay was first developed by Mosmann (1983), with later modifications to 
include use of DMSO as the solvent (Carmichael et al. 1987; Twentyman and 
Luscombe 1987).  The method here has also been used by others (Cherdshewasart 
and Sriwatcharakul 2008; Jin et al. 2010; Li et al. 2008) in both MCF7 and MDA-MB-
231 cells for similar isoflavone screening assays. 
While the MTT assay is frequently used to assess proliferation in MCF7 and MDA-
MB-231 cells, there is a question as to whether the isoflavones themselves cause 
an overestimation of the MTT assay results (see section 6.1.1).   For this reason, the 
assay was validated for use here by comparison to the Trypan Blue cell counting 
method, with isoflavones present (see section 2.4.6).  It was also optimised during 
the pilot phase for cell seeding density and treatment duration (see section 2.4.3).  
Additionally, an aliquot of the purple formazan DMSO solution was analysed with a 
scanning spectrophotometer (Thermo Helios α) to determine that maximal 
absorption was achieved between around 550 and 570 nm, confirming that 550nm 
was an appropriate wavelength with which to analyse the plates. 
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2.4.2 Preparation of solutions 
Stock solutions 
A stock solution of 1x10-2M (10mM) E2 (Sigma) was prepared in DMSO.  Stock 
solutions of 5x10-2 M (0.0316M) genistein and daidzein (both Sigma) were also 
prepared in DMSO.  Each was filtered using sterile 22μm polytetrafluoroethylene 
(PTFE; Whatman) syringe filters and stored in sterile glass universals at -20oC until 
use and thawed at room temperature.  Serial dilutions were prepared in filtered 
DMSO down to concentrations of 1x10-8M (10nM) for the phytoestrogens and 1x10-
9M (1nM) for E2.  A 5μl of the relevant stock dilution was added to 5ml of 
experimental medium to give the relevant ligand dose in a final DMSO concentration 
of 0.1% (i.e. to prepare medium with a genistein concentration of 1nM, 5μl of the 
1μM stock was added to 5ml medium) . In the case of the combined treatments the 
final DMSO concentration was 0.2%.  This was impossible to avoid because the E2 
and isoflavones were dissolved to their maximum concentrations.  These stock 
solutions were stored at -20oC and used for all experiments to follow.  
MTT working solution 
MTT working solution (100μl of 0.5 mg/ml MTT in DMEM without FBS) was 
prepared fresh on the day of use, from a stock solution of 5 mg/ml MTT (Sigma) in 
PBS.  The stock solution was filtered using a 0.22µm mixed cellulose ester (MCE) 
syringe filter (Millex Millipore) and stored in the dark at 4-8oC.  The working solution 
was prepared fresh on a weekly basis, although this preparation may be stable for 
up to six weeks (Twentyman and Luscombe 1987).   
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2.4.3 Optimisation of the MTT proliferation assay 
To generate the protocol described, the MTT proliferation assay required 
optimisation prior to use.  In order to do this, the MCF7 cell line was seeded in 96 
well tissue culture plates (Nunc) at a range of densities from 1000 to 9000 cells per 
well, and treated for a range of durations (from 24 to 96 hours) with experimental 
medium or medium containing 1nM E2.  The latter acted as a positive control for the 
induction of proliferation in this cell line.  The MTT assay was then conducted as 
described in the next section.  Optimisation of this protocol was carried out with 
MCF7 cells only. 
Sample results are described in Figure 2.2.  Based on this, the experimental 
conditions of a 72 hour treatment and seeding density of 6000 cells per well were 
selected.  These conditions allowed for maximum effect of the E2 treatment without 
being negatively impacted by overcrowding and lack of nutrients or being overly 
sparse preventing accurate measurement. 
Additionally prior to data collection, the effect of various doses of solvents on the 
proliferation of MCF7 cells was examined (Figure 2.3).  This was to confirm that the 
chosen dose of vehicle had no effect on proliferation by itself.  Both ethanol and 
DMSO were examined, at doses ranging from 0.1 to 5%, and compared to untreated 
cells.  DMSO was toxic in a dose-responsive manner, with percentage proliferation 
compared to untreated cells dropping at concentrations above 1%.   
This suggests that 0.1 and 0.2% DMSO were appropriate under these 
circumstances, as no effect on proliferation was observed up to 0.5%.  However, 
ethanol at concentrations of 0.5% and above promoted the proliferation of the cells.  
This is an interesting result which could have implications for the results of many 
studies, as ethanol is a frequently used solvent.  This data is in agreement with that 
of Singletary et al. (2001).  For this research, use of ethanol as a solvent was 
discontinued. 
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Figure 2.2: Impact of seeding density and treatment duration on MCF7 
proliferation 
Mean optical density (measured at 550nm) after MTT assay of MCF7 cells 
incubated with or without 1nM E2 over a period of time up to 96 hours.  Cells were 
initially seeded in 96 well plates in oestrogen free media at a range of cell densities 
per well (A: 1000, B: 3000, C: 6000 and D: 9000 cells per well) and incubated for 24 
hours to allow washout of oestrogenic effects.  Following this, medium was replaced 
with fresh media in the presence (grey line) or absence (black line) of 1nM E2, and 
incubated for up to 96 hours.  Data shown is the mean optical density (read at 
550nm) of at least three wells prepared on three separate occasions (n=3). 
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Figure 2.3: Effect of various solvents on the proliferation of MCF7 
MCF7 cells were prepared as described, before the addition of fresh medium 
containing the stated concentrations of ethanol or DMSO, and incubated for 72 
hours.  Data presented is the mean + standard deviation of the value from 8 wells 
prepared on the same day.  a: significant difference from the untreated control (p 
<0.05). 
  
137 | P a g e  
 
2.4.4 MTT proliferation assay protocol 
Upon reaching 80 to 90% confluence, the cells were rinsed with PBS, trypsinised, 
and counted using a haemocytometer.  They were then seeded in 96 well tissue 
culture plates at a density of 6000 cells per well, in 0.2 ml experimental media.  The 
cells were returned to the incubator and allowed to adhere for a period of 24 hours.  
This also served to wash out oestrogenic compounds in the growth media.  At this 
time, the medium was removed by inverting and gentle tapping, and 0.2ml fresh 
experimental medium added to each well, with the inclusion of the compounds to be 
tested.  Once prepared, the plates were returned to the incubator.  On each plate at 
least 3 “blank” wells were included, containing medium but no cells, which were 
treated in the same manner as the cell-containing wells throughout.   
Following treatment for 72 hours, the medium was removed by inverting and gentle 
tapping, and replaced with 100μl of MTT working solution.  The cells were incubated 
at 37oC in the dark for a further 4 hours to allow reduction of the MTT.  From this 
point sterile conditions were no longer required.  The MTT solution was removed by 
inversion and gentle tapping.  Formazan crystals were solublised by addition of 
100μl DMSO to each well, and after 5 to 10 minutes and gentle tapping, the density 
of the purple colour determined in a multiwell-plate spectrophotometer (Dynex MRX) 
at a wavelength of 550nm. 
Each treatment was replicated in at least 3 wells on the plate, and in at least 3 
plates prepared on different occasions.  No treatments contained more than 0.2% 
DMSO. Results were presented as the percentage of the appropriate vehicle-only 
control.   
% change in proliferation for each well was calculated as: 
(OD* reading – blank) ÷ (mean control OD – blank) x 100 
*OD: Optical Density 
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2.4.5 Test conditions for the MTT assay 
Controls 
The single treatments of isoflavone and E2 were compared with their vehicle-only 
control (0.1% DMSO).  The combined E2 and isoflavone treatments contained 0.2% 
DMSO, so this slightly higher concentration of the vehicle was used as the control 
treatment in these instances.  To determine the appropriateness of these solvent 
levels as controls, proliferation was assessed in both MCF7 and MDA-MB-231 cells 
grown with no additions, or the vehicle only (0.1% and 0.2% DMSO) for 72 hours.   
Oestrogen Treatment 
Proliferation was assayed in both cell lines after treatment with 1 pM (1x10-12M; 
postmenopausal) and 1 nM (1x10-9M; premenopausal) E2.  These values were 
chosen based on published serum levels of total E2 (Gruber et al. 2002).  In 
premenopausal women E2 levels vary with the menstrual cycle, with 1nM 
representing the mid-point of this range.  This was intended to confirm past results 
and act as a positive control for the induction of proliferation in ERα+ (MCF7) cells. 
Isoflavone Treatment 
Following this, both cell lines were treated with genistein and daidzein between 
0.01nM (1x10-11M) and 31.6µM (1x10-4.5M) to allow confirmation of their effects on 
proliferation as single treatments.  This concentration range is physiologically 
achievable in serum through diet alone, and represents both very high and 
low/never consumers of soy products, and women taking isoflavone supplements 
(Arai et al. 2000; Verkasalo et al. 2001).  It was hoped that this would allow the full 
range of stimulatory and inhibitory dose-dependent effects of these isoflavones on 
proliferation to be seen (Maggiolini et al. 2001; Matsumura et al. 2005).   
Combined Treatment 
Finally, the proliferative and apoptotic effects of genistein and daidzein were 
measured again, at the concentration ranges described, in combination with 1nM or 
1pM E2.  The results of these combined treatments were compared to the effect of 
the relevant E2 treatment alone, to characterise whether the isoflavone is capable of 
modifying proliferation in a physiologically relevant E2 environment. 
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2.4.6 Validation of the MTT assay 
To validate the results of the MTT assay, key treatments in both MCF7 and MDA-
MB-231 cells were compared with the results of the Trypan Blue dye exclusion 
viability assay. 
Both cell lines were seeded in 12 well plates (Greiner) in 1ml experimental medium 
per well, at a density of 5 x 104 cells/ml.  As with the MTT assay, the cells underwent 
a 24 hour oestrogen washout period, then the medium was replaced with 1ml fresh 
medium containing the experimental treatments.   
These comprised: 
 Untreated medium 
 
 0.1nM genistein 
 
 0.1% DMSO 
 
 1µM genistein 
 
 1nM E2 
 
 31.6µM genistein 
 
 
After three days of incubation, the medium was removed, and the cells were 
trypsinised by addition of 300µl trypsin per well.  Once all cells were in suspension, 
the trypsin was deactivated by addition of 300µl medium per well, and each cell 
suspension was transferred to a 1.5ml polypropylene microcentrifuge tube (Fisher).  
These were centrifuged (Eppendorf 5415 R) for 5 minutes at 150xG (room 
temperature).  Following this, the supernatant was removed, and the pellet was 
resuspended in 75µl PBS and 125µl Trypan Blue, as described in Section 2.3.  The 
total volume in each tube, including the pellet was around 250µl. 
The number of viable cells (per ml) in each sample was calculated as described 
(section 2.3.2).  This value was divided by four to determine the total number of 
viable cells per well (i.e. each 250µl sample contained all the detached cells from a 
1ml well). 
This procedure was carried out on two separate occasions.   The results for the 
MCF7 Trypan Blue viability assay are provided in Figure 2.4 , and for the MDA-MB-
231 in Figure 2.5.  In each case the data is compared with the results of the same 
experimental treatments in the MTT assay.   
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Figure 2.4: Comparison of MTT and Trypan blue validity assay results in MCF7 
cells 
MCF7 cells were assayed using the MTT assay and Trypan Blue dye exclusion 
assay as described, after 72 hour incubation in medium with no additions, vehicle-
only, 1nM E2, or genistein (0.1nM, 1µM and 31.6µM).  A: Numbers of cells per well 
(left hand side; mean ± range) and optical density at 550nm (right hand side; mean 
± SD for each).  For the MTT assay n = 3, and for the Trypan Blue assay n = 2.  B: 
Mean cell numbers and optical densities for each treatment, and the Pearson’s 
correlation coefficient (r, n = 12) describing the relationship between the two 
datasets. 
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Figure 2.5: Comparison of the MTT and Trypan blue validity assay results in 
MDA-MB-231 cells 
MDA-MB-231 cells were assayed using the MTT assay and Trypan Blue dye 
exclusion assay as described, after 72 hour incubation in medium with no additions, 
vehicle-only, 1nM E2, or genistein (0.1nM, 1µM and 31.6µM).  A: Numbers of cells 
per well (left hand side; mean ± range) and optical density at 550nm (right hand 
side; mean ± SD for each).  For the MTT assay n = 3, and for the Trypan Blue assay 
n = 2.  B: Mean cell numbers and optical densities for each treatment, and the 
Pearson’s correlation coefficient (r, n = 12) describing the relationship between the 
two datasets. 
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Pearson’s correlation coefficients (r) were calculated (SPSS version 19, IBM 
Statistics, 2010) to determine the relationship between the mean OD values and cell 
counts for each cell line and treatment (see Figure 2.4B and Figure 2.5B), along with 
the significance of this relationship (p, n = 12). 
For both cell lines the results of the two assays followed similar patterns.  In MCF7 
the Pearson’s correlation coefficient was 0.502 (p one tailed <0.05, n = 12) 
indicating a fairly strong positive correlation between the MTT and Trypan Blue 
assay results, although this just failed to achieve significance at the two tailed level 
(p = 0.096).  A stronger correlation was achieved with the MDA-MB-231 results (r = 
0.665, p two tailed <0.05, n = 12).  This suggests that the MTT assay is valid for use 
in determining the effects of isoflavone treatments on the proliferation of MCF7 and 
MDA-MB-231 breast cancer cells. 
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2.4.7 Statistical analysis 
All values are the mean result of at least nine wells.  Data is assumed to be normally 
distributed.  Data is represented as the mean percentage change in proliferation 
compared to the control (0.1% DMSO unless otherwise stated) and standard 
deviation.  Significant variation from the control results was determined using one 
way ANOVAs, with post hoc Bonferroni correction for multiple comparisons (SPSS 
version 19, IBM Statistics, 2010), and a value of p < 0.05 (two-tailed) was 
considered to be significant.  The EC50 (concentration required for a half-maximal 
effect) for each isoflavone on proliferation was determined by nonlinear regression 
using Graphpad Prism software (Graphpad Software Inc, Version 5.01, 2007). 
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2.5 Annexin V-Cy3 Apoptosis Assay  
2.5.1 Background to the Annexin V-Cy3 Apoptosis Assay method 
The Annexin V-Cy3™ Apoptosis Detection Kit (Sigma, APOAC) is quick to use, and 
detects apoptosis earlier in the apoptotic pathway than DNA-based methods such 
as TUNEL staining.  The assay is based on a 15 minute incubation with a solution 
containing Ca2+, labelled Annexin V, and a counter-probe.  It allows differentiation, 
using fluorescence microscopy, between early apoptotic, necrotic and viable cells.  
The Annexin V-Cy3.18 conjugate fluoresces more brilliantly for fluorescent 
microscopy that its Annexin-FITC counterpart used for flow cytometric methods.   
The kit contains two fluorescent dyes.  The first, Cy3.18 conjugated to Annexin V, 
binds to PS on the surface of apoptotic and necrotic cells.  The second dye is the 
non-fluorescent compound 6-carboxyfluorescein diacetate (6-CFDA), which enters 
the cell and is hydrolyzed by the esterases present in living cells into the fluorescent 
compound 6-carboxyfluorescein, indicating that the cells are viable.  The 
combinations of these dyes allow the state of the cells to be determined by 
fluorescence microscopy, as summarised in Table 2.1.  Annexin V positive, 6-CFDA 
positive cells are still actively engaged in metabolism but also externalising PS so 
are in the early stages of apoptosis.  Necrotic cells stain as Annexin V positive 6-
CFDA negative.  Finally viable cells are Annexin V negative, 6-CFDA positive.  The 
results of random microscopic fields were photographed and quantified. 
Table 2.1: Summary of Annexin V-Cy3 dye combination results 
Cell type Dye result Cell colour               
(composite image) 
Annexin V-Cy3 
(red)  
6-CFDA (green) 
Viable - + Green 
PS externalising 
(apoptotic) 
+ + Yellow                              
(Green + Red) 
Necrotic + - Red 
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The Annexin V-Cy3 kit been used successfully to determine apoptosis in both MCF7 
and MDA-MB-231 cell lines by other laboratories (Perillo et al. 2000; Wiebe et al. 
2010), and a related adherent breast cancer cell line MD- MB-435 (Castillo-Pichardo 
et al. 2009).  A similar kit designed for flow cytometric analysis, Annexin V-FITC, has 
also been used with both cell lines in studies similar to this, investigating the role of 
isoflavones in apoptosis (Li et al. 2008; Sergeev 2004).  There was no evidence that 
the isoflavones interfered with the activity of the fluorescent stains.  This suggests 
that this kit is an appropriate method of quantification for apoptosis in the present 
investigation. 
The binding buffer should contain Ca2+ between 1 and 3mM (1.8mM is optimal for 
many cell lines, higher concentrations will promote non-specific binding of Annexin V 
to other aminophospholipids), and simple salts.  Phosphate buffers should be 
avoided (Krysko et al. 2008).   For this reason RPMI growth medium is not advised 
due to its low Ca2+ high phosphate content.  DMEM medium satisfies the PS-binding 
properties of Annexin V (Krysko et al. 2008). 
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2.5.2 Preparation of Solutions 
The Annexin V-Cy3 kit contained the following:  
• Annexin V-Cy3.18 conjugate (10 µg protein, 100 µg/ml) dissolved in 
50mM Tris HCl, pH 7.5,  
• 6-Carboxyfluorescein diacetate (6-CFDA) 10 mg 
• 10x binding buffer 20ml containing 100mM HEPES/NaOH, pH 7.5 with 
1.4M NaCl and 25mM CaCl2 
In advance, the following solutions were prepared from the kit, according to 
manufacturer’s instructions: 
1x binding buffer  
10 fold dilution of 10x binding buffer with deionised water 
50mM 6-CFDA in acetone solution 
Dissolve 2.32mg 6-CFDA in 0.1ml acetone, store in amber vial at -20oC, protected 
from light 
Double label staining solution (1 µg/ml Annexin V-Cy3 and 500 µM 6-CFDA in 1x 
binding buffer) 
Mix 20µl of the Annexin V-Cy3 100µg/ml solution, 20 µl of 50 mM 6-CFDA acetone 
solution, 200µl 10x binding buffer, and 1.76ml deionised water.  Store in amber vial 
and protect from light 
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2.5.3 Optimisation and positive control 
Exposure levels for capturing red and green fluorescence were optimised with the 
positive and negative control cells and then used throughout.   In addition, at an 
early stage, cells treated with genistein or E2 (but not stained) were exposed to the 
excitation light source.   There was no auto-fluorescence detected (results not 
shown).   
Seeding conditions were optimised by testing a number of seeding densities (1 x 104 
to 1 x 106 cells per well) and durations (24 to 72 hours) to determine the conditions 
which would yield approximately 100 cells per microscopic field.  This was assessed 
visually using the Nikon Eclipse TS100 microscope (data not shown).  Optimum 
conditions required to give the appropriate final cell numbers were determined to be 
a 48 hour washout and seeding density of 5 x 104 cells per well.  This is similar to 
conditions used in several related studies (Jin et al. 2010; Schmidt et al. 2005). 
Treatment with hydrogen peroxide is known to induce apoptosis in a number of cell 
lines, including human leukaemia HL-60 cells (Wagner et al. 2002), human 
histiocytic lymphoma U937 cells (Perez et al. 2004) and various tumour cell lines 
(Wang et al. 2002).  In MCF7 cells treatment with 5mM H2O2 for 90 minutes resulted 
in approximately 50% of cells to become apoptotic (Perillo et al. 2000).  Likewise, in 
murine lymphocyte FL5.12 cells lower doses of 0.25 to 1mM H2O2 also induced 
apoptosis although over a longer timeframe (Hockenbery et al. 1993).  Based on 
these studies a one hour incubation in medium containing either 1mM or 5mM H2O2 
treatment was used as a positive control for the induction of apoptosis in this project. 
Plates (12 well) were prepared as described with both MCF7 and MDA-MB-231 
cells, in 1ml experimental medium, and incubated at 37oC in a humidified 5% CO2 
incubator for 72 hours.  H2O2 was added to the medium from a stock of 0.09M, to 
achieve a final concentration of 1mM or 5mM.  These doses were tested for 
durations ranging from one to four hours.  These were initially assessed visually, 
and then several treatments were stained and examined as described (see section 
2.5.4).   
Sample images are provided in Figure 2.6 and results are displayed in Figure 2.7.  
Significant increases were seen in the percentage of apoptotic MCF7 cells after 
treatment with both 1 and 5mM H2O2 compared with no treatment.  The impact H2O2 
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treatment on MDA-MB-231 cells was lower in magnitude, but a significant increase 
in PS-externalising apoptosis was still observed in the MDA-MB-231 cells after 5mM 
H2O2 treatment for an hour.   This suggests that the test is capable of generating 
comparable results to those seen in other published studies for the induction of 
apoptosis in these cell lines (Perillo et al. 2000). 
 
Figure 2.6: Representative images showing the results of the Annexin V-Cy3 
apoptosis assay on hydrogen peroxide treated MCF7 cells 
MCF7 cells prepared as described then treated with 1mM H2O2 for 1 hour, stained 
with the Annexin V-Cy3 apoptosis detection kit, and fluorescent images captured. A: 
green fluorescence from 6-CFDA dye.  B: red fluorescence from Annexin V 
conjugate dye.  C: Composite image.  In each image 1 indicates a number of viable 
cells, stained by 6-CFDA only, and 2 indicates apoptotic cells stained with both.  In 
this region of the slide apoptosis was calculated to be 68.54%. 
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Figure 2.7: Induction of apoptosis by hydrogen peroxide treatment (1 hour) 
Cells were seeded in oestrogen free medium and incubated for 48 hours to allow 
oestrogens to wash out.  Following this, medium was replaced with fresh oestrogen 
free medium.   After a further 24 hour incubation, hydrogen peroxide was added at 1 
and 5 mM, for 1 hour, to induce apoptosis.  Results presented as mean % PS 
externalising apoptotic cells per treatment and SD (n=3).  Significant variation from 
the relevant untreated controls are indicated by a (p < 0.001) or b (p < 0.05).  
Subsequently, treatment with various test ligands was piloted using the described 
protocol for both 24 hours and 48 hours (results determined visually, data not 
shown).  Both time periods are frequently used to generate significant results in 
MCF7 and MDA-MB-231 cell lines for the induction of apoptosis by isoflavone 
treatment, although to date this has not been assessed by the Annexin V-Cy3 
method (Garvin et al. 2006; Jin et al. 2010; Li et al. 2008; Sergeev 2004; Shim et al. 
2007).  Based on this pilot testing, 24 hour treatment was chosen. 
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2.5.4 Annexin V-Cy3 apoptosis assay protocol 
This procedure for MCF7 and MDA-MB-231 cells is based on the manufacturer’s 
instructions and the method used by Castillo-Pichardo et al. (2009) for adherent 
MDA-MB-435 breast cancer cells.  Optimisation of conditions were described 
previously in section 2.5.3. 
Upon reaching 80 to 90% confluence, the cells were rinsed with PBS, trypsinised, 
and counted using a haemocytometer.  They were then seeded in 12 well plates 
(Greiner) at a density of 5 x 104 cells per well in 1 ml  experimental medium, on 10 
mm glass cover slips (Agar Scientific).  Prior to placing in the wells, the cover slips 
were sterilised by autoclaving. 
The plates were returned to the incubator and the cells allowed to adhere and grow 
for a period of 48 hours.  This also served to wash out oestrogenic compounds in 
the growth media.  Following this, the medium was gently removed by pipette, and 
replaced with 1 ml of experimental, oestrogen free medium containing appropriate 
doses of the ligands under scrutiny.  The plates were then returned to the incubator 
for another 24 hours. 
The following stages did not require sterile conditions.  To stain, each cover slip was 
extracted gently from the well with watchmaker’s forceps, and washed twice gently 
with 100µl PBS.  Excess liquid was blotted off with a tissue gently at the side of the 
cover slip, not directly on top, as this would damage or dislodge the cells.  
Subsequently, the surface of the cover slip with the adherent cells was washed 
gently three times with 50µl 1x binding buffer, blotted each time as before, and 
placed cell side up on a slide or Petri dish.  50µl double staining solution was 
dropped onto the cover slip, which was then covered with foil and incubated for 15 
minutes at room temperature.  After staining, each cover slip was washed five times 
with 50µl 1x binding buffer as before, to remove excess label.  Following this, 35µl of 
1x binding buffer was dropped onto the cover slip, which was then inverted over a 
glass slide. 
The results were observed and rapidly photographed using a fluorescence 
microscope (Nikon Eclipse TS100) with a 20x/0.50 Nikon Plan Fluor objective.  6-
CFDA is excited by light at 485nm, and emitted light is transmitted through a 505 nm 
dichroic mirror and long-pass 520 nm emission filter (B-2A filter, Nikon) to be 
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observed as green fluorescence.  Annexin V-Cy3.18 is excited by light at 530 nm, 
and emitted light is transmitted through a 575 nm dichroic mirror and 580 nm 
emission filter (G-2A filter, Nikon) appearing as red fluorescence.   Images were 
captured using a Diagnostic Spot RT Colour 2.2.1 camera, and thresholded and 
analysed with Image J software (NIH: Version 1.44).  This stage was completed 
rapidly, with minimum exposure of the cells to the light source, to reduce the 
potential for leakage and bleaching of the dye.  The analyst was blinded to the 
treatment as far as possible, by assigning all images a numerical name unrelated to 
the experimental conditions.  A sample set of images is provided in Figure 2.8. 
Three random areas from each cover slip were analysed, and at least three 
separate cover slips were prepared on different occasions for each treatment.  At 
x200 magnification approximately 100 cells were visible per field, resulting in 
approximately 900 to 1000 cells being assessed for each treatment.   
Percentage induction of PS externalising apoptotic cells for each cover slip field was 
determined as follows: 
% apoptotic cells = (no. apoptotic cells) ÷ (total no. cells*) x 100 
* Total no. cells = viable + apoptotic + necrotic 
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Figure 2.8: Sample images of Annexin V-Cy3 kit results 
MCF7 cells seeded as described then treated with 1µM genistein for 24 hours.  
Following this, the Annexin V-Cy3 apoptosis assay was carried out and digital 
images acquired.  6-CFDA fluoresces green (A) and Annexin V-Cy3 fluoresces red 
(B).  A composite image (C) has been generated for illustrative purposes.  Cells 
which fluoresce green only (1) are viable and cells which fluoresce in both colours 
(2; appear yellow in composite image) are apoptotic.    
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2.5.5 Test conditions 
Positive and negative controls 
Untreated cells, and cells grown for 24 hours in medium containing the vehicle only 
treatments of 0.1% DMSO were tested for induction of apoptosis in MCF7 and MDA-
MB-231 cell lines.  In addition, the impact of 0.2% DMSO was assessed in MCF7 
cells.  The DMSO-only controls were compared to the untreated cells to verify that 
they did not significantly modify levels of apoptosis in either cell line.  This confirmed 
their appropriateness to act as controls for the other test conditions. 
Oestrogen and isoflavone single treatments 
Apoptosis and was quantified in both cell lines after 24 hour treatment with 1 pM and 
1 nM E2.  Similarly, both cell lines were treated with physiological levels of genistein 
and daidzein (0.1, 1, 10 and 31.6 µM).  These treatments were intended to confirm 
the results in the scientific literature. 
Combined Treatment 
Finally, the apoptotic effects of genistein and daidzein were assayed again, at the 
concentration ranges described, in combination with 1nM and 1pM E2.  This was 
conducted in the MCF7 cells only due to financial constraints.  As the combination of 
E2 and isoflavones had little further effect on proliferation of MDA-MB-231 cells over 
that of the isoflavones alone, this treatment was not expected to modify the levels of 
apoptosis in these cells.  The results of the combined MCF7 treatments were 
compared to the effect of the relevant E2 treatment alone and isoflavone 
concentration alone, to characterise whether the isoflavone was capable of inducing 
apoptosis in a physiologically relevant E2-containing environment. 
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2.5.6 Statistical analysis 
For all conditions the mean and standard deviation of the percentage induction of 
apoptosis data was determined.  Data is assumed to be normally distributed.  The 
single treatments of isoflavone and E2 were compared to their vehicle only control 
(0.1% DMSO).  Combined E2 and isoflavone treatments were compared to the 
relevant E2 only treatment as a control.  Significant variation from the control results 
was determined using one way ANOVAs with Bonferroni post hoc corrections 
(SPSS version 19, IBM Statistics, 2010), and a value of p < 0.05 (two-tailed) was 
considered to be significant. 
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2.6 DAPI staining and determination of apoptotic nuclear 
morphology 
2.6.1 Background to method 
The second measure of apoptosis used was DAPI staining and subsequent 
determination of changes to nuclear morphology: namely the appearance of a bright 
fluorescent ring of condensed DNA around the outside of the nucleus, subsequent 
spreading of this to encompass the whole nucleus, which becomes smaller and 
more brightly stained, before fragmenting (Hacker 2000).   
DAPI is a blue fluorescent dye that fluoresces brightly when bound to the minor 
groove of double-stranded DNA.  In this state its fluorescence is approximately 20-
fold greater than when unbound. This selectivity for DNA, along with cell 
permeability, allows the staining of nuclei with little background interference, making 
DAPI a classic nuclear dye for assessing apoptosis.  Use of DAPI staining followed 
by assessment of the percentage of cells displaying apoptotic nuclear morphology 
has been used in a number of cell lines, including MDA-MB-231 (Miglietta et al. 
2006), the human gastric cancer cell line SGC7901 (Wang et al. 2010) and several 
human ovarian cancer cell lines (Lai et al. 2003) to quantify apoptosis.  On several 
of these occasions apoptosis was also assessed by other methods, and the results 
were comparable (Miglietta et al. 2006; Wang et al. 2010). 
Briefly, the MCF7 and MDA-MB-231 cells were treated with vehicle only, genistein, 
daidzein and 17β-oestradiol both alone and in combination, and then stained with 
DAPI after 3 hours to assess any early apoptotic nuclear changes.  Following this, 
digital images of the fluorescent cells were collected and analysed, and the 
percentage of cells displaying nuclear apoptotic morphology was calculated.   
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2.6.2 Preparation of Solutions 
10% Formalin (Formaldehyde) solution 
Formalin (37%; Sigma) diluted with deionised H2O. 
60% Isopropanol (2-propanol / isopropyl alcohol) 
Isopropanol (≥ 99.7%; Sigma) diluted with deionised H2O. 
DAPI stock solution 
DAPI was dissolved in deionised H2O (1mg/ml), then stored at -20
oC in the dark. 
DAPI working solution 
Add 100µl DAPI stock to 9.9ml PBS (10µg/ml final concentration) and filter using a 
0.22µm MCE syringe filter (Millex Millipore).  Store at -20oc in the dark 
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2.6.3 Optimisation of the DAPI apoptosis assay 
As with the Annexin V assay (optimisation section 2.5.3), auto-fluorescence was 
assessed and determined to be of no concern. 
Initial observations (not shown) indicated the necessity of the formalin fixation step, 
and allowed optimisation of the DAPI concentration used and cell seeding density. 
The latter was of particular importance as sufficient cell numbers were needed to 
ensure generation of reproducible results, while attempting to avoid large numbers 
of overlapping cells.  Overlapping was of particular concern for the MCF7 cell line as 
they had a tendency to clump.   
The positive control for induction of apoptosis (H2O2) and untreated MCF7 cells 
were used to optimise the DAPI assay (Figure 2.9).    Treatment with 1mM H2O2 
resulted in a significant increase in the percentage of apoptotic cells after 120 mins, 
although not 60 minutes.  All the durations tested with 5mM H2O2 resulted in an 
increased percentage of apoptotic cells, and this was statistically significant at 120 
minutes.  This suggests that apoptotic changes in nuclear morphology (nuclear 
condensation and fragmentation) were taking place, and that this method was valid 
for their quantification.   
Following this stage, genistein (1 and 31.6μM), 0.1% DMSO, and 1nM E2 were 
assayed after two, three and four hours of treatment in MCF7 and MDA-MB-231 
cells  to determine the timescale which would allow any changes in nuclear 
morphology to be reproducibly measured (assessed visually, data not shown).  
Based on this, three hour incubation was deemed to be optimum. 
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Figure 2.9: Induction of apoptotic nuclear morphology in MCF7 by hydrogen 
peroxide treatment  
MCF7 cells were seeded as described and incubated for 48 hours to allow 
oestrogens to wash out.  Following this, medium was replaced with fresh oestrogen 
free medium.   This was either left with no additions for 120 mins, or H2O2 (1 and 
5mM) for between 30 and 120 mins, to induce apoptosis.  The percentage of 
apoptotic cells was determined after DAPI staining.  Results are presented as mean 
and SD (n=3) for each treatment.   Significant variation from the untreated control is 
indicated by a (p < 0.01) and b (p < 0.05). 
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2.6.4 DAPI apoptosis assay protocol 
This procedure is based on that described by Doonan and Cotter (2008).  Similar 
techniques have been used in other human cancerous cell lines (Lai et al. 2003; 
Wang et al. 2010). 
MCF7 and MDA-MB-231 cells were seeded in 24 well plates (Greiner) at a density 
of 1 x 104 cells per well in 0.5ml experimental (oestrogen free) medium.  They were 
incubated for 48 hours at 37oC in a humidified 5% CO2 environment to allow for 
oestrogen washout.  The medium was removed and each well was washed once 
with 1ml PBS (37oC). 
Positive control for apoptosis (MCF7 only): 
Each well was filled with 0.5 ml experimental medium and H2O2 (1 and 5mM) and 
incubated at 37oC in a humidified 5% CO2 environment for up to two hours.   
For test compounds (MCF7 and MDA-MB-231): 
To each well 0.5ml of experimental medium was added with appropriate 
concentrations of the test compounds or vehicle only to get a final DMSO 
concentration of 0.1 or 0.2%.  Plates were incubated for 3 hours at 37oC in a 
humidified 5% CO2 environment. 
For all plates: 
Formalin fixation 
After 3 hours (or the stated duration), the medium was removed from the wells, and 
0.3ml of 10% formalin was added to each well.  This was incubated for 10 minutes 
at room temperature, then the formalin was discarded and the same volume of fresh 
formalin was added.  This was incubated for at least an hour, although at this stage 
the plates could be left for a couple of days, wrapped in Parafilm to prevent 
evaporation.  The formalin was then removed, wells were washed with 60% 
isopropanol (0.3ml per well) and allowed to air dry completely. 
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DAPI staining 
Following fixation, each well was washed twice gently with warmed PBS, this was 
removed, and 200μl DAPI working solution was added to each well.  This was 
incubated at room temperature in the dark for 20 minutes, agitating gently 
occasionally to ensure complete coverage.  Each well was washed five times gently 
with warmed PBS to remove any unbound DAPI.   
The results were observed and photographed using a fluorescence microscope 
(Nikon Eclipse TS100) with a 20x/0.50 Nikon Plan Fluor objective.  The excitation 
wavelength for DAPI was 345nm, and the emission wavelength was 455nm, 
observed as blue fluorescence using UV-2A filter (Nikon) with 400nm dichroic mirror 
and barrier filter of 420nm.  Images were captured using a Diagnostic Spot RT 
Colour 2.2.1 camera, and analysed with Image J software (NIH, Version 1.44).  Six 
images from each well were captured, each containing approximately 50 cells.  This 
stage was completed rapidly, with minimum exposure of the cells to the light source, 
to reduce the potential for leakage and bleaching of the dye.  Each treatment was 
repeated on three separate occasions, meaning that for each experimental 
treatment approx. 1000 cells were analysed. 
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2.6.5 Calculation of the percentage of cells displaying apoptotic 
morphology 
Images were analysed using ImageJ software.  As far as possible, the analyst was 
blinded to the experimental treatment, by assigning each digital image a numerical 
identifier independent of the treatment.  For each image, the total number of cells, 
and the number displaying apoptotic nuclear condensation, punctuated nuclei or 
fragmentation (Figure 2.10) as defined by Hacker (2000) was determined.    
The percentage of cells displaying apoptotic morphology for each image was 
calculated as follows: 
% apoptotic cells = (no. apoptotic cells) ÷ (total no. cells*) x 100 
* Total no. cells = apoptotic + non-apoptotic 
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Figure 2.10: Breast cancer cells displaying normal or apoptotic nuclear 
morphology  
Following treatment, MCF7 (A, B, C) and MDA-MB-231 (D, E, F) cells were stained 
with DAPI and nuclear morphology was assessed by fluorescence microscopy. A, D: 
0.1% DMSO.  B: 31.6µM daidzein.  C: 1mM H2O2.  E:  31.6µM genistein.  F: 31.6µM 
daidzein + 1pM E2.  Cells with evenly stained, rounded nuclei (white arrows) were 
counted as non-apoptotic.  Cells displaying condensed chromatin (blue arrows) or 
punctuated nuclei (red arrows) were considered to be apoptotic. 
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2.6.6 Test conditions 
Positive and negative controls 
Positive controls for MCF7 apoptosis of 1 and 5mM H2O2 were used based on the 
results of the Annexin V-Cy3 apoptosis assay.  These were tested at half, one and 
two hours, to ensure the capture of early apoptotic nuclear morphological changes.  
Following this, untreated cells, and cells treated with 0.1 and 0.2% DMSO were 
used to quantify the level of apoptosis measured by this method under control 
conditions in both MCF7 and MDA-MB-231 cells. 
Oestrogen and isoflavone single treatments 
As with the Annexin V-Cy3 apoptosis assay, nuclear morphology was assessed in 
MCF7 and MDA-MB-231 cells after a three hour treatment with 1pM and 1nM E2.  
Both cell lines were then treated with a physiological range of concentrations of 
genistein and daidzein (0.01, 1, 10 and 31.6 µM).   
Combined Treatments 
Changes to nuclear morphology were assessed in both MCF7 and MDA-MB-231 at 
the concentrations of genistein and daidzein described, in combination with 
premenopausal and postmenopausal E2 levels.  The decision to extend this assay 
to the MDA-MB-231 cell line was based on the results of the Annexin V-Cy3 
apoptosis assay suggesting a slight increase in the levels of PS externalising 
apoptosis in these cells by both isoflavones and E2 as single treatments.   
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2.6.7 Statistical analysis 
For all conditions the mean and standard deviation of the percentage of apoptotic 
cells were determined.  Normal distribution of the data was assumed.  The single 
treatments of phytoestrogen and E2 were compared with their vehicle-only control 
(0.1% DMSO).  Combined E2 and phytoestrogen treatments were compared with 
the 0.2% DMSO vehicle only control, and the relevant E2 only and single isoflavone 
treatments.  Significant variation was determined using one way ANOVAs with 
Bonferroni post hoc corrections (SPSS version 19, IBM Statistics, 2010), and a 
value of p<0.05 (two-tailed) was considered to be significant. 
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CHAPTER 3. Results: proliferation and apoptosis  
3.1 MTT proliferation assay  
3.1.1 MCF7 proliferation results 
3.1.1..1 Impact of control treatments and oestradiol on MCF7 proliferation  
72 hour treatment with 0.1% DMSO had no significant affect on proliferation 
compared to an untreated control (Figure 3.1).  Treatment with 0.2% DMSO caused 
a slight reduction in proliferation compared to the untreated cells, but this did not 
achieve statistical significance.  The relative values for proliferation were 100 
±10.34%, 96.96 ± 10.35% and 74.03 ± 12.18%, for untreated, 0.1% DMSO and 
0.2% DMSO respectively.   
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Figure 3.1 Impact of DMSO treatment on MCF7 proliferation 
MCF7 cells were prepared as described.  After a 24 hour oestrogen washout, their 
medium was replaced with medium containing no additions, or DMSO at 0.1 and 
0.2%.  They were incubated in this for 72 hours.  Results were expressed as 
percentage of the untreated value (mean + standard deviation, n=3).  
The single treatments of E2 and isoflavone used the DMSO vehicle at 0.1%, and 
consequently this treatment is considered appropriate as a control for these 
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conditions.  The combined E2/isoflavone treatments described to follow contained 
DMSO at 0.2%.  As this dose of the solvent did not have a significant impact upon 
MCF7 proliferation it was also considered to be an appropriate vehicle and control 
treatment for these experiments.   
Treatment for 72 hours with 1pM E2 promoted the proliferation of MCF7 significantly 
(p <0.05; Figure 3.2 and Table 3.1).  The higher dose of 1nM E2 had an even 
greater effect (p <0.001). 
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Figure 3.2: Impact of 17β-oestradiol on MCF7 proliferation 
MCF7 cells were prepared as described.  After a 24 hour oestrogen washout, their 
medium was replaced with medium containing vehicle-only, or E2 at 1pM or 1nM.  
They were incubated in this for 72 hours.  Results were expressed as a percentage 
of the control treatment (mean + standard deviation, n=3).  a: significance of 
difference from vehicle-only control (p) < 0.05, b: significant difference from vehicle-
only control (p) <0.001.  
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3.1.1..2 Biphasic effect of isoflavones on MCF7 proliferation 
The results of the experiments looking at the effects of isoflavones on MCF7 
proliferation are shown in Figure 3.3, and Table 3.1.   
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Figure 3.3: Effect of genistein and daidzein on MCF7 proliferation 
MCF7 cells were prepared as described.  After a 24 hour oestrogen washout, their 
medium was replaced with medium containing the vehicle only, or genistein or 
daidzein between 1x10-11 M (0.01nM) and 5x10-4M (31.6µM) and incubated in this 
for 72 hours.  Proliferation was assessed by MTT assay and expressed as a 
percentage of the control treatment (mean + SD).  a: significance of difference from 
vehicle-only control (p) < 0.01, b: significant difference from vehicle-only control (p) 
<0.001. 
Genistein between 0.01 and 1nM had no significant effect on MCF7 proliferation 
compared to the 0.1% DMSO control.  However, from 10nM up to the highest 
concentration tested of 31.6µM, proliferation was significantly increased, peaking at 
10µM (p < 0.001).  Up to and including 10µM a clear dose response can be seen, 
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with an EC50 of 12.88nM.  The biphasic effect seen by some groups was not 
completely apparent here, as the highest concentration of genistein used (31.6µM) 
still resulted in some increase in proliferation compared to the control, but the trend 
is heading in a downward direction, and it is very likely that if higher doses were 
used then a toxic effect would become apparent. 
Very similar effects, although slightly lower in magnitude (this difference never 
achieved statistical significance), were seen with 72 hour daidzein treatments for 
MCF7.  Doses up to and including 1nM had no significant effect on proliferation. 
Higher doses significantly promoted proliferation in a dose-responsive manner, 
peaking at 1µM (p < 0.001).  The EC50 for the effect of daidzein on MCF7 
proliferation was calculated to be 72.1nM, suggesting that genistein was five times 
more effective at promoting MCF7 proliferation than daidzein.  As with genistein, 
higher doses of daidzein continued to have a significant positive effect on 
proliferation compared to the control although again the trend was heading in a 
downward direction.  As above, if higher doses were used then it is likely that a toxic 
effect would become apparent. 
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Table 3.1: Results of single treatments on MCF7 proliferation 
Treatment % Proliferation1 SD P2 
No treatment 103.14 11.29 NS 
0.1% DMSO 100.00 11.25 - 
0.2% DMSO 76.35 13.24 NS 
G 0.01nM 116.37 17.79 NS 
G 0.1nM 116.52 12.94 NS 
G 1nM 120.42 22.51 NS 
G 10nM 142.21 18.31 <0.01 
G 100nM 164.74 29.60 <0.001 
G 1µM 177.90 29.54 <0.001 
G 10µM 178.04 41.76 <0.001 
G 31.6µM 139.49 20.55 <0.01 
D 0.01nM 103.14 21.20 NS 
D 0.1nM 114.33 14.84 NS 
D 1nM 121.44 25.12 NS 
D 10nM 138.62 36.41 <0.01 
D 100nM 143.99 18.12 <0.01 
D 1µM 160.73 29.80 <0.001 
D 10µM 147.83 20.80 <0.001 
D 31.6µM 140.53 24.05 <0.001 
E2 1pM 126.80 16.19 <0.05 
E2 1nM 162.24 31.19 <0.001 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: standard deviation, NS: not 
significant (p ≥ 0.05) 
1 % proliferation compared to control cells treated with vehicle only (0.1% DMSO) 
2 significance of difference compared to cells treated with vehicle only (0.1% DMSO) 
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3.1.1..3 Synergistic effect of isoflavones and oestradiol on MCF7 
proliferation  
The effects of the combined isoflavone/E2 treatments on MCF7 are displayed in 
Figure 3.4 and Table 3.2.  Compared with the 0.2% DMSO control, all of the 
combined E2/isoflavone treatments resulted in a significant increase in MCF7 
proliferation. 
The combinations of postmenopausal E2 (1pM) and genistein appear to affect 
proliferation in additive manner (Figure 3.4A), with most of the genistein treatments 
increasing proliferation significantly on top of the effect of the oestrogenic effect.  
Percentage proliferation peaked at 10µM genistein, mirroring the effects seen with 
the single treatments.  The impacts of these combined treatments on proliferation 
are very similar numerically to the sum of the relevant single treatments. 
The impact of daidzein and 1pM E2 on proliferation was comparable to that seen 
with genistein (Figure 3.4B), again peaking at the same concentration as the single 
daidzein treatment (1µM).  Genistein and daidzein in combination with 
premenopausal E2 (1nM) levels was less dramatic.  There is a trend towards an 
additional effect but in many cases the isoflavone fails to induce any statistically 
significant increases in proliferation on top of the effect of 1nM E2.   
Furthermore, virtually all of the E2-isoflavone combinations resulted in significantly 
greater induction of MCF7 proliferation that the relevant isoflavone alone treatment.  
For p values see Table 3.2. 
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Figure 3.4: Effect of isoflavones at physiological E2 levels on MCF7 
proliferation 
MCF7 cells were prepared as described.  After a 24 hour oestrogen washout, their 
medium was replaced with medium containing genistein (A) or daidzein (B) between 
1x10-11M (0.01nM) and 5x10-4M (31.6µM) with pre- or post-menopausal E2 
concentrations (1nM and 1pM respectively) and incubated for 72 hours.  
Proliferation was assessed by MTT assay and results were expressed as a 
percentage of the control treatment (mean ± SD, n = 3). Significant differences 
indicated from 1nM E2 (a: p <0.05, b: p <0.001) or from 1pM (d: p <0.05, e: p 
<0.001).   
 
 
Table 3.2: Results for combined treatments on MCF7 proliferation 
Treatment Mean % change 
compared to 0.2% DMSO 
Standard 
Deviation 
Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding ISF alone 
0.2% DMSO 100 13.24 - - - - 
G 0.01nM + 1nME2 180.94 28.49 <0.001 NS - <0.01 
G 0.1nM + 1nME2  202.19 43.70 <0.001 NS - <0.001 
G 1nM + 1nME2 220.55 36.17 <0.001 <0.05 - <0.001 
G 10nM + 1nME2 208.44 48.37 <0.001 NS - <0.01 
G 100nM + 1nME2 215.79 44.65 <0.001 0.086 - <0.05 
G 1µM + 1nME2 214.85 49.16 <0.001 NS - NS 
G 10µM + 1nME2 207.66 40.31 <0.001 NS - NS 
G 31.6µM + 1nME2 167.63 57.94 <0.001 NS - NS 
G 0.01nM + 1pME2 154.08 22.64 0.014 - NS NS 
G 0.1nM + 1pME2 209.60 49.86 <0.001 - <0.01 <0.001 
G 1nM + 1pME2 215.92 50.68 <0.001 - <0.01 <0.001 
G 10nM + 1pME2 232.42 66.51 <0.001 - <0.001 <0.001 
G 100nM + 1pME2 264.31 94.75 <0.001 - <0.001 <0.001 
G 1µM + 1pME2 264.76 77.33 <0.001 - <0.001 <0.01 
G 10µM + 1pME2 287.63 71.61 <0.001 - <0.001 <0.001 
G 31.6µM + 1pME2 187.53 34.30 <0.001 - NS NS 
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Treatment Mean % change 
compared to 0.2% DMSO 
Standard 
Deviation 
Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding ISF alone 
D 0.01nM + 1nME2 188.08 28.48 <0.001 NS - <0.01 
D 0.1nM + 1nME2 221.51 45.58 <0.001 <0.05 - <0.001 
D 1nM + 1nME2 225.63 37.10 <0.001 <0.01 - <0.001 
D 10nM + 1nME2 203.08 42.54 <0.001 NS - <0.01 
D 100nM + 1nME2 211.50 38.17 <0.001 NS - <0.01 
D 1µM + 1nME2 253.63 41.15 <0.001 <0.001 - <0.001 
D 10µM + 1nME2 248.52 59.46 <0.001 <0.001 - <0.001 
D 31.6µM + 1nME2 178.61 29.18 <0.001 NS - NS 
D 0.01nM + 1pME2 160.21 23.36 <0.001 - NS <0.05 
D 0.1nM + 1pME2 188.01 32.69 <0.001 - <0.05 <0.001 
D 1nM + 1pME2 216.91 57.61 <0.001 - <0.001 <0.001 
D 10nM + 1pME2 200.34 45.51 <0.001 - <0.001 <0.01 
D 100nM + 1pME2 253.38 37.82 <0.001 - <0.001 <0.001 
D 1µM + 1pME2 305.02 53.79 <0.001 - <0.001 <0.001 
D 10µM + 1pME2 246.40 56.70 <0.001 - <0.001 <0.001 
D 31.6µM + 1pME2 197.37 28.01 <0.001 - <0.01 <0.01 
G: genistein, D: daidzein, E2: 17β-oestradiol, ISF: isoflavone, NS: not significant (p ≥ 0.05) 
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3.1.2 MDA-MB-231 proliferation results 
3.1.2..1 Impact of control treatments and oestradiol on MDA-MB-231 
proliferation 
The result of 72 hour treatment with 0.1% DMSO on MDA-MB-231 proliferation was 
not significantly different from the untreated control (Figure 3.5).  0.1% DMSO is 
considered as an appropriate control for the rest of the data.  However, 0.2% DMSO 
treatment for 72 hours resulted in a significant reduction in proliferation compared to 
the untreated control.  This must be borne in mind while considering the results of 
the combined treatments, which use this DMSO level as a vehicle and control.   The 
relative values for proliferation were 100 ± 25.35%, 90.15 ± 19.31% and 75.93 ± 
13.48%, for untreated, 0.1% DMSO and 0.2% DMSO respectively.   
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Figure 3.5: Impact of DMSO on MDA-MB-231 proliferation 
MDA-MB-231 cells were prepared as described.  After a 24 hour oestrogen 
washout, their medium was replaced with medium containing no additions, or DMSO 
at 0.1 and 0.2%.  They were incubated in this for 72 hours.  Proliferation was 
assessed by MTT assay and results expressed as a percentage of the untreated 
control (mean + standard deviation, n=3).  a: significance of difference from 
untreated control (p) < 0.05. 
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72 hour treatment of MDA-MB-231 with pre- and post-menopausal concentrations of 
17β-oestradiol inhibited the proliferation of MDA-MB-231 cells compared to the 0.1% 
DMSO control (Figure 3.6).  With postmenopausal E2 (1 pM) this difference 
achieved statistical significance.   
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Figure 3.6: 17β-oestradiol reduces MDA-MB-231 proliferation 
MDA-MB-231 cells were prepared as described.  After a 24 hour oestrogen 
washout, their medium was replaced with medium containing vehicle-only, or E2 at 
1pM or 1nM (1000pM).  They were incubated in this for 72 hours.  Proliferation was 
assessed by MTT assay and results expressed as a percentage of the control 
treatment (mean + standard deviation, n=3).  a: significance of difference from 
vehicle-only control (p) < 0.05. 
3.1.2..2 Isoflavones inhibit proliferation of MDA-MB-231 
The results for the experiments looking at the impact of single treatments on the 
proliferation of MDA-MB-231 are shown in Table 3.3 and Figure 3.7.  All 72 hour 
genistein treatments between 0.01 nM and 10µM slightly inhibited proliferation, 
although did not reach statistical significance.  The highest dose (31.6µM) caused a 
dramatic and significant (p<0.01) decrease in proliferation.   Daidzein treatment 
resulted in a broadly similar pattern, with the exception that 0.01nM significantly 
inhibited proliferation also (p<0.001). 
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Figure 3.7: Effect of genistein and daidzein on MDA-MB-231 proliferation 
MDA-MB-231 cells were prepared as described.  After a 24 hour oestrogen 
washout, their medium was replaced with medium containing the vehicle only or 
genistein or daidzein between 1x10-11 M (0.01nM) and 5x10-4M (31.6µM) and 
incubated in this for 72 hours.  Proliferation was assessed by MTT assay and 
expressed as a percentage of the control treatment (mean + standard deviation, 
n=3).  a: significance of difference from vehicle-only control (p) < 0.01, b: 
significance of difference (p) from vehicle-only control <0.001. 
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Table 3.3: Impact of single treatments on MDA-MB-231 proliferation 
Treatment % 
proliferation1  
SD P2 
No treatment 109.05 26.38 NS 
0.1% DMSO 100 20.43 - 
0.2% DMSO 84.97 15.25 NS 
G 0.01nM 75.34 6.83 NS 
G 0.1nM 76.59 16.39 NS 
G 1nM 77.97 16.68 NS 
G 10nM 77.19 22.96 NS 
G 100nM 86.92 14.21 NS 
G 1µM 83.59 25.85 NS 
G 10µM 84.68 13.19 NS 
G 31.6µM 48.53 12.57 <0.01 
D 0.01nM 58.26 9.40 <0.001 
D 0.1nM 87.09 18.82 NS 
D 1nM 88.52 14.53 NS 
D 10nM 80.11 16.18 NS 
D 100nM 94.00 23.08 NS 
D 1µM 88.45 19.04 NS 
D 10µM 98.21 16.16 NS 
D 31.6µM 48.40 13.06 <0.001 
E2 1pM 76.95 16.34 <0.05 
E2 1nM 86.46 26.62 NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: standard deviation, NS: not 
significant (p ≥ 0.05) 
1 % proliferation compared to control cells treated with vehicle only (0.1% DMSO) 
2 significance of difference compared to cells treated with vehicle only (0.1% DMSO) 
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3.1.2..3 Absence of synergy between isoflavones and oestradiol with MDA-
MB-231 proliferation 
The results for the MTT assays undertaken with combined treatments of genistein 
(A) and daidzein (B) with pre- and post-menopausal E2 concentrations are shown in 
Figure 3.8, with the p values for all comparisons in Table 3.4.     
Although the majority continue to demonstrate a trend towards inhibition of 
proliferation compared with the 0.2% DMSO control, no value was significantly 
different from the control, or from the E2-alone treatment.  Likewise, only three of 
the combinations tested differed significantly from the relevant isoflavone single 
treatment, and there was no pattern to them.  These were 10nM genistein / 1nM E2 
(p < 0.05), 1nM daidzein / 1nM E2 (p < 0.01) and 10µM daidzein / 1pM E2 (p< 0.05).   
The combinations of 1pM E2 and daidzein were more effective at reducing 
proliferation in MDA-MB-231 cells than any other combined or single treatment, 
resulting in values of around 70% of the control level of proliferation, although the 
only significant difference achieved was between 10µM daidzein and the combined 
10µM daidzein/1pM E2 treatment (p < 0.05; Figure 3.8B).  This set of combined 
treatments showed a trend towards a synergistic inhibitory effect, with the majority of 
the sets of conditions resulting in slightly lower proliferation than either daidzein or 
1pM E2 alone.  The other E2/isoflavone combinations were less effective at 
reducing proliferation than the isoflavones alone, although in several cases there 
was still a slight effect. 
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Figure 3.8: The effects of isoflavones at physiological E2 levels on MDA-MB-
231 proliferation 
MDA-MB-231 cells were prepared as described.  After a 24 hour oestrogen 
washout, medium was replaced with medium containing the vehicle only (0.2% 
DMSO) or genistein (A) or daidzein (B) between 1x10-11 M and 5x10-4M with pre- or 
post-menopausal E2 concentrations (1nM and 1pM respectively) and incubated in 
this for 72 hours.  Proliferation was assessed by MTT assay and expressed as the 
percentage of the control treatment (mean + SD, n=3).  Significant difference from 
the relevant isoflavone-only treatment is indicated by a (p < 0.05) or b (p < 0.01). 
 
 
Table 3.4 Results for the combined treatments on MDA-MB-231 proliferation 
Treatment Mean % change 
compared to 0.2% DMSO 
Standard 
Deviation 
Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding ISF alone 
0.2% DMSO 100.00 17.95 - - - - 
G 0.01nM + 1nME2 101.01 34.38 NS NS - NS 
G 0.1nM + 1nME2  111.99 29.16 NS NS - NS 
G 1nM + 1nME2 101.71 27.61 NS NS - NS 
G 10nM + 1nME2 118.20 37.05 NS NS - <0.05 
G 100nM + 1nME2 98.78 26.86 NS NS - NS 
G 1µM + 1nME2 107.05 32.33 NS NS - NS 
G 10µM + 1nME2 93.96 25.98 NS NS - NS 
G 31.6µM + 1nME2 84.62 28.95 NS NS - NS 
G 0.01nM + 1pME2 102.48 35.39 NS - NS NS 
G 0.1nM + 1pME2 86.91 37.65 NS - NS NS 
G 1nM + 1pME2 111.82 35.77 NS - NS NS 
G 10nM + 1pME2 87.62 25.52 NS - NS NS 
G 100nM + 1pME2 105.12 35.28 NS - NS NS 
G 1µM + 1pME2 92.77 29.33 NS - NS NS 
G 10µM + 1pME2 102.52 32.35 NS - NS NS 
G 31.6µM + 1pME2 85.18 28.73 NS - NS NS 
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Treatment Mean % change 
compared to 0.2% DMSO 
Standard 
Deviation 
Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding ISF alone 
D 0.01nM + 1nME2 92.60 25.57 NS NS - NS 
D 0.1nM + 1nME2 97.62 34.56 NS NS - NS 
D 1nM + 1nME2 102.86 36.37 NS NS - NS 
D 10 nM + 1nME2 99.65 37.32 NS NS - NS 
D 100nM + 1nME2 99.99 40.75 NS NS - NS 
D 1µM + 1nME2 106.84 38.98 NS NS - NS 
D 10µM + 1nME2 91.97 29.86 NS NS - NS 
D 31.6µM + 1nME2 98.36 18.33 NS NS - <0.01 
D 0.01nM + 1pME2 75.98 19.07 NS - NS NS 
D 0.1nM + 1pME2 77.40 18.52 NS - NS NS 
D 1nM + 1pME2 73.40 15.87 NS - NS NS 
D 10 nM + 1pME2 71.47 15.66 NS - NS NS 
D 100nM + 1pME2 71.11 16.98 NS - NS NS 
D 1µM + 1pME2 73.90 12.26 NS - NS NS 
D 10µM + 1pME2 69.59 20.05 NS - NS <0.05 
D 31.6µM + 1pME2 65.20 20.62 NS - NS NS 
G: genistein, D: daidzein, E2: 17β-oestradiol, ISF: Isoflavone, NS: not significant (p ≥ 0.05) 
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3.2 Annexin V-Cy3™ Apoptosis Assay Results 
3.2.1 MCF7 Annexin V-Cy3 apoptosis results 
3.2.1..1 Impact of control treatments on PS externalisation in MCF7  
Neither 0.1% or 0.2% DMSO had any significant effect on the percentage of PS 
externalising apoptotic cells compared to no treatment in MCF7 (Figure 3.9). A 
representative set of images is provided in Figure 3.10, suggesting that at these 
levels DMSO is an appropriate vehicle for the ligands and does not impact upon the 
induction of MCF7 PS-externalising apoptosis.   
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Figure 3.9: Induction of PS-externalising apoptosis in MCF7 by control 
treatments 
MCF7 cells were prepared as described.  Following 48 hours of oestrogen washout, 
medium was replaced with fresh oestrogen free medium with no addition, or 0.1 or 
0.2% DMSO, and incubated for a further 24 hours.  Results presented as mean % 
PS externalising apoptotic cells per treatment + SD (n=3).  There were no significant 
differences between these results. 
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Figure 3.10: Captured images of MCF7 cells treated with 0.1% DMSO 
MCF7 cells were prepared as described then incubated for 24 hours with medium 
containing 0.1% DMSO, stained with the Annexin V-Cy3 apoptosis detection kit, and 
fluorescent images captured. A: green fluorescence from 6CFDA dye.  B: red 
fluorescence from Annexin V-conjugate dye.  C: Composite image where yellow 
indicates overlap of the two colours.  In each image 1 indicates a number of viable 
cells, stained by 6-CFDA only, and 2 indicates PS externalising apoptotic cells 
stained with both.  In this region of the slide apoptosis was calculated to be 5.21%. 
3.2.1..2 Effect of 17β-oestradiol treatments on PS externalisation in MCF7   
24 hour treatment with pre- or post-menopausal concentrations of 17β-oestradiol 
(1nM and 1pM respectively) had no significant impact on the percentage of PS 
externalising apoptotic cells calculated for MCF7 (Figure 3.11).   
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Figure 3.11: Induction of MCF7 PS-externalising apoptosis by 17β-oestradiol 
MCF7 cells were prepared as described.  Following 48 hour oestrogen washout, 
medium was replaced with fresh oestrogen free medium containing vehicle only, or 
1pM (1x10-12) or 1nM (1x10-9) E2, and incubated for a further 24 hours.  Results 
represented as mean % PS externalising apoptotic cells per treatment + SD (n=3).  
There were no significant differences between these results. 
3.2.1..3 Isoflavones increase PS externalising apoptosis in MCF7  
A sample set of images from the Annexin V-Cy3 assay in MCF7 with single 
isoflavone treatments are displayed in Figure 3.12.  The results of these assays and 
the p values for comparisons to 0.1% DMSO are given in Figure 3.13 and Table 3.5.   
There is a trend towards a greater rate of apoptosis with PS externalisation in MCF7 
cells after 24 hour genistein or daidzein treatment, between 0.1 and 31.6µM 
compared to the vehicle only.  With 1 and 10µM daidzein and 1µM genistein this 
increase in the percentage of apoptotic cells became statistically significant (p 
<0.05).  The highest rate measured was with 1µM genistein.  However, there is no 
dose effect or appreciable difference between the two isoflavones.  Each data point 
has a wide SD, reflecting great variation in the levels of apoptosis seen in the cells 
on the separate occasions that the tests were repeated. 
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Figure 3.12: Captured images of MCF7 cells treated with 1µM genistein 
MCF7 cells were prepared as described then incubated for 24 hours with medium 
containing 1µM genistein, stained with the Annexin V-Cy3 apoptosis detection kit, 
and fluorescent images captured. A: green fluorescence from 6CFDA dye.  B: red 
fluorescence from Annexin V conjugate dye.  C: Composite image where yellow 
indicates overlap of the two colours.  In each image 1 indicates a number of viable 
cells stained by 6CFDA only, and 2 indicates apoptotic PS externalising cells 
stained with both.  In this region of the slide apoptosis was calculated to be 21.3%. 
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Figure 3.13: Induction of PS-externalising apoptosis in MCF7 by isoflavones 
MCF7 cells were prepared as described.  Following 48 hour oestrogen washout, 
medium was replaced with fresh oestrogen free medium with vehicle only (0.1% 
DMSO), genistein or daidzein, between 0.1µM and 31.6µM, and incubated for a 
further 24 hours.  Results presented as mean % PS externalising apoptotic cells per 
treatment + SD (n=3).  Significant variation from the vehicle-only control (p < 0.05) 
indicated by a.   
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Table 3.5: Results for induction of PS-externalising apoptosis by single 
treatments in MCF7 
Treatment MCF7 
% apoptosis1 SD P2 
No treatment 4.56 4.48 NS 
0.1% DMSO 6.16 4.91 - 
0.2% DMSO 8.43 7.32 NS 
G 0.1µM 13.37 9.06 NS 
G 1µM 29.77 15.74 <0.05 
G 10µM 16.09 7.12 NS 
G 31.6µM 21.89 19.17 NS 
D 0.1µM 8.91 8.99 NS 
D 1µM 29.62 20.28 <0.05 
D 10µM 28.41 15.42 <0.05 
D 31.6µM 16.04 6.50 NS 
E2 1pM 6.99 3.92 NS 
E2 1nM 7.90 5.09 NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not 
significant (p ≥ 0.05) 
1 mean percentage apoptotic PS externalising cells per treatment 
2 significant differences compared to cells treated with vehicle only (0.1% DMSO) 
3.2.1..4 Combinations of isoflavones and 17β-oestradiol induce PS 
externalising apoptosis in MCF7  
The impact of combinations of isoflavones and E2 on PS-externalising apoptosis in 
MCF7 is shown in Figure 3.14A (genistein) and B (daidzein) and Table 3.6.  Each of 
the combination treatments resulted in a greater percentage of PS-externalising 
apoptosis than the 0.2% DMSO control.  This achieved statistical significance on a 
number of occasions (highlighted in Table 3.6).    
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B: Daidzein and 17-oestradiol
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Figure 3.14: Induction of PS-externalising apoptosis in MCF7 by isoflavones 
combined with 17β-oestradiol 
Cells were prepared as described.  Following 48 hour oestrogen washout, medium 
was replaced with fresh oestrogen free medium with vehicle only, genistein (A) or 
daidzein (B) between 0.1µM and 31.6µM, with or without E2 at pre- and post-
menopausal concentrations, and incubated for a further 24 hours.  Results 
presented as mean % apoptotic PS externalising cells per treatment and SD (n=3).   
Significant difference from 1nM E2 is indicated by a (p < 0.05) and b (p < 0.01).  
Significant difference from 1pM E2 is indicated by c (p < 0.05) and d (p < 0.01).   
 
 
Table 3.6: Induction of PS externalising apoptosis in MCF7 by combinations of isoflavones and E2 
Treatment % apoptosis1 SD Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding isoflavone alone 
0.2% DMSO 8.43 19.19 - - - - 
G 0.1µM + 1nME2 28.45 12.31 NS <0.05 - NS 
G 1µM + 1nME2 18.98 9.83 NS NS - NS 
G 10µM + 1nME2 22.81 6.68 NS NS - NS 
G 31.6µM + 1nME2 19.03 7.86 NS NS - NS 
G 0.1µM  + 1pME2 31.33 19.14 0.061 - <0.05 NS 
G 1µM + 1pME2 31.68 20.52 <0.05 - <0.05 NS 
G 10µM + 1pME2 36.29 21.35 <0.01 - <0.01 NS 
G 31.6µM + 1pME2 32.39 19.02 <0.05 - <0.01 NS 
D 0.1µM  + 1nME2 19.29 18.01 NS NS - NS 
D 1µM + 1nME2 28.41 14.37 0.099 <0.05 - NS 
D 10µM + 1nME2 31.96 16.22 <0.05 <0.01 - NS 
D 31.6µM + 1nME2 25.21 17.14 NS NS - NS 
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Treatment % apoptosis1 SD Significance (p) compared to: 
0.2% DMSO 1nM E2 1pM E2 corresponding isoflavone alone 
D 0.1µM  + 1pME2 16.46 12.90 NS - NS NS 
D 1µM + 1pME2 16.42 12.31 NS - NS NS 
D 10µM + 1pME2 17.73 15.36 NS - NS NS 
D 31.6µM + 1pME2 23.66 19.19 NS - NS NS 
1 mean percentage of apoptotic PS externalising cells per treatment  
G: genistein, D: daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not significant (p ≥ 0.05) 
1
9
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Likewise, the combined treatments each resulted in a greater level of PS 
externalisation that the relevant E2-alone treatment, reaching statistical significance 
on the occasions indicated.  The combination of genistein and 1pM E2 
(postmenopausal) appeared to be particularly effective at inducing PS externalising 
apoptosis in MCF7 compared to 1pM E2 alone (Figure 3.14A).  Furthermore, each 
genistein and 1pM E2 combination also resulted in a higher percentage of PS 
externalising apoptotic cells than genistein alone at the same concentrations, 
although none of these comparisons achieved significance.    
The lack of statistical significance for many of the combined treatments compared to 
either the 0.2% DMSO or appropriate E2-alone treatment reflects the variability in 
the data (see the SDs, in Table 3.6).  Despite this, virtually all the individual values 
were numerically higher. 
None of the isoflavone/E2 combination results differed significantly in their effect on 
PS-externalising apoptosis compared to the relevant isoflavone alone.  However, 
there is variability in the results, with no consistent pattern.  A number of the 
isoflavone/E2 combinations induce a lower level of apoptosis than the isoflavone 
alone (not significant), and some had no clear impact upon the induction of PS 
externalising apoptosis in either direction.  The results for genistein and daidzein at 
both E2 concentrations are largely comparable, and no clear dose-related patterns 
emerge.   
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3.2.2 MDA-MB-231 Annexin V-Cy3 apoptosis results 
3.2.2..1 The impact of DMSO on PS-externalising apoptosis in MDA-MB-231 
cells 
After 24 hours treatment, 0.1% DMSO had no significant impact upon PS-
externalisation compared to medium with no additions.  The respective values 
(mean ± standard deviation, n = 3) for untreated and 0.1% DMSO treated cells were 
9.66 ± 8.22% and 6.74 ± 6.15% PS externalising apoptosis.   All Annexin V-Cy3 
assays in this cell line were conducted at the 0.1% solvent dose.  As this had no 
significant impact upon PS-externalising apoptosis, it is considered to be an 
appropriate control. These results are summarised in Table 3.7.    
3.2.2..2 Effect of 17β-oestradiol on PS-externalising apoptosis in MDA-MB-
231 cells 
The impact of physiological concentrations of E2 on the induction of PS-
externalising apoptosis in this cell line is shown in Figure 3.15 and Table 3.7.  These 
treatments had no impact on the percentage of PS externalising apoptotic cells after 
24 hours. 
3.2.2..3 Isoflavones increase PS externalising apoptosis in MDA-MB-231 
In MDA-MB-231, 24 hour treatment with genistein or daidzein led to a slight increase 
in the rate of PS externalising apoptotic cells compared to vehicle only controls, 
however this effect is not statistically significant (Figure 3.17; representative images 
in Figure 3.16).  The full dataset is provided in Table 3.7.  Daidzein was slightly 
more effecting at inducing apoptotic PS externalisation than genistein at each 
concentration used, with the highest rate recorded after 10µM daidzein treatment, 
although the difference between the isoflavones is non-significant.  The very wide 
range of actual results on the different occasions that the tests were repeated, 
reflected by the wide standard deviations seen, may underpin the lack of statistical 
significance to the results.  As with the MCF7 cells, there is no clear dose-effect. 
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Figure 3.15: The effect of 17β-oestradiol on PS-externalising apoptosis in 
MDA-MB-231 cells 
MDA-MB-231 cells were prepared as described.  Following 48 hour oestrogen 
washout, medium was replaced with fresh oestrogen free medium with vehicle only 
(0.1% DMSO), or 1pM or 1nM E2, and incubated for a further 24 hours.  Results 
represented as mean % PS externalising apoptotic cells per treatment and SD 
(n=3).  There were no significant differences between these results. 
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Figure 3.16: Captured images of MDA-MB-231 cells treated with 1µM daidzein 
MDA-MB-231 cells were prepared as described then incubated for 24 hours with 
medium containing 1µM daidzein, stained with the Annexin V-Cy3 apoptosis 
detection kit, and fluorescent images captured. A: green fluorescence from 6CFDA 
dye.  B: red fluorescence from Annexin V conjugate dye.  C: Composite image 
where yellow indicated overlap of the two colours.  In each image 1 indicates a 
number of viable cells, stained by 6CFDA only, 2 indicates apoptotic cells stained 
with both, and 3 indicates necrotic cells stained with the Annexin V conjugate only.  
In this region of the slide apoptotic PS-externalisation was calculated to be 65.56%. 
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Figure 3.17: Induction of PS-externalising apoptosis in MDA-MB-231 by 
isoflavones 
Cells were prepared as described, then the medium was replaced with fresh 
oestrogen free medium with vehicle only (0.1% DMSO), or genistein or daidzein 
between 0.1µM and 31.6µM, and incubated for a further 24 hours.  Results 
presented as mean percentage PS externalising apoptotic cells per treatment and 
SD (n=3).  There were no significant differences between treatments and control. 
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Table 3.2: Results for the induction of PS-externalising apoptosis in MDA-MB-
231 cells by single isoflavone and oestradiol treatments 
Treatment % 
apoptosis1 
SD P2 
No treatment 9.66 8.22 NS 
0.1% DMSO 6.74 6.15 - 
G 0.1µM 15.90 12.32 NS 
G 1µM 13.15 12.23 NS 
G 10µM 13.52 12.18 NS 
G 31.6µM 18.30 11.14 NS 
D 0.1µM 17.52 14.31 NS 
D 1µM 22.60 24.52 NS 
D 10µM 22.67 18.35 NS 
D 31.6µM 20.43 18.38 NS 
E2 1pM 11.41 12.84 NS 
E2 1nM 9.86 9.89 NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not 
significant (p ≥ 0.05) 
1 mean percentage apoptotic PS externalising cells per treatment 
2 significant differences compared to cells treated with vehicle only (0.1% DMSO) 
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3.3 Results of DAPI Staining and Determination of Nuclear 
Changes 
3.3.1 MCF7 DAPI results 
3.3.1..1 Effect of control treatments on MCF7 nuclear morphology 
Results for the control experiments on the percentage of MCF7 cells displaying 
apoptotic nuclear morphology are depicted in Figure 3.18.  DMSO up to 0.2% had 
no significant effect on the percentage of apoptotic cells compared to untreated cells 
after three hours.  Representative sets of fluorescent, bright field and composite 
images showing no evidence of apoptotic nuclear changes are provided for 0.1% 
DMSO treatment (Figure 3.19).   
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Figure 3.18: The impact of various concentrations of DMSO on the percentage 
of MCF7 cells displaying apoptotic nuclear morphology 
MCF7 cells were prepared as described, and incubated for 48 hours to allow 
oestrogens to wash out.  Following this, medium was replaced with fresh oestrogen 
free medium with no additions, 0.1 or 0.2% DMSO.  The percentage of apoptotic 
cells after DAPI staining was determined.  Results are presented as mean + SD for 
each treatment (n=3).  There were no significant variations (p < 0.05) in results.   
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Figure 3.19: MCF7 
breast cancer cells 
treated with 0.1% DMSO 
Representative images of 
MCF7 cells treated as 
described with 0.1% 
DMSO.  A: DAPI 
fluorescent image, B: 
bright field, C: composite.  
No evidence of apoptotic 
nuclear changes.   
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3.3.1..2 17β-Oestradiol does not induce apoptotic nuclear morphology in 
MCF7  
The results of the experiments looking at the effects of physiological concentrations 
of E2 on the induction of apoptotic nuclear morphology are shown in Figure 3.20 
and Table 3.8.  There was no effect apparent after three hour treatment with either 
concentration compared to the vehicle only control. 
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Figure 3.20: Induction of apoptotic nuclear morphology by 17β-oestradiol in 
MCF7 
MCF7 cells were prepared as described.  Following this, medium was replaced with 
fresh oestrogen free medium with 0.1% DMSO or 17β-oestradiol at pre- and post-
menopausal concentrations (1 x 10-9M and 1 x 10-12M respectively).  Levels of 
apoptosis were quantified after DAPI staining, by calculation percentage of cells 
displaying apoptotic nuclear morphology and results presented as mean and SD for 
each treatment (n=3).  There were no significant variations from the vehicle-only 
control (p < 0.05). 
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3.3.1..3 The effect of isoflavones on nuclear morphology in MCF7 
The impact of isoflavones on apoptotic nuclear morphology in MCF7 is shown in 
Figure 3.21 and Table 3.8.  Three hour treatment of MCF7 with genistein between 
10nM and 10µM had no significant effect on apoptotic nuclear morphology.   
However, the highest concentration of genistein used (31.6μM) resulted in a 
significant increase in the percentage of apoptotic cells (p < 0.01).  Daidzein had no 
significant effect at any concentration.    
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Figure 3.21: The effect of isoflavones on apoptosis in MCF7 breast cancer 
cells 
MCF7 cells were prepared as described, and incubated for 48 hours to allow 
oestrogens to wash out.  Following this, medium was replaced with fresh oestrogen 
free medium with 0.1% DMSO, or genistein or daidzein at 0.01, 1, 10 and 31.6μM.  
Induction of apoptosis was quantified by calculation of the percentage of cells 
displaying apoptotic nuclear morphology after DAPI staining, and results presented 
as mean + SD for each treatment (n=3).  a indicates significant variation from the 
vehicle-only control (p < 0.01). 
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Table 3.8: Effect of single isoflavone and 17β-oestradiol treatments on 
apoptotic nuclear morphology in MCF7 cells 
Treatment % apoptosis1 SD   P2 
untreated  6.12 6.08 NS 
0.1% DMSO 6.28 12.36 - 
0.2% DMSO 9.75 13.82 NS 
1pM E2 5.78 11.84 NS 
1nM E2 7.82 11.30 NS 
10nM G 5.92 15.39 NS 
1μM G 6.24 8.85 NS 
10μM G 7.24 8.66 NS 
31.6μM G 18.90 21.63   <0.01 
10nM D 9.18 16.32 NS 
1μM D 6.40 8.59 NS 
10μM D 9.01 14.58 NS 
31.6μM D 9.71 11.22 NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not 
significant (p ≥ 0.05) 
1 mean percentage of cells displaying apoptotic nuclear morphology per treatment 
2 significant differences compared to cells treated with vehicle only (0.1% DMSO) 
3.3.1..4 The effect of combined isoflavones and E2 on MCF7 apoptotic 
nuclear morphology  
The results for the effect of combinations of isoflavones at physiological 
concentrations with pre- or postmenopausal E2 levels on apoptotic nuclear 
morphology in MCF7 breast cancer cells are described in Figure 3.22 and Table 3.9.   
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B: Daidzein and 17-oestradiol
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Figure 3.22: The effect of combinations of isoflavones and 17β-oestradiol on 
apoptotic nuclear morphology in MCF7 
MCF7 cells were prepared as described.  After 48 hours the medium was replaced 
with fresh oestrogen free medium with 0.2% DMSO, 1nM or 1pM E2 with or without 
genistein (A) or daidzein (B) at (0.01, 1, 10 and 31.6μM).   Induction of apoptosis 
was quantified by percentage of apoptotic cells after DAPI staining, and results 
presented as mean + SD for each treatment (n=3).  There were no significant 
variations (p < 0.05) between any results.  
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Table 3.9: Results for the percentage of MCF7 cells displaying apoptotic 
nuclear morphology after treatment with combinations of isoflavones and 17β-
oestradiol 
Treatment mean 
% 
SD Significance (p) compared to: 
0.2% 
DMSO 
1nM 
E2 
1pM 
E2 
corresponding 
ISF alone 
1pM E2 10nM D 3.17 4.82 NS - NS NS 
1pM E2 1μM D 3.98 7.80 NS - NS NS 
1pM E2 10μM D 7.88 15.29 NS - NS NS 
1pM E2 31.6μM D 15.87 27.48 NS - 0.075 NS 
1nM E2 10nM D 3.73 5.68 NS NS - NS 
1nM E2 1μM D 2.62 3.11 NS NS - NS 
1nM E2 10μM D 5.05 3.74 NS NS - NS 
1nM E2 31.6μM D 8.40 12.00 NS NS - NS 
1pM E2 10nM G 5.38 8.54 NS - NS NS 
1pM E2 1μM G 4.37 5.92 NS - NS NS 
1pM E2 10μM G 5.29 8.66 NS - NS NS 
1pM E2 31.6μM G 11.80 20.10 NS - NS NS 
1nM E2 10nM G 0.28 1.14 NS NS - NS 
1nM E2 1μM G 5.50 11.71 NS NS - NS 
1nM E2 10μM G 3.43 8.14 NS NS - NS 
1nM E2 31.6μM G 9.61 13.37 NS NS - NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, ISF: 
Isoflavone, NS: not significant (p ≥ 0.05) 
None of the combination isoflavone/E2 treatments differed significantly from the 
0.2% DMSO control, or the relevant single concentrations of isoflavone or E2 with 
regard to the percentage of cells displaying apoptotic nuclear morphologies. As with 
the single isoflavone treatments, the combinations of the highest concentration of 
genistein and daidzein used (31.6µM) with 1pM or 1nM E2 tended to induce a 
slightly greater percentage of apoptotic cells compared to the control, and the 
combination of 1pM E2 / 31.6µM daidzein approached a significant difference from 
the E2 alone treatment (p = 0.075). 
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3.3.2 MDA-MB-231 DAPI apoptosis results 
3.3.2..1 Effect of control treatments on MDA-MB-231 nuclear morphology 
DMSO up to 0.2% had no significant effect on the percentage of MDA-MB-231 cells 
displaying apoptotic nuclear morphology after DAPI staining (Figure 3.23).  
Representative images of this treatment are shown in Figure 3.24. 
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Figure 3.23: Effect of DMSO on the percentage of MDA-MB-231 cells 
displaying apoptotic nuclear morphology 
MDA-MB-231 cells were prepared as described.  Following this, medium was 
replaced with fresh oestrogen-free medium with no additions, 0.1 or 0.2% DMSO.  
Induction of apoptosis was quantified by calculating the % of apoptotic cells after 
DAPI staining.  Results are presented as mean and SD for each treatment (n=3).  
There were no significant variations (p < 0.05) in results.   
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Figure 3.24: MDA-MB-
231 treated with 0.1% 
DMSO 
Representative images of 
MDA-MB-231 cells treated 
as described with 0.1% 
DMSO.  A: DAPI 
fluorescent image, B: 
bright field, C: composite.  
No evidence of apoptotic 
nuclear changes and cells 
maintain elongated 
shapes indicative of 
normal growth. 
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3.3.2..2 The effect of 17β-oestradiol on nuclear apoptotic morphology in 
MDA-MB-231 cells 
The results for the impact of E2 at physiological concentrations on the percentage of 
MDA-MB-231 cells displaying apoptotic nuclear morphology are displayed in Figure 
3.25 and in Table 3.10.  Although these treatments had very little impact, there was 
a slight trend towards increasing induction of apoptosis with increasing E2 
concentration. 
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Figure 3.25: The impact of E2 on apoptotic nuclear morphology in MDA-MB-
231 cells 
MDA-MB-231 cells were prepared as described.  Following this, medium was 
replaced with fresh oestrogen-free medium with vehicle only or 17β-oestradiol at 
pre- and post-menopausal concentrations (1 x 10-9M and 1 x 10-12M respectively).  
Levels of apoptosis were quantified after DAPI staining, by calculation percentage of 
cells displaying apoptotic nuclear morphology and results presented as mean and 
SD for each treatment (n=3).  There were no significant variations from the vehicle-
only control (p < 0.05). 
3.3.2..3 Isoflavones induce apoptotic nuclear morphology in MDA-MB-231 
Sample images of this cell line after treatment with 1nM and 31.6μM genistein are 
provided (Figure 3.26 and Figure 3.27).  The results showing the percentage of 
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MDA-MB-231 cells displaying apoptotic nuclear morphology after three hour 
treatment with isoflavones are displayed in Table 3.10 and Figure 3.28.  Treatment 
for three hours with isoflavones resulted in a trend towards increasing levels of 
apoptotic nuclear morphology in this cell type, at all concentrations tested.  This 
achieves statistical significance with 31.6µM genistein (p < 0.01) and 10nM daidzein 
(p < 0.001).   In addition, the increase seen after 31.6µM daidzein treatment 
approached significance (p = 0.09).  With genistein treatment, there is a slight dose 
effect.   
Table 3.10: Full results showing the effect of single isoflavone and 17β-
oestradiol treatments on the induction of apoptotic nuclear morphology in 
MDA-MB-231 cells 
Treatment % apoptosis SD P1 
Untreated  6.59 11.87 NS 
0.1% DMSO 9.94 10.74 - 
0.2% DMSO 5.87 6.02 NS 
1pM E2 13.25 16.11 NS 
1nM E2 15.25 17.88 NS 
10nM G 15.68 18.88 NS 
1μM G 12.17 12.88 NS 
10μM G 17.78 16.21 NS 
31μM G 23.46 23.05 <0.01 
10nM D 28.61 24.89 <0.001 
1μM D 18.43 17.86 NS 
10μM D 18.53 19.52 NS 
31.6μM D 21.44 21.04 0.09 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not 
significant (p ≥ 0.05) 
1 Significance of difference compared to 0.1% DMSO 
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Figure 3.26: MDA-MB-
231 cells treated with 
10nM genistein 
Representative images of 
MDA-MB-231 cells treated 
as described with 10nM 
genistein.  A: DAPI 
fluorescent image, B: 
bright field, C: composite.  
No evidence of apoptotic 
nuclear morphology, and 
cells show characteristic 
elongated shape 
indicative of normal 
growth.  
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Figure 3.27: MDA-MB-231 
cells treated with 31.6μM 
genistein 
Representative images of 
MDA-MB-231 cells treated 
as described with 31.6μM 
genistein.  A: DAPI 
fluorescent image, B: bright 
field, C: composite.  There 
is evidence of apoptotic 
nuclear fragmentation, 
resulting in irregular nuclear 
forms, and nuclear 
condensation.  Blebbing of 
the plasma membrane is 
also apparent. 
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Figure 3.28: The effect of isoflavones on apoptosis in MDA-MB-231 cells 
MDA-MB-231 cells were prepared as described.  Medium was replaced with fresh 
oestrogen free medium with 0.1% DMSO, or genistein or daidzein at 0.01, 1, 10 and 
31.6μM.  Induction of apoptosis was quantified by calculating the percentage of cells 
displaying apoptotic morphology after DAPI staining, and results presented as mean 
and SD for each treatment (n=3).  Where results differed significantly from the 
vehicle-only control this is indicated by a (p < 0.01) or b (p < 0.001). 
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3.3.2..4 The combination of isoflavones and 17β-oestradiol induces 
apoptotic nuclear morphology in MDA-MB-231 
A representative image of these cells treated with 1nM E2 and 31.6μM genistein is 
provided in Figure 3.29.  The results for the effect of combinations of isoflavones at 
physiological concentrations with pre- or postmenopausal E2 on the percentage of 
cells displaying apoptotic nuclear morphology in MDA-MB-231 breast cancer cells 
are described in Figure 3.30 and Table 3.11.  As with the single isoflavone 
treatments in this cell line, the combined E2/isoflavone treatments show a trend 
towards an increase in the level of apoptotic nuclear morphology apparent after 
three hours, with a number of these being significantly higher than the control value 
(see Table 3.11). 
Several of the combined treatments also induced significantly greater levels of 
apoptosis than the relevant single E2 treatments.  These were daidzein at 31.6µM 
with both E2 concentrations, and 31.6µM genistein with 1pM E2 (p < 0.001 for 
each), and the combination of 10µM genistein with 1pM E2 (p < 0.05).  In addition, a 
number of the combined treatments also induced a greater level of apoptosis than 
the relevant isoflavone alone (largely the same combinations as above; see table 
3.11).   
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Figure 3.29: MDA-MB-231 
treated with 1nM E2 and 
31.6μM genistein 
Representative images of 
MDA-MB-231 cells treated 
as described with a 
combination of 31.6μM 
genistein and 1nM E2.  A: 
DAPI fluorescent image, B: 
bright field, C: composite.  
Apoptotic nuclear 
condensation and 
fragmentation are apparent, 
resulting in irregular nuclear 
forms.  Plasma membrane 
blebs are evident on some 
cells, indicating apoptosis.  
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B: Daidzein and 17-oestradiol
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Figure 3.30: The effect of combinations of isoflavones and 17β-oestradiol on 
apoptosis in MDA-MB-231 cells 
MDA-MB-231 cells were seeded as described.  After 48 hours, the medium was 
replaced with fresh oestrogen free medium with 0.2% DMSO, 1nM or 1pM E2 with 
or without genistein (A) or daidzein (B) at (0.01, 1, 10 and 31.6μM).   Induction of 
apoptosis was quantified by calculation of the percentage of cells displaying visible 
signs of apoptotic nuclear morphology after DAPI staining, and results presented as 
mean and SD for each treatment (n=3).  Significant variation from the 1nM E2-alone 
treatment is indicated by a (p < 0.05) and b (p < 0.001), and from the 1pM E2-alone 
treatment by c (p < 0.05) and d (p < 0.001).  Significant variation from the relevant 
isoflavone-alone treatment is indicated by e (p < 0.05) and f (p < 0.001).    
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Table 3.11: Full results for isoflavone/17β-oestradiol combinations on the 
induction of apoptotic nuclear morphology in MDA-MB-231 breast cancer cells 
Treatment mean % 
apoptosis 
SD Significance (p) compared to: 
0.2% 
DMSO 
1nM 
E2 
1pM 
E2 
corresponding 
isoflavone alone 
1pM E2 10nM D 8.30 11.90 NS  NS <0.05 
1pM E2 1μM D 22.01 26.16 NS  NS NS 
1pM E2 10μM D 19.14 24.34 NS  NS NS 
1pM E2 31.6μM D 40.21 19.96 <0.001  <0.001 <0.05 
1nM E2 10nM D 25.46 20.72 <0.05 NS  NS 
1nM E2 1μM D 22.40 17.64 NS NS  NS 
1nM E2 10μM D 24.49 14.17 <0.05 NS  NS 
1nM E2 31.6μM D 50.10 25.59 <0.001 <0.001  <0.001 
1pM E2 10nM G 11.54 13.36 NS  NS NS 
1pM E2 1μM G 16.43 16.35 NS  NS NS 
1pM E2 10μM G 28.08 11.21 <0.001  <0.05 NS 
1pM E2 31.6μM G 45.61 27.99 <0.001  <0.001 <0.001 
1nM E2 10nM G 7.41 7.80 NS NS  NS 
1nM E2 1μM G 13.13 12.49 NS NS  NS 
1nM E2 10μM G 28.32 18.28 <0.01 NS  NS 
1nM E2 31.6μM G 33.51 32.93 <0.001 NS  NS 
G: Genistein, D: Daidzein, E2: 17β-oestradiol, SD: Standard Deviation, NS: not 
significant (p ≥ 0.05) 
  
215 | P a g e  
 
3.4 Summary of the effects of soy isoflavones on 
proliferation and apoptosis in MCF7 and MDA-MB-231 
cells 
This section briefly summarises the impact of genistein and daidzein, in the 
presence and absence or premenopausal and postmenopausal E2 levels, on the 
proliferation and apoptosis outcomes measured here in MCF7 and MDA-MB-231 
breast cancer cells.  For a full discussion of these results see sections 6.1 and 6.2. 
3.4.1 MCF7 
The MTT proliferation results confirm the biphasic effect of isoflavones on this cell 
line that was expected.  Maximal proliferation was achieved between 1 and 10µM 
for both isoflavones, and was similar in magnitude to that observed after E2 
treatment, although approximately 1000-fold greater isoflavone concentrations were 
required for a comparable effect.  Genistein was slightly more effective at promoting 
proliferation than daidzein, as evidenced by their EC50 concentrations.  This 
confirms the validity of the growth conditions used and suggests that the cell line is 
behaving as expected, and has not experienced genetic drift or contamination.  In 
each case, a higher concentration of isoflavone would be required (outwith the 
physiological range) to inhibit proliferation. 
The combined isoflavone/E2 treatments at both premenopausal (1nM) and 
postmenopausal (1pM) levels resulted in very high rates of proliferation in MCF7.  
Numerically, the evidence for an additive effect for isoflavones and the 
postmenopausal E2 dose is strong.  This suggests a synergistic effect on 
proliferation rather that the protective mechanism hypothesised.  Some synergy 
remains between the isoflavones and the higher premenopausal E2 dose, although 
the effect is less striking.   
Both measures of apoptosis used suggested that premenopausal and 
postmenopausal E2 levels had no effect on the induction of apoptosis in MCF7.  
However, physiological levels of genistein and daidzein, particularly at the higher 
concentrations tested, did result in an increase in the percentage of apoptotic cells 
both externalising PS and displaying distinctive apoptotic nuclear morphology.  The 
characteristics of this response differ according to the analysis method used.  Either 
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way, this increase in the induction of apoptosis seen especially with the higher 
concentrations may relate to the decrease in proliferation observed with the highest 
isoflavone concentrations. 
The impacts of the combined isoflavone/E2 treatments on the induction of apoptosis 
were largely similar to that seen with the single isoflavone treatments, regardless of 
assay method.  This is perhaps unsurprising since in both cases E2 was found to 
have little effect on apoptosis.   
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3.4.2 MDA-MB-231 
As expected, premenopausal and postmenopausal E2, and the single isoflavone 
treatments up to and including 10µM all resulted in a trend towards inhibition of 
MDA-MB-231 proliferation compared to the control treatment.  There was no dose 
effect apparent.  As with the MCF7 cells, this confirms that the conditions used are 
valid for the experiments to follow, and suggests that the cell line has not 
experienced genetic drift or contamination with other cells.  The highest 
concentrations of genistein and daidzein used resulted in a sharp drop in 
proliferation to around 50% of control levels. 
The addition of E2 to the isoflavones seemed to largely abrogate the inhibitory effect 
of the lower concentrations, although the drop seen at the highest isoflavone 
concentration was still apparent.  The exception to this was the combination of 
daidzein and postmenopausal E2, which was particularly effective at inhibiting 
proliferation.  As the level of solvent used in these latter experiments (0.2% DMSO) 
was found to have a slight inhibitory effect on MDA–MB-231 proliferation itself, it is 
possible that this confounds or masks the results slightly, and must be considered in 
this context. 
Both methods of assessing the induction of apoptosis agree that E2 had very little 
impact upon the induction of apoptosis in MDA-MB-231 cells.  However, the 
isoflavones at all single concentrations tested result in a slight increase in the 
percentage of apoptotic cells, which achieved significance on several occasions.  No 
dose effects were observed.  This corresponds with the inhibition of proliferation 
seen and may suggest a mechanism. 
The combinations of E2 and isoflavones were not assessed by the Annexin V-Cy3 
method.  However, the DAPI assay suggests that the addition of E2 does not 
prevent the isoflavone-induced induction of apoptosis observed, and indeed hints at 
a possible synergistic effect with the higher isoflavone concentrations.   
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CHAPTER 4. Methods: volume regulation and potassium 
channel activity  
The impact of physiological levels of isoflavones and E2 on MCF7 volume regulation 
and macroscopic voltage gated K+ channel activity was assessed.  Volume changes 
were measured using the calcein volume change assay (section 1.6.2..5), and the 
whole cell patch clamping technique was used to identify and analyse macroscopic 
K+ currents (section 1.6.2..1).  Measuring changes in fluorescence intensity is one of 
several standard and sensitive techniques used to infer volume change in cultured 
cells.  Whole cell patch clamping is the “gold standard” technique with which to 
assess the characteristics of ion channels under physiological membrane potential 
conditions.  In addition, the MTT assay (described previously; section 2.4) was used 
to assess the role of these K+ channels in general, and several specific channels, on 
the proliferation of MCF7 breast cancer cells.   
These experiments were conducted with MCF7 cells only, and not the MDA-MB-231 
cell line.   This was partly due to time constraints, but also because very little is 
known regarding the types and activities of K+ channels in the MDA-MB-231 cell line 
(consequently no data exists to compare any results with).  
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4.1 Calcein cell volume assay 
4.1.1 Background to method 
Isoflavones are known to inhibit RVD in numerous cell types (Section 1.6.8..2), but 
this is a response to non-physiological environmental changes.  Whether they 
directly modulate cell volume over the short term in MCF7 is not known.  This may 
relate to their ability to regulate proliferation or apoptosis (see Chapter 3), either as a 
regulatory mechanism or as a downstream effect.   Here, acute changes in MCF7 
volume were assessed over 30 minutes (the maximum time period during which the 
cells remained viable) during treatment with genistein or E2 by measuring the 
changes in intensity of intracellular calcein fluorescence, in a method initially 
described by Crowe et al. (1995), and used recently by Chen et al. (2011) to assess 
volume changes in lung adenocarcinoma cells (SPC-A1).  Volume changes have 
been measured in MCF7 previously (Roy et al. 2008; vanTol et al. 2007), although 
not by this method.  Both groups used a similar process of light microscopy, digital 
photography, and analysis of the area of the cell based on the radius measured.  
However, this method is based on the assumption that the cells are spherical, which 
is rarely the case. 
After a two day oestrogen washout, the cells were loaded with the dye in its 
membrane permeable ester (AM) form.  Once internalized, intracellular esterases 
remove the acetomethoxy group, and the molecule becomes trapped within the cell.  
Upon hydrolysis, calcein fluoresces green.  Prior to experimentation, the absorption 
wavelength of 480nm was determined to be optimal, and was used throughout.  
Emission peaked at 515nm.  Once the remaining extracellular dye was washed 
away, the quantity of calcein within the cells remained relatively constant over the 
short term (up to approximately 45 minutes; data not shown).  Fluorescence 
intensity varied directly with dye concentration (and cell volume), and so acted as a 
marker for cell size. 
In accordance with standard procedures, these experiments were conducted at 
37oC.  Volume regulation is known to occur at measurable levels in MCF7 at both 
this and room temperature, but the magnitude of the response is greater at the 
higher temperature (vanTol et al. 2007). 
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4.1.2 Preparation of solutions 
Normal Tyrode (NT) 
The following were dissolved in 1l deionised water: NaCl (Fisher Scientific; 7.831g, 
134mM), KCl (Sigma; 0.447g, 6mM), MgCl2.6H2O (Sigma; 1mM), CaCl2.6H2O 
(Sigma; 1mM) and HEPES (Sigma; 2.383g, 10mM).  This was titrated to pH 7.4 at 
37oC with 4M NaOH (Fisher Scientific; approximately 1.29ml was required for 1l 
buffer), and stored at 4oC.  Glucose (Sigma; 10mM, 180mg per 100ml) was added 
immediately prior to use. 
 
Zero Sodium Tyrode 
The following were dissolved in 1l deionized water: MgCl2.6H2O (1mM), CaCl2.6H2O 
(1mM) and HEPES (2.383g, 10mM).  This was titrated to pH 7.4 at 37oC with 4M 
KOH (BDH Prolabo; approximately 1.29ml was required for 1l buffer).  This was 
stored at 4oC. 
 
Hyposmotic buffer (50% Na Tyrode) 
This was prepared by mixing 50% each of the NT and zero sodium Tyrodes, and 
was also stored at 4oC.  Again, glucose (10mM, 180mg per 100ml) was added 
immediately prior to use. 
 
Test Tyrodes 
To 100ml NT, glucose (180mg) and 100µl of DMSO (0.1%) or the appropriate stock 
concentration of genistein or E2 (also in DMSO) were added (i.e. to prepare 100ml 
of 1nM E2 Tyrode, 100µl of 1x10-6M E2 was added to 100ml NT).  In each case 
0.1% DMSO was present.  This was stored for a maximum of 4 days at 4oC. 
Calcein-AM stock 
A 1mM stock of calcein-AM (Molecular Probes) was prepared in DMSO, and stored 
in the dark at -20oC. 
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4.1.3 Calcein volume change protocol  
MCF7 cells were seeded in six well plates (Greiner) on 10mm sterile glass cover 
slips (Agar Scientific).  Prior to placing in the wells, the cover slips were sterilised by 
autoclaving (121oC for 15 minutes).  The cells were seeded at an initial density of 
1x105 cells per well, in 3ml of experimental medium.  This was returned to the 
incubator for 48 hours to allow the cells to grow and adhere, and for the washout of 
any oestrogenic compounds. 
Following this, sterile conditions were no longer required, and all reagents were 
warmed to 37oC prior to use. 
4.1.3..1 Calcein loading 
After incubation, the medium was removed, and cells were washed twice gently with 
1ml NT.  Fresh NT was added (1ml) along with 5µl of 1mM calcein-AM stock (final 
calcein concentration 5µM).  This is well below the concentrations which would 
trigger calcein self-quenching (section 1.6.2..5).  The dye was allowed to load for 1 
hour, incubated in the dark at 37oC.  Following this, any dye not taken up by the 
cells was removed by washing three times each with 1ml NT, and 1ml fresh NT was 
added to the well.  Intracellular calcein-AM was allowed to esterify to calcein during 
a further 30 minute incubation period (37oC in the dark) as per standard 
proceedures (Pan et al. 2007). 
4.1.3..2 Perfusion and measurement of fluorescence 
The perfusion and assessment of fluorescence intensity was carried out using a 
Cairn Optoscan Monochromator (Cairn Research Ltd., Kent) mounted to an inverted 
microscope (Olympus, OM-2; Japan).  Perfusion of the cells with various Tyrodes 
was carried out by a peristaltic pump (Gilson Minipuls 3) and in-line thermostatically 
controlled stage heating system (Warner Instrument Corporation, TC-324B).  This 
was calibrated prior to use to maintain a constant flow rate and temperature of 
1ml/min and 37oC.  Images were captured at a rate of two per second using a digital 
camera (Hamamatsu C4742-95), which was controlled, along with the excitation 
wavelength (480nm) and bandwidth (10nm), by WinFluor software (V.3.0.8, John 
Dempster, University of Strathclyde Electrophysiology Software). 
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Prior to the addition of cells, the microscope chamber was flushed with pre-warmed 
NT for at least five minutes, to allow the temperature of the NT in the dish to reach 
37oC.  Once this was achieved, a coverslip of loaded cells was removed gently from 
its well with watchmaker’s forceps, and placed (cell side up) on the bottom of the 
microscope chamber.  Using the forceps, the plate was carefully pressed to the 
bottom of the dish, so that capillary suction would hold it in place.  Cells were 
visualized by light microscopy (magnification x100) to find an appropriate region of 
the coverslip to assess, with sufficient cells which were not densely packed and so 
able to change in volume freely.  The microscope light was then switched off and the 
equipment curtained off with black curtains to prevent extraneous light “noise” 
affecting the image. 
The cells were illuminated with the excitation light (480nm) and light emitted at 
>515nm was collected by the microscope dichroic and filter system (Omega 
XF2058) and transmitted to the camera.  Regions of interest (ROIs) in the live image 
were monitored using the software to show gross changes and confirm that the 
intensity of fluorescence was stable prior to analysis, but this data was discarded, 
and not used for the later analysis. 
Once fluorescence with NT perfusion had stabilized, recording was initiated.  
Solutions were perfused over the cells as described below.  The system has an 
approximate lag time of two minutes due to the physical dead volume of the tubing, 
from changing a solution to it reaching the cells.  This was considered when 
analyzing the results.  Once the end of a protocol was reached, the coverslip was 
discarded and the perfusion system flushed before re-use. 
At an early stage, as with pervious fluorescence protocols (Annexin optimisation 
Section 2.5.3), cell auto-fluorescence was assessed and determined to have 
negligible effect (i.e. was the same as the background of a cell-free area of the 
coverslip). 
4.1.3..3 Image analysis 
Images were analysed using ImageJ software (NIH: Version 1.44).  Files containing 
every third frame or more were too large for ImageJ to process.  Mean fluorescence 
intensity from a three minute interval of an image set of MCF7 cells (n = 3 cells: the 
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same ones were selected on each occasion) was compared following the export and 
analysis of every 4th, 6th, 8th and 10th frame (Figure 4.1). 
Mean fluorescence intensity at varying frame intervals
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Figure 4.1: Comparison of results after exporting every ‘n’th frame 
MCF7 cells were prepared and assessed for calcein fluorescence as described. The 
mean fluorescence intensity of the same three cells over a three minute interval 
(minus background) was determined using ImageJ after the export and analysis of 
every 10th, 8th, 6th and 4th frame, as indicated.   
The results from every 4th, 6th and 8th frame followed a similar pattern, which was not 
apparent after the export of every 10th frame.  Why the results obtained after the 
export of every 8th frame were higher than the other sets of data is not known, 
although it is possible that slightly different regions of the cells were selected for 
analysis, resulting in greater mean fluorescence intensity.  Based on this the export 
and analysis of every 8th frame into ImageJ was deemed appropriate. 
Each file was assessed as an 8 bit greyscale image.  Circular ROIs were chosen in 
the centre of at least ten cells, and a further one in an area of cell-free background 
(Figure 4.2).  Cells were excluded from the analysis on the basis of being cropped 
by the edge of the image, death or dislodgement from the cover slip prior to the end 
of the recording, or excessive movement excluding the possibility of finding a 
constant region within the cell.   
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Figure 4.2: Representative image of calcein-loaded MCF7 cells 
ImageJ analysis of MCF7 cells.  ROIs (indicated) are selected inside cells which 
meet the criteria, ensuring that they remain within the cell as the image series 
progresses.  A cell-free background ROI (a) is also selected. 
The background value was subtracted from the cell values at each time point.  
Following this, ImageJ was used to calculate the fluorescence intensity (mean grey 
value; arbitrary units from 0 to 255) in each selected cell region, every four seconds 
(from every 8th frame) for the duration of the experiment.  For each treatment, this 
procedure was repeated on three independent occasions, on different days and with 
different cell preparations, so that n = 3, and includes data from at least 30 cells. 
Data is presented as a graph of the mean fluorescence intensity over time. 
To determine the rate of change of fluorescence intensity (Δf per second), and thus 
the rate of cell swelling or shrinkage, for each cell the slope of the line between two 
points (indicated) was determined by linear regression using Graphpad Prism 
software (Graphpad Software Inc, Version 5.01, 2007).  Mean slope (ratio between 
the change in time and the change in fluorescence) and SD were calculated, and 
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expressed as the rate of fluorescence intensity change per second (Δf).  For the test 
conditions, the slope was calculated in the final two minutes of DMSO treatment (8 
to 10 minutes DMSO), then at 10 to 12 minutes, and 15 to 17 minutes into the 
experimental treatment.  These are referred to as Δf0, Δf10, and Δf15 respectively. 
The adjusted rates of change (aΔf10 and aΔf15) were determined for each treatment 
at 10-12 and 15-17 minutes respectively to show the impact of that treatment alone, 
without any background or DMSO effects.  This was calculated as follows: 
aΔf = Δf(treatment) – Δf0(same treatment) 
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4.1.4 Test conditions 
Hyposmotic shock 
MCF7 cells are known to undergo RVD rapidly after an initial swelling phase during 
hyposmotic shock (Roy et al. 2008; vanTol et al. 2007).  This was used as a positive 
control to determine that the above protocol was appropriate for assessing volume 
changes in this cell line.  
Images were captured during perfusion for 10 minutes with NT, then perfusion was 
switched to the hyposmotic buffer for 30 minutes, then returned to NT for 20 
minutes.  These time points were chosen to ensure that the full hypotonic swelling 
and ensuing RVD response were captured (Roy et al. 2008; vanTol et al. 2007). 
17β-oestradiol and genistein 
To determine the effect of E2 and genistein on MCF7 volume, the cells were 
perfused with these compounds following Calcein loading.  Images were recorded 
for 5 minutes in NT, then 10 mins 0.1% DMSO so each cell acted as its own control.  
Following this the cells were perfused for 30 minutes with the test Tyrode (either 
1nM E2, or 1 or 31.6µM genistein).  If the cells remained viable following this 
treatment, then they were followed for a further 10 minutes in normal Tyrode to 
determine if the effects were reversible, but cell damage due to the UV light 
prevented this from occurring frequently enough to generate usable data. 
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4.1.5 Statistical analysis 
For the hyposmotic shock data, the fluorescence values from 1 minute regions in the 
centre of the sections of the trace of interest were collated, and the mean and SD 
calculated.  These were compared with each other by paired Student’s t test (SPSS 
version 19, IBM Statistics, 2010), and significant variations (p, two tailed < 0.05) 
were indicated. 
In addition, the Δf values were compared by paired t tests as above, and significant 
variations (p, two tailed < 0.05) indicated. 
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4.2 MTT assay: assessing the role of potassium channels in MCF7 
proliferation  
The activities of the VGKCs on proliferation were pharmacologically identified using 
broad and specific channel blockers (see Table 1.9 for more information).  These 
comprised Tetraethyl ammonium (TEA; a non-specific K+ channel blocker), 4-amino 
pyridine (4-AP; VGKC blocker), astemizole (AST; blocks hEAG and hERG channels) 
and dofetilide (DOF; blocks hERG). 
MCF7 proliferation was assessed using the previously optimized MTT assay, as 
described in Section 2.4, after treating the cells with a range of concentrations of the 
channel blocking compounds.   
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4.2.1 Preparation of solutions 
TEA 
A stock solution of 1M TEA (Sigma) was prepared in deionised water (d.H2O), and 
filtered using a 0.22 µm mixed cellulose ester (MCE) syringe filter (Millex Millipore).   
4-AP 
The lower concentration of 0.5M was used for the stock solution of 4-AP (Tocris 
Bioscience).  Again this was prepared in d.H2O and filtered as above.  
AST 
AST (Sigma) was dissolved to the maximum stock concentration of 50mM in sterile 
DMSO.  This was filtered using a 0.22μm Polytetrafluoroethylene (PTFE) syringe 
filter (Whatman). 
DOF 
DOF (Sigma) would only dissolve in DMSO to the stock levels of 10mM.  This was 
filtered using a 0.22µM PTFE syringe filter. 
Serial dilutions of each compound were prepared in sterile DMSO or sterile water as 
appropriate.  These were stored at -20oC until use, and thawed at room 
temperature.  For experimental use, 5μl of the appropriate AST or DOF stock 
dilution was added to 5ml of experimental medium to give the relevant channel 
blocker, with DMSO concentration never exceeding 0.1%.   As higher final 
concentrations of 4-AP and TEA were required, but their solubility in water was a 
limiting factor, a maximum final solvent concentration of 4% was unavoidable.  The 
impact of this change in osmolarity upon the growth of the cells was inescapable but 
minimal. 
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4.2.2 MTT assay protocol 
As previously, MCF7 cells were seeded into 96 well plates at a density of 6000 cells 
per well in 0.2ml experimental medium, and incubated at 37oC in a humidified 5% 
CO2 environment.  After a 24 hour period of oestrogen washout, the medium was 
replaced with fresh experimental medium containing a range of concentrations of 
the K+ channel blockers.  Care was taken to ensure that DMSO never exceeded 
0.1% in any preparation.  After incubation for 72 hours, the MTT assay was carried 
out using the protocol described (Section 2.4).  Again, proliferation was expressed 
as the percentage of proliferation compared to the appropriate control treatment.   
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4.2.3 Test conditions  
Controls 
DMSO (0.1%) was used as the control for the AST and DOF experiments.  The 
impact of this on the proliferation of MCF7 had been assessed previously, and was 
not found to affect growth. 
TEA and 4-AP were dissolved in d.H2O, containing up to a maximum of 4% of the 
solvent.  Accordingly, a series of treatments containing from 0.1% to 4% d.H2O were 
prepared, to determine the effect of this on MCF7 proliferation.   
K+ channel blockers 
Cells were incubated with the following: 
 TEA between 1μM and 20mM 
 4-AP between 1μM and 20mM (adjusted where necessary to contain 4% 
filtered d.H2O) 
 AST between 1nM and 50μM 
 DOF between 1nM and 10μM 
 
As no specific blockers of the hEAG channel were available, the combination of AST 
and DOF was used to pharmacologically identify the activity of this channel.  That is, 
it was hypothesized that if an activity is prevented by AST treatment but not DOF, 
then it is likely to be the hEAG-blocking component of AST that is responsible in that 
instance. 
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4.2.4 Statistical analysis 
AST and DOF results were compared to the 0.1% DMSO control.  The TEA 
treatments were compared to the 2% H2O control.  To determine the effects of the 
4-AP treatments the 4% H2O control was used for comparison.  The treatments 
containing 0.1 to 4% d.H2O were compared to the untreated control from Section 
3.1.1..1.  The impact of 0.1% DMSO on MCF7 proliferation had been determined 
previously (Section 3.1.1..1).   The significance of variation from the appropriate 
control treatment was determined by ANOVA (SPSS version 19, IBM Statistics, 
2010) with Bonferroni post hoc corrections for multiple comparisons, and significant 
values (p, two tailed, <0.05) are indicated. 
Where a compound was found to inhibit proliferation sufficiently, the IC50 was 
determined by non-linear regression using Graphpad Prism software (Graphpad 
Software Inc., Version 5.01, 2007). 
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4.3 Whole cell patch clamping to assess potassium channel 
physiology  
4.3.1 Background to method 
In parallel to this, the impact of genistein and E2 on MCF7 K+ current was identified, 
by whole cell patch clamping, and preliminary attempts were made to 
pharmacologically identify the specific channels through which they might be acting. 
Electrophysiological measurement using the patch clamping technique is the gold 
standard technique for measuring the characteristics of ion channels, as it allows the 
channels to be gated by physiologically relevant membrane potentials (Birch et al. 
2004).  This is particularly important as the gating (opening and closing) of 
numerous channels is affected by voltage.  This technique is used to measure ionic 
currents in whole cells under a voltage clamp, in which near-perfect control of 
membrane potential is possible.  It is routinely used to measure ion channels in 
virtually any cell type, including MCF7 breast cancer cells (Ouadid-Ahidouch et al. 
2000; Roy et al. 2008; Sontheimer and Olsen 2007).  It operates along the principle 
that channel activity results in changes in membrane resistance, which can be 
studied by measuring current at a constant (clamped) membrane voltage.  In these 
conditions, membrane resistance is directly proportional to the current under 
scrutiny (Sontheimer and Olsen 2007).  This is the fundamental principle of Ohm’s 
law, dictating that the current between two points is directly proportional to the 
potential difference between those points, and indirectly proportional to the degree 
of resistance (opposition to current flow).  A comprehensive discussion of this 
technique can be found in the Plymouth Workshop Handbook (Ogden 1994).   
Ohm’s law:   I = V ÷ R 
I = current (Amps), V = voltage / potential difference (Volts),       
R = resistance (Ohms) 
With cells bathed in the appropriate media and test compounds, a glass micro-
pipette electrode is used to form a seal with the surface of one cell, and electrical 
continuity is achieved.  From this point, voltage is manipulated and current 
continuously recorded and analysed.  The whole cell patch clamp technique is most 
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widely used to measure macroscopic currents.   It is common practice to design the 
composition of the bathing solution to resemble the extracellular environment that 
the cell would be exposed to in vivo, whilst reducing all ionic currents with the 
exception of the current of interest.  Many natural toxins and pharmacological 
agents can be used to reduce or eliminate the activity of specific channels or a 
broader range of channels.  This allows the isolation and assessment of specific 
currents (Sontheimer and Olsen 2007).  It is a limitation of this technique that this 
treatment of the cell will result in its death, so recordings must be made quickly, 
within 20 minutes, before the results are affected (Coiret et al. 2007). 
Firstly the K+ channel signature of untreated MCF7 cells was measured at a range of 
voltages.  This allowed confirmation that the system was functional and that the 
currents present were mostly due to K+ flux and not other ions (Ouadid-Ahidouch et 
al. 2000).  Following this, the effect of the non-specific K+ channel blocker, TEA, and 
the VGKC blocker 4-AP on the patch clamp signature for MCF7 cells was assessed 
at a range of voltages, confirming the role of the VGKCs on K+ current in these cells.  
Finally, the effect of the specific channel blockers for the hEAG and hERG K+ 
channels on the patch clamp signature was assessed at a range of voltages.  This 
was intended to confirm the presence of these channels in the cells studied, and 
also that their activity was as expected (Ouadid-Ahidouch and Ahidouch 2008).  The 
specific activity of each channel was measured by blocking it and subtracting the 
resulting trace from an untreated K+ channel signature (Cayabyab and Schlichter 
2002; Ouadid-Ahidouch et al. 2000).   
The next step was to investigate whether E2, genistein and daidzein influenced K+ 
flux and the activities of the VGKCs, including hEAG and hERG in MCF7.  As far as 
possible following this, the intention was to begin to elucidate which of the channels 
they affect.  This was done by whole cell patch clamping before and after co-
incubation with both the specific channel blocker and the isoflavone.  If the 
isoflavone and the channel blocker inhibit the activity of different K+ channels, their 
effects on the K+ signature would be expected to be additive.  There would be no 
further inhibitory effect if they both act on the same channel (Coiret et al. 2007).   
The following experiments were carried out at room temperature (21 to 23oC), 
although this is non-physiological.  As discussed (section 1.6.2) the impact of this 
reduced temperature compared to 37oC is likely to be minimal.  Additionally, the use 
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of room temperature made these results comparable with other groups looking at K+ 
current in MCF7 (Coiret et al. 2007; Ouadid-Ahidouch et al. 2000; Ouadid-Ahidouch 
et al. 2004b), and it reduces the potential for electrical interference from the heating 
equipment. 
This was a complex, multistage procedure, with a number of steps built in to ensure 
the standardization of the settings used and measurements taken throughout.  The 
stages were carried out in the order described in Sections 4.3.3 and 4.3.4. 
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4.3.2 Preparation of solutions 
Normal Tyrode buffer  
Extracellular solution, described in section 4.1.2.  
 
Intracellular / pipette solution  
This was intended to match the intracellular environment as closely as possible in 
terms of the concentration of the main ions present.  The following were dissolved in 
d.H2O: KCl (150mM), HEPES (10mM), EGTA (Sigma; 0.1mM), MgCl2 (2mM).  It was 
the titrated to pH7.2 with 4M KOH at room temperature. 
 
 
Test Tyrodes 
As required, appropriate quantities of K+ channel blocker solutions, genistein, E2 or 
DMSO were added to the perfusing NT buffer.  DMSO concentration never 
exceeded 0.1%. 
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4.3.3 Whole cell patch clamp protocol 
4.3.3..1 Optimisation of seeding conditions 
Seeding density and duration of incubation were optimized prior to experimentation 
to allow sufficient cells in each dish whilst avoiding the cells reaching confluence, or 
becoming too densely packed to select individual target cells.  Densities between 
1x104 and 1x106 cells per dish were assessed visually after 24 and 48 hours growth 
(data not shown).  An optimal density of 1x105 cells per dish was selected. 
4.3.3..2 Preparation of cells 
For whole cell patch clamping, MCF7 cells were seeded at a density of 1x105 cells 
per dish in experimental media in individual glass bottomed ethanol sterilised 35mm 
dishes.  Each dish contained 2ml media.  The cells were then incubated at 37oC in a 
humidified 5% CO2 environment for 48 hours. 
The remaining steps were conducted at room temperature, and did not require 
sterile conditions.  All removal and addition of solutions was conducted with care to 
avoid dislodging cells.  When required, medium was removed from the dish by 
pipette.  The cells were washed once with 1ml NT buffer, this was removed, and 
replaced with 2ml fresh NT. 
4.3.3..3 Pulling pipette electrodes 
Micropipettes for the intracellular electrode were prepared from 1.5mm diameter 
filamented borosilicate glass thin walled capillaries 100mm long (GF150, Harvard 
Apparatus UK).  Each capillary made two pipettes.  A Narashige PB-7 two stage 
vertical pipette puller was used for this.  The first pull and heating stage extends the 
tube by 5 to 8mm, thinning the middle section to around 0.1mm diameter, but not 
allowing this to shear.  During the second heating and pull stage the tube is pulled 
apart by gravity.  A tip of around 1µM with electrical resistance of between 3 and 
10MΩ is optimal for whole cell patch clamping (Ogden and Stanfield 1994).  
Reducing the weight applied and increasing the temperature of the second pull 
made a thinner electrode with higher tip resistance.   
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The settings for the first and second pull, and applied weight, were optimised for the 
capillaries used, with the procedure described to measure tip resistance in Section 
4.3.3..5.  To compensate for drift, tip resistance was checked each time, and the 
settings adjusted if necessary.   
Following the manufacturer’s instructions, the capillary was inserted so that 1.5cm 
(approximately) appeared above the top of the apparatus.  No weights were used.  
The first pull was set to have a drop of 6mm, with the temperature set to 88.  
Following this the capillary was adjusted to be 3mm lower, so that the filament was 
in the centre of the thinned region.  For the second pull the temperature was set to 
93.  With these settings the tip resistance was consistently between 3 and 7MΩ.  
With careful storage the pipettes can be prepared several hours or a day in advance 
of use. 
4.3.3..4 Preparing the platform 
MCF7 cells were patch clamped using a Cairn Optopatch amplifier rig (Cairn 
Research Ltd., Kent) with a microscope (Olympus OM-2, Japan; Figure 4.3), inside 
a Faraday cage to reduce airborne electromagnetic radiation, and on an 
antivibration table (TMC Vibration Control, Massachusetts).   The latter uses a 
cushion of air to prevent vibrations from the surroundings being transferred to the 
cell and electrode, as this would be fatal to the stability of the seal.  Cells were 
visualised at x200 using light microscopy. 
A fresh dish of MCF7 cells in NT buffer was inserted into the stage of the 
microscope.  This was perfused with NT using a peristaltic pump (Gilson Minipuls 3) 
at a rate of 1ml/min to wash away debris or non-adherent cells.  The AgCl bath 
electrode was submerged in the NT solution in the dish.   During current recordings 
the pump was required to be switched off as it introduced electrical interference 
(noise) into the circuitry. 
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Figure 4.3: Olympus microscope and headstage inside the Faraday cage 
Bath electrode (A), pipette holder / internal electrode (B), headstage (C) and coarse 
manipulator (D) are indicated. 
When handling and using the micropipettes, great care was required at all times to 
avoid damaging the tips.  A pre-prepared micropipette was filled to about 2/3 full 
with intracellular solution using a syringe needle fitted with a 0.22µm PTFE filter.  
The internal filament allows a continuous liquid circuit through the pipette, 
uninterrupted by bubbles due to capillary action.  However large bubbles in the tip 
were dislodged by tapping.  Once filled, the pipette was attached to the electrode 
holder on the headstage, ensuring that the silver electrode wire was in contact with 
the solution inside the pipette.  The pipette was then lowered into the bath using the 
course manipulator.  This completes the electrical circuit (Figure 4.4).  Slight 
pressure (0.5ml of displaced air) was applied and locked in place using a syringe 
attached to the air line to prevent debris contacting the electrode tip.  The amplifier, 
camera and antivibration table were switched on at this stage.   
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Figure 4.4: Basic schematic of whole cell patch clamp circuitry 
Image from Molleman (2002).  The voltage is “clamped” by the experimenter, and 
the current between the bath and pipette electrodes is continuously measured.  Any 
change in plasma membrane resistance (i.e. channel activity) is immediately 
compensated for by a change in current, which is then recorded. 
4.3.3..5 Checking pipette resistance 
Pipette resistance was checked regularly to determine consistency.  With the 
electrode in the bath, whether using the Cairn amplifier or the seal test window in 
the associated computer software (WinWCP: V.4.4.1, John Dempster, University of 
Strathclyde Electrophysiology Software, 2011) a 10mV pulse was applied from a 
holding potential of 0mV, for 35ms.  This will be referred to as pulse 1.  The junction 
potential was adjusted to compensate for the difference in ionic compositions 
between the bath and electrode solutions (this generates an ion bridge potential) 
using the amplifier until there was no current at zero applied voltage (junction 
potential will be approximately 160mV using the solutions described).  The electrode 
resistance was noted.  The ideal range was between 3 and 10MΩ, corresponding 
with the appropriate tip diameter for whole cell patching large cells such as MCF7.  
Pipettes with tip resistances outwith this range were discarded.  The junction 
potential settings were then switched off, as when the pipette is in contact with the 
cell there should be no junction potential. 
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The system was initially calibrated with a “dummy cell” (Cairn) of known resistance 
and capacitance, so the readings generated were considered accurate. 
4.3.3..6 Generating the Giga-ohm seal on the cell 
A cell was selected visually which sat isolated from other cells, as immediate 
neighbours could interfere with the signal measured.  Care was taken to select cells 
of similar sizes on each instance.  Using the coarse manipulators, then the fine 
micromanipulator (Narashige MWH-3 water hydraulic 3 way) the cell was 
approached with the tip of the pipette, until the tip sat just above the centre of the 
cell, as viewed on the monitor.  Another 0.5ml of pressure was gently applied using 
the syringe and air line, to slightly depress the surface of the cell.  Using only the 
micromanipulator, the tip was lowered incrementally towards the plasma membrane. 
Contact with the membrane is determined by watching the current signal and 
resistance generated by pulse 1.  This is indicated by a sudden (although slight) 
increase in resistance at the tip of the pipette electrode and a drop in current by 
around 10%.  Quickly, the plasma membrane was pulled onto the pipette by 
releasing the pressure on the air line.   
If the membrane seals around the tip (if both the tip and membrane are un-
occluded) the resistance will rise to above 3GΩ (the gigaseal, or giga-ohm seal), 
reflecting the very close association between the pipette and the membrane.  Seals 
of less than 3GΩ were insufficient for the integrity of the circuit, and would result in 
overwhelming leakage of electrolytes from the cell.  Seals of 10GΩ or more were 
optimal.  Once the gigaseal had formed, the current recorded from pulse 1 was 
virtually zero (Figure 4.5 and Figure 4.6A).  Where the cell failed to form a seal 
around the pipette tip (or at later stages the seal ruptured), the pipette was 
discarded, a new cell selected, and the process repeated. 
Once a stable 10GΩ seal was generated, the software was used to change the 
holding potential to -50mV (closely matching the membrane potential of the cell).  
The 10mV 35ms pulse was maintained.  These settings will be referred to as pulse 
2.  The seal was allowed to stabilise at the new settings. 
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Figure 4.5: Schematic representation of a whole cell patch clamp 
4.3.3..7 Creating the whole cell patch 
With a tight and stable seal formed around the pipette, the next stage was to rupture 
the plasma membrane inside the tip.  This was achieved by applying sharp suction 
to the air line.  Successful formation of the whole cell patch was indicated by a 
sudden increase in current, a drop in resistance, and the formation of fast transient 
spikes of current at either side of the trace generated by pulse 2 (Figure 4.6B). 
The trace generated by pulse 2 was then adjusted electrically to get a square 
current pulse and compensate for the capacitance currents and series resistance.  
This was carried out by switching the amplifier to resistance capacitance 
compensation mode, and adjusting the series resistance and capacitance. The fast 
and slow mag and tau settings were used to eliminate transient elements of the 
current.  The series resistance and capacitance were noted, since these were 
characteristic to MCF7.   
The membrane capacitance of biological membranes is relatively predictable, and is 
determined roughly by cell size (approximately 1pF per 100µm2 of membrane).  The 
average surface area of MCF7 is around 800µm2 (Nassarre et al. 2003) so the 
capacitance was predicted to be approximately 8pF.  Cells were discarded if 
uncompensated series resistance exceeded 25mV.    
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Figure 4.6: Example traces generated during whole cell patch clamping 
The very high resistances generated when the giga-seal forms result in virtually no 
current during the 10mV pulse for 35ms from a holding potential of 0mV (A; pulse 1).  
When the membrane within the pipette is ruptured and a successful whole cell patch 
is achieved, resistance drops and a current is generated with fast transient 
capacitance spikes when pulse 2 is applied (B; 10mV pulse for 35ms from a holding 
potential of -50mV). 
4.3.3..8 VGKC activating voltage stepping protocol 
Whole cell currents were allowed to stabilize for up to five minutes after patching, 
due to gradual equilibration of pipette contents and cell cytoplasm.  Following this, a 
voltage stepping protocol was then applied to the cell to determine the activity of the 
VGKCs.  The same protocol was used throughout.  From the holding potential of -
50mV, voltage was sequentially stepped up from -70mV to 120mV in 10mV 
increments for 250ms, with 250ms between each step at the holding potential 
(Figure 4.7A).  Similar protocols are widely used in MCF7 to assess VGKCs (Coiret 
et al. 2007; Ouadid-Ahidouch et al. 2000). 
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Figure 4.7: Voltage stepping protocol and resulting voltage sensitive current 
recording from MCF7 
Schematic representation of the voltage stepping protocol (A) from a holding 
potential of -50mV voltage was sequentially stepped from -70mV to 120mV in 10mV 
increments held for 250ms.  The resulting current from a whole cell patch clamped 
MCF7 cell (B) showing very little current response at and around the holding 
potential, but increasingly activating as the cell becomes more depolarized. 
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4.3.4 Test conditions 
For each successfully patched cell the above voltage stepping protocol was applied 
prior to treatment.  If this confirmed the activity of VGKCs (Figure 4.7B), then the cell 
was perfused for up to 20 minutes with NT containing test compounds in the 
appropriate concentrations.  Table 4.1 describes the concentrations of the various 
channel blockers, control and test agents chosen, in relation to their IC50 
concentration for proliferation (determined in Section 5.2.2) where appropriate and 
any previously published information regarding an impact on K+ channel activity.   
The concentrations of the K+ channel blockers used were based on similar studies, 
as they were sufficient to block the channels in question to a greater or lesser extent 
without showing significant cytotoxicity (under the IC50, or resulted in no significant 
inhibition of proliferation) over the time-scales used (Coiret et al. 2007; Coiret et al. 
2005; Roy et al. 2008; Yao and Kwan 1999). 
Table 4.1: Concentrations of test agents used for patch clamping 
Treatment IC50 for MCF7 
proliferation 
IC50 for K
+ channel activity1 Dose used 
TEA 18.8mM 5mM 10mM 
4-AP 2.69mM Between 0.1 and 4 mM 1mM 
AST 4.91µM 200nM 1µM 
DOF  1μM (effective concentration)2 1µM 
Genistein  30 to 100µM (effective 
concentration)3 
31.6µM 
Daidzein   31.6µM 
E2   1nM 
DMSO   0.1% 
Untreated (NT)   N/A 
Genistein + 4-AP  31.6µM + 1mM 
Genistein + AST  31.6µM + 1µM 
1 See Table 1.9 
2 (Wang et al. 2002) 
3 See Section 1.6.7 
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The voltage stepping protocol was applied again at 1, 3, 5, 7, 9, 12, 15, 17, and 20 
minutes into the treatment, or as long as the seal integrity remained.  Note that at 
each time point the perfusion pump was required to be briefly switched off to prevent 
interference, and that the pump had a two minute lag time due to the volume of the 
tubes.  In the instances where normal Tyrode was in the tubing, 2 minutes was 
subtracted from all the measurement time points post-treatment to compensate. 
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4.3.5 Analysis of results 
WinWCP software (John Dempster, University of Strathclyde Electrophysiology 
Software, 2011) was used to determine the current at each voltage step.  At each 
voltage level the mean current was calculated for a section of the trace in the 
second half of the 250ms step, as the current was generally more stable than early 
in the step, and this avoids the effects of the Na+ channels. 
The effect of each treatment on the macroscopic MCF7 current was initially 
assessed at each time point, and 5 minutes treatment (not including the 2 minute lag 
time) was chosen for the comparison of treatments.  This allowed for maximum 
effect of the treatment (when evident) and avoided the subsequent degradation of 
the seal interfering with results. 
Each treatment was repeated on at least three independent occasions on different 
days.  Current/voltage (I/V) curves showing the mean I/V relationship before and 5 
minutes into the treatment were plotted.   
There was an unavoidable element of current leakage in many of the cells.  Whether 
this was due to the cells and the presence of secreted matrix proteins, their 
treatment, or the equipment was not known.  It is standard practice to assume that 
leakage is relatively constant over time as long as the seal retains integrity, so to 
determine the net effect of the treatment on the outward curent, the recorded current 
after treatment was subtracted from the initial (untreated) current at each voltage 
step, in the manner of Ouadid-Ahidouch et al. (2000).  With some equipment, leak 
subtraction can be carried out automatically (Grissmer et al. 1994; Ouadid-Ahidouch 
et al. 2000).  This I/V response generated is referred to as the “treatment” sensitive 
current.  In this manner, when the treatment inhibited current, the element sensitive 
to it was positive, and when the treatment increased current the sensitive element 
appeared negative.  The effect of current over the course of the protocol was 
illustrated for each treatment, at the voltage which induced the greatest magnitude 
of treatment-sensitive effect (i.e. the greatest difference before and 5 minutes after 
treatment).  
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4.3.6 Statistical analysis 
For each treatment, the results for each cell before and 5 minutes into the protocol 
were compared using the General Linear Model (GLM; SPSS version 19, IBM 
Statistics, 2010) for repeated measures, using the within subject (cell) variables of 
treatment (before and after) and voltage (20 levels).  Since there were only two 
levels in the treatment variable, sphericity was assumed.  Results are quoted as the 
F value, degrees of freedom of the model (dfM) and residual degrees of freedom of 
the model (dfR) and the significance (p) of F.  Where p<0.05 F was assumed to be 
significant.  Where a significant effect of 5 mins treatment on response to voltage 
was found, further analysis was conducted by MANOVA (Simple Effects Analysis) to 
determine the effect of treatment at each level of voltage within a cell (F and p). 
The treatment-sensitive elements of the combined treatments (genistein and 4-AP 
or AST) were compared to the relevant single treatments using ANOVA (SPSS 
version 19, IBM Statistics, 2010) with Bonferroni post hoc corrections for multiple 
comparisons, and significant values (p, two tailed, < 0.05) are indicated. 
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CHAPTER 5. Results: volume regulation and potassium 
channel activity 
5.1 Results of the calcein cell volume assay in MCF7 
5.1.1 Hyposmotic shock 
The response of MCF7 cells (n=3) to a hyposmotic shock is shown in in Table 5.1 
and Figure 5.1, highlighting four specific regions of interest (1, 2, 3, 4). 
Table 5.1: MCF7 fluorescence levels during hyposmotic shock 
Region of 
trace 
Time 
(secs) 
Mean 
fluorescence 
SD p(2)* p(4)* 
1 240-300 91.00 5.31 <0.001  
2 566-626 94.60 6.62 - NS 
3 962-1022 92.05 8.99 <0.001  
4 1426-1480 94.83 10.76 NS - 
* Significance of difference compared with region 2 or 4 as indicated 
The increase in fluorescence (1 to 2) was significant (p < 0.001), and occurred 
approximately 2.5 minutes into the hyposmotic treatment, taking into account the 2 
minute lag.  This may be an early effect of the treatment.  An increase in 
fluorescence can suggest cell shrinkage, however cell size appeared unaffected 
(visual observation; Figure 5.1B). 
Approximately seven minutes after the change to hypotonic solution, fluorescence 
intensity dropped as the cells underwent hypotonically induced swelling (2 to 3).  
This continued for around five minutes, and the difference between the mean values 
at 2 and 3 was significant (p < 0.001).   The mean rate of fluorescence intensity 
change per second (Δf) during this time (700 to 1000 seconds) was -0.008 ± 0.021. 
 
250 | P a g e  
 
 
300 600 900 1200 1500 1800
80
85
90
95
100
2
4
3
NT
Hyposmotic
1
B
Time (sec)
F
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (

 d
y
e
 c
o
n
c
e
n
tr
a
ti
o
n
)
 
Figure 5.1: MCF7 calcein fluorescence during hyposmotic shock 
MCF7 cells were prepared as described.  Fluorescent images (excitation at 480nm) 
taken at four second intervals were analysed, following initial perfusion with NT, then 
30 minutes in a 50% Na (hyposmotic) Tyrode.  Sample images are provided in A, 
and the results of the analysis are shown in B (mean of three independent 
experiments, following 54 cells).  Indicated are 60 second regions representing the 
cells prior to hyposmotic shock (1), after an initial increase in fluorescence (2), 
following swelling and resulting fluorescence drop (3) and after RVD (4).  The 
numbered images in A correspond with these regions in B. 
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Immediately after this, the cells underwent a period of RVD (3 to 4), as the 
fluorescence, and their volume, returned to the levels seen in 2, by approximately 16 
minutes after the change to hypotonic solution.  This increase in fluorescence was 
again significant (p < 0.001), and Δf for this (1004 to 1300 seconds) was 0.010 
±0.020.  Comparison between the two slopes (2-3 and 3-4) by paired t test indicated 
that they were significantly different (p < 0.001).   
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5.1.2 17β-oestradiol and genistein induce opposing changes in MCF7 
cell volume 
The mean results of the experiments looking at calcein fluorescence intensity in 
MCF7 after treatment with 1nM E2, 1µM genistein and 31.6µM genistein are shown 
in Figure 5.2, Figure 5.3 and Figure 5.4 respectively (n = 3 for each).  For each 
treatment Δf for region 1 (Δf0; after 8 minutes treatment with 0.1% DMSO), region 2 
(Δf10; after 10 minutes treatment with the test agent) and region 3 (Δf15; 15 minutes 
into treatment) are provided in Figure 5.5.   
The background change in fluorescence or the impact of 0.1% DMSO varied greatly 
between treatments.  Prior to 1nM E2 treatment (Figure 5.2) mean fluorescence was 
relatively stable, and did not appear to be impacted upon by the vehicle-only 
treatment.  Prior to the 1µM genistein treatment (Figure 5.3), mean fluorescence 
intensity was increasing.  Again this was not affected by the presence of the control 
treatment.  However, prior to the 31.6µM genistein treatment (Figure 5.4) there was 
a decrease in mean fluorescence associated with the addition of 0.1% DMSO.  
Whether these changes were in response to the solvent or the treatment protocol 
was unknown.  Overall the mean fluorescence change during 0.1% DMSO 
treatment was slight (Δf0 = 0.003 ± 0.017; Figure 5.5).   
To eliminate the variable background or vehicle-effects on fluorescence seen, Δf for 
each treatment/time was compared to its own pre-treatment 0.1% DMSO value in a 
paired fashion, rather than the mean Δf0.  Likewise, adjusted Δf values (aΔf10 and 
aΔf15) for each treatment/time point were calculated as the difference between the 
slopes in regions 1 and 2, or 1 and 3 (Figure 5.6). 
Overall, 1nM E2 treatment resulted in a drop in fluorescence intensity (Figure 5.2) 
associated with a significant reduction from a positive Δf0 to negative values at both 
10 and 15 minutes into treatment (p <0.001 and <0.01 respectively), and 
consequently negative values for aΔf (Figure 5.5 and Figure 5.6).   Together this 
suggests that by 10 minutes into this treatment, an increase in cell volume has 
resulted. 
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Figure 5.2: MCF7 calcein fluorescence during treatment with 1nM E2 
MCF7 cells were prepared as described.  Fluorescent images (excitation at 480nm) 
taken at four second intervals  were analysed, following initial perfusion with NT, 
then 10 minutes in a 0.1% DMSO Tyrode, and 30 minutes in Tyrode containing 1nM 
E2.  Results shown are the mean of three independent experiments, following 39 
cells.  Indicated are 2 minute regions representing the cells after 8 minute perfusion 
with 0.1% DMSO (1; 920 to 1040 seconds) and 10 (2; 1640 to 1760 seconds) and 
15 (3; 1940 to 2060 seconds) minutes perfusion with 1nM E2. 
There was no evidence of E2 auto-fluorescence, determined by assessing the 
background fluorescence in a cell-free area before and during perfusion with 1nM 
E2 Tyrode, mean and SD fluorescence were 14.08 ± 3.22 and 14.01 ± 3.31 
respectively, p (Student’s t test, two tailed) ≥ 0.05. 
The strong background upward trend in mean fluorescence intensity seen in the 
1µM genistein-treated cells continued after treatment, although to a lesser extent 
(Figure 5.3).  This is reflected by a drop in Δf from Δf0, which achieved statistical 
significance (p < 0.001) by 15 minutes into the treatment regime (Δf15), although not 
at 10 minutes (Δf10; Figure 5.5).   Likewise, aΔf has a small negative value after 10 
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minutes treatment, but this has become more negative by 15 minutes (Figure 5.6).  
This indicates that despite the background upward trend in fluorescence, 1µM 
genistein treatment results in an increase in MCF7 cell volume, although this is 
slightly slower to take effect than that seen with 1nM E2.   
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Figure 5.3: MCF7 calcein fluorescence during 1µM genistein treatment 
MCF7 cells were prepared as described.  Fluorescent images (excitation at 480nm) 
taken at four second intervals  were analysed, following initial perfusion with NT, 
then 10 minutes in a 0.1% DMSO Tyrode, and 30 minutes in Tyrode containing 1µM 
genistein.  Results shown are the mean of three independent experiments, following 
34 cells.  Indicated are 2 minute regions representing the cells after 8 minute 
perfusion with 0.1% DMSO (1; 880 to 1000 seconds) and 10 (2; 1600 to 1720 
seconds) and 15 (3; 1900 to 2020 seconds) minutes perfusion with 1µM genistein.   
In the 31.6µM genistein treated cells there was an initial (pre-treatment) trend 
towards decreasing fluorescence intensity (Figure 5.4).  The genistein treatment 
rapidly reversed this, initially resulting in the fluorescence stabilising, and then after 
10 minutes intensity began to increase, suggesting shrinkage.  This is confirmed by 
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a significant increase from negative to positive values for Δf10 (p <0.001), and a 
subsequently large positive aΔf at this time point (Figures 5.5, and 5.6). 
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Figure 5.4: MCF7 calcein fluorescence during 31.6µM genistein treatment 
MCF7 cells were prepared as described.  Fluorescent images (excitation at 480nm) 
taken at four second intervals  were analysed, following initial perfusion with NT, 
then 10 minutes in a 0.1% DMSO Tyrode, and 30 minutes in Tyrode containing 
31.6µM genistein.  Results shown are the mean of three independent experiments, 
following 22 cells.  Indicated are 2 minute regions representing the cells after 8 
minute perfusion with 0.1% DMSO (1; 1000 to 1120 seconds) and 10 (2; 1720 to 
1840 seconds) and 15 (3; 2020 to 2140 seconds) minutes perfusion with 31.6µM 
genistein.   
However, by 15 minutes into the 31.6µM genistein treatment, fluorescence intensity 
had returned to its downward trend.  Accordingly Δf15 has a small negative value.  
However, this is still significantly lower in magnitude to the downward rate of change 
seen in Δf0 (p <0.01), and accordingly aΔf15 still has a positive value, although lower 
than that seen at aΔf10.  This suggests that although the MCF7 cells continued to 
256 | P a g e  
 
shrink after 15 minutes, it was not rapid enough to counter the background loss in 
fluorescence seen in these cells. 
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Figure 5.5: Rate of MCF7 calcein fluorescence change per second, prior to, 
and 10 and 15 minutes into treatment 
Values were calculated as described for the mean and standard deviation of Δf after 
8 to 10 minutes of 0.1% DMSO treatment (Δf0), 10 to 12 minutes (Δf10) and 15 to 17 
minutes (Δf15) treatment with 1nM E2, 1µM genistein, and 31.6µM genistein.  
Significant differences from the indicated Δf0 value (p < 0.05) are provided.  The 
control value is the mean of the 0.1% DMSO Δf0 results.  Positive Δf indicates 
increasing fluorescence, and negative Δf indicates reducing fluorescence. 
 
257 | P a g e  
 
1uM Gen 31.6uM Gen 1nM E2
-0.04
-0.02
0.00
0.02
0.04
10 minutes
15 minutes
Shrink
Swell
Treatment
a

f
  
Figure 5.6: Adjusted rate of MCF7 calcein fluorescence change after treatment 
Adjusted Δf (aΔf) was calculated as described  at 10 and 15 minutes into treatment 
of MCF7 with 1µM genistein, 31.6µM genistein, and 1nM E2 (mean and standard 
deviation). Positive aΔf indicates shrinkage, and negative aΔf indicates swelling. 
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5.2 Results of the MTT assays assessing the role of K+ channels in 
MCF7 proliferation  
5.2.1 Control treatments 
TEA and 4-AP used water as a solvent, so for reference it was determined whether 
this had an effect on proliferation.  The addition of water up to and including 2% did 
not affect proliferation, but 4% water resulted in a slight reduction in proliferation 
compared to the untreated control (Figure 5.7).  This may have been due to dilution 
of nutrients. 
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Figure 5.7: The impact of increasing quantities of added water on MCF7 
proliferation 
MCF7 cells were prepared as described, and incubated for 72 hours in experimental 
medium containing d.H2O added at levels between 0 and 4%, then cell proliferation 
was assessed by the MTT assay.  The impact of these treatments on percentage 
proliferation, compared to the untreated (0%) control are shown (mean ± SD, n=3).  
Significant variation from the untreated control (p< 0.01) is indicated (a). 
The TEA experiments used a maximum of 2% water.  As this level had no impact on 
MCF7 proliferation, it was considered appropriate as a control treatment, and the 
effect of each concentration of TEA on proliferation was compared to this.  However, 
a higher level of 4% water was unavoidable for the highest of the 4-AP 
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concentrations, due to limitations of its solubility.  To factor in the impact of this level 
of water on MCF7 proliferation, all remaining 4-AP treatments were adjusted to 
contain 4% H2O, then this level of water was used for control comparison with these 
treatments.  The channel blockers DOF and AST used DMSO as a solvent.  This did 
not exceed 0.1% in any instance, and had already been shown to have no effect on 
MCF7 proliferation at this dose (Section 3.1.1..1).    
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5.2.2 The impact of various K+ channel blockers on MCF7 proliferation 
Treatment with increasing concentrations of TEA reduced the proliferation of MCF7 
in a dose-responsive manner, compared to the control (Figure 5.8).  This achieved 
statistical significance at 10 and 20mM (p <0.01 and <0.001 respectively).  The IC50 
for the effect of TEA on MCF7 proliferation was determined to be 18.84mM.   
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Figure 5.8: The impact of TEA on MCF7 proliferation 
MCF7 cells were prepared as described, and incubated for 72 hours in experimental 
medium containing TEA between 1µM and 20mM, then proliferation was assessed 
by the MTT assay.  The impact of these treatments on percentage proliferation, 
compared to the 2% d.H2O control are shown (mean ± SD, n=3).  Significant 
variation from the control is indicated (a; p < 0.001, b; p < 0.01). 
Treatment with 4-AP reduced MCF7 proliferation to a comparable extent (Figure 
5.9), with significantly lower percentage proliferation values calculated at all 
concentrations above and including 1mM (p <0.001).  The IC50 for this channel 
blocker on MCF7 was the slightly lower value of 2.7mM.  This implies that of the K+ 
channels involved in MCF7 proliferation, the VGKCs undoubtedly play an important 
role.   
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Figure 5.9: The impact of 4-AP on MCF7 proliferation 
MCF7 cells were prepared as described, and incubated for 72 hours in experimental 
medium containing 4-AP between 1µM and 20mM, then proliferation was assessed 
by the MTT assay.  The impact of these treatments on percentage proliferation, 
compared to the 4% d.H2O control are shown (mean ± SD, n=3).  Significant 
variation from the control (p< 0.001) is indicated (a). 
To narrow down some of the individual K+ channels implicated in MCF7 proliferation, 
the specific channel blockers AST and DOF were also tested.   AST, a blocker of the 
hEAG and hERG channels, resulted in a dose responsive inhibition of MCF7 
proliferation (Figure 5.10), which achieved statistical significance at all 
concentrations tested above 1µM (p <0.001).  The IC50 for this treatment on MCF7 
proliferation was calculated to be 4.9µM.   
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Figure 5.10: The impact of AST on MCF7 proliferation 
MCF7 cells were prepared as described, and incubated for 72 hours in experimental 
medium containing AST between 1nM and 50µM, then proliferation was assessed 
by the MTT assay.  The impact of these treatments on percentage proliferation, 
compared to the 0.1% DMSO control are shown (mean ± SD, n=3).  Significant 
variation from the control (p< 0.001) is indicated (a). 
However, there was no significant effect of DOF on the percentage of MCF7 
proliferation measured at any of the concentrations tested up to and including 10µM 
(Figure 5.11).  Together these last two experiments illustrate that AST but not DOF 
inhibit the proliferation of MCF7 cells, and so accordingly suggest that the hEAG 
channel, but not hERG, are involved in this response. Alternatively, higher 
concentrations of DOF may be required to have an impact on proliferation, but due 
to limitations in its solubility, this would have required unacceptable quantities of 
solvent present. 
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Figure 5.11: The impact of DOF on MCF7 proliferation 
MCF7 cells were prepared as described, and incubated for 72 hours in experimental 
medium containing DOF between 1nM and 10µM, then proliferation was assessed 
by the MTT assay.  The impact of these treatments on percentage proliferation, 
compared to the 0.1% DMSO control are shown (mean ± SD, n=3).  There was no 
significant variation from the control.  
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5.3 Results of the whole cell patch clamping experiments assessing 
the impact of isoflavones on K+ channel activity in MCF7 cells 
5.3.1 Cell characteristics  
The characteristics of the patched cells and electrodes used in the following 
experiments are provided in Table 5.2. 
Table 5.2: Characteristics of cells and electrodes used in MCF7 patch clamp 
experiments 
 Mean SD 
Electrode resistance (MΩ) 3.56 0.34 
Uncompensated series resistance (MΩ) 9.16 5.34 
Uncompensated capacitance (pF) 25.74 14.99 
 
The electrode resistances measured were well within the tolerable range of 3 to 
10MΩ, and as such were appropriate for whole cell patch clamping.   
The series resistance value confirms that cells were excluded if the uncompensated 
series resistance exceeded 25MΩ.  Series resistance relates to the degree of 
clogging that occurs inside the pipette tip, and is further discussed in section 6.4.2.  
Although it was compensated for electronically, it cannot be completely eliminated, 
and is consequently a source of error.  The values here indicate that this was 
reduced as far as possible.   
Finally, the capacitance figures give an indication of the size of cells used.  The 
average surface area of MCF7 is 800µm2, providing an approximate capacitance 
reading of 8pF (section 4.3.3..7).  The readings generated here suggest that the 
cells being used were larger than average, although they were roughly 
representative of the individual cells observed which were not constrained by the 
proximity of their neighbours. 
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5.3.2 The impact of control treatments on macroscopic current in 
MCF7 
The voltage sensitivity of the macroscopic current was assessed in MCF7 cells 
under untreated control conditions (Figure 5.12).   
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Figure 5.12: Current/voltage relationship in untreated MCF7 cells  
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cells were perfused with normal 
Tyrode.  The voltage sensitivity of the current was recorded again at various time 
points into the treatment.  The effect of voltage on current is shown after 0 and 5 
minutes treatment (A), and the time-course of the current at 50mV (mean and SD) is 
provided (B).  The net effect of 5 minutes treatment with normal Tyrode is shown in 
C.  All graphs are the mean result of three MCF7 cells assessed on different days. 
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In normal Tyrode with no additions, depolarization from -50mV to 110mV resulted in 
an increase in outward current at 0 and 5 minutes (Figure 5.12A).  The magnitude of 
this current increased over time slightly, with the greatest increase occurring 
between 1 and 3 minutes into the protocol (Figure 5.12B).  The resulting impact of 5 
minutes perfusion with NT on the current/voltage (I/V) relationship is shown in 
Figure 5.12C.  Analysis of variance for repeated measures (GLM) indicated that the 
effect of 5 minutes further treatment on the response to voltage within cells was 
significant, F (19, 38) = 2.782, p < 0.01. Further scrutiny by Simple Effects Analysis 
showed that this achieved significance within cells at voltages equaling and above    
-20mV (Table 5.3). 
Table 5.3: Simple Effects Analysis of the impact of the protocol on voltage 
sensitivity 
Voltage F p  Voltage F p 
-70 0.21 NS  30 486.23 <0.01 
-60 0.09 NS  40 345.52 <0.01 
-50 1.16 NS  50 404.00 <0.01 
-40 3.82 NS  60 524.60 <0.01 
-30 11.04 NS  70 133.37 <0.01 
-20 29.94 <0.05  80 96.59 <0.05 
-10 93.53 <0.05  90 61.05 <0.05 
0 338.43 <0.01  100 50.55 <0.05 
10 4336.39 <0.001  110 42.77 <0.05 
20 2368.33 <0.001  120 27.36 <0.05 
 
Extrapolation of the initial untreated I/V curve predicts that the reversal potential 
(point at which there is no current before it reverses direction) would be 
approximately -80mV.  The reversal potential is close to the resting membrane 
potential of the cell.  In MCF7 this is largely dictated by the K+ equilibrium potential, 
and is known to be around -85mV (Klimatcheva and Wonderlin 1999; Ouadid-
Ahidouch et al. 2000; Wonderlin and Strobl 1996).   This suggests that while other 
ions are likely to play a role in the current recorded here, it is largely due to 
movement of K+ ions.    
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The impact of 5 minutes treatment with 0.1% DMSO on the macroscopic current in 
MCF7 was similar to that of normal Tyrode (Figure 5.13).   
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Figure 5.13: Current/voltage relationship in 0.1% DMSO treated MCF7 cells 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -50mV to 110mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 0.1% DMSO.  The voltage sensitivity of the current was recorded again at 
various time points into the treatment.  The effect of voltage on current is shown 
after 0 and 5 minutes treatment (A), and the time-course of the current at 110mV 
(mean and SD) is provided (B).  The net effect of 5 minutes treatment is shown in C.  
All graphs are the mean result of three MCF7 cells assessed on different days. 
Example traces before and after 5 minutes 0.1% DMSO treatment are provided in D. 
This treatment resulted in a slight increase in the depolarization-activated element of 
the current, however, within cells the effect of five minutes treatment with 0.1% 
DMSO on the current response to voltage was not significant, F (16, 32) = 1.187.  
The reversal potential of the current here (approximately -10mV) is more positive 
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than previously recorded, but it remains negative.  This suggests that while 
movement of K+ ions contributes to the current, it has other elements also.  Figure 
5.13B shows the time-course for current at 110mV during perfusion with 0.1% 
DMSO.  This indicates that current was relatively stable over time with this 
treatment. 
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5.3.3 The effect of K+ channel blockers on the MCF7 macroscopic 
current 
Having identified the impact of the solvent, and the treatment protocol on the voltage 
sensitivity of the macroscopic MCF7 current, the next step was to determine to what 
extent it was mediated by the potassium channels.  Accordingly, following initial 
perfusion with normal Tyrode, the cells were perfused with a range of general and 
specific K+ channel blockers.  
Perfusion with 10mM TEA (non-specific K+ channel blocker) resulted in a sudden 
(within 1 minute) drop in depolarization activated current (Figure 5.14).  This 
suggests that the K+ channels mediate an element of this current, shown in Figure 
5.18.  The reversal potentials of these currents were negative (between -20 and       
-30mV) suggesting again that K+ ion movement played a role.  The inhibition of 
current then remained stable.  This treatment also reduced the leakage seen at 
negative potentials.  The effect of 5 minutes treatment with TEA on the voltage 
response of MCF7 was significant, F (14, 42) = 4.396, p < 0.001.  Further analysis 
(Table 5.4) indicated that this became significant within cells for all potentials above 
20mV. 
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Figure 5.14: Current/voltage relationship in MCF7 treated with TEA 50mV 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -60mV to 110mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 10mM TEA, and the voltage sensitivity of the current was recorded again.  
The effect of voltage on current is shown after 0 and 5 minutes treatment (A), and 
the time-course of the current at the potential which showed the greatest impact of 
treatment (50mV; mean and SD) is provided (B). Both graphs are the mean result of 
four MCF7 cells assessed on different days. Example traces before and after 5 
minutes TEA perfusion are shown in C.   
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Table 5.4: Simple Effects Analysis of the impact of TEA on voltage sensitivity 
Voltage F p  Voltage F p 
-60 1.77 NS  20 14.11 <0.05 
-50 0.97 NS  30 23.27 <0.05 
-40 0.41 NS  40 29.88 <0.05 
-30 0.04 NS  50 29.99 <0.05 
-20 0.07 NS  60 27.41 <0.05 
-10 1.11 NS  70 24.11 <0.05 
0 3.25 NS  80 21.32 <0.05 
10 7.06 NS     
 
Treatment of MCF7 for 5 minutes with the VGKC specific blocker 4-AP (1mM) 
resulted in a similar, if lower in magnitude inhibition of voltage activated current 
(Figure 5.15), suggesting that the VGKCs were responsible for an element of this 
(the 4-AP sensitive current; Figure 5.18).  Again, extrapolation of the I/V curves 
suggests that the reversal potential would be approximately -90mV, confirming that 
K+ is responsible for the majority of the current in this case.  The inhibition of current 
attributed to 4-AP treatment acted within the first minute of treatment then remained 
relatively stable.  The effect of 5 minutes treatment with 4-AP on the voltage 
response of MCF7 was significant, F (19, 38) = 2.747, p < 0.01.  Further analysis 
indicated that there was a significant within-cell effect of treatment at each voltage 
tested (Table 5.5). 
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Figure 5.15: Current/voltage relationship in MCF7 cells treated with 4-AP 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 1mM 4-AP.  The voltage sensitivity of the current was recorded again at 
various time points into the treatment.  The effect of voltage on current is shown 
after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (120mV; mean and SD) is 
provided (B).  Both graphs show the mean result of three MCF7 cells assessed on 
different days.  Example traces before and after 5 minutes 4-AP perfusion are 
shown in C.   
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Table 5.5: Simple Effects Analysis of the impact of 4-AP on voltage sensitivity 
 
 
 
 
 
 
 
 
Treatment of MCF7 with 1µM AST for 5 minutes also resulted in a reduction of the 
voltage activated outward current (Figure 5.16).  The reversal potential of these 
currents was approximately -30mV, suggesting that K+ movement was responsible 
for a large part of it.  The AST-sensitive current observed is shown in Figure 5.18.  
This confirms that hEAG and hERG are responsible for some of the K+ current 
observed.  Again this effect was rapid, acting within a minute of treatment, and the 
reduction in current was stable following this.  However, analysis with GLM for 
repeated measures  found that within individual cells the effect of AST treatment on 
the voltage sensitivity of the MCF7 macroscopic current failed to achieve 
significance, F (17, 34) = 0.096, p ≥ 0.05.   
Voltage F p  Voltage F p 
-70 28.77 <0.05  30 144.73 <0.01 
-60 47.85 <0.05  40 182.82 <0.01 
-50 70.96 <0.05  50 218.48 <0.01 
-40 77.98 <0.05  60 182.29 <0.01 
-30 83.47 <0.05  70 199.31 <0.01 
-20 84.48 <0.05  80 204.84 <0.01 
-10 86.66 <0.05  90 202.49 <0.01 
0 93.65 <0.05  100 365.74 <0.01 
10 109.73 <0.01  110 405.73 <0.01 
20 135.66 <0.01  120 203.16 <0.01 
274 | P a g e  
 
-60 -40 -20 0 20 40 60 80 100 120
-200
0
200
400
600
A
5 mins
0 mins
Voltage (mV)
I 
(p
A
)
2 4 6 8 10
0
200
400
600
800
B
Time (mins)
I 
(p
A
)
C
100ms
500pA
Control AST
 
Figure 5.16: Current/voltage relationship in MCF7 cells treated with AST 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -50mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 1µM AST.  The voltage sensitivity of the current was recorded again at 
various time points into the treatment.  The effect of voltage on current is shown 
after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (40mV; mean and SD) is 
provided (B).  Both graphs show the mean result of three MCF7 cells assessed on 
separate occasions.  Example traces before and after 5 minutes perfusion with AST 
are provided in C. 
There was no observable effect of 1µM DOF on the macroscopic current recorded in 
MCF7 at any voltage over the entire treatment period (Figure 5.17).  The reversal 
potential of these currents were between -70 and -80mV, indicating that it was 
largely due to K+ flux.  GLM repeated measures analysis confirmed this, F (19, 38) = 
0.351, p ≥ 0.05.  This indicates that the current AST-sensitive current observed 
above was mediated by the hEAG channel, and hERG had no measurable impact. 
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Figure 5.17: Current/voltage relationship in MCF7 cells treated with DOF 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 1µM DOF.  The voltage sensitivity of the current was recorded again at 
various time points into the treatment.  The effect of voltage on current is shown 
after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (110mV; mean and SD) is 
provided (B).  Both graphs show the mean result of three MCF7 cells assessed on 
separate occasions.  Example traces before and after 5 minutes perfusion with DOF 
are provided in C. 
When the currents sensitive to the various channel blockers are compared (Figure 
5.18), it is apparent that 10mM TEA has the greatest impact on macroscopic K+ 
current in MCF7, inhibiting current at positive potentials and enhancing it at negative 
potentials.   
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Treatment with 1mM 4-AP has resulted in slight inhibition of an outward  K+ current, 
which becomes more active at more depolarized potentials.  A similar profile to TEA 
treatment was achieved with 1µM AST, although smaller in magnitude.  This 
suggests inhibition of a current which becomes active at depolarization to potentials 
of around -10mV or more positive.  Finally, treatment with 1µM DOF did not inhibit 
macroscopic current in MCF7, having even less impact than the DMSO-only control.  
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Figure 5.18: I/V relationships of potassium channel blocker sensitive currents 
The voltage dependent current in MCF7 was assessed using a voltage stepping 
protocol as described.  The I/V curve after 5 minutes treatment with various K+ 
channel blockers (and 0.1% DMSO for reference) was subtracted from  the 
current/voltage curve recorded prior to commencing treatment (time = 0 minutes) to 
show the element of the current that was sensitive to each channel blocker.  The I/V 
curves shown are the mean of at least 3 cells.   
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5.3.4 Treatment with 17β-oestradiol enhances the MCF7 macroscopic 
current 
Treatment of MCF7 cells with 1nM E2 for 5 minutes resulted in a significant increase 
in the voltage activated current (Figure 5.19A), F (17, 34) = 7.927, p < 0.001.   
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Figure 5.19: Current/voltage relationship of MCF7 cells treated with E2  
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 1nM E2.  The voltage sensitivity of the current was recorded again at 
various time points into the treatment.  The effect of voltage on current is shown 
after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (50mV; mean and SD) is 
provided (B).  The net effect of 5 minutes E2 treatment on the I/V response is shown 
in C.  All graphs show the mean result of three MCF7 cells assessed on different 
days.  Example traces before and after 5 mins perfusion with E2 are provided in D. 
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Further analysis found that the effect of treatment was significant at the within-cell 
level (p < 0.05) at depolarization to levels between 40 and 90mV (Table 5.6).  The 5 
minute E2-induced element of the current is shown in Figure 5.19C.   The increase 
seen occurred rapidly (within 1 minute of treatment at 110mV) and continued rise 
beyond 5 minutes treatment (Figure 5.19B).  Again, the reversal potential of the 
recorded currents was approximately -20mV, suggesting that K+ was responsible for 
an element of this. 
Table 5.6: Simple Effects analysis of the impact of E2 treatment on voltage 
sensitivity in MCF7 
Voltage F p  Voltage F p 
-50 2.21 NS  40 34.76 <0.05 
-40 1.01 NS  50 74.6 <0.05 
-30 0.27 NS  60 117.73 <0.01 
-20 0 NS  70 101.51 <0.05 
-10 0.26 NS  80 44.65 <0.05 
0 1.43 NS  90 26.85 <0.05 
10 3.55 NS  100 18.29 NS 
20 8.11 NS  110 15.97 NS 
30 15.47 NS  120 14.49 NS 
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5.3.5 Soy isoflavones inhibit the macroscopic MCF7 current 
Treatment of MCF7 cells with 31.6µM genistein for 5 minutes resulted in a 
significant reduction in the voltage activated current (Figure 5.20), F (149, 38) 
=2.431, p < 0.05.   
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Figure 5.20: Current/voltage relationship in MCF7 cells treated with genistein 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 31.6µM genistein.  The voltage sensitivity of the current was recorded 
again at various time points into the treatment.  The effect of voltage on current is 
shown after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (100mV; mean and SD) is 
provided (B).  Both graphs show the mean result of three MCF7 cells assessed on 
different days.  Example traces from before and after 5 minutes genistein perfusion 
are provided in C. 
280 | P a g e  
 
However, further analysis of each individual depolarization level found that the effect 
of treatment failed to achieve statistical significance at any individual voltage point.  
The genistein sensitive current after 5 minutes is shown in Figure 5.22.   The time-
course of inhibition of macroscopic current at 100mV suggests that the inhibitory 
effect of genistein was slow to develop; taking 5 minutes to reach its maximum level 
(Figure 5.20B).   The reversal potential of the currents recorded in these 
experiments averaged at around 0mV.  These were the greatest (most positive) 
reversal potentials identified.  This implies that while genistein treatment appears to 
inhibit K+ current, it is likely that it inhibits the movement of other ions also. 
Treatment of MCF7 with 31.6µM daidzein for 5 minutes resulted only in a very slight 
inhibition of voltage activated current (Figure 5.21A) which was not significant, F (18, 
36) = 1.295.  There was no clear effect over time (Figure 5.21B).  The daidzein 
sensitive element of the voltage sensitive macroscopic current is shown in Figure 
5.22.  The reversal potentials of these currents were more negative, averaging 
around -20mV.  This indicates that while K+ flow was a factor in the current, it may 
also have other elements. 
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Figure 5.21: Current/voltage relationship in MCF7 cells treated with daidzein 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing 31.6µM daidzein.  The voltage sensitivity of the current was recorded 
again at various time points into the treatment.  The effect of voltage on current is 
shown after 0 and 5 minutes treatment (A), and the time-course of the current at the 
potential which showed the greatest impact of treatment (110mV; mean and SD) is 
provided (B).  Both graphs show the mean result of three MCF7 cells assessed on 
different days.  Example traces from before and after 5 minutes perfusion with 
daidzein are provided in C. 
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Figure 5.22: I/V relationships of isoflavone sensitive currents in MCF7 
The voltage dependent current in MCF7 was assessed using a voltage stepping 
protocol as described.  The I/V curve after 5 minutes treatment with genistein or 
daidzein (31.6µM)  was subtracted from  the current/voltage curve recorded prior to 
commencing treatment (time = 0 minutes) to show the element of the current that 
was sensitive to each isoflavone.  The I/V curves shown are the mean result from 3 
cells. 
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5.3.6 The impact of combinations of genistein and K+ channel blockers 
on the macroscopic MCF7 current 
To begin to elucidate which channels were the molecular targets of genistein in 
MCF7, the cells were treated with combinations of genistein and 4-AP or genistein 
and AST.  TEA was considered too non-specific to provide any information 
regarding target specificity, and DOF had no measurable effect on K+ current in this 
cell line. 
Treatment of MCF7 cells for 5 minutes with the combination of 31.6µM genistein 
and 1mM 4-AP resulted in a slight increase in current at the more depolarized 
voltages tested (Figure 5.23A), although this effect did not achieve statistical 
significance, F (19, 38) = 0.671, p ≥ 0.05.   
The reversal potential of the current was between -50 and -60mV, indicating that it 
was largely due to movement of K+ ions.  Up to and including 5 minutes into the 
treatment regime, the current measured at 40mV was relatively stable, however 
after this point the seal began to lose integrity in two of the three cases (Figure 
5.23B), suggesting that this combined treatment may have been toxic to the cells. 
Overall the I/V curve for the element of the current sensitive to the combination of 4-
AP and genistein was lower than that calculated for either genistein or 4-AP alone 
(Figure 5.23C), suggesting that rather than acting synergistically, the two treatments 
interfered with each others activity.  However, the net impact of the combined 
treatment was not significantly different from either of the corresponding single 
treatments at any voltage (p ≥ 0.05, ANOVA).   
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Figure 5.23: Current/voltage relationship in MCF7 cells treated with the 
combination of 4AP and genistein  
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing the combination of 31.6µM genistein (GEN) and 1mM 4-AP.  The voltage 
sensitivity of the current was recorded again at various time points into the 
treatment.  The effect of voltage on current is shown after 0 and 5 minutes treatment 
(A), and the time-course of the current at the potential which showed the greatest 
impact of treatment (40mV; mean and SD) is provided (B).  C: the I/V responses of 
the elements of the current sensitive to the various treatments.  Each graph shows 
the mean result of three MCF7 cells assessed on different days, with the exception 
of one point (a) for which n=2. 
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Treatment of MCF7 with the combination of 31.6µM genistein and 1µM AST led to a 
reduction in the depolarization-activated element of the macroscopic current after 3 
minutes treatment (Figure 5.24A and B).  However, the difference in the effect of 
voltage before and after the treatment failed to achieve significance, F (18, 36) = 
0.245, p ≥ 0.05.  The reversal potential of this current was around -70mV suggesting 
that it was largely mediated by K+ ion movement.   After this time point the seal on 
the patched cells became unstable in two of the three cases.  For this reason, the 3 
minute time point was used for comparison in this case.   
Recorded current was not significantly different after 3 minutes treatment with 
genistein compared to 5 minutes, with the sole exception of at 0mV (Table 5.7).  The 
I/V curve for the genistein and AST-sensitive current at 3 minutes was similar to that 
obtained after 3 minutes treatment with 1µM AST alone or 31.6µM genistein (no 
significant differences, p ≥ 0.05, ANOVA; Figure 5.24C).  Since there was no 
additional effect of AST over that of genistein, this suggests that the hEAG channel 
is potentially a molecular target of genistein in MCF7.  Furthermore, the combination 
of AST and genistein appeared to be particularly toxic to the cells in these 
experimental conditions. 
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Figure 5.24: Current/voltage relationship in MCF7 cells treated with the 
combination of AST and genistein 
The voltage dependent current in MCF7 was elicited by whole cell patch clamping 
and a series of depolarizing voltage steps from a holding potential of -50mV, 
ramping from -70mV to 120mV in 10mV steps.  After recording the initial (time = 0 
minutes) current with no additional treatment, the cell was perfused with Tyrode 
containing the combination of 31.6µM genistein (GEN) and 1µM AST.  The voltage 
sensitivity of the current was recorded again at various time points into the 
treatment.  The effect of voltage on current is shown after 0 and 3 minutes treatment 
(A), and the time-course of the current at the potential which showed the greatest 
impact of treatment (110mV; mean and SD) is provided (B).  C: the I/V responses of 
the elements of the current sensitive to the various treatments.  Each graph shows 
the mean result of three MCF7 cells assessed on different days, with the exception 
of the points indicated with a (n=2) and b (n=1).  Example traces from before and 
after 3 minutes perfusion with AST + genistein are provided in C. 
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Table 5.7: Current recorded after 3 and 5 minutes of treatment with 31.6µM 
genistein 
Voltage 3 minutes 5 minutes p 1 
Mean SD Mean SD 
-80 -506.04 260.46 -530.33 204.89 NS 
-70 -434.32 240.86 -470.85 185.38 NS 
-60 -375.17 214.02 -402.62 156.03 NS 
-50 -311.35 174.72 -335.03 128.94 NS 
-40 -245.56 147.35 -275.93 101.07 NS 
-30 -181.65 117.89 -211.44 83.21 NS 
-20 -120.76 93.93 -147.22 66.92 NS 
-10 -57.67 68.50 -90.42 46.32 NS 
0 38.44 22.43 -18.36 26.01 < 0.05 
10 102.65 34.21 51.00 37.32 NS 
20 165.83 65.78 119.47 71.55 NS 
30 223.30 94.81 180.41 103.02 NS 
40 297.96 140.91 245.19 137.12 NS 
50 361.78 181.91 307.18 171.06 NS 
60 437.84 230.96 372.95 210.78 NS 
70 508.50 279.66 442.19 258.28 NS 
80 577.01 334.02 509.91 308.45 NS 
90 628.92 390.13 580.90 376.05 NS 
100 698.91 456.06 642.46 422.33 NS 
110 769.94 525.52 705.97 480.32 NS 
1 significance of difference between current recorded after 3 and 5 minutes 
(ANOVA) 
SD: standard deviation 
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5.4 Summary of the changes in MCF7 cell volume and K
+
 
channel activity observed 
This section briefly summarizes the changes in MCF7 cell volume and K+ channel 
activity recorded upon treatment with soy isoflavones or E2.  For a full discussion of 
the results see sections 6.3 and 6.4. 
Treatment of MCF7 for 10 minutes with 1nM E2 resulted in swelling of the cells.  In 
parallel to this, a significant increase in voltage sensitive whole cell current was 
observed.  Treatment of MCF7 with 1µM genistein (proliferative concentration) also 
increased cell volume.  These treatments and responses are in line with the 
expected proliferative response. 
On the contrary, short term treatment with the higher concentration of 31.6µM 
genistein resulted in a brief period of cell shrinkage, and inhibition of outward 
macroscopic MCF7 current.  Daidzein treatment inhibited current also, although to a 
considerably lesser extent.   
DOF treatment had no effect on MCF7 proliferation or whole cell current.   However, 
the K+ channel blockers TEA, 4-AP and AST each resulted in dose-responsive 
inhibition of MCF7 proliferation.  This implicated the VGKCs, and in particular the 
hEAG channel in the proliferation of this cell line.  To begin to determine if the 
inhibition of specific K+ channels by soy isoflavones could be a mechanism through 
which they may be protective against breast cancer proliferation, preliminary 
attempts were made to characterize which K+ channels were the specific targets of 
genistein.  To this end, several combined treatments of K+ channel blockers and 
genistein were used.  The combination of 4-AP and genistein appeared to have a 
negative effect on the stability of the cells, and as a result lead to extraneous results 
that little can be concluded from.  However, the combination of AST and genistein 
lead to comparable current inhibition to each individual treatment.  This suggests 
that the hEAG channel (a target of AST) is likely to be a key molecular target of 
genistein in MCF7, and accordingly a potential mechanism through which genistein 
could reduce the proliferation of this cell line.  
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CHAPTER 6. Discussion 
6.1 Isoflavones and breast cancer cell line proliferation  
6.1.1 Technique: the MTT assay 
A major criticism of the MTT assay (described in sections 1.4.2 and 2.4) and related 
techniques such as the MTS or WST-1 assays, is that they measure proliferation 
indirectly, by assessing the rate of metabolism (or viability) of the cells.  While cell 
number will have a great impact on the quantity of MTT (or other dye) that is 
metabolised, other factors will also have an effect, such as the size and age of the 
cells, and the number of mitochondria.  None-the-less, the above methods are less 
labour intensive, and higher throughput than the traditional alternative method of 
counting viable cells using the Trypan Blue dye exclusion assay.    
A number of groups report that the MTT assay routinely overestimates viability or 
cell numbers when compared to other methods, in a number of cell types including 
human lung cancer cells (Carmichael et al. 1987; Ulukaya et al. 2008), Chinese 
hamster lung  fibroblast V79 cells,  and Manin–Darby canine kidney cells (Vellonen 
et al. 2004).  The reasons behind this discrepancy are unclear, although it has been 
suggested that compared to Trypan Blue cell counting the MTT assay is more 
sensitive, as is not open to subjective errors by the observer.  However, the two 
methods correlate well where they are both used (Carmichael et al. 1987; Simoes-
Wust et al. 2002). 
Another proposed limitation of the MTT assay is that isoflavones themselves may 
lead to an overestimation of the amount of growth or viability of the cells.  This effect 
has been demonstrated in a number of cell types including MCF7 breast cancer 
cells, Jurkat cells, L-929 transformed mouse fibroblasts (Pagliacci et al. 1993) and 
lymphocytic leukaemia cells (Bernhard et al. 2003) with genistein, resveratrol, and 
quercetin at concentrations above 20µM.  Very high concentrations (100µM 
genistein) appear to be able to reduce MTT even in the absence of cells (Bernhard 
et al. 2003).  This may relate to the antioxidant capacity of the isoflavones, as this 
group found that vitamin C acted similarly.  Others suggest that genistein at these 
concentrations may influence mitochondrial number and function (Pagliacci et al. 
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1993) and induce swelling in isolated rat mitochondria (Salvi et al. 2002).  In each 
case the net result has again been an overestimation of viability by the MTT method.  
However, it must be noted that the very high concentrations of isoflavones which 
have been associated with this effect (>100µM) are not associated with the present 
study.  Importantly, in MCF7 cells, the presence of genistein between 3.7 and 74µM 
was shown to have no impact upon mitochondrial reduction of MTT (Peterson and 
Barnes 1996). 
On the contrary, numerous groups demonstrate unequivocally that concentrations of 
isoflavone phytoestrogens above 10µM reduce the proliferation of a range of breast 
cancer cell lines, including the MCF7 and MDA-MB-231 lines used in this study 
(section 1.4.5).  Likewise, the effects of lower concentrations appear to relate to the 
ER-status of the cell line (sections 1.4.3 and 1.4.4), and there is no evidence of an 
overestimation of growth when the MTT assay has been used.  Indeed, in the 
present investigation MDA-MB-231 cells treated with 1nM to 10µM genistein 
resulted in around 80% of the control level of proliferation when measured by the 
MTT assay (section 3.1.2..2), confirming that there was no inherent overestimation 
of proliferation associated with the MTT assay in this case.   
To further validate the use of the MTT assay to accurately determine the extent of 
cell proliferation in this investigation, it was compared to the results of the Trypan 
blue dye exclusion assay in both MCF7 and MDA-MB-231 cells (see section 2.4.6).  
In each cell line, the correlations between cell number and optical density were 
positive and significant.  Furthermore, others have found the results of the MTT 
assay and the Trypan blue dye exclusion assay to correlate well in the above two 
cell lines (Simoes-Wust et al. 2002).  Altogether, this suggests that the MTT assay is 
a valid method to assess proliferation under these circumstances, and that the 
concerns discussed regarding overestimation of proliferation appear to be 
unfounded. 
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6.1.2 The solvent and control treatments 
Due consideration was given to the choice of solvent used for the isoflavones and 
E2, and the concentration of solvent to be present in the control (vehicle only) 
experiments.  Ethanol was rejected as a solvent despite its wide use (Table 1.3) as 
preliminary investigations found it to promote MCF7 proliferation (Figure 2.3).  
These results agree with those of Singletary et al. (2001), who demonstrated that 
ethanol, at a range of physiologically relevant concentrations (10 to 100 mM) can 
induce the proliferation of MCF7 cells.  This is likely to have implications for some of 
the other work discussed where groups have used ethanol as a solvent and control 
treatment. 
Furthermore, it was apparent that DMSO inhibited MCF7 proliferation in a dose-
responsive manner (Figure 2.3).  However, compared to an untreated control, doses 
of DMSO up to and including 0.2% were found to have no significant impact on the 
proliferation of MCF7 (Figure 3.1).  As 0.1% DMSO was the most widely used 
solvent and dose in previous studies (Table 1.3), it was felt that levels of 0.1% and 
0.2% were appropriate for use in the current investigation, and that they would 
impart minimal impact on the proliferation of the cells.  The related studies 
presented by Umehara et al. (2009) and Cherdshewasart et al. (2008) describe 
using DMSO in MCF7 cells at 1 and 2% respectively.  These doses are likely to be 
toxic and may interfere with the results.  Interestingly, Blom et al. (1998) found that 
0.8 and 1% DMSO decreased MCF7 cell proliferation, but 0.1 to 0.6% DMSO had a 
growth promoting effect. They propose a reason for this:  since proliferation was 
assessed after only 24 hours in the experimental medium, in some cases the cells 
may have still been in the initial “lag” phase of growth, while in others they may have 
passed more quickly into the “exponential” growth phase.  The effect of various 
organic solvents on MCF7 proliferation does not appear to have been published on 
any other occasions. 
Use of 0.1% DMSO in MDA-MB-231 cells had no significant impact upon 
proliferation, but 72 hour treatment with the 0.2% dose resulted in a significant, if 
slight, reduction in cell proliferation (Figure 3.5).  There do not appear to be any 
instances where the impact of solvents on the proliferation of this cell line has been 
published.  Use of the 0.2% DMSO dose was unavoidable in the combined 
treatments, due to limitations in the solubility of the isoflavones.  The additional 
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impact upon the level of MDA-MB-231 cell proliferation of this level of solvent over 
and above that of any treatment, must be considered in the analysis of the results.  
Furthermore, in two of the MDA-MB-231 proliferation studies discussed, 0.2% 
DMSO was used for the vehicle-only control treatment (Jacobs et al. 2000; Seo et 
al. 2011), and may have had an unforeseen effect on their results.  When 
considering the current results for this cell line, and indeed for the MCF7 cells, in the 
context of other published studies, it is essential to note the choice and dose of 
solvent used, the presence or absence of experimental controls, and the potential 
impact this may have on the results. 
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6.1.3 MCF7 proliferation – single isoflavone and 17β-oestradiol 
treatments 
The results of the single treatments of genistein, daidzein and E2 on MCF7 (ERα+) 
proliferation were very much in line with previous findings.  Both the pre- and post-
menopausal E2 doses resulted in a significant increase in proliferation (Figure 3.2).  
This confirmed that the MCF7 cells obtained were capable of responding to E2 in 
the manner expected and described on numerous occasions (Davis et al. 2008; 
Jacobs et al. 2000; Lau et al. 2009; Matsumura et al. 2005; Rajah et al. 2009; 
Schmidt et al. 2005; Song et al. 2007).  Furthermore, this acted as a positive control 
for the induction of MCF7 proliferation, allowing optimisation of the assay and 
confirming that the protocol used was appropriate for the measurement of changes 
in the proliferation of this cell line. 
Likewise, the effects of the single isoflavone treatments on MCF7 proliferation 
(Figure 3.3) confirmed previous findings, whereby doses up to 10µM genistein and 
daidzein increased proliferation in a dose responsive manner (Hwang et al. 2006; 
Kang et al. 2009; Liu et al. 2010; Maggiolini et al. 2001; Matsumura et al. 2005; Seo 
et al. 2006; Yang et al. 2010; Yuan et al. 2012), and at concentrations above this 
point proliferation begins to drop (Table 1.4).   
The proliferative effects of genistein and daidzein are mediated, at least in part, 
through their ability to bind with and induce E2-like transcription of genes through 
ERα (Hwang et al. 2006; Kuiper et al. 1998; Maggiolini et al. 2001), the dominant 
ER in MCF7 (Section 1.1.4).  Typically, they bind to ERα with around a hundred to 
thousand-fold lower affinity than E2.  The relative binding affinities (RBAs) compared 
to E2, and the ability of the soy isoflavones and E2 to induce the binding of the ERs 
to the oestrogen responsive element (ERE; a conserved region of oestrogen 
induced gene promoters), as a measure of the ability of the various ligands to 
induce ER-mediated transcription, are provided in Table 6.1.   
The more strongly an isoflavone binds to an ER, the more effective it is at inducing 
E2-responsive transcription of reporter genes or proliferative genes (Hwang et al. 
2006; Kuiper et al. 1998; Sotoca et al. 2008). This was reflected in the proliferation 
results, with approximately a thousand-fold more isoflavone required to induce a 
comparable proliferation response to E2 (1µM compared to 1nM).  Furthermore, the 
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lower maximum impact of daidzein on MCF7 proliferation than genistein may reflect 
its lower ERα RBA.  
Table 6.1: Ability of isoflavones and E2 to bind to the ERs and induce ER-ERE 
interaction 
Ligand ERα ERβ 
RBA1 ER-ERE EC50
2 RBA1 ER-ERE EC50
2 
17β-oestradiol 100 0.03 100 0.01 
Genistein 3.10 50 18.13 0.03 
Daidzein 0.25 >300 0.79 0.35 
1 RBA – relative binding affinities of isoflavones, calculated as a ratio of the 
concentration required to displace radiolabelled [3H]-E2 by 50% from ERα in a liquid 
phase competition binding assay (Hwang et al. 2006) 
2 EC50 – in µM, the half maximal concentration of the ligand determined for 
promoting the interaction between the ER and the oestrogen response element 
(ERE), using Surface Plasmon Resonance (Kostelac et al. 2003).  Note: this 
technique uses purified receptors and ligands, so concentrations may not be an 
exact reflection of the response in vivo or in cell culture.  
 
The magnitude of the peak effect of genistein was in the range expected.  In the 
current study peak genistein-induced proliferation was at 178% of the control level 
after 3 days treatment with 10µM isoflavone.  Similarly, previous studies using the 
MTT assay reported MCF7 proliferation of approximately 300% (after 6 days of 1µM 
genistein treatment) and 180% (after 3 days of 3.2µM genistein) of the control level 
(Maggiolini et al. 2001; Yuan et al. 2012). 
As described in Table 1.4, the growth inhibitory effects of genistein in MCF7 cells 
were reported after a range of different treatment durations and isoflavone 
concentrations, between 1 and 14 days, and with 3.5µM up to 50µM genistein 
required to see an inhibitory effect.  However, in two cases, although proliferation 
had peaked at a lower concentration and was dropping with increasing genistein 
dose, the proliferation recorded at the maximum dose was still greater than that of 
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the control treatment (50uM and 80uM respectively; Liu et al. 2010; Yuan et al. 
2012).  The results of the current investigation sit in approximately the middle of this 
range.  While proliferation had peaked at 1µM (daidzein) and 10µM (genistein), and 
was dropping, no net inhibitory effect of either was recorded even at the highest 
concentration used of 31.6µM.  Extrapolation of the graph suggests that an 
inhibitory effect would be seen with higher concentrations, but as the purpose of this 
project was to investigate the impact of physiological concentrations of isoflavones, 
and the stated issues regarding isoflavone solubility and vehicle doses, this was not 
pursued. 
Overall, this implies that the results of 72 hour treatment with genistein and daidzein 
(single treatments) on MCF7 proliferation, assessed by the MTT assay, agree with 
the many other studies in this field.   As was the intention, this confirms the ability of 
the cell line to respond to these treatments at their physiological (dietary) levels, and 
indicates that the assay and protocol described are appropriate for their intended 
use. 
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6.1.4 MCF7 proliferation after combined treatments 
Genistein or daidzein at the range of physiological concentrations tested, in 
combination with E2 at the postmenopausal level, had a synergistic, additive effect 
on MCF7 proliferation, which achieved statistical significance in numerous cases 
(Figure 3.4).  Where the isoflavones were added in combination with a 
premenopausal E2 level, the results were less dramatic.  Although higher than either 
the isoflavone or E2 treatments alone, the magnitude of this effect was less than 
was observed with the lower, postmenopausal E2 concentration, and in many cases 
(genistein and premenopausal E2 particularly) failed to achieve statistical 
significance from the single treatments.  This is summarized in Figure 6.1.  
 
Figure 6.1: MCF7 proliferation after treatment with isoflavone/E2 combinations 
The single treatments of genistein, daidzein or E2 (at pre- or postmenopausal 
levels) each induced MCF7 cell proliferation.  In combination, the effect of the 
isoflavones was mostly masked by the stronger proliferation-enhancing effect of the 
premenopausal E2 level (1nM), although there was a slight additive effect.  However 
the postmenopausal E2 level (1pM) and isoflavones showed a clear synergistic 
effect on MCF7 proliferation. 
This is the first instance, according to the published literature, that the impact of 
genistein and daidzein on the proliferation of MCF7 cells has been determined in a 
full range physiologically relevant isoflavone and E2 concentrations.  Much of the 
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previous research has used the higher E2 levels, better reflecting premenopausal 
women, genistein only, or selected isoflavone concentrations rather than a 
physiological range.  The majority of the evidence supporting the role of isoflavones 
in postmenopausal E2 concentrations on cell proliferation is based on ER-mediated 
reporter gene transcription rather than proliferation itself.  There are no previous 
studies available where the effect of low physiological concentrations of daidzein on 
the proliferation of any breast cancer cell line at postmenopausal E2 levels has been 
discussed.   
The synergistic effect of genistein and daidzein with postmenopausal E2 levels on 
MCF7 proliferation is in agreement with the reported additive effect of 10pM E2 and 
daidzein (and several of its metabolites including equol and tetrahydrodaidzein) 
between 1nM and 1µM on the activity of an ERα promoter reporter gene construct in 
HEK239 cells (Hwang et al. 2006).  Genistein was not tested on that occasion, and 
while this group claimed that similar results were seen for MCF7 cell proliferation, 
they did not publish their results. Likewise, these results are strengthened by the 
increase in DNA synthesis seen in MCF7 after treatment for 24 hours with genistein 
and postmenopausal E2 levels compared to E2 (10pM) alone (Wang and Kurzer 
1998).   
As previously discussed (Section 1.4.6), many of the other studies published in this 
field have used isoflavones with premenopausal E2 (10 to 0.1 nM) concentrations, 
and their results fail to reach a consensus.  The confusing state of the literature 
appears to reflect the varying experimental conditions and outcome measures used.  
Low concentrations of isoflavones can act as ER antagonists in ERα+ cell lines such 
as MCF7, dampening its effect due to their high concentrations but lower 
oestrogenic activity (Casanova et al. 2012; Hwang et al. 2006).  Alternately, in some 
experimental situations the effect of the isoflavones is masked by the stronger effect 
of E2 (Matsumura et al. 2005; Schmidt et al. 2005).  Meanwhile, higher isoflavone 
concentrations (>10µM) inhibited proliferation in a manner which was not mediated 
by the ERs, and unaffected by the presence of E2 (section 1.4.6).  It is important to 
note that several of the key studies described have used ER-mediated expression of 
a reporter gene as their outcome measure (Casanova et al. 1999; Hwang et al. 
2006).  This may not be the only mechanism through which isoflavones impact upon 
cell proliferation. 
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Accordingly, it has been reported that 10µM glycitein (and genistein and daidzein to 
a lesser extent) resulted in considerably reduced MCF7 proliferation compared to 
the vehicle-only control, even in the presence of 10nM or 0.3nM E2 (Sakamoto et al. 
2010; Zava and Duwe 1997).  Alternately, a number of groups suggest that 
treatment with 10µM genistein and other isoflavones can reverse the growth 
promoting effect of premenopausal E2 levels on MCF7 cells, resulting in no net 
change in proliferation compared to a control (Maggiolini et al. 2001; Matsumura et 
al. 2005; Miodini et al. 1999; Peterson and Barnes 1996; So et al. 1997; Wang and 
Kurzer 1998).  Similarly, tetrahydrodaidzein (1nM to 1µM) inhibited 1nM E2-induced 
activation of the ERα promoter reporter gene construct described by Hwang et al. 
(2006).  Finally, there exists a third body of evidence suggesting that any effect of 
isoflavones (0.1nM to 1µM) on MCF7 proliferation (and the activity of an E2-
responsive reporter gene construct transfected into MCF7) is masked by the 
presence of 1nM E2 (Matsumura et al. 2005; Schmidt et al. 2005; Wang and Kurzer 
1998). 
With the current results, the trend towards a reduction in MCF7 proliferation by the 
highest concentrations of genistein and daidzein is still apparent in the presence of 
both 1pM and 1nM E2 levels, although as with the single isoflavone treatments, 
higher doses would be required to see inhibition of proliferation compared to the 
vehicle-only control.  However, this agrees with the investigations described above, 
suggesting that higher concentrations of isoflavones could reverse E2-induced 
MCF7 proliferation, in this case at both pre- and post-menopausal E2 
concentrations.  However the isoflavone levels required for observation of these 
effects would be outwith the range of physiologically relevant concentrations which 
are the focus of this project. 
The combinations of isoflavones with the premenopausal E2 level generated some 
interesting results with regard to MCF7 proliferation.  No oestrogen-antagonistic 
activity was observed, unlike several of the studies described.  However, the 
reduced synergy observed with the premenopausal E2 combinations, in comparison 
to the postmenopausal E2 combinations, particularly with genistein, bears a marked 
resemblance to several other studies which proposed that any effect of isoflavones 
on the proliferation of MCF7 was negated by the stronger E2 effect of this 
concentration (Matsumura et al. 2005; Schmidt et al. 2005; Wang and Kurzer 1998).   
Furthermore, it was reported that with postmenopausal E2, isoflavones acted 
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synergistically on E2-responsive promoter activity, but when premenopausal E2 was 
added the isoflavones inhibited the effect of E2 (Casanova et al. 2012; Hwang et al. 
2006).  A mechanism for the reduction in premenopausal breast cancer risk 
described in section 1.3.1 cannot be directly inferred from these results.  However, 
they do imply that premenopausally, isoflavones may confer no additional breast 
cancer risk (or only a slight increase) over and above the carcinogenic effect of 
endogenous oestrogens.   
A criticism of a number of the studies previously described is that either the final 
solvent content is not provided, or it greatly exceeds the 0.2% DMSO level used in 
this study (see Table 1.3; Hwang et al. 2006; Maggiolini et al. 2001; Peterson and 
Barnes 1996; Sakamoto et al. 2010; So et al. 1997).  In two cases, an untreated 
control was used (Miodini et al. 1999; Schmidt et al. 2005), and others did not report 
the make-up of their control treatment (Wang and Kurzer 1998).  As discussed in 
section 6.1.2, use of these levels of solvent may have unforeseen effects on 
proliferative outcome measured. 
However, overall, this data suggests that genistein and daidzein, at a range of 
physiologically achievable concentrations between 0.01nM and 31.6µM, are capable 
of inducing the proliferation of MCF7 cells over and above that seen with 
postmenopausal E2, and to a lesser extent with premenopausal E2.  There is no 
evidence from this current project to suggest that either isoflavone can reduce 
oestrogen-induced proliferation of the MCF7 cell line, although higher, non-
physiological concentrations may have this effect.  This appears to suggest that soy 
isoflavones could increase the proliferation of ERα+ (medically classified as ER+) 
breast tumours, particularly among postmenopausal women (the group most likely 
to consume isoflavone supplements for the relief of menopausal symptoms; see 
Section 1.2.5).  This supports the advice provided by UK Health Boards 
contraindicating use of isoflavone supplements in post menopausal breast cancer 
survivors (NICE 2009b). 
Based in the results of this one cell line, there is no explanation for the discrepancy 
between the epidemiological evidence, which suggests that consumption of soy 
isoflavones can reduce the risk of incidence, mortality, and recurrence, particularly 
for ERα+ tumours  (see Sections 1.3.1 and 1.3.5), and the in vitro evidence from 
ERα+ cell lines discussed.  However, the increased benefit of dietary soy seen for 
300 | P a g e  
 
premenopausal breast cancer, compared to postmenopausally, may be partly 
explained by the reduced additional proliferative capacity of the isoflavones in MCF7 
over the effect of the higher dose of E2, in comparison to the clearly oestrogen 
agonistic synergistic behaviour seen at the lower postmenopausal E2 level.  
Furthermore, it is important to note that there is no epidemiological evidence for any 
health risks associated with dietary soy.  However, the long term safety of the higher 
isoflavone intakes associated with supplement use has yet to be determined 
(Section 1.2.6). 
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6.1.5 MDA-MB-231 proliferation - single treatments of isoflavones and 
17β-oestradiol 
The effect of E2 on the proliferation of MDA-MB-231 cells has not been widely 
assessed, as they have traditionally been regarded as ER- and so not responsive to 
E2.  However, as discussed, they do express ERβ (Section 1.4.1).  The current 
finding, whereby 72 hour treatment with 1nM E2 had no significant impact on the 
proliferation of this cell line (Figure 3.6), is in agreement with previous research 
showing that 1 and 10nM E2 (72 hours; Rajah et al. 2009), and that 1nM treatment 
(5 to 14 days; Jacobs et al. 2000) did not affect MDA-MB-231 cell proliferation. 
This was the first study to assess MDA-MB-231 cell proliferation after treatment with 
the lower (postmenopausal) level of 1pM E2. This treatment reduced proliferation to 
77% of the control level.  One explanation for the apparent disparity between the 
results of the two E2 levels is that 1nM E2 treatment did result in a reduced mean 
level of percentage proliferation (86%) compared to the control, but that the 
individual results were particularly variable for this treatment (see Table 3.3) and the 
net effect failed to achieve statistical significance.    
This investigation showed a slight, if non-significant reduction in MDA-MB-231 cell 
proliferation after 72 hour genistein treatment at its range of physiological levels 
from 0.01nM up to 10µM (Figure 3.7).  This agrees with the only other similar study 
in this field to use a wide range of physiologically achievable genistein levels (Rajah 
et al. 2009).   
There exists a greater body of evidence to support the sharp drop in MDA-MB-231 
cell proliferation observed after 72 hour treatment with 31.6µM genistein (Figure 
3.7).  Related studies have shown that genistein treatment, at a range of relatively 
high concentrations between 25 and 100µM (between 1 and 3 days) reduced the 
proliferation of this cell line to approximately 50% of the control level (Ferenc et al. 
2010; Kang et al. 2009; Li et al. 2008; Rajah et al. 2009; Seo et al. 2011).  Apigenin 
and quercetin were reported to have no impact upon MDA-MB-231 cell proliferation 
after 3 day treatment with 1 or 10µM, but again 100µM treatment of either caused a 
dramatic reduction in MDA-MB-231 proliferation (Seo et al. 2011).   
The impact of daidzein on MDA-MB-231 proliferation was broadly similar to that of 
genistein, both in pattern and magnitude (Figure 3.7).  This study represents the first 
302 | P a g e  
 
instance where the effect of daidzein on MDA-MB-231 proliferation has been 
reported. 
As discussed in section 1.4.4, the relative levels of ERα and ERβ may explain the 
differences seen in proliferative differences between ERα+ MCF7 cells (expressing 
a small amount of ERβ) and ERα-/ERβ+ MDA-MB-231 cells: with ERα mediating 
many of the pro-proliferative effects of E2 and the isoflavones (up to 10µM), while 
through ERβ these treatments have a negative impact on proliferation.  Meanwhile, 
the universal cytotoxic effects seen with higher isoflavone concentrations, above 
10µM, are independent of the ERs (section 1.4.5). 
Microarray analysis revealed that the two receptors regulated the expression of 
distinct sets of genes in response to E2 treatment, both positively and negatively, 
and that only half of the E2-regulated genes were common to both receptors (Chang 
et al. 2006).  Among the genes known to be differentially regulated in this manner 
are a number with roles in cell cycle regulation.  Cyclin D1 is a cell cycle progression 
gene.  In the models described above (breast cancer cell lines with and without ERβ 
transfection), and in ER- HeLa cells transfected either ER, E2 enhanced cyclin D1 
expression through ERα.  However, through ERβ, E2 inhibited cyclin D1 expression, 
even in the presence of ERα (Liu et al. 2002; Paruthiyil et al. 2004; Strom et al. 
2004).  Associated with this was differential regulation of the cell cycle progression 
genes cyclin E, CDK25a and p45skp2, and the cell cycle inhibitor p27 (Strom et al. 
2004).  Interestingly, ERβ potently activated the cyclin D1 promoter after treatment 
with the antioestrogens ICI 182780, tamoxifen or raloxifene, suggesting a regulatory 
role for ERβ on ERα induced activation of pro-proliferative gene targets (Liu et al. 
2002; Paruthiyil et al. 2004).   
These factors may be significant to the protective effects of isoflavones on breast 
cancer cells, as while ERα is the dominant receptor subtype in most tumours and 
the MCF7 cell line (Balfe et al. 2004; Kurebayashi et al. 2000; Ziv et al. 2004), ERβ 
is often present also, and isoflavones are known to bind to it with greater affinity 
than to ERα (Table 6.1).  In addition, isoflavones may also have stronger 
transcriptional-inducing activity through the ERβ receptor.  Specifically, genistein 
creates an Activation Function-2 (AF-2) surface on ERβ which recruits the GRIP1 
co-activator (activating regulatory protein) more efficiently than on ERα, while 17β-
oestradiol promotes GRIP1 recruitment non-selectively to both ERs (An et al. 2001).  
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However, while the negative regulatory effect of physiological levels (up to 10µM) of 
isoflavones and E2 on cell proliferation can be explained by the presence of ERβ in 
the MDA-MB-231 cell line, the absence of any dose-effect of the isoflavones up to 
10µM, observed in the current study and by Rajah et al. (2009) is interesting.  On 
several occasions, maximal activity of ERβ-luciferase induction  by genistein was 
reported to be three times greater than was seen with E2 (Legler et al. 1999; Sotoca 
et al. 2008).  This was due both to the relatively high affinity of the isoflavone for that 
particular receptor, and the higher ERβ receptor-mediated induction of gene 
expression by genistein described, and led to the term “superagonist” being coined 
for isoflavones such as genistein acting via ERβ (Legler et al. 1999).  If, due to 
“superagonism”, maximal isoflavone/ERβ mediated inhibition of MDA-MB-231 
proliferation had been achieved at a lower concentration threshold that was not 
tested, then no dose effect would be observed.  This corresponds with the 
epidemiological studies discussed earlier (section 1.3.1), which found no dose effect 
for breast cancer incidence other than the difference between the highest and 
lowest soy consumers.  This again suggests a threshold isoflavone level is required 
to achieve a protective effect. 
This phenomenon is of significance to the use of isoflavones in the treatment of 
ERα-/ERβ+ breast cancer, and warrants further study.  In particular, it is necessary 
to determine the impact of ER antagonists on the inhibition of MDA-MB-231 
proliferation by low dose isoflavones, to confirm the role of ERβ in this.  Regrettably 
no specific ERβ antagonists have yet been developed, however several specific 
ERβ agonists exist which may be interesting to test, referred to as SERM-beta1 and 
SERM-beta2 (Clark et al. 2012).  Furthermore, it would also be of value to 
investigate the effect on proliferation of transfecting the MDA-MB-231 cell line with 
ERα or silencing the ERβ gene in this cell line with siRNA.  An alternate line of study 
would be to assess the impact of soy isoflavones on mammary tissue and mammary 
tumourigenesis in the βERKO (ERβ knockout) mouse line.  This could be compared 
to wild-type mice, but regrettably the αERKO mouse line would not be appropriate 
for use, as these mice do not develop mammary glands beyond the rudimentary 
ductal structure which is present from birth (Hewitt and Korach 2003). 
. 
6.1.6 MDA-MB-231 proliferation after combined treatments 
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With the exception of the combination of premenopausal E2 concentration (1nM) 
and genistein at a range of physiological concentrations (Rajah et al. 2009), the 
impact of combinations of genistein or daidzein with pre- or post-menopausal E2 
concentrations on MDA-MB-231 cell proliferation does not appear to have been 
previously investigated. 
The synergy reported by Rajah et al. between genistein and 1nM E2 to inhibit MDA-
MB-231 proliferation to a greater extent than either as single treatments, was not 
present in this investigation, and so consequently, their suggestion that genistein-
ERβ / E2-ERβ heterodimers may be more effective at reducing proliferation than 
genistein-ERβ homodimers is unlikely to be the case.  Indeed it is possible that the 
opposite occurs, and the heterodimer has less impact than the isoflavone-ERβ 
homodimers, although there is no evidence to support this. 
The current results indicate that for the combinations of 1nM E2 with genistein or 
daidzein (≤ 10µM), and 1pM E2 with genistein, any inhibitory effect on MDA-MB-231 
proliferation induced by the corresponding single treatments has been lost in 
combination (Figure 3.8).  However, with the combinations of daidzein and 1pM E2 
there was still a trend towards reduction in proliferation, to around 70% of the control 
value, although these comparisons were non-significant.  Furthermore, these values 
were lower than either the daidzein (≤ 10µM) or 1pM E2 as single treatments (i.e. 
proliferation was reduced to approximately 90% and 77% with daidzein and E2 
respectively; although again the comparisons failed to achieve statistical 
significance) suggesting possible synergy between the two compounds.  This is 
summarized in Figure 6.2. 
In all but one case (31.6µM daidzein and 1nM E2) the combined treatments 
including the highest isoflavone concentrations continued to demonstrate the drop in 
proliferation associated with 31.6µM isoflavone alone, although this drop was less 
dramatic than that seen with the single isoflavone treatments.  As this effect occurs 
regardless of the ER status of the cell line, and does not appear to be mediated by 
the ERs (see Section 1.4.6), it is not surprising that it was still apparent here.  Again, 
this effect was observed in the only comparable investigation, where genistein 
(≥25µM) in the presence of 1nM E2 resulted in a sharp decrease in MDA-MB-231 
proliferation (Rajah et al. 2009).  Why this effect would be apparent but muted in the 
current investigation is not known, however it may have been obscured by the 
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variability of the data generated, as evidenced by the large standard deviations 
calculated for the mean results. 
 
Figure 6.2: MDA-MB-231 proliferation after treatment with isoflavone/E2 
combinations 
The single treatments of genistein, daidzein or postmenopausal E2 each reduced 
MDA-MB-231 cell proliferation.  In combination with premenopausal E2 (1nM) the 
inhibitory effect of the isoflavones was largely lost.  However the postmenopausal 
E2 level (1pM) and some of the isoflavone treatments (in particular daidzein and the 
highest concentrations used) showed a slight synergistic effect on the inhibition of 
cell proliferation. 
An explanation for the apparent interference between the isoflavones and E2 in 
MDA-MB-231 may be that the isoflavones (particularly daidzein) are acting as 
oestrogen agonists at low (1pM) doses of E2, further contributing to any ERβ-
mediated proliferation inhibitory effect.  However, at higher (1nM) E2 concentrations 
they become antagonistic, competing with E2 for ERβ binding sites, due to their high 
affinity for the receptor, and weakening the effect of E2.  This suggestion is 
supported by the results of Hwang et al. (2006).  Their paper describes a situation 
where human embryonic kidney (293) cells were transfected with either ERα or ERβ 
tagged with a luciferase reporter gene and treated with premenopausal (1nM) or 
postmenopausal (10pM) E2 concentrations, and daidzein or its metabolites, 
including equol and tetrahydrodaidzein.  At postmenopausal levels, the isoflavones 
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acted as E2 agonists, and further increased the E2-induction of luciferase activity 
through either ER.  However, premenopausally, particularly through ERβ, they 
inhibited E2 induced luciferase activity.  This scenario can explain why daidzein and 
E2 are synergistic in a postmenopausal environment, but premenopausally they 
have no net effect.  However, it does not explain the lack of effect of genistein and 
1pM E2.  Alternately, E2, genistein and daidzein may each be acting through 
different, as yet unresolved mechanisms to regulate the proliferation of MDA-MB-
231 cells.  The physiological or phenotypic effects of soy isoflavones and E2 
together in vivo has not been investigated. 
In addition, it is possible that the slight toxicity of the 0.2% DMSO level used 
throughout (Figure 3.5) may be masking any effects of the isoflavone-E2 
combinations in this cell line, although to limit the impact of this, 0.2% DMSO was 
used as the control for comparisons for these treatments.  As discussed, this was 
impossible to reduce due to limitations in the solubility of the isoflavones and the use 
of serial dilutions of stock solutions.  A potential alternative to prevent this for future 
investigations would be to dissolve the E2 in ethanol, and compare the results of the 
combined treatments to a 0.1% DMSO / 0.1% ethanol control.  However, for the 
present study it was felt that for the effects of soy isoflavones and E2 to be 
comparable, the same solvent should be used. 
The results generated by this section of the investigation were fairly variable, and 
resulted in large SDs for the calculated means.  It is likely that this contributed to the 
lack of statistical significance demonstrated for the comparisons.  It is possible that 
the multiple variables including the isoflavones and E2 acting on the MDA-MB-231 
cell line through different mechanisms, and also the slightly toxic effect of 0.2% 
DMSO have contributed to the variability seen.  In future investigations, use of a 
different solvent, further optimisation of the protocol, or use of a different method to 
assess MDA-MB-231 proliferation may circumvent this. 
The slight inhibitory effect of the single isoflavone treatments on ERα-/ERβ+ MDA-
MB-231 cells, which was statistically significant in some cases even at relatively low 
physiologically achievable concentrations, suggests that soy isoflavones may be of 
potential chemotherapeutic benefit to the sizeable group of women with breast 
cancer of the same receptor status (18%; Skliris et al. 2008).  However, there are a 
number of important issues which must first be addressed. 
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Firstly, their potentially reduced efficacy in a physiologically relevant premenopausal 
oestrogen environment must be considered. Other models for premenopausal ERα-/ 
ERβ+ breast cancer must be found, to pursue the contradictory results generated by 
this and the only other study in this field.  Due to the concerns discussed regarding 
the appropriateness of rodent models of breast cancer (Section 1.3.3), primary 
tissue samples may be a more beneficial route to follow.  However, soy isoflavones 
may still be of benefit to postmenopausal women with ERα-/ERβ+ breast cancer 
due to their ability to work differentially as oestrogen agonists and antagonists 
depending on the level of oestrogen present.  Furthermore, it is possible that higher, 
non-physiological doses of isoflavones may have a greater inhibitory effect.  
However this was outwith the mandate of this project to investigate, and as 
discussed, raises questions regarding the safety of such pharmacological doses. 
One factor that is evident is from this and other studies, is that there is no evidence 
that soy isoflavones could increase the proliferation of ERα-/ERβ+ cell lines such as 
MDA-MB-231.  This could cautiously be extrapolated to the population of women 
with ERα-/ERβ+ breast cancer, suggesting that even relatively high levels of dietary 
isoflavones may be safe for consumption.  
However, as discussed (Section 1.1.1), the presence of ERβ is not routinely 
assessed in breast tumours, as it is has traditionally been regarded to be of little 
clinical relevance.  For there to be any potential benefit of soy isoflavones to women 
with breast cancer, ERβ expression levels would have to be routinely assessed in 
the tumours, in parallel to ERα.    Regrettably, no clinically significant downstream 
marker of ERβ expression has been identified (Skliris et al. 2008).  Furthermore, 
although the full length ERβ isoform is the dominant form in breast tumours, the 
presence of its truncated isoforms (Section 1.1.4) can complicate its assessment.  
Depending on their target sequence, various ERβ antibodies vary in their isoform 
specificity (Skliris et al. 2008). 
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6.2 Isoflavones and the induction of apoptosis in breast 
cancer cell lines 
6.2.1 Techniques: The Annexin V-Cy3 and DAPI nuclear morphology 
assays  
As discussed (Section 1.5.3), due to the lack of any “gold standard” method with 
which to assess apoptosis, and the slight morphological and biochemical variations 
seen in apoptosis across different cell types and apoptotic induction methods, the 
best practice is to use two complementary techniques which assess different 
apoptotic markers.  The Annexin V-Cy3 kit, assessing PS exposure on the outer 
plasma membrane, and DAPI fluorescent dye, to quantify apoptotic changes in 
nuclear morphology, were used in this project. 
Use of Annexin V-based dyes to assess apoptosis is commonplace.  As the dye is 
membrane impermeable, and only required to bind to externalised PS, no fixation or 
processing of the cells is required, resulting in minimal manipulation and loss of the 
sample (Brumatti et al. 2008; Galluzzi et al. 2009).   The Annexin V-Cy3 dye emits 
light of a relatively long wavelength (red; >570nm) which permits the use of 
counterstains emitting in the blue or green spectral range.  In this case the dye 6-
CFDA was used.  This is a membrane permeable fluorescein derivative, which 
permits cell viability to be assessed simultaneously, as described (section 2.5).   
However, this method does have a number of limitations.  Damage to the plasma 
membrane by intense scraping or trypsinisation (standard tissue culture techniques 
to remove adherent cells from a surface) can cause non-specific binding of Annexin 
V (Brumatti et al. 2008).  This was minimised by growing the cells on a cover slip, 
which was then stained directly.  PS externalisation can be a feature of some other 
forms of regulated cell death (Galluzzi et al. 2011) and can become accessible 
during certain stages of necrosis where the cell membrane becomes permeable, 
leading to false positive results (De Saint-Hubert et al. 2009).  Counterstaining with 
6-CFDA prevented this population of cells from confounding the results.   
Finally, PS is not externalised when certain autophagy deficient cells undergo 
apoptosis (Qu et al. 2007).  Autophagy is a pathway often accompanied by massive 
vacuolation of the cytoplasm.  It has several physiological roles, including 
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cytoprotection in cells undergoing stress, and it can be responsible for cell death in 
some cancer cell lines deficient in certain apoptotic regulatory proteins like Bax, Bak 
and caspases (Galluzzi et al. 2011).  However, both MCF7 and MDA-MB-231 cells 
are known to be able to undergo autophagy (Cui et al. 2007; Indelicato et al. 2010), 
so this was of no concern in this case.   
Similarly, use of membrane permeable DNA-binding fluorescent dyes, such as DAPI 
or Hoechst, to assess changes in nuclear morphology is widely used in apoptosis 
detection (sections 1.5.3 and 2.6).  In bacterial cells (E. coli) DAPI and Hoechst 
have been shown to give comparable quality results for the quantity of DNA present, 
as assessed by flow cytometry, over much of their concentration ranges (Bernander 
et al. 1998).  However, in MCF7 DAPI demonstrates greater DNA binding activity 
than Hoechst, and is less cytotoxic (Bielawski et al. 2001).   
In MCF7, apoptotic nuclear changes (Hoechst method) have been demonstrated to 
occur in parallel to numerous other apoptotic events including gross morphological 
changes such as membrane blebbing and changes in membrane permeability 
determined by Yo-PRO-1 and PI staining (Akter et al. 2012).  Likewise, in primary 
neuronal cultures, nuclear changes (DAPI NAF method; see section 1.5.3) and 
double stranded DNA breaks (TUNEL staining) both occurred after treatment with 
phospholipase A2 (a potent apoptotic inducer), although  each achieved significance 
at different time points after treatment (Daniel and DeCoster 2004).  This 
emphasizes the importance of timing for the measurement of apoptosis, as many 
apoptotic events occur chronologically.   A range of treatment time scales were 
assessed during the optimisation phase of this study, to determine a treatment 
duration which would allow reproducible induction of apoptosis to be measured 
(section 2.6.3). 
Fixation prior to staining with DAPI is common practice with numerous cell types, 
including MCF7 and MDA-MB-231 (Daniel and DeCoster 2004; Koch and Stratling 
2004; Miglietta et al. 2006; Wang et al. 2010).   It is widely accepted that although 
DAPI is membrane permeable, and so can stain both live and fixed cells, the fixation 
process aids its passage through the plasma membrane and so improves the 
efficiency of staining.  This was upheld during the optimisation of this protocol 
(section 2.6.3), and fixation was deemed to be necessary.  Numerous techniques 
exist for fixation of cells prior to microscopy, discussed in section 1.5.3.  Formalin 
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(formaldehyde) fixation was chosen, due to its nucleic acid crosslinking 
characteristics which commend it for the study of nuclear changes (Bacallo et al. 
2006). 
It has been suggested that one of the intracellular triggers for apoptotic nuclear 
condensation and fragmentation is caspase 3 (Hacker 2000).  This caspase is 
known to be absent from MCF7 cells (see section 1.5.3). Furthermore, although 
widespread, apoptotic nuclear changes are not considered to be an essential 
apoptotic event (Hacker 2000).  Based on this, it is possible that apoptotic nuclear 
changes do not occur in MCF7 cells.  However, this was not the case, as they have 
been observed in this cell line (Akter et al. 2012), and also in MDA-MB-231 
(Miglietta et al. 2006).  Hacker et al. propose that caspase 6 or 2 may provide an 
alternate triggering method. 
As with any technique assessing a morphological change, this method is operator 
dependent, and prone to underestimation of the degree of apoptosis, since cells in 
the early stages of apoptotic pathways may not yet display morphological changes 
(Galluzzi et al. 2009).   In addition, there are a number of non-specific issues which 
relate to the use of fluorescence in both the Annexin V and DAPI assays.  As 
discussed, quenching is a concern during any fluorescence technique (section 
1.5.3).  This was of particular relevance to the DAPI technique, as the fluorescence 
of this dye is known to be quenched by high concentrations of divalent cations 
(Mg2+, Ca2+) and heavy metals  (Arbildua et al. 2006).  However, DAPI fluorescence 
is largely stable between pH4 and 11, and in the current study pH was buffered at 
7.4 by PBS.  Under standard experimental conditions, quenching of Annexin V-Cy3 
does not occur (Galluzzi et al. 2009).   
Auto-fluorescence (section 1.5.3) was assessed in the case of each dye used and 
determined to be absent.  However, the issues of bleaching by UV light, or leakage 
of the dye from the cell could not be so easily eliminated.  To minimize their impact, 
images were collected rapidly, and UV exposure was reduced.  When not required 
the UV light source was cut off. 
As a further level of control for both apoptosis assays, H2O2 (at various 
concentrations and times) was used as a positive control for apoptosis.  As 
discussed (section 2.5.3), this treatment is known to induce apoptosis in a range of 
cell types, presumably due to oxidative stress.  Significant induction of apoptotic 
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nuclear morphology was identified in MCF7 cells (section 2.6.3), and PS-
externalising apoptosis was recorded in both MCF7 and MDA-MB-231 after this 
treatment (section 2.5.3).  This indicates that both techniques are capable of 
measuring changes in the level of apoptosis induced under the experimental 
conditions described. 
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6.2.2 Solvents 
To allow comparison between the results of the proliferation and apoptosis assays, 
the same range of DMSO concentrations were used.  Accordingly, the effect of 0.1% 
DMSO on the induction of both PS-externalising apoptosis and apoptotic nuclear 
morphology was assessed in both MCF7 and MDA-MB-231 cells, and the impact of 
0.2% DMSO was assessed by both techniques in MCF7, and on DAPI nuclear 
morphology in MDA-MB-231 cells, as described (sections 3.2.1..1, 3.2.2..1, 3.3.1..1 
and 3.3.2..1).  Neither DMSO concentration had any impact on the induction of 
either apoptotic marker measured in either cell line.  Accordingly, use of DMSO up 
to 0.2% as a solvent and control treatment was considered appropriate in MCF7 
cells for both the Annexin V-Cy3 PS externalisation assay and DAPI nuclear 
morphology assay.  Likewise, in the MDA-MB-231 cell line, 0.1% DMSO was valid 
for use with both apoptosis techniques, and the higher solvent level of 0.2% DMSO 
was appropriate for the nuclear morphology assay. The impact of 0.2% DMSO on 
the induction of PS-externalising apoptosis in MDA-MB-231 cells was not assessed 
as this solvent level and cell line combination was not used in any of the Annexin V-
Cy3 assays. 
However, higher solvent doses have been found previously to result in an increase 
in the level of apoptosis recorded by several groups.  After 12 hour treatment with 
2% (v/v) DMSO an increase in apoptosis (DNA laddering) was measured in mouse 
macrophages (Marthyn et al. 1998).  A similar increase in DNA laddering was 
recorded in MCF7 cells after 48 hour treatment with 1% polyethylene glycol / ethanol 
mixture (55 and 45% respectively; Vandhana et al. 2010).  Furthermore, many of the 
previous investigations looking at the induction of apoptosis in both MDA-MB-231 
and MCF7 (Table 1.6) have not disclosed the maximum solvent level used. As 
DMSO may have either an influence on the induction of apoptosis at higher levels, 
this could have an impact, and should be considered in the analysis of these results.   
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6.2.3 MCF7 apoptosis - single treatments of isoflavones and            
17β-oestradiol 
The E2 treatments (both pre- and postmenopausal levels) had no significant impact 
on the induction of apoptosis in MCF7 cells, by either assay method (sections 
3.2.1..2 and 3.3.1..2).  The agreement between the two sets of results, and 
consequently, two different markers of apoptosis, adds strength to these results.   
Conversely, previous studies (section 1.5.5) suggested that E2 treatment, at 
physiological levels such as these would reduce the induction of both basal 
(Schmidt et al.2005; Song et al. 2007) and serum starvation induced apoptosis 
(Sakamoto et al. 2010).  However, the two studies above looking at basal (without 
stress) induction of apoptosis used longer time scales (4 and 5 days E2 treatment) 
compared to the 3 and 24 hour treatments described for the current investigation.  
This implies that any inhibitory effects of E2 on apoptosis in MCF7 may take longer 
than 24 hours to manifest. 
The single isoflavone treatments showed a tendency towards increasing the level of 
PS-externalising apoptosis at all concentrations tested (0.1µM upwards; Figure 
3.13), and a significant increase in the presentation of apoptotic nuclear morphology 
was observed with the highest genistein concentration used.  These results, and 
those of the other treatments in this cell line are summarized in Table 6.2.  This 
contradicts the results of Schmidt et al. (2005) who found an inhibitory (oestrogen-
like) effect of genistein and daidzein (0.1 to 10µM) on MCF7 apoptosis.  However, 
they are more in line with the results of numerous other studies (although lower in 
the magnitude of the result) which indicate that soy isoflavones above 25µM can 
induce numerous apoptotic markers in this cell line (section 1.5.4).  The lesser 
degree of apoptosis observed in the current study is not surprising given the dose-
effect for apoptotic induction demonstrated with both genistein (Shim et al. 2007) 
and daidzein (Jin et al. 2010) in this cell line.   
There are a number of factors which could potentially underpin the discrepancy in 
the results of lower isoflavone concentrations, casting doubt on the results of 
Schmidt et al. (2005).  Firstly, they treated the MCF7 cells for five days in the test 
conditions, which may have resulted in the depletion of nutrients, or the cells 
approaching confluence, especially for the faster growing cultures.  This could have 
influenced their results, but is not addressed in the publication.  Secondly, their 
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results are compared to an untreated control, rather than vehicle-only.  Although 
0.1% DMSO was the maximum solvent level used in their study, and is unlikely to 
influence the results, it could still have had a slight impact.  Furthermore, contrary to 
the advice of the NCCD, they only used one measure of apoptosis: flow cytometry to 
assess the proportion of cells in sub-G1 phase of the cell cycle.  This technique is 
widely used, but it has some key limitations which are discussed in section 1.5.3.  
Use of multiple distinct measures of apoptosis (see section 1.5.3) would strengthen 
the evidence that they present. 
Table 6.2: Summary of apoptosis results in MCF7 cells (both methods) 
 Annexin V-Cy3:                      
PS externalisation 
DAPI: apoptotic 
nuclear morphology 
E2 NE NE 
Genistein ++ ++ (31.6µM only) 
E2 + genistein ++ (as genistein) + (31.6µM only) 
Daidzein ++ NE 
E2 + daidzein ++ (as daidzein) + (31.6µM only) 
E2: 17β-oestradiol, NE: no effect, + non-significant increases in apoptosis,             
++ significant increases in apoptosis seen at some doses.  
 
On the whole, the data generated here regarding the generation of apoptotic nuclear 
morphology and externalization of PS provides an explanation for some of the 
proliferative properties of E2 and isoflavones.  The lack of effect (or inhibitory effect) 
of E2 on the induction of MCF7 apoptosis corresponds with its strong positive 
impact on the proliferation of this cell line.  Similarly, low doses of soy isoflavones 
(up to 10µM) which cause the dose-responsive increase in MCF7 proliferation, have 
very minimal (or indeed a slight inhibitory) impact upon apoptosis.  However, higher 
levels, such as 31.6µM genistein (section 3.3.1..3) or 25µM daidzein (Jin et al. 2010) 
result in more pronounced induction of apoptosis.  This will have a negative effect 
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on cell numbers, resulting in the biphasic effect of isoflavones seen on MCF7 
proliferation.   
This supports the theory proffered by Sakamoto et al. (2010), whereby in MCF7 
ERα is heavily involved in the proliferative effects of soy isoflavones, but that their 
pro-apoptotic effects are mediated by other, ER-independent mechanisms.  They 
support this with evidence showing that silencing of ERα (siRNA) had no impact on 
the apoptotic effects of isoflavones.  The ER-blocker ICI 182780 alone (10nM to 
10µ) resulted in a dramatic and significant dose-responsive increase in the rate of 
apoptosis, and co-incubation with ICI 182780 and genistein or daidzein resulted in a 
further increase in apoptosis over and above that caused either individually 
(Sakamoto et al. 2010; Schmidt et al. 2005).  Much is already known regarding the 
mechanisms through which the soy isoflavones induce apoptosis in MCF7 cells.  
This has been discussed previously (section 1.5.4).    
As the impact of soy isoflavones on MCF7 proliferation is known to be both dose- 
and time-dependent (Shim et al. 2007), it stands to reason that higher isoflavone 
concentrations or longer treatment times would result in the more pronounced 
induction of MCF7 apoptosis.  However, higher concentrations would be of limited 
physiological relevance, and very long term isoflavone treatment in cell culture is 
both impractical and unrealistic.  The longest treatment duration in the studies 
described was five days (Schmidt et al. 2005).  A different approach was taken by 
Garvin et al. (2006), who implanted MDA-MB-231 cells into female athymic mice, 
and then treated them with daily injections of the isoflavone resveratrol 
(25mg/kg/day) for three weeks.  This treatment resulted in a striking and significant 
increase in the level of apoptotic DNA fragmentation in the tumour (TUNEL 
staining).  However, as discussed, it is difficult to compare the isoflavone doses 
provided in vitro and in vivo (section 1.3.3).  Furthermore, it must be noted that this 
was a model of ERα-/ERβ+ breast cancer (see section 6.2.5), and used resveratrol, 
not the soy isoflavones.  None of the other animal studies described (section 1.3.3) 
investigated the effect of soy isoflavones on markers of apoptosis in any ER-status 
model of the disease. 
There is very little information regarding the effect of isoflavone intake on the rate of 
apoptosis in human breast cancer.  However, one small pilot study of breast cancer 
patients undergoing a core needle breast biopsy (n=17), and then a two week soy 
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isoflavone supplementation (50mg/day) prior to surgery investigated the induction of 
apoptosis (Sartippour et al. 2004).  Although no significant effects were seen 
compared to a historical control group (n=26), possibly due to the subjective 
apoptosis assessment method (microscopy), small numbers and short intervention 
duration, the intervention did result in a trend towards inhibition of proliferation 
associated with an increase in the ratio of apoptotic to mitotic cells.  This data 
suggests that the induction of apoptosis in vivo (human) by soy isoflavones warrants 
further investigation, as this may be a mechanism through which their protective 
effects are mediated. 
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6.2.4 MCF7 apoptosis – the combination of isoflavones and 17β-
oestradiol  
The results described in sections 3.2.1..4 and 3.3.1..4 represent the first 
documented occasion where the induction of MCF7 apoptosis by genistein and 
daidzein in a physiologically relevant E2 environment has been reported, with the 
exception of a series of experiments by Schmidt et al. (2005).  However, while this 
group used a range of E2 concentrations (1, 10 and 100pM) for their combined 
treatments, they only included one concentration of genistein and daidzein (10µM).  
Although this represents the high serum levels of isoflavones seen in very high soy 
consumers, it cannot be related to more moderate or low consumption of 
isoflavones, and imparts little about isoflavone/E2 interactions in most women. 
In the current results for the MCF7 cell line, treatment with the combinations of 
isoflavones and E2 had largely the same impact as the single genistein and daidzein 
treatments on the induction of either apoptotic PS-externalisation (Figure 3.14) or 
apoptotic nuclear morphology (Figure 3.22).   As with the single isoflavone 
treatments (discussed in section 6.2.3), time- and concentration-dependent were 
apparent.  After 3 hours treatment (DAPI nuclear morphology assay) there was no 
impact on apoptosis until the highest isoflavone concentration (31.6µM) was 
reached.  However, after 24 hour treatment (Annexin V-Cy3 PS externalization 
assay) each isoflavone/E2 combination resulted in some induction of apoptotic PS-
externalisation compared to the control.  In each combined treatment case, where 
an increase in the rate of apoptosis was observed compared to the control 
treatment, it was also higher than the rate documented after treatment with the 
relevant E2-only treatment.  This is not surprising given that E2 alone had no impact 
on levels of MCF7 apoptosis in this investigation (Figures 3.11 and 3.20). 
The lack of significant differences in the PS-externalising apoptosis data described 
for many of the combined treatments when compared to the control or E2 alone, 
despite considerably higher mean percentage values reported reflects the large 
range of actual values calculated (Table 3.6).  Its roots may lie in error introduced by 
the apoptosis detection method.  However, the optimisation proceedures and 
positive control treatments were designed to prevent this as far as possible.  
Consequently, this variability in the data probably reflects natural variation in the 
system.  
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These results are comparable to the only previous study, which suggested that 
10µM genistein or daidzein in combination with E2 (1pM to 100pM) induced 
apoptosis in MCF7 to a similar extent than was seen with the isoflavones alone 
(Schmidt et al. 2005).  However, in addition to the limitations of this study discussed 
in section 6.2.3, they have not directly compared the level of apoptosis calculated 
after the single isoflavone treatments and the isoflavone/E2 combinations.  For one 
data set (single treatments) they reported the rate of apoptosis, and for the other 
(combined treatments) the results are in the form of the percentage of apoptotic 
cells out of the total population.  It is apparent that each set of results follows a 
similar pattern, but the inconsistency in their outcome measures is not explained, 
and it rules out a direct comparison.   
Further confirming the lack of any modulatory effect of E2 on the induction of MCF7 
apoptosis by genistein or daidzein is work by Sakamoto et al. (2010).  In their study 
of serum starvation-induced MCF7 apoptosis, they demonstrated that treatment with 
combinations of genistein or daidzein (10µM) with 1nM E2 induced apoptosis to a 
similar degree than with the isoflavone alone.  However, their focus on apoptosis 
induced by serum starvation (5 days in 0.5% serum conditions) limits the 
physiological relevance of these results.  As discussed (section 1.5.3), apoptosis 
induced by different stimuli can present many of the same morphological and 
biochemical characteristics, but the route of induction can lead to slight changes in 
the biochemistry and apoptotic phenotype observed  (Hacker 2000; Kroemer et al. 
2009).   It is possible that this non-physiological apoptotic stimulus could result in a 
different role for isoflavones than with another stimulus in MCF7. 
Overall, the data generated in this study builds on the previous studies, to further 
confirm that soy isoflavones are capable of inducing apoptosis in the MCF7 breast 
cancer cell line, despite the presence of E2 and even at relatively low, 
physiologically relevant concentrations.  However, these pro-apoptotic effects occur 
in parallel (probably regulated by different mechanisms) to the massive synergistic, 
proliferation enhancing effect that both isoflavones and E2 have on MCF7 at these 
concentrations.  At the isoflavone concentrations which represent the serum levels 
seen in low to even relatively high soy consumers (up to 10µM), the slight induction 
of apoptosis observed is insufficient to counter the strong, ERα-mediated  impact of 
both the isoflavones and E2.  However, there was a trend towards increasing 
induction of apoptosis with the highest isoflavone concentration used (31.6µM), 
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confirming the dose-effects documented previously.  This may provide a mechanism 
for the growth inhibitory component of the biphasic effect of the isoflavones on 
MCF7 proliferation, which was apparent with both single and combined treatments.   
While the ability of the isoflavone concentrations used in this study to induce 
apoptosis was limited, this data suggests that greater concentrations of genistein or 
daidzein (outwith the remit of this investigation) could induce apoptosis at a high 
enough rate to reverse these growth promoting properties.   Furthermore, regulatory 
and mechanistic differences between in vitro models of breast cancer and the 
tumour environment in women mean that the ability of even relatively low levels of 
isoflavones to induce breast cancer cell apoptosis may contribute to their 
epidemiological protective effect.  In addition, the cumulative effect of time on the 
apoptosis inducing effect of isoflavones argues for a greater benefit with longer term 
exposure in different models of breast cancer.  However, as mentioned, evidence in 
this field from more complex models of breast cancer, such as humans or rodents, is 
scant.  This argues that further research into the ability of soy isoflavones to induce 
apoptosis in ERα+ breast tumours is warranted. 
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6.2.5 MDA-MB-231 apoptosis - single treatments of 17β-oestradiol and 
isoflavones 
Previous publications have described how genistein, at concentrations above 5µM, 
induces various apoptotic markers in MDA-MB-231 cells, including the proportion of 
cells in sub-G1/G0 phase of the cell cycle (Seo et al. 2011), the presence of single 
stranded DNA (Davis et al. 2008), PS externalisation and caspase 3 activity (Li et al. 
2008).  This was associated with a reduction in Bcl2 protein levels, and a 
corresponding increase in Bax (Li et al. 2008).  These treatments ranged between 
48 and 72 hours, and the response was dose-dependent.  However, prior to the 
current study, nothing was known regarding the impact of lower levels of genistein 
on the induction of apoptosis in this cell line. 
The current results show that even relatively low levels of genistein (10 and 100nM) 
are capable of inducing a trend towards increasing the level of apoptosis in MDA-
MB-231 cells over 3 and 24 hours of treatment.  These results were comparable for 
both the induction of nuclear morphology (Figure 3.28) and PS externalisation 
(Figure 3.17), and the effect on nuclear morphology became statistically significant 
at the highest genistein concentration used (31.6µM).  The remainder of the results 
failed to achieve statistical significance.   However, despite the variability in the 
generated data points, the majority were numerically higher than the control mean.  
All the apoptosis results in the MDA-MB-231 cell line are summarized in Table 6.3. 
Very similar results were seen for daidzein treatment with this cell line.  This too 
achieved statistical significance on one occasion (10nM) with regard to the impact 
on nuclear morphology (Figure 3.28).  This represents the first occasion where 
daidzein at any concentration has been shown to induce apoptosis in an ERα-/ERβ+ 
cell line.  This is an important result, as it shows that the induction of apoptosis by 
isoflavones in MDA-MB-231 cells is not limited to genistein. 
 
  
321 | P a g e  
 
Table 6.3: Summary of apoptosis results in MDA-MB-231 (both methods) 
 Annexin V-Cy3:                  
PS externalisation 
DAPI: apoptotic 
nuclear morphology 
E2 NE NE 
Genistein + ++ 
E2 + genistein  ++ (31.6µM, synergy?) 
Daidzein + ++ 
E2 + daidzein  ++ (31.6µM, synergy?) 
E2: 17β-oestradiol, NE: no effect, + non-significant increases in apoptosis,             
++ significant increases in apoptosis seen at some doses.  
 
These results correspond with the reduction in proliferation of MDA-MB-231 cells 
observed at the same concentrations (Figure 3.7).  Although the inhibition of MDA-
MB-231 proliferation by isoflavones is thought to relate to a genomic effect mediated 
by ERβ (see section 6.1.5), this data suggests that the induction of apoptosis may 
also play a part in the reduction in cell numbers observed. 
It was shown that E2 at its pre- and post-menopausal concentrations had little or no 
impact on the level of either apoptotic marker tested in MDA-MB-231 cells (Figures 
3.15 and 3.25).  This represents the first occasion where this has been tested.  The 
implication is that apoptosis has no role in E2-inhibiton of proliferation in this cell line 
(Figure 3.6), and that other mechanisms, such as an ERβ-mediated genomic effect 
are responsible. 
The induction of apoptosis by high (≥10µM) soy isoflavone concentrations is widely 
agreed to occur to a similar extent in both ERα+ cell lines such as MCF7 and    
ERα-/ERβ+ MBA-MB-231 cells (section 1.5.4; current results).  This study has 
generated novel data illustrating that the same occurs at lower isoflavone 
concentrations, of more physiological relevance to the serum levels observed in 
women.  However, in keeping with the dose-responses observed, the magnitude of 
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the apoptotic effect of these lower concentrations was reduced compared to very 
high, non-physiological doses.  This suggests that despite the strong proliferative 
effect of physiological levels of isoflavones seen in vitro with ERα+ cell lines, in 
parallel they also induce apoptosis, in a manner which is not mediated by ERα.  
Where ERα is absent, such as in MDA-MB-231 cells, there is nothing to mask the 
pro-apoptotic effect seen.  The role of ERβ in breast cancer cell apoptosis is 
unknown and as yet un-tested.   
Several possible alternate (non-ER) mechanisms for the induction of MDA-MB-231 
apoptosis by isoflavones have been investigated.  Genistein treatment at apoptosis-
inducing levels between 5 and 20µM was associated with a reduction in the levels of 
NF-κB protein and activity, and protein levels of MEK5, ERK5 and phospho(active)-
ERK5 (Li et al. 2008).  Although many questions remain regarding the role of these 
signaling kinases in breast cancer, evidence exists supporting a role for them as 
anti-apoptotic in murine thymocytes and porcine aortic endothelial cells 
(Lennartsson et al. 2010; Sohn et al. 2008).  Inhibition of the MEK5/ERK5/NF-κB 
signaling pathway may be a key mechanism through which isoflavones are acting to 
induce apoptosis in MDA-MB-231 cells.  Genistein treatment has also been shown 
to increase the level of active p53 (a tumour suppressor) and p21 (a pro-apoptotic 
and cell cycle inhibiting regulatory protein) in MDA-MB-231 cells (Seo et al. 2011), 
although these may be downstream of MEK5/ERK5/NF-κB signaling. 
Overall, this field of study appears promising with regard to understanding one of the 
mechanisms through which isoflavones may be protective against breast cancer.  In 
particular, it is important to elucidate whether ERβ mediates the induction of 
apoptosis by isoflavones.  This could be resolved by reassessing apoptosis with 
isoflavones in the presence of an ER antagonist, or silencing the ERβ gene.  
Furthermore, as with the anti-proliferative effects of isoflavones in MDA-MB-231 
cells, it would be of value to identify whether their pro-apoptotic effects in vitro are 
mirrored in more comprehensive models of the disease, such as animals, primary 
tissue samples, or even in women.  However, difficulties arise with the latter due to 
the large number of women that it would be necessary to recruit in order to have 
sufficient ERα-/ERβ+ cases for analysis after stratification by ER status. 
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6.2.6 MDA-MB-231 apoptosis – the combination of isoflavones and 
17β-oestradiol 
As seen in MCF7, the ability of soy isoflavones to induce apoptosis in MDA-MB-231 
cells at concentrations ≤10µM was not affected by the presence of E2.  However, 
with the highest concentrations of genistein and daidzein (31.6µM) there was clear 
evidence of synergy between the isoflavones and E2, with the combined treatments 
all inducing considerable levels of apoptosis, which was significantly higher than the 
isoflavone or E2 single treatments in virtually all of the comparisons.  The conclusion 
to be drawn from this is that in a physiological E2 environment (either pre- or post-
menopausal) levels of genistein and daidzein that can be achieved in the serum of 
high soy consumers or women consuming isoflavone supplements can induce a 
considerable level of MDA-MB-231 cell apoptosis.   
In addition to the ERβ-mediated effects of isoflavones discussed previously, this 
increase in the rate of apoptosis could partly explain the anti-proliferative effect of 
isoflavone/E2 treatments on MDA-MB-231 cells.  This provides evidence for a 
protective mechanism for isoflavones in ERα-/ERβ+ breast cancer.  However, this 
study was the first of its kind to investigate the impact of isoflavones in 
physiologically relevant E2 conditions on the induction of apoptosis in an            
ERα-/ERβ+ breast cancer model.  These promising results pave the way for further 
studies.  Firstly this effect requires confirmation in MDA-MB-231 cells by assessing 
a second apoptotic marker (this set of conditions were only tested with the DAPI 
nuclear morphology assay, PS exposure was not assessed).  Secondly, as 
discussed, little is known regarding the mechanism for the effect of isoflavones and 
E2 on apoptosis in this cell line, or indeed the reason for the synergistic effect at 
high isoflavone concentrations.  As genistein and daidzein have potential as 
chemotherapeutic agents against ERα-/ERβ+ breast cancer, this area should be a 
priority.  
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6.3 Volume changes in MCF7  
6.3.1 Technique: Calcein fluorescence 
Although numerous techniques have been used to asses volume change in cultured 
cells (see section 1.6.2..5), the most reproducible and widely used is electronic 
sizing (Coulter Counter): measuring changes in the volume of liquid displaced as 
suspended cells pass an aperture of known size.  However, this requires specialist 
equipment which was not available for the current research.  Many alternate 
methods utilize light microscopy, and as cells are perfused with various test agents 
image analysis software is used to assess their area based on changes in radius or 
height.  This technique has been used to assess volume regulation in MCF7 (Roy et 
al. 2008; vanTol et al. 2007).  However, this assumes a degree of circularity, and 
uniformity of shape which is not representative of the majority of cultured cells.  
Assessment of changes in Calcein fluorescence intensity (sections 1.6.2..5 and 4.1) 
produced reproducible results which were not limited to the uniformly circular cells in 
the population.  Where this method has been previously used in rabbit corneal 
epithelial cells (Pan et al. 2007) and human lung adenocarcinoma cells (Chen et al. 
2011) it has generated comparable results to the other techniques. 
However, there were several key limitations to the technique which required 
addressing.  Firstly, unlike the fluorescent dyes discussed previously, Calcein is 
susceptible to self-quenching.  This is a phenomenon whereby fluorescence 
intensity decreases with increasing dye concentration above a threshold of 3mM 
(Hamann et al. 2002).  This is around 1000 times more concentrated than the typical 
levels used to load the cells in most experiments (5µM Calcein was used in the 
current investigation), and it is generally considered impossible for dyes such as 
Calcein to accumulate inside cells to concentrations >1mM, unless microinjection of 
the dye is undertaken (Hamann et al. 2002; Verkman 2000).  Self-quenching was 
not observed on any occasion in this research.   
Furthermore, despite the use of regulatory volume decrease during hyposmotic 
shock as a reference for measurable volume change in MCF7 to confirm the 
appropriateness of the test conditions, background changes in Calcein fluorescence 
intensity were found to be variable.  In particular this was apparent with the 0.1% 
DMSO control treatment used prior to each test condition.  This may have related to 
325 | P a g e  
 
slight changes in temperature, or incomplete esterification of Calcein.  As discussed, 
WinFluor software was used to assess the stability of fluorescence prior to 
beginning the test protocol.  This software was only capable of measuring changes 
in individual pixels rather than whole cell regions due to the ROI selection method, 
and as a result it failed to detect the background changes in fluorescence which 
were later detectable using ImageJ.  This was accepted as an unavoidable limitation 
of the equipment used, but it is apparent from these results that WinFluor live image 
analysis was considerably less sensitive than ImageJ.  Future investigation in this 
field will require further optimisation to determine the balance between time taken to 
allow dye esterification and avoiding fluctuations in the stability of cells brought on 
by extended periods of Tyrode perfusion.  Alternately, more accurate software could 
be acquired to assess the stability of fluorescence prior to experimentation. 
To reduce the impact of background changes in cell Calcein fluorescence on the 
treatment effect, the mean rate of fluorescence change per second was calculated 
during the control treatment and test treatment for each experiment (Δf0, Δf10 etc.) 
and the net effect of the treatment over that of the background change was 
calculated (aΔf), as described in section 4.1.3..3.  Similar calculations were used in 
related studies where Calcein fluorescence intensity was used to determine volume 
changes in SPC-A1 human lung adenocarcinoma cells (Chen et al. 2011) and rabbit 
corneal epithelial cells (Pan et al. 2007). 
RVD in response to hyposmotic shock in MCF7 has been widely investigated, and is 
relatively well understood (section 1.6.8..1).  The results described in section 5.1.1 
show an initial phase of swelling in MCF7 cells from approximately 10 to 16 minutes 
into the hypotonic stress, illustrated by the reduction in Calcein fluorescence 
intensity observed.  Following this, RVD occurred, restoring fluorescence intensity 
(and hence cell volume) to close to the pre-swelling values by around 23 minutes in 
the hyposmotic solution.  These results are in agreement with those of other groups 
assessing RVD in MCF7 cells, and are over a similar time scale (Roy et al. 2008; 
vanTol et al. 2007).  This suggests that the protocol described is appropriate for the 
measurement of volume changes in MCF7 cells over the time scales described. 
However, each of the previous studies has focused on RVD after hyposmotic stress.  
As discussed previously (section 1.6.8) although the response is based on the 
mechanisms which regulate shrinkage during apoptosis, this stimulus is non-
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physiological.  In the current research the main focus was to identify acute changes 
in volume after isoflavone or E2 treatment.  Despite the links between swelling and 
proliferation, and shrinkage and apoptosis being well established (section 1.6.5; 
Chen et al. 2011; Ishibashi et al. 2011) the impact of E2 and isoflavone treatments 
on these responses in cancer cell lines has not previously been studied. 
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6.3.2 The impact of 17β-oestradiol and genistein on MCF7 volume 
6.3.2..1 Swelling 
Treatment with both 1nM E2 and 1µM genistein resulted in a significant reduction in 
Δf compared to the pre-treatment value (Figure 5.5), and accordingly negative 
values for aΔf (Figure 5.6).  This implies that these treatments have caused a 
reduction in fluorescence intensity over and above any background effects, and are 
causing Calcein concentration within the cell to drop due to an increase in size.  
This result is not surprising in the face of data which suggests that swelling is a 
necessary step in S phase progression during proliferation (Dubois and Rouzaire-
Dubois 2004; Hoffmann 2011), and both treatments have previously been shown to 
result in a dramatic increase in MCF7 proliferation (sections 3.1.1..1 and 3.1.1..2.).  
The specific ion channels thought to be involved in proliferative swelling of MCF7 
cells are not known, although the Na+-K+-Cl- co-transporters and the Cl--H+ and Cl- 
HCO3
- exchangers may play a role (Dubois and Rouzaire-Dubois 2004).  It is not 
known whether E2 and isoflavones directly act upon the channels mediating the 
swelling of MCF7, and thus further promote proliferation in this manner over and 
above their other known mechanisms, or whether swelling is a down-stream effect. 
It is relevant to note the speed with which E2 and genistein have begun to induce 
proliferation-like responses in MCF7 cells.  In each case the difference achieved 
statistical significance after 10 or 15 minutes of treatment.  This argues for a rapid 
induction of the proliferative signaling kinase pathways, or direct interaction with the 
membrane ion channel proteins which regulate cell volume.  Slower induction of 
ERα-mediated transcription of pro-proliferative genes may occur in parallel to this, or 
downstream.   
The suggestion that E2 treatment may induce very rapid signaling responses in 
MCF7 is not new.  Treatment of MCF7 cells with 0.1nM E2 induces the activation 
(phosphorylation) of the signaling kinases IGF-1R and EGFR within 5 minutes (Song 
et al. 2007).  By subsequent knockout (siRNA) of IGF-1R then EGFR, this group 
suggested that E2 sequentially induces the activation of IGF-1R, EGFR, then 
MAPK, in a cascade of activation.   
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MAPK signaling is also integral to the induction of MCF7 proliferation by genistein 
(Mawson et al. 2005; Yang et al. 2010), although the speed of the activation of these 
kinase signaling cascades by genistein treatment is not so clear.  It has been 
suggested that up-regulation of ERα transcriptional activity by isoflavones requires 
MAPK / ERK1/2 signaling (Liu et al. 2010; Yang et al. 2010).  Supporting this, Yang 
et al. (2010) present evidence suggesting that treatment with 10μM genistein 
induces phosphorylation of ERα in MCF7 cells. 
This may relate to the hypothesis that even in the absence of ligands, 
phosphorylation of Ser118 of ERα by various signaling kinases increases its 
transcriptional efficiency (Deblois and Giguere 2003; Lucki and Sewer 2011; Yang et 
al. 2010).  Phosphorylation of MCF7 Ser118 in ERα is induced rapidly (within 15 
minutes) in response to 10 nM E2 treatment (Hamilton-Burke et al. 2010).   The role 
of phosphorylation at this site in breast cancer is complex, with studies reporting 
paradoxical results with regard to its impact upon prognosis (Kok et al. 2009; Sarwar 
et al. 2006; Yamashita et al. 2008).   
In addition to this, there is considerable evidence suggesting that both isoflavones 
and E2 can act on K+ channel activity rapidly, within minutes or seconds (sections 
1.6.6).  As discussed, the activity of these channels can directly impact upon cell 
volume (see sections 1.6.1, 1.6.5 and 1.6.8).  It has been suggested that E2 
interacts directly with the plasma membrane BK channels of MCF7 (Coiret et al. 
2005).  To this end evidence was presented showing that 10nM membrane 
impermeable E2 (conjugated with BSA) had a comparable impact upon MCF7 
proliferation to unconjugated E2 (10nM), and that both E2 and BSA-E2 induced BK 
channel activity to a similar extent.  Furthermore, E2-induction of BK activity was 
rapid (within a minute) and not mediated by the ERs, as the addition of the ER 
antagonist ICI 182780 did not prevent E2-induction of BK activity.  In addition, the 
BK channel blockers iberiotoxin, charybdotoxin and TEA prevented E2-induced 
MCF7 proliferation.  However, although the expression levels of BK are cell cycle 
dependent (Ouadid-Ahidouch et al. 2004a), its role in basal (non-stimulated) MCF7 
proliferation appears minimal.  Blockade of BK by the same agents in the absence 
of E2 has no impact upon MCF7 proliferation (Coiret et al. 2005; Ouadid-Ahidouch 
et al. 2000; Ouadid-Ahidouch et al. 2004a; Ouadid-Ahidouch et al. 2004b).   
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Whether E2 works in the same extracellular manner on other ion channels is not 
known.  Neither has the activity of a membrane impermeable form of genistein been 
investigated with regard to any aspect of MCF7 proliferation, apoptosis, or ion 
channel activity.   
6.3.2..2 Shrinkage 
In contrast to the other treatments, 31.6µM genistein treatment resulted in a 
significant shift in the rate of fluorescence change, from a negative to positive value, 
and a positive value for aΔf after 10 minutes treatment.  This indicates that the dye 
is becoming more concentrated, and the MCF7 cells are shrinking. This corresponds 
with the previous results, showing that this treatment induced apoptosis in MCF7 
(Figures 3.13 and 3.22).  This may be evidence of apoptotic volume decrease 
(AVD), proposing a mechanism through which high concentrations of isoflavones 
could induce apoptosis in breast cancer cell lines such as MCF7.  If so, then this 
could relate to the protective effect of dietary isoflavones against breast cancer 
discussed previously.  Mechanisms such as this are potentially important to the anti-
cancer properties of isoflavones, and provide information regarding novel 
pharmacological targets for future chemotherapeutic treatments. 
As discussed (section 1.6.5), AVD is an essential early stage of apoptosis, it occurs 
prior to many of the other key apoptotic events, and requires K+ efflux.  In particular, 
the K+ channels hERG, Kv1.1 and Kv1.3 appear to be involved in this process. In this 
manner, the apoptosis inducer would result in plasma membrane depolarization, 
activating the above K+ channels.  The resulting K+ efflux hyperpolarizes the plasma 
membrane.  As with the membrane potential model of proliferation (see section 
1.6.4), this results in an increase in [Ca2+]i following its electrochemical gradient into 
the cell.  However, this increase is greater in magnitude than is seen during 
proliferation, sustained, and bolstered by the release of endoplasmic reticulum Ca2+ 
stores.  The sudden and sustained increase in [Ca2+]i that ensues activates the 
mitochondrial apoptotic pathway (Figure 1.3) and calpains (Ca2+ activated apoptotic 
proteases; see section 1.5.4).  This activates the caspase cascade as described.   
However, there is cross-talk between the elements of this pathway, as caspase 8 or 
9 activity is required for the induction of AVD, depending upon the route of apoptotic 
induction (Vu et al. 2001).  For a summary of this potential pathway see Figure 6.3. 
330 | P a g e  
 
 
Figure 6.3: Revised model for the induction of intrinsic apoptosis, including 
the proposed role for K+ channels  
Apoptotic stimuli result in membrane depolarization, triggering the activity of hERG 
and Kv1.1 (and Kv1.3).  The resulting plasma membrane hyperpolarisation causes 
an increase in [Ca2+]i largely due to the release in intracellular stores.  This triggers 
formation of the apoptosome by mitochondria, and the activation of calpains.  The 
resulting caspase cascade results in apoptosis.  There is an element of cross-talk, 
as caspase 9 activity is required for the initial efflux of K+. 
By 15 minutes into the treatment, the trend towards a reduction in fluorescence 
intensity has resumed, although to a lesser extent than prior to the treatment.  
However, aΔf still has a positive value, implying that the treatment still retains some 
of its net fluorescence-increasing capacity over and above the background changes.  
It is possible that the treatment has resulted in a loss of membrane integrity in these 
experimental conditions, resulting in loss of Calcein from the cell.  Alternately, the 
shrinkage observed may be a temporary phenomenon, and the MCF7 cells 
recovered.   
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6.4 K+ channel activity in MCF7 cells  
6.4.1 The role of the VGKCs in MCF7 proliferation 
The experiments looking at the impact of various VGKC blockers on the proliferation 
of MCF7 used the previously validated and optimised MTT assay, which is 
discussed in full in sections 1.4.2..1, 2.4 and 6.1.1.   
By using pharmacological K+ channel blocking agents of increasing specificity, it 
was possible to identify the impact of specific channels or groups of channels on the 
proliferation of this cell line.  Firstly, TEA was calculated to have an IC50 for MCF7 
proliferation of 18.84mM (Figure 5.8).  TEA is a non-specific blocker of numerous K+ 
channels.  This indicates that K+ channels are present in MCF7 and play a role in 
proliferation.  Although slightly higher, this is generally comparable to the results of 
others showing that the IC50 for MCF7 proliferation with TEA is around 6mM 
(Ouadid-Ahidouch et al. 2004a; Wonderlin and Strobl 1996).  In agreement with 
Coiret et al. (2007), lower concentrations below 1mM had little impact on the 
proliferation of this cell line.  
Treatment with 4-AP confirmed that among the K+ channels involved in MCF7 
proliferation, the VGKCs played a role.  The IC50 for MCF7 proliferation by 4-AP was 
calculated to be 2.7mM (Figure 5.9).  This value is very similar to that previously 
published by Wonderlin and Strobl (1996) of 1.6mM.  However, it must be noted that 
due to limitations in the solubility of 4-AP, a solvent (water) dose of 4% was required 
for the highest 4-AP concentration (20mM).  The earlier finding that the addition of 
this level of water to the growth medium reduced MCF7 proliferation (Figure 5.7) 
was a concern.  To minimize the impact of this, 4% d.H2O was added to each 4-AP 
treatment and the control used. Although this may have affected the result, any 
influence was universal to all 4-AP concentrations.  At this level, it is probable that 
the reduction in MCF7 proliferation associated with the addition of water was related 
to the dilution of nutrients or an osmotic effect.  
As the intention of this research was to study the K+ currents mediated by the 
VGKCs hEAG and hERG, it was necessary to confirm the role of these channels on 
MCF7 proliferation also.  The hERG blocker DOF was used for this purpose, along 
with AST, which blocks both hEAG and hERG.  No specific hEAG blockers exist.  
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This technique is similar to that used by Roy et al. (2008), although in that case the 
hERG blocker E-4031 was used. 
AST was found to inhibit MCF7 proliferation with an IC50 of 4.9µM (Figure 5.10).   
This is comparable with the finding of Ouadid-Ahidouch et al. (2004b) who observed 
approximately 50% reduction in MCF7 proliferation with 5µM AST.  However, others 
have found 10µM AST to be ineffective at reducing MCF7 proliferation, or 30µM to 
be required to reduce it to 50% (Borowiec et al. 2007; Roy et al. 2008).  The 
variation in results seen may reflect the different treatment durations and assays 
used.  While Ouadid-Ahidouch et al. used an MTS assay kit after four days of 
treatment, Borowiec et al. used this assay after only 48 hours, and Roy et al. used 
the 3H-thymidine incorporation proliferation assay after 72 hours of treatment. 
Meanwhile DOF treatment up to 10µM had no impact on MCF7 proliferation after 72 
hour treatment (Figure 5.11).  While the effect of this K+ channel blocker on MCF7 
proliferation has not been assessed previously, the lower dose of 1µM DOF was 
sufficient to virtually completely prevent hERG current in the murine atrial tumor cell 
line HL-1 (Wang et al. 2002).  Another specific hERG blocker E-4031 (300nM) had 
no effect on MCF7 proliferation (Roy et al. 2008) despite having an IC50 for hERG 
current of 7.7 nM (HEK-293 cells; Zhou et al. 1998).   
Both the hEAG and hERG channels are known to be expressed in MCF7 (Table 
1.8).  As discussed previously, it was hypothesized that if an activity was blocked by 
AST (blocked hEAG and hERG) but not a specific hERG blocker, then it is likely to 
be the hEAG-specific component of AST’s activity that is responsible.  In this 
manner, the data suggests that the K+ channel hEAG, but not hERG, has a role in 
MCF7 proliferation.  This same conclusion was reached by Roy et al. (2008).  In 
summary, this data confirms that the MCF7 cells in use respond to the K+ channel 
blockers TEA, 4-AP, AST and DOF in the manner expected from previous 
publications. 
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6.4.2 Technique: whole cell patch clamping  
Whole-cell patch clamping is a technique which can be applied to virtually any cell or 
tissue type, and has allowed great advances in the field of cell electrophysiology.   
As previously discussed in sections 1.6.2..1 and 4.3, it is the gold standard 
technique with which to assess the activity of ion channels, both in cultured cells and 
tissue, due to the ability to assess minute changes in the current across the plasma 
membrane in real time, under physiologically relevant membrane potentials.  
However, because of the nature of the technique, it is error-prone and may not 
always generate accurate recordings. There are a number of limitations which must 
be understood and corrected for in order to make accurate recordings.   
Series resistance relates to the physical properties of the pipette tip, and clogging of 
the tip, introducing another source of resistance in series with the plasma membrane 
resistance under scrutiny.  This is a major source of error in patch clamp recordings.  
To minimise this, voltage clamping is only considered to be successful when the 
membrane resistance greatly exceeds series resistance.  As described by 
Sontheimer and Olsen (2007), uncompensated series resistance introduces error in 
the current recorded, which increases with the amplitude of the current.  The patch 
clamp amplifier hardware can be used to compensate for series resistance to a 
certain extent, but not fully.  Thus, to reduce this source of error several steps are 
essential.  A maximum uncompensated series resistance (often 10MΩ) should be 
set as a cut off (Ouadid-Ahidouch et al. 2004a) and should be declared in the 
methodology.  High concentrations of ethylene glycol tetracidic acid (EGTA) in the 
pipette solution can help to reduce “healing” of the plasma membrane inside the 
pipette, which can be a major source of clogging. 
In addition, whole cell patch clamping requires several assumptions to be made 
regarding the plasma membrane.  Firstly, it assumes that the membrane potential is 
equal at all points on the cell surface, and secondly, that current or voltage clamping 
(which affects the potential) is universally disseminated to all points on the plasma 
membrane. However, under most experimental (and naturally occurring) 
circumstances these are not necessarily appropriate (Sontheimer and Olsen 2007). 
Furthermore, many experiments have looked in real time at the acute effects of 
compounds on channel activity, usually recording events occurring within 10 or 20 
minutes of treatment.  It is in the nature of the patch clamp methodology that 
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membrane integrity begins to deteriorate after this time, as the cell dies.  Pre-
treatment for longer periods would be required to occur in advance, and therefore 
longer term effects on K+ currents cannot be measured in real time (Sundelacruz et 
al. 2009).  The result is that only short term effects are seen, which are more likely 
to reflect post-translational regulation, direct channel gating, and activation 
cascades, rather than changes in gene expression, translational regulation, or 
protein half-life.  In addition, as most systems, including the current one, are 
designed to study single cells, one at a time, the technique is laborious, low-
throughput, and does not reflect cell-cell interactions.  However, systems are being 
developed allowing electrophysiological recordings of many cells to be recorded in 
parallel, using microchips with numerous apertures serving as patch electrode tips 
(Sundelacruz et al. 2009).   
Another potential limitation of patch clamping methodology is that typically, the 
experiments are carried out at room temperature rather than 37oC.  Reportedly, the 
lower temperature increases the stability of the patch.  Where the effect of 
temperature on current under patch clamp has been assessed, large drops in 
temperature (29oC to 9oC) had a measurable impact on some elements of the 
macroscopic current particularly the transient components, but the change from 
20oC to 29oC had little effect on the overall current recording (snail neurons; Lux and 
Brown 1984).  This suggests that the difference in temperature between room 
temperature and 37oC may not have a significant impact.  However this has not 
been fully assessed in all cell types.   
Finally, it is unrealistic to compare the concentrations of compounds used for K+ 
channel experiments with the concentrations known to regulate other cellular 
processes in vivo or in cell culture conditions, such as a PTK inhibitory IC50 or doses 
which promote proliferation.  This is due to the requirement for slightly different 
experimental conditions.  While every attempt is made to make the media for a 
patch clamp experiment as physiologically relevant as possible, in order to 
accurately manipulate currents, the serum normally added to cell culture media is 
absent, and various ion concentrations and pharmacological agents are frequently 
used to allow the experimenter to isolate individual currents.  It was suggested that 
serum may bind drugs such as 4-AP, and can reduce both their channel blocking 
and anti-proliferative properties (Wonderlin and Strobl 1996).  Also, the pipette 
solution which bathes the intracellular space needs to mimic the normal intracellular 
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milieu as closely as possible, but it is at best a compromise.  The result is that while 
comparable IC50 doses for reducing channel activity and proliferation might be used 
to argue for a common target, different values cannot be proposed as evidence to 
reject this hypothesis (Wonderlin and Strobl 1996).   This makes it impossible to 
make direct links between K+ flux effects and alterations in the proliferative or 
apoptotic activity of cells.  However, as discussed, studies which have silenced 
specific channel genes, or transfected them into cells known to not normally express 
them, add strength to the arguments here.  
Due to the diverse nature of plasma membrane ion channels, a number of standard 
measures were built into the patch clamp protocol used to optimise the recording of 
K+ currents, and not those mediated by other ions.  These have been discussed in 
greater detail in section 1.6.2..1, but are summarized briefly here.  The speed of 
activation and inactivation of ion currents can vary greatly.  In these experiments, 
each voltage step was relatively slow, lasting 250ms, and current was assessed in 
the second half of this.  This minimised interference from the Na+ currents, which 
typically activate and inactivate quickly, within 5ms (Sontheimer and Olsen 2007; 
Standen et al. 1994).  Likewise, the choice of holding potential from which the 
voltage steps are applied from can separate different current types.  Many K+ 
currents will activate from a range of holding potentials, but the level of  -50mV used 
here allows the activation of the delayed rectifier K+ currents, including numerous 
VGKCs, whilst preventing many transient K+ currents. 
Pharmacological agents of varying specificity can be used to block undesirable 
currents, leaving the one under scrutiny.  However, this can have unforeseen effects 
on the activity of the cell.  Instead, the best practice is to assess the current in the 
presence and absence of the ligand under scrutiny, and subtract to observe the 
responsive element.  This approach was adopted in this study, and was discussed 
in greater detail in section 4.3.5.   
Finally, the use of current/voltage (I/V) curves to assess the data can generate 
information regarding the characteristics of the current which can aid in its 
identification.  As discussed, these parameters include the reversal potential, 
voltage dependence, and quality of the patch clamp.  Much of this information is 
difficult to infer from the raw patch clamp data. 
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The use of statistical analysis (General Linear Model for repeated measures; GLM) 
and discussion of the mean result of a number of repeated experiments (n ≥ 3) to 
determine the significance of the effect of treatment on the voltage-response of the 
current (section 4.3.6) strengthens the results generated here in comparison to 
many related investigations.  In contrast, numerous key studies in this field have 
elected simply to use descriptive statistics to describe the currents recorded, and 
discuss the results of individual, apparently representative, sets of results (Borowiec 
et al. 2007; Coiret et al. 2005; Garcia-Ferreiro et al. 2004; Ouadid-Ahidouch et al. 
2004a).  This is a key short-fall of these studies. 
As discussed, in several cases an observed effect failed to achieve statistical 
significance despite showing a clear trend towards an increase or decrease in 
macroscopic current after treatment.  This is likely to relate to the variability between 
cells in the recorded current.  It is possible that a factor in this is differences in size 
of the cells used (section 5.3.1; a cell with greater surface area may have more ion 
channels present in the plasma membrane and hence, larger whole-cell current).  
Although measures were taken to reduce the impact of this, a degree of variability in 
cell size persisted due to visual observation of cell size.  In future studies, this can 
be minimized further by reporting current density as a ratio of current and 
size/capacitance (i.e. pA/pF), in the manner of the Ouadid-Ahidouch group 
(Borowiec et al. 2007; Ouadid-Ahidouch et al. 2004a).  Regrettably this was not 
possible for the current dataset.  Alternately, this variation may reflect differences in 
the growth cycle stage of the selected cells.  Many K+ channels in MCF7 are known 
to be expressed differentially at various stages of the growth cycle, including hEAG 
(Ouadid-Ahidouch and Ahidouch 2008) and BK (Ouadid-Ahidouch et al. 2004a).  
Synchronization of the cell cycle prior to experimentation may reduce this.  A final 
possible explanation for this variability is that MCF7 cells are known to secrete 
numerous proteins into the extracellular matrix, including metalloproteinases and the 
glycoprotein fibrinogen, each with roles in tumour invasiveness (Liu et al. 2002; 
Rybarczyk and Simpson-Haidaris 2000).  Trypsinisation prior to patch clamping is a 
standard technique used by some groups to minimize interference from secreted 
protein (Ouadid-Ahidouch et al. 2000; Ouadid-Ahidouch et al. 2004a), however it 
provided no additional benefit in the current research, so was omitted from the 
protocol.   
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The reversal potential (i.e. potential where the net current flow was 0mV) of the 
recorded currents was often around -80mV, indicating that the current recorded was 
largely due to K+ ions (see section 5.3.2; the equilibrium potential for K+ is around -
85mV, so at potentials more negative than this, K+ ions will flow inward, and at more 
positive potentials K+ will flow outward).  However on several occasions the reversal 
potential was more positive.  This may reflect the activation or inactivation of other 
ion channels by that treatment, in addition to the K+ channels.  Alternately, this 
variation may reflect slight methodological variations between the experiments, such 
as slight inconsistencies in the K+ ion content of the extracellular and intracellular 
solutions used. 
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6.4.3 Control treatments  
As shown in Figure 5.12, the patch clamping protocol with no additional treatment 
did impact upon the recorded MCF7 K+ current significantly.  Overall, the within cell 
effect of treatment became significant after depolarization from -50mV to -20mV, 
and all potentials greater than this.  However, by higher potentials (≥80mV) the 
mean magnitude of this effect became minimal compared to that of the increasing 
applied voltage.  By the highest membrane potential applied (120mV) the mean 
difference in current before and after treatment was negligible (although within 
individual cells is was still significant).  This data implies that the protocol, and 
possibly handling of the cells, does have an impact upon the recorded K+ current. 
In the published literature (section 1.6) there was no occasion where the effect of 
the control treatment over time on the recorded current was discussed.  It is not 
known how wide spread this phenomenon is. 
Furthermore, even at very negative potentials there was a slight current recorded, 
which in some cases was negative.  This suggests that despite achieving the 
prerequisite Giga-Ohm seal, the seal of the plasma membrane around the 
micropipette suffered from some leakage.  In a hypothetically ideal voltage gated ion 
current (see Figure 4.7), there is virtually no current at very negative potentials, and 
as the potential steps up past the activation potential of the channels in question, 
positive current flows.    However, this was not always the case.  It was thought this 
may relate to the secretion of matrix proteins by MCF7 (observed visually).  
Attempts were made to minimize the impact of this, including trypsinisation of the 
cells prior to patch clamping (a standard technique to remove extracellular protein), 
and using newly passaged cells which had not had the opportunity to secrete fresh 
protein.  Regrettably they provided no benefit.  For future studies, further time taken 
during the optimisation stages should reduce the impact of this. 
As the time-course shows (Figure 5.12B) after the initial increase in current between 
one and three minutes, there was minimal further degradation of the seal (which 
would be indicated by a further increase in current).  To allow analysis of the 
remaining results, it was assumed that leakage occurred at a constant rate for each 
cell.  This is an unavoidable limitation of the present study, and possibly the 
technique in general. 
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Both the pre-treatment I/V trace, and the 5 minute I/V trace show a response to the 
increasing voltage steps (voltage sensitivity).  Furthermore, both have a reversal 
potential (the voltage at which the recorded current changes from negative, flowing 
into the cell, to positive, flowing out of the cell) of between approximately -50 and -
80mV.  As described in section 5.3.2, this indicates that the majority of the current is 
due to the flow of K+ ions, as this value is close to the K+ equilibrium potential. 
As illustrated in Figure 5.13, 0.1% DMSO treatment for 5 minutes resulted in a slight 
increase in the depolarization activated current, as with the untreated cells.  
However this never achieved statistical significance, and after the initial increase (in 
the first minute) it too stabilised.  This suggests that the presence of DMSO could 
act to stabilise the seal between the pipette and the MCF7 plasma membrane.  
However, it is more likely that at 0.1% in the perfusing Tyrode, DMSO has no 
significant impact upon K+ current or seal integrity. 
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6.4.4 Pharmacological characterization of the whole cell MCF7 current 
using K+ channel blockers 
The impact of the K+ channel blockers TEA, 4-AP, AST and DOF on macroscopic 
current in MCF7 was investigated.  This was to confirm that the system and the cell 
line were capable of generating reproducible results that were in line with what was 
previously published. 
TEA and 4-AP are both fairly broad spectrum channel blockers: TEA blocks the 
majority of the K+ channels, while 4-AP prevents VGKC activity (Table 1.9).  At the 
selected concentrations, both resulted in rapid (within 1 minute) and significant 
reduction in voltage activated current (Figures 5.14 and 5.15), which remained 
stable for several minutes following this.  In both cases the difference within cells 
before and after treatment was statistically significant. 
The concentration of TEA used (10mM) for this was below the IC50 for MCF7 
proliferation calculated previously (18.8mM; section 5.2.2), so the impact on channel 
activity was unlikely to be due to a non-specific cytotoxic effect.  The IC50 for current 
inhibition by TEA has been previously calculated as around 2mM (Ouadid-Ahidouch 
et al. 2004a), which is comparable to the 10mM dose used here.   Previously, after 3 
minutes perfusion with 5mM TEA, whole cell MCF7 current was reduced by 
approximately 88% (400ms depolarising step to +60mV from a holding potential of   
-60mV; Ouadid-Ahidouch et al. 2000).  In the current study, on depolarization 
stepping to +60mV current was reduced by TEA by 26% (777.3 to 574.9 pA).  A 
greater percentage reduction (32%) was seen on depolarization to +40mV.  These 
results are more in line with those of Coiret et al. (2007), who describe a reduction in 
MCF7 current of around 40% after perfusion with 0.5mM TEA, upon stepping the 
potential from -100 to +100mV.  In all cases, treatment with TEA inhibits current 
mediated by the movement of K+ ions, confirming that this ion plays a significant role 
in whole cell MCF7 current. 
As with TEA, the chosen 4-AP concentration of 1mM is below its IC50 for MCF7 
proliferation (2.7mM; Figure 5.9). Again, this was selected to minimize the potentially 
cytotoxic effects of higher concentrations.   The impact of 4-AP on K+ current in 
MCF7 has not been determined prior to this.  Accordingly, there is no calculated IC50 
for the inhibition of MCF7 macroscopic current by 4-AP.  In other cell types it has 
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been calculated as between 0.1 and 4mM (Table 1.9).  After 5 minutes perfusion 
with 1mM 4-AP K+ current was inhibited by approximately 11% (388.4 to 346.0pA), 
upon a voltage step from the holding potential of -50mV to 120mV.  Although there 
are no other published results to compare this to, this suggests that the K+ current 
measured in MCF7 is partly mediated by the VGKCs.  It stands to reason that the   
4-AP sensitive VGKC element of the current would be less than the TEA-sensitive 
current element, as it is one of many components to this current (the K+ channel 
types inhibited by TEA are listed in Table 1.9.) 
Perfusion of MCF7 with 1μM AST (blocker of hEAG and hERG currents) for 5 
minutes inhibited a macroscopic current which became active upon depolarization to 
potentials of -10mV or more positive (Figures 5.16 and 5.18).  The non-significance 
of this result may relate to variation in the size of cell selected for experimentation, 
as discussed in section 6.4.2.  It is known that the hERG channel has a greater 
sensitivity to AST than the hEAG channel.  The whole cell current in HEK293 cells 
with cloned hEAG was determined to have an AST IC50 of 196nM (Garcia-Ferreiro 
et al. 2004), while in HEK293 transfected with hERG the AST IC50 was 0.9nM (Zhou 
et al. 1999).   This suggests that 1μM AST treatment should be able to inhibit both 
channels adequately.  As discussed, treatment with 1μM DOF (blocks only hERG) 
had no impact upon MCF7 whole cell current (Figures 5.17 and 5.18).  The 
conclusion is that the AST-sensitive current recorded is mediated by the hEAG 
channel, and not hERG. 
The voltage sensitivity of the AST-sensitive hEAG current in MCF7 has not 
previously been demonstrated, despite 5μM AST being shown to inhibit whole cell 
MCF7 current on several occasions.  The sensitivity of the current to AST was 
dependent on cell cycle stage, with the maximum effect being seen in G1 phase 
(Ouadid-Ahidouch et al. 2004b).  This group later demonstrated that 5μM AST 
inhibited MCF7 current by 21% in cells arrested in G1 phase by 24 hour serum 
starvation (Borowiec et al. 2007).  Although the conditions of this experiment were 
not analogous to the current study, the observed magnitude of the AST-sensitive 
current was similar.  In this case, 5 minute perfusion with 1μM AST inhibited the 
MCF7 current recorded during a voltage step from -50mV to 40mV by 27.9% (note 
that these cells were not synchronized to any cell cycle stage). 
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Where the hEAG channel was cloned into HEK293 cells, depolarization steps 
between 0 and 120mV (from a holding potential of -70mV) showed that hEAG 
current was activated by depolarization but became insensitive to voltage at 
potentials above 60mV (Garcia-Ferreiro et al. 2004).  This was consistent with the 
current results, which showed AST-sensitive current in MCF7 reaching a peak at 
40mV, and reducing at membrane potentials ≥ 50mV.  
Assuming that the activity of the hEAG channel is comparable between MCF7 cells 
and HEK293 model described above, the selected concentration of 1μM is above 
the IC50 for AST inhibition of hEAG current calculated by Garcia-Ferriero et al. 
(2004), but below its IC50 for MCF7 proliferation (4.9μM; Figure 5.10).  As with 4-AP 
and TEA, this maximizes the effect of AST on the recorded current, whilst reducing 
the impact of non-specific cytotoxic effects of the agent.   
Interestingly, no DOF-sensitive current was observed in MCF7, despite the 
presence of hERG channels being previously shown in these cells (Table 1.8).  This 
suggests that either this channel is absent in this particular MCF7 strain, or it is not 
active under the basal conditions used.  The latter corresponds with the known role 
of hERG in apoptosis in a number of cell types (section 1.6.5).  This requires 
confirmation either by seeking hERG protein in the MCF7 cell line, or the 
assessment of hERG (DOF-sensitive) current under pro-apoptotic conditions.  
Furthermore, it would be of value to determine whether incubation with DOF 
impeded the ability of MCF7 cells to undergo apoptosis. 
Current mediated by the hERG channel is known to be temperature sensitive, and 
increased in HEK293 cells transfected with hERG upon increasing temperature from 
23 to 35oC (Zhou et al. 1998).  The DOF experiments were conducted at room 
temperature.  Although a higher temperature may increase the DOF-sensitive 
current, the cost would be a reduction in the stability of the patch seal (section 
6.4.2).  Again this would be interesting to follow up. 
Due to the lack of effect of the range of DOF concentrations used on MCF7 
proliferation (1nM to 10μM; Figure 5.11), and corresponding inability of E-4031 
(another hERG blocker; see Table 1.9) to impact upon the proliferation of this cell 
line, it was difficult to select an appropriate dose for the patch clamp experiments. 
Likewise, no published data regarding the inhibitory effect of this agent on MCF7 
whole cell current was available.  However, 1μM DOF was effective at inhibiting 
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hERG current in a number of cell types including HEK293 and HL-1 cells during 2.5 
second depolarization steps from -60 to +40mV from the holding potential of -80mV 
(Wang et al. 2002).  Based on this it is likely that this dose is appropriate for use in 
MCF7.  In a more comprehensive study based on this initial data, higher 
concentrations of DOF could be tested for an effect on MCF7 hERG current. 
Wang et al. (2002) reported that hERG current in SK-BR-3 breast cancer cells, 
HEK293 and HL-1 cells under control conditions was active at potentials more 
positive than -40mV.  However, they found that the addition of H2O2 to the perfusing 
solution both increased the magnitude of the hERG current, and lowered its 
activation potential to -60mV.  These experiments were conducted at 36oC, in cell 
lines which do not express VGKCs, which were then stably transfected with vectors 
containing the hERG gene.  The result is that all the observed current activity can be 
attributed to the hERG channel, but that the protein is in a non-physiological 
environment, and consequently, may not be regulated in a wild-type manner.    In 
the MCF7 model used, numerous K+ channels may be involved in any given current.  
While this makes analysis of the results more complex, it is more physiologically 
relevant, as no channel will act in isolation, and all are regulated by the correct 
mechanisms.  It is possible that in the MCF7 model, the activity of other channels 
masks any effect of DOF on the hERG channel.  Alternately, in MCF7 this channel 
may only become active upon pro-apoptotic stimulation.  
Overall, this data from four K+ channel blockers of varying target specificity confirms 
that the VGKCs, and in particular the hEAG channel are active in MCF7, and play a 
role in the proliferation of this cell line.  It also confirms that the hERG channel is not 
involved in basal MCF7 proliferation.  Furthermore, in non-stimulated and 
unstressed conditions this channel is not active in this cell line. 
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6.4.5 17β-oestradiol enhances MCF7 macroscopic current 
Treatment of MCF7 cells with 1nM E2 resulted in a rapid (within 1 minute) and 
significant increase in outward K+  current (Figure 5.19).  This continued to increase 
for up to 10 minutes into the treatment.  After 5 minutes treatment, upon voltage 
stepping from the holding potential of -50mV to +120mV, current was increased by 
approximately 35%, from 762.9 pA to 1032.3 pA. 
E2 treatment is known to increase the activity of MCF7 BK channels (section 1.6.6).  
This effect of E2 was not mediated by the ERs, largely because it occurred very 
rapidly, but in addition, co-treatment with the ER-antagonist ICI 182780 had no 
effect (Coiret et al. 2007; Coiret et al. 2005).  Furthermore, tamoxifen, in its growth 
promoting concentrations also increased BK current.  
However, the role of the BK channels in MCF7 proliferation is not straightforward.  
The BK channel blockers IbTx (100nM) and CTx (50nM) have previously been 
shown to have no impact on basal MCF7 proliferation (Table 1.9).  They also did not 
inhibit 10nM E2-stimulated MCF7 proliferation, but did reduce BSA-E2 (10nM; does 
not enter the cell) induced proliferation (Coiret et al. 2005).  Interestingly, IbTx and 
CTx also inhibited 10nM tamoxifen-stimulated MCF7 proliferation (Coiret et al. 
2007).  This suggests that E2 acts to promote MCF7 proliferation by two parallel 
mechanisms: the classical genomic (ER driven) mechanism which is independent of 
the K+ channels, and a non-genomic mechanism, which is driven by extracellular E2 
and tamoxifen, comprising direct or indirect activation of the BK channels.  The E2-
mediated increase in macroscopic MCF7 current described above may to relate to 
E2-induced proliferation by the second pathway. 
The K+ current recorded here that was enhanced by E2 treatment is outwardly 
rectifying (passes current more readily in the outward direction).  How it relates to 
the E2-induced inward flow of osmolytes, and hence the swelling observed is not 
apparent from this data, although it seems clear that the VGKCs (mediating outward 
flow of K+ ions) do not play a role, at least in the first few minutes after treatment.  It 
would be interesting to determine whether inhibition of the inwardly rectifying K+ 
channels such as the GIRK channels is capable of preventing E2-induced swelling 
of MCF7.   
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It is possible that E2 treatment is enhancing the current mediated by other outward 
K+ channels known to be involved in MCF7 proliferation, in addition to BK activity, 
such as the hEAG or Kv1.1 channels.   However, the specific MCF7 K
+ channel 
targets of E2 continue to require elucidation.  Knockout or silencing of the specific 
channels in MCF7, or treatment with specific channel inhibitors along with E2 would 
help to achieve this end in the future.  However, even without that information, this 
study provides evidence for a rapid, non-genomic mechanism through which E2 
could promote the proliferation of MCF7 cells. 
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6.4.6 Soy isoflavones inhibit MCF7 macroscopic current 
As discussed in section 1.6.7, the impact of genistein and daidzein on K+ channel 
activity, including many of the key channels involved in proliferation and apoptosis, 
is widely studied.  However, this investigation represents the first instance where the 
impact of soy isoflavones on K+ channel activity has been considered in a breast 
cancer cell line. 
Treatment with 31.6µM genistein appeared to inhibit an outwardly rectifying voltage-
sensitive K+ current in MCF7 cells (Figures 5.20 and 5.22), although this failed to 
achieve statistical significance.  The genistein-sensitive current was particularly 
apparent upon depolarization steps from the holding potential to 0mV or more 
positive potentials.  After 5 minutes genistein treatment the current recorded at the 
100mV voltage step was inhibited by 24.4%.   
Daidzein treatment (31.6µM) had a similar impact upon outward whole cell MCF7 K+ 
current; although the magnitude of the effect was considerably lower (Figures 5.21 
and 5.22).  In this case 5 minutes treatment resulted in only 7.6% inhibition of the 
current recorded upon voltage stepping from the holding potential to 110mV.   
Previously, genistein has been shown to inhibit current carried by a number of the 
K+ channels known to be expressed in breast cancer cell lines, including the hERG 
channel transfected into HEK293 cells (Zhang et al. 2008) and its rat homologue 
rERG in rat microglial cells (Cayabyab and Schlichter 2002), Kv1.3 in human T 
lymphocytes (Teisseyre and Michalak 2005), the delayed rectifier K+ current carried 
by Kv7.1 and KCNE1 in HEK293 cells (Dong et al. 2010), and a similar current in 
guinea pig ventricular myocytes (Missan et al. 2006).  In each case genistein was 
apparently acting as a PTK inhibitor, although whether it acts directly on the channel 
protein or on upstream signaling pathways is not known.   
The genistein concentration used in many of these studies (10 to 40µM) was 
comparable with the dose used in this investigation, described in sections 4.3 and 
5.3 of this thesis.  However, in some cases up to 100µM genistein has been used 
(Dong et al. 2010; Missan et al. 2006).  The physiological relevance of these very 
high doses is limited.  The sensitivity of the current to genistein appears to be 
channel and cell type specific.  Kv1.3 current in human T lymphocytes was 
approximately half blocked by genistein between 10 and 40µM (Teisseyre and 
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Michalak 2005). Likewise, in HEK293 cells stably expressing the Kv7.1/KCNE1 
channel, the delayed rectifier K+ current was inhibited by approximately 50% by 
30µM genistein (Dong et al. 2010).  However, a similar current in guinea pig 
ventricular myocytes (specific channels not identified) was less sensitive to 
genistein, as the IC50 was calculated to be around 64µM (Missan et al. 2006).  It 
would be of value to determine the dose-response for genistein on the MCF7 
macroscopic current recorded. 
The studies described in section 1.6.7 use similar voltage stepping protocols to the 
protocol used here to analyse the impact of genistein on various VGKCs.  These 
comprise a holding potential of -80mV, then voltage steps lasting up to two seconds 
from -60mV up to +60 or +70mV (Dong et al. 2010; Missan et al. 2006; Teisseyre 
and Michalak 2005; Zhang et al. 2008).  In each case they found that genistein 
inhibited the voltage activated element of the whole cell current, the effect took 5 to 
8 minutes to reach its full magnitude, and upon genistein washout the current 
inhibition reversed.  The relatively long time taken for the inhibitory effect of 
genistein to develop was mirrored in the present study, during which the current 
reduced gradually over 5 minutes treatment before stabilising.    
The minimal inhibitory effect of daidzein observed in MCF7 cells echoes previous 
studies in other cell types, where daidzein was found to have considerably less 
current inhibitory effect than genistein (Dong et al. 2010; Missan et al. 2006), or 
none at all (Cayabyab and Schlichter 2002; Teisseyre and Michalak 2005).  In each 
case this was related to the lack of PTK-inhibitory properties of daidzein compared 
to genistein.  Furthermore, genistin, the PTK-inactive precursor of genistein also had 
no impact upon K+ current (Missan et al. 2006). 
The mechanisms through which genistein, and to a lesser extent daidzein, may be 
working on MCF7 plasma membrane K+ channels are not known.  There is some 
evidence that both may have some direct K+ channel blocking activity, although this 
is dependent on the channel type and cell line (section 1.6.7).   Furthermore, a 
number of tyrosine kinases, including the Src-family kinases and/or EGFR have 
been implicated in the regulation of a number of K+ channel types (section 1.6.7).  
However, despite the known PTK-inhibitory action of genistein (Peterson 1995), very 
high concentrations of 190µM were required to see significant inhibition of EGFR 
tyrosine phosphorylation in MCF7, and these concentrations also caused massive 
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and rapid cell death (Peterson and Barnes 1996).  Furthermore, genistein up to this 
concentration had no effect on tyrosine phosphorylation of a number of other key 
signaling kinases in MCF7, including MAPK and phosphatidylinositol 3-kinase (PI-3-
K; Peterson and Barnes 1996).  Lower concentrations of genistein (≤10µM) actually 
increased the phosphorylation (activation) of a number of key signaling kinases 
including ERK1/2 and Src (Liu et al. 2010; Lucki and Sewer 2011; Maggiolini et al. 
2004; Yang et al. 2010).  This suggests that at the concentrations used in the 
present and previous studies, K+ current inhibition by genistein is not mediated by 
PTK inhibition of these signaling kinases.  However, there is considerable indirect 
evidence suggesting that numerous K+ channels are directly or indirectly regulated 
by tyrosine phosphorylation, including studies involving a range of PTK inhibitors.   
It is possible that genistein inhibits direct phosphorylation, and hence activation, of 
the channel proteins.  These are described in section 1.6.7.  Many of the K+ 
channels do appear to be regulated by direct phosphorylation of the channel protein.  
The mammalian 2-pore domain K+ channels, including several members of the 
TASK channel family, are inhibited by direct channel phosphorylation by protein 
kinase A (PKA) and PKC (Patel and Honore 2001).  On the other hand, the 
Kv7.1/KCNE1 channel forms a macromolecular complex with a number of proteins 
including PKA, resulting in the serine phosphorylation of a residue on the amino 
terminus of the Kv7.1 protein, and activation of the channel (Chen and Kass 2011).  
Tyrosine phosphorylation of the amino terminal of a number of VGKCs increases 
channel activity, including the Kv1.2 and Kv1.3 channels (Davis et al. 2001 and 
references therein).  Tyrosine phosphorylation is also implicated in the regulation of 
other K+ channel groups, including BK, and the Kir channels (Davis et al. 2001).  
However, to date, the effect of genistein on direct phosphorylation of the various K+ 
channel proteins is as yet unknown.  Whether phosphorylation has a positive or 
negative influence on channel activity appears to depend upon the channel type and 
site of phosphorylation. 
Preliminary attempts were made to characterize some of the channels on which 
genistein might be acting.  Combining treatments is a frequently used method in this 
field, designed to highlight synergy, interference, or no additional effect between 
compounds with known channel targets, such as AST, IbTx and TEA, and an 
uncharacterized molecule, in the manner of the Ouadid-Ahidouch group (Borowiec 
et al. 2007; Coiret et al. 2007; Coiret et al. 2005; Ouadid-Ahidouch et al. 2004a; 
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Ouadid-Ahidouch et al. 2004b).  In this manner the K+ channel targets of E2 have 
been ascertained (section 1.6.6).   However, this technique has not previously been 
used to identify the K+ channel targets of genistein. 
The combination of 4-AP and genistein was intended to confirm that genistein 
inhibited the VGKCs in MCF7.  However, 5 minute treatment resulted in a non-
significant increase in whole cell current (Figure 5.23).  Upon stepping voltage to 
+40mV, the current was increased by 21.7%.  Three minute treatment had a similar 
effect (not shown).  While it is possible that the two agents interfered with each 
others activity, what is more likely, due to the rapid degradation of the patch clamp 
seal following this point, is that the treatment had a toxic effect upon the cells, and 
resulted in their early death.  
Equally, the patched cells were unstable with the combined genistein-AST 
treatment, and only 3 minutes of recordings were achieved at the n=3 level (Figure 
5.24).  However, after 3 minutes this combined treatment inhibited a voltage gated 
current which was apparent upon depolarization to potentials of -40mV or more 
positive.  The current was calculated to be reduced by 15.4% at the 100mV voltage 
step after treatment.  This current was very similar both in characteristics and 
magnitude to the AST-sensitive current.  This suggests that the hEAG channel is 
potentially a key molecular target of genistein in MCF7 cells.  Future experiments 
looking at the effects of combined genistein and K+ channel blockers may benefit 
from the use of lower concentrations of both agents, once dose-responses have 
been characterized in MCF7. 
The role of the hEAG channel in MCF7 has previously been confirmed (Figure 5.10).  
Furthermore, MCF7 proliferation with genistein concentrations >10µM was sub-
maximal and reducing as concentration increased (Figure 3.3).  The current data 
suggests that in addition to the slight increase in the induction of apoptosis seen in 
MCF7 with 31.6µM genistein, in parallel this treatment inhibits hEAG current in a 
rapid non-genomic manner, which has a further negative impact on cell proliferation. 
The mechanism through which genistein inhibits hEAG current is not known. 
Others have described genistein mediated inhibition of hERG current also, although 
not in MCF7 cells to date (section 1.6.7..6).  Although this channel had no activity 
under basal conditions in MCF7, it would be of interest to investigate the activity of 
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hERG in pro-apoptotic genistein concentrations, due to the known role of this 
channel in apoptosis (section 1.6.5). 
The role of the VGKCs, including hEAG, in volume regulation is not yet known, and 
unfortunately little can be inferred from the current results with genistein for cell 
volume and K+ channel activity.  One set of data shows that 31.6µM genistein 
results in (apoptotic) shrinkage of MCF7 cells, which is frequently mediated by an 
outward flux of ions including K+, but in parallel, this concentration of genistein 
inhibits outward K+ current, including that mediated by the hEAG channel.   This 
implies that hEAG is not involved in genistein-induced AVD in MCF7.  However, it is 
apparent that many of the K+ channels are involved in both pro-apoptotic and pro-
proliferative responses in some cell lines, depending upon the stimulus, intermediate 
regulatory mechanisms, and potential for cross-talk between pathways.  It is hoped 
that this pilot data will lead to further research regarding the mechanisms through 
which soy isoflavones regulate ion channel activity, and hence proliferation and 
apoptosis in breast cancer cells. 
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6.5 The discrepancy between the in vitro and in vivo effects 
of soy isoflavones  
The aims of this investigation were two-fold.  Firstly, the intention was to better 
characterize the proliferative and apoptotic effects of physiologically relevant 
concentrations of genistein and daidzein on two breast cancer cell lines of differing 
ER status, and to understand more clearly the impact of pre- and post-menopausal 
E2 concentrations on these responses. Secondly, this project was designed to begin 
to elucidate several novel mechanisms through which the soy isoflavones may be 
mediating these proliferative and apoptotic effects.  
In ERα+ MCF7 cells, the increase in proliferation due to the isoflavones was 
compounded by the presence of physiological postmenopausal E2 levels, and 
premenopausal to a lesser extent, suggesting that in this particular breast cancer 
model, physiological levels of isoflavones are associated with an increase in breast 
cancer risk.  However, this contradicts gathering epidemiological evidence which 
points to a protective effect of even relatively modest intakes of soy isoflavones 
against breast cancer incidence, recurrence, and mortality.  Furthermore, this 
benefit appears to be greater for ERα+ breast cancer.   
In the course of this research, a number of possible reasons behind this discrepancy 
have been uncovered and investigated, which will be discussed in the following 
section. 
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6.5.1 Recommendation to re-classify ER status in breast cancer 
This study builds on the evidence suggesting that soy isoflavones could be of 
benefit for breast cancers expressing greater levels of ERβ than ERα.  The current 
evidence is in the form of the reduction in proliferation, and associated increase in 
the induction of apoptosis described in the ERα-/ERβ+ breast cancer cell line MDA-
MB-231.  This supports the hypothesis that ERβ mediates many of the protective 
effects of soy isoflavones seen, while through ERα they act to enhance proliferation. 
There is a case for the actions of ERβ explaining some of the discrepancies 
between the in vitro and epidemiological effects of soy isoflavones on breast cancer.  
The level of ERβ expression in the breast tumours of the women involved in all the 
epidemiological studies regarding isoflavones and breast cancer is not known.  As 
described, the epidemiological studies categorized the women according to their 
ERα expression level as either ER+ or ER-, according to standard medical practice, 
due to the clinical significance of ERα expression levels indicating the potential for 
benefit from endocrine therapy.  However, to better understand the impact of soy 
isoflavones on breast cancer in the future, if possible four categories should be 
used, based on the relative levels of both ERs (Figure 6.4). 
This hypothesis may explain the net reduction in risk and recurrence of ERα+ (ER+) 
breast cancer associated with a high intake of isoflavones.  It is possible that, 
despite the potential for an increase in risk in the minority ERα+/ERβ- subgroup of 
this population, for the majority of the ERα+ women, their tumours would also 
express ERβ, potentially at high enough levels to be associated with a reduction in 
risk with high isoflavone intakes. 
Likewise, the ERα-/ERβ+ sub-population could also benefit from high isoflavone 
intakes, for the reasons described.  This was not evident from the epidemiological 
evidence for the ERα- (ER-) population, possibly due to low numbers or masking by 
the lack of any effect of physiological levels of isoflavones in the final ERα-/ERβ- 
group. 
However, before clinical practice can be changed, or recommendations can be 
made, considerable further research is needed in this field.  While a great deal is 
understood regarding the mechanisms through which isoflavones may modulate 
breast cancer risk, much more research is required.   
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Figure 6.4: Conventional and suggested new categories for breast cancer ER 
classification 
Diagrammatical representation of how the conventional breast cancer ER 
classifications of ER+ and ER- would subdivide into four new categories, based on 
the levels of both ERs.  The percentages represent the estimated frequency of that 
ER subtype occurring, as published by Skliris et al. (2008). 
As discussed, this must include unequivocal confirmation of the role of ERβ.  Initially 
steps should include knockout or silencing of the ERβ gene in MDA-MB-231, or 
isoflavone feeding to βERKO mice to confirm that ERβ mediates the protective 
effects of isoflavones in ERβ-dominant scenarios.  If specific ERβ antagonists can 
be developed than they would aid this field also.  Furthermore, the epidemiological 
evidence for the protective effect of isoflavones should be revisited, with a focus in 
the expression levels of ERβ. 
In the longer term, it must be determined whether the cost of routine testing for ERβ 
outweighs its potential benefit to women with breast cancer.  This would require 
clinical testing.  Furthermore, this would likely highlight the difficulties surrounding 
testing for ERβ.  Due to its many isoforms (Figure 1.2), the various ERβ antibodies 
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currently in use vary in their isoform specificity depending on their target sequence.  
To date there are no specific downstream clinical markers of ERβ expression which 
can be used diagnostically (Clark et al. 2012).  Many questions remain which must 
be addressed, regarding the physiological roles of the individual isoforms, which 
vary in their ligand binding and transcriptional activating abilities (section 1.4.2; 
Cappelletti et al. 2006; Maruyama et al. 1998; Ogawa et al. 1998).  
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6.5.2 Isoflavones and breast cancer survivors: interactions with 
treatment regimes 
It is of key importance to further investigate whether isoflavones interact with any 
chemotherapeutic treatments that women with breast cancer may undergo.  As 
many of these agents work as oestrogen antagonists, or interfere with oestrogen 
synthesis or other key signaling pathways, any interaction between them and 
isoflavones has the potential to be of great benefit or harm to the women.    
In one prospective cohort of Chinese breast cancer survivors, among the group with 
ERα+ cancer (n =3181), a protective effect was associated with high soy intake for 
mortality (all causes) and breast cancer recurrence and mortality, in both tamoxifen 
and non-tamoxifen users (Shu et al. 2009).  Among non-tamoxifen users the hazard 
ratio (HR) and 95% CI for breast cancer recurrence and mortality with the highest 
quartile of total soy intake compared to the lowest (1: reference) was 0.65 (0.36-
1.17).  For women using tamoxifen these values were 0.93 (0.58-1.51) for women in 
the lowest quartile of soy intake and 0.66 (0.40-1.09) for the highest soy intake 
quartile.  Interestingly, this suggests that among the women in the highest soy intake 
quartiles, use of tamoxifen did not appear to provide any additional protection.  
When the HR was calculated for isoflavone intake (mg/day) instead of total soy, the 
values were similar. 
However, another smaller prospective cohort of Chinese women with breast cancer 
reported no additional benefit of postmenopausal ERα+ breast cancer recurrence 
with increasing isoflavone intake (Kang et al. 2009).  Importantly, they did not 
observe any increased risk associated with interference between the isoflavones 
and tamoxifen.  It may be of relevance that numbers in this study were low (438 
women received tamoxifen).   
Overall, a pooled analysis of breast cancer survivor cohorts (which did not include 
the above study, reported no significant effect of soy intake on the inverse 
relationship between tamoxifen use and breast cancer recurrence and mortality 
(Nechuta et al. 2012).  This study pooled the results of four cohorts from both the 
US and China, and included 9514 breast cancer cases.  
On the other hand, high soy intake appeared to have an additional benefit for breast 
cancer recurrence among postmenopausal women receiving anastrazole, an 
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aromatase inhibitor which interferes with E2 biosynthesis (Kang et al. 2009).  Among 
anastrazole users (n=86) compared to the lowest quartile of soy intake, women in 
the highest quartile had significantly reduced risk of recurrence (HR 0.65, 95% CI 
0.47-0.85, p for trend = 0.005).  
As both tamoxifen and E2 are known to act similarly on the activity of the BK 
channel (section 1.6.6; Coiret et al. 2007), it would be interesting to characterize the 
impact of genistein and daidzein on this channel.  In each case where they have 
been tested, daidzein has shown considerably reduced or no effect on K+ current, 
compared to genistein.  It is possible that this difference between the two molecules 
may provide a mechanism for their opposing effects on tamoxifen-inhibition of 
cancer cell proliferation observed in animal models of the disease (section 1.3.3). 
Overall, these studies are promising, and argue that dietary isoflavones do not 
antagonize the effects of tamoxifen and anastrazole treatment.  In addition, 
depending upon the treatment regime, they may be able to reduce the risk of breast 
cancer recurrence or mortality independently, conferring an additional benefit.  
Regrettably, animal studies using various rodent models have failed to conclusively 
back this up (section 1.3.3).  However, as discussed, the use of rodent models for 
breast cancer may be of limited value.  There have been no studies in other model 
systems, including both primary tissue and cultured cells which were specifically 
designed to investigate this outcome. 
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6.5.3 The choice of breast cancer model: in vitro versus in vivo  
In an attempt to understand some of the mechanisms behind the effects of 
isoflavones on breast cancer risk, two in vitro models of breast cancer were used: 
the cell lines MCF7 and MDA-MB-231.  MCF7 cells are the most widely used cell 
line in the world (Burdall et al. 2003), although MDA-MB-231 cells are commonly 
used also.  As described, they differ in their ER status (Table 1.2).  Both cell lines 
were a gift from the Hannah Research Institute (Prof. D. Flint).   There are many 
advantages to using cultured cell lines.  In particular, due to their wide use, they 
allow reproducible results, and aid comparison between studies.   However they are 
prone to contamination, genetic drift over time, and their phenotypes can change 
when they are continuously cultured (see section 2.1.1, regarding the use of phenol 
red free experimental medium for MCF7 cells). 
An alternative for future study is the use of primary cell culture, directly derived from 
tumours.  Their characteristics more accurately reflect the original tumour.  
However, they have a finite lifespan, often only surviving several passages, and they 
are easily contaminated by non-cancerous cells.  Both cell lines and primary cells 
will behave differently to the parent tissue as the cell-cell interactions present in the 
organ are lost in vitro (Burdall et al. 2003).  Whichever model is used, it is important 
to bear in mind its limitations.  In addition, comparison between studies in vitro is 
often complicated by the use of a diverse range of growing conditions, cell lines, and 
tests.  In this field, rodent models are not particularly appropriate, for a number of 
reasons, discussed previously (section 1.3.3).  Furthermore, clinical trials in women 
with breast cancer are complicated by the burden of their disease, and the potential 
for the increase in ERα+ cancer proliferation, and as discussed, supplementation in 
this group continues to be contraindicated for this reason (NICE  2009b). 
In the current cell culture models a number of potentially protective mechanisms of 
soy isoflavones were documented, including the induction of apoptosis (MDA-MB-
231 and MCF7), shrinkage, which may relate to AVD (MCF7), and inhibition of 
hEAG current (MCF7).  In addition, numerous other protective mechanisms of soy 
isoflavones have been proposed, including modulation of oestrogen synthesis, cell 
cycle control, breast tissue development, antioxidant activity, angiogenesis and 
protein tyrosine kinase inhibition (Steiner et al. 2008).  These are too numerous to 
discuss in any detail.   
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However, despite the innumerable protective mechanisms frequently associated 
with physiological isoflavone levels such as those used in this investigation, the 
inhibition of breast cancer cell growth by isoflavones is outweighed by their ability to 
induce ERα-mediated cell proliferation, at all but the very highest (non-physiological) 
concentrations.  There is growing evidence to suggest that the balance between the 
protective and proliferative effects of soy isoflavones may be in greater favour of 
their growth-inhibitory pro-apoptotic properties in a human in vivo model of the 
disease. 
As discussed above, there are the obvious differences between cell culture and 
women, including the cell-cell interactions, organs, and immune system, which could 
impact upon the efficacy of isoflavones.  Furthermore, genistein and daidzein do not 
circulate in the serum of soy consumers in isolation, but exist with alongside a 
number of secondary metabolites with varying activities (discussed in section 1.2.3). 
The report by Hwang et al. (2006) highlights the fact that the impact of the 
isoflavone metabolites frequently differed to that of the parent molecule, and thus 
they had varying abilities to promote ERα-mediated proliferation, and act as E2 
agonists or antagonists.   Due to the significant inter-species and inter-individual 
variation in isoflavone metabolism it is difficult to design studies and draw 
conclusions regarding this.  However, Hwang et al. (2006) suggested that many of 
the key metabolites of soy isoflavones, including dihydrogenistein, O-
demethylangolensin and tetrahydrodaidzein induce MCF7 proliferation to a 
considerably lower extent that the parent isoflavones.   
In addition, a study feeding male and female Sprague-Dawley rats with genistein, 
firstly via the lactating dam, then post-weaning with supplemented feed (5 and 500 
µg/g genistein) for 140 days from birth compared the serum and tissue levels of total 
genistein and the free (aglycone) form (Chang et al. 2000).  They found that 
compared to the serum levels, mammary gland tissue levels of genistein had a 
greater proportion of the free genistein fraction, and less total genistein.  This 
suggests that the non-polar aglycone form accumulates more readily in mammary 
tissue, due to the high adipose content, than the more polar conjugates. 
The impact of the varying levels of certain metabolites on the protective 
mechanisms observed in MCF7, including the induction of apoptosis and hEAG 
current identified in this project, requires characterization.  It is possible that some 
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metabolites of genistein and daidzein may retain the protective roles of the parent 
molecules, whilst having a minimal impact on proliferation at physiological 
concentrations.  In this manner, metabolism of isoflavones may explain some of the 
discrepancy between the conclusions drawn from in vitro and in vivo research.  
However, the impact and degree of isoflavone metabolism varies between 
individuals. 
In addition to the issue of isoflavone metabolism, questions have been raised 
regarding the impact of long term isoflavone exposure, specifically adolescent soy 
intake (discussed fully in section 1.3.2).  This seems to provide lifelong benefit by 
altering the development of breast tissue during puberty, rendering it less 
susceptible to carcinogens.  Importantly, this protective effect of soy is independent 
of, and acts in addition to the cancer reducing properties of adult isoflavone intake.  
Indeed, where adolescent and current adult soy intakes have been assessed, high 
levels of each had a cumulative beneficial effect on breast cancer risk (Wu et al. 
2002).   
Finally, the isoflavone concentrations used in this and many other studies were 
based upon the serum levels seen in women consuming various quantities of soy.  
However, as covered in section 1.2.4, the levels of isoflavones in the breast tissue 
itself may not reflect the serum levels.  It is possible that isoflavones accumulate in 
the breast tissue, to greater levels than are seen in the serum, allowing them to 
achieve the ≥50µM concentrations associated with the greatest inhibition of breast 
cancer cell proliferation observed in vitro.  However, equally, tissue levels could be 
lower than that measured in the serum.  Studies to date, assessing the isoflavone 
levels in nipple aspirate fluid (Hargreaves et al. 1999; Maskarinec et al. 2008) or in 
tissue samples from biopsies (Bolca et al. 2010; Maubach et al. 2004) are 
inconclusive.  These studies are limited by the invasiveness of the respective 
procedures, resulting in very low numbers, high drop out rates, and experimental 
population selection bias.   A larger and more comprehensive study looking at the 
tissue levels of isoflavones and their metabolites is required, but for these reasons, 
may be difficult to undertake.  Until this is forthcoming, the serum concentrations of 
isoflavones remain the best available evidence of their in vivo levels.   
Due to the reasons discussed, there is no ideal model with which to study the 
interactions between soy isoflavones and breast cancer.  Despite the limitations 
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associated with cell culture models of the disease, such as MCF7 and MDA-MB-231 
cells, their use continues to be necessary, as part of a multifaceted, multidisciplined 
approach, including cell culture, primary tissue, animal studies, epidemiological 
studies, and clinical trials with greater numbers of women with and without breast 
cancer. 
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CHAPTER 7. Summary and conclusions 
The aims of this research were to determine the effect of achievable (physiological 
serum) levels of genistein and daidzein, at pre- and post- menopausal oestrogen 
concentrations, on breast cancer cell apoptosis and proliferation in two cell lines: 
MCF7 and MDA-MB-231.  Following this, to begin to characterize some of the 
mechanisms through which genistein and daidzein may be acting, preliminary 
results were gathered regarding their impact upon MCF7 volume regulation and K+ 
channel activity, as both these are known to influence proliferation and apoptosis. 
This project makes a significant contribution to the analysis of the proliferative and 
apoptotic effects of soy isoflavones in competition with E2.  Indeed, to date, it is the 
most comprehensive study undertaken where physiological levels of genistein and 
daidzein have been investigated at both pre- and postmenopausal E2 levels.  No 
previous study has gathered data regarding such a comprehensive range of 
conditions.  Of particular note amongst the proliferation experiments are the 
combinations of postmenopausal E2 and daidzein in MCF7, and in MDA-MB-231 
cells daidzein alone, all the E2-daidzein combinations, and genistein at 
postmenopausal E2 levels.  The effect of these treatments on cell proliferation has 
not previously been investigated.  In addition, very little was previously known 
regarding the effects of physiological concentrations of isoflavones on the induction 
of apoptosis in these cell lines.  This study contributes key new information 
regarding the effect of genistein and daidzein, both alone and in combination with 
E2, on MDA-MB-231 apoptosis.  In addition, with the exception of one very limited 
study, this was the first occasion where the induction of MCF7 apoptosis by a range 
of achievable concentrations of genistein and daidzein in a physiologically relevant 
E2 environment has been described.  As many of the effects of the soy isoflavones 
are thought to relate to their oestrogen agonistic or antagonistic properties, how they 
compete with or displace endogenous oestrogens was thought to be an important 
potential mechanism for their protective effects in vivo, and so this element of the 
research was highly relevant. 
Investigation of the impact of E2 and genistein on MCF7 volume regulation by the 
calcein fluorescence method was a novel field of research, based on existing 
knowledge regarding the roles of shrinkage and swelling in apoptosis and 
proliferation respectively (i.e. shrinkage is an essential early step in apoptosis, and 
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swelling is required for S phase progression during proliferation).  Volume regulation 
has been characterized in MCF7 previously in response to non-physiological 
osmotic stimuli, but never due to a physiologically relevant E2 or isoflavone 
treatment.  Mechanisms such as this may be valuable in understanding the 
protective effects of isoflavones in breast cancer cells, and provide important 
information regarding potential pharmacological targets for future chemotherapeutic 
treatments. 
Finally, despite the well established ability of genistein to block current through 
numerous K+ channels, and the known role of many of these channels in 
proliferation and/or apoptosis in non-excitable cell lines such as MCF7 or MDA-MB-
231, K+ channel blockade by the soy isoflavones has never previously been 
considered in breast cancer cells.  In addition to the inhibitory effect of genistein, 
and to a lesser extent daidzein, on macroscopic MCF7 current, there were a number 
of other elements to this section of the project which contribute novel and important 
information to this field.  Firstly, there is no documented evidence of the impact of 
control treatments (vehicle only and no solvent) or DOF on whole cell MCF7 current 
over time.  In addition, the impact of 4-AP and DOF on MCF7 proliferation has never 
previously been characterized. Overall, this section of the project has provided 
important pilot information regarding a novel mechanism through which the soy 
isoflavones, in particular genistein, as a novel mechanism through which they may 
mediate some of their chemoprotective properties. 
In the MCF7 cell line (representative of ERα+ breast cancer) evidence is presented 
showing that at physiologically relevant concentrations soy isoflavones induce 
several anti-cancer protective mechanisms: namely the induction of apoptosis, cell 
shrinkage, and the inhibition of outward macroscopic K+ current through a number of 
channels including hEAG.  K+ current through a number of channels, including 
hEAG, has an established role in the proliferation of a number of cell types and 
lines, including MCF7.  Furthermore, the increase in the induction of apoptosis 
observed after treatment with the isoflavones in combination with pre- or 
postmenopausal E2 was comparable to increase recorded after treatment with the 
isoflavones alone.  However, in this model of breast cancer, these protective 
mechanisms were insufficient to counter the ERα-mediated increase in proliferation 
observed, although at the highest concentrations used a dramatic downward shift in 
proliferation was documented.  Had higher isoflavone concentrations been tested 
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then a significant inhibition of cell proliferation would likely have been observed, 
although this was outwith the remit of the investigation and would have had limited 
physiological relevance.   
In addition, rather than antagonize E2-induced MCF7 proliferation as hypothesized, 
genistein and daidzein acted in an additive, synergistic manner with 
postmenopausal E2 levels, and to a lesser extent premenopausally, to further 
increase the proliferation of this cell line.  This data suggests that in a physiologically 
relevant E2-enviroment, soy isoflavones might increase ERα+ breast cancer cell 
proliferation.  This conclusion is repeatedly echoed in the relevant published in vitro 
literature.  However, it contradicts with a growing body of epidemiological evidence, 
including several meta-analyses of large prospective cohorts.  The possible reasons 
behind this have been discussed in the previous section. 
However, in the MDA-MB-231 model of ERα-/ERβ+ breast cancer used, evidence is 
presented for a protective effect of the soy isoflavones genistein and daidzein in 
their physiological concentrations, particularly postmenopausally.  In this cell line the 
isoflavones induced apoptosis and inhibited proliferation at concentrations which are 
achievable in the serum through diet alone.  It is hypothesized that this effect may 
be mediated by ERβ.  In accordance with the documented E2-insensitivity of this 
cell line, the presence of E2 had no impact upon isoflavone-induced apoptosis.  In 
many cases the combined E2/isoflavone treatments had a reduced inhibitory effect 
on MDA-MB-231 cell proliferation compared to the single isoflavone treatments, but 
a downward trend in proliferation was still observed with the combinations of 
postmenopausal E2 and daidzein, and where the highest isoflavone concentrations 
were used.  This argues for a protective role of soy isoflavones against ERα-/ERβ+ 
breast cancer.  As discussed, there is no epidemiological evidence to support or 
contradict this to date, as ERβ is not routinely assessed upon breast cancer 
diagnosis.  However, this receptor status group is believed to account for around 
18% of all breast tumours (Skliris et al. 2008). 
As identified in the previous sections, a most pressing continuation of this research 
will be to confirm or reject the role of ERβ in the isoflavone-induced reduction of 
proliferation observed in the MDA-MB-231 model.  To this end, the use of ER 
antagonists can be used, although no specific ERβ antagonists exist to date.  
Alternatively, silencing of the ERβ gene by use of siRNA may be a useful technique.  
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Furthermore, whether soy isoflavones inhibit the proliferation of other ERα-/ERβ+ 
models of breast cancer would be of value to determine.  In particular, if sufficient 
numbers are achievable, it would be of great value to determine the impact of 
dietary isoflavones on survival and recurrence in a clinical trial or prospective 
manner with women with ERα-/ERβ+ cancer, although understandably this currently 
would be very difficult to accomplish.  Confirmation of the role of ERβ in the 
inhibition of ERα-/ERβ+ breast cancer by levels of isoflavones achievable in the 
serum through diet alone would be powerful evidence supporting the case for 
routine assessment of ERβ expression levels in breast cancer.  This would allow 
this large group of women to benefit from the potential chemotherapeutic properties 
of soy isoflavones, a cheap, safe, and readily available treatment. 
In the MCF7 model, and indeed in MDA-MB-231 cells, it is important to follow up the 
preliminary findings presented here regarding the ability of the soy isoflavones, and 
in particular genistein, to inhibit current through numerous K+ channels.  While the 
link between K+ current and proliferation and/or apoptosis in breast cancer cell lines 
is not new, this represents the first of hopefully many investigations looking into K+ 
current modulation as a novel mechanism for the chemotherapeutic benefits of 
isoflavones.  In particular, it would be of benefit to characterize the modulation of 
other K+ channels by isoflavones, including Kv1.1, Kv1.3 and the Ca
2+ activated K+ 
channels (BK, IK and SK), as each of these has a suggested role in proliferation.   
Furthermore, it still remains to identify hERG channel activity in MCF7.  It is possible 
that in this cell line the hERG channel is only active under apoptotic stimulation.  In 
this vein, it would be interesting to determine whether genistein and daidzein at their 
pro-apoptotic concentrations can induce hERG current, or whether the hERG 
blocker DOF can prevent isoflavone-induced apoptosis in MCF7.   In each case 
these experiments can be conducted using specific K+ channel blockers in the 
manner of this investigation.  However, further characterization of the activities of 
the various channels can also be attempted by silencing the channel gene (such as 
with siRNA).  To date little is known regarding the expression of K+ channels in 
MDA-MB-231 cells.  To follow up whether inhibition of K+ current in this cell line is a 
mechanism through which isoflavones mediate their proliferation-reducing 
properties, this would also require clarification. 
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In summary, there continue to exist two contradictory hypotheses regarding soy and 
breast cancer which are both supported by aspects of this research.  These are: 
1.  Soy isoflavones are protective against breast cancer, and can reduce its 
incidence, recurrence and mortality, through numerous mechanisms.  The 
potential for benefit may be greater for some groups (i.e. women with ERα-
/ERβ+ tumours) but as yet these populations are not defined on a large 
scale.  As a result soy should be consumed by healthy women and women 
with breast cancer as part of a healthy diet and lifestyle. 
 
2. Evidence shows that soy isoflavones can increase the proliferation of ERα+ 
(ER+) breast cancer cells and as such should be avoided by women with, or 
at high risk of breast cancer. 
However, to date there remains no really convincing supporting evidence for either 
case, with many of the mechanisms for both only occurring in vitro.  Furthermore, for 
each hypothesis there exists a great deal of contradictory evidence.  Until further 
research can be conducted, the only conclusion which can be drawn regarding soy 
isoflavones is that for the general population, and women with breast cancer, normal 
dietary levels appear safe, do not incur any additional risk for breast cancer or other 
conditions, and can be a healthy way to reduce saturated fat intake in the Western 
diet by replacing meat products.  On the other hand, the safety of the higher levels 
of isoflavones achieved by supplement use is not yet established.  In conclusion, if 
healthy women, or breast cancer patients and survivors enjoy soy foods, then there 
is no reason why they should not continue to consume them, in moderation, and as 
part of a healthy balanced diet and lifestyle, and they may contribute towards a 
reduction in breast cancer risk.  However, in line with current medical guidance, 
isoflavone supplementation for the relief of menopausal symptoms should be 
avoided by certain groups of women, such as breast cancer survivors or those with 
a strong family history of the disease, as the risks and benefits are not yet 
established clearly. 
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